Clinical trial NCT01982955
Conditions: Non-small Cell Lung Cancer
Keywords: MSC2156119J Gefitinib Pemetrexed Cisplatin MET positive Tepotinib Carboplatin INSIGHT
Sponsor: Merck KGaA, Darmstadt, Germany
Start date: 2013-12-23; Completion date: 2021-10-14
Enrollment: 88 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This is a multi-center, open-label, randomized, Phase 1b/2 study to determine the recommended phase 2 dose (RP2D) and to evaluate the efficacy in terms of progression free survival (PFS) of Tepotinib when used in combination with gefitinib in partcipants with T790M negative, MET positive locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation and having acquired resistance to Prior EGFR-Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy. This study has 2:1 randomization (Tepotinib/Gefitinib arm versus Chemotherapy arm).

Detailed description:

Arms: arm 1: Participants received Tepotinib 300 milligram (mg) along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment. arm 2: Participants received Tepotinib 500 milligram (mg) along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment. arm 3: Participants randomized to receive Tepotinib recommended Phase 2 dose 500 mg once daily along with 250 mg Gefitinib tablets orally once daily over a 21-day cycle until progressive disease, intolerable toxicity or withdrawal from treatment. arm 4: Participants randomized to receive 500 milligram per square meter (mg/m\^2) of Pemetrexed as intravenous infusion over 10 minutes in combination with Cisplatin (75 mg/m2 as an intravenous infusion over 2 hours) or Carboplatin (intravenously at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator) on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity or withdrawal from treatment or up to 6 cycles if or 4 cycles followed by Pemetrexed maintenance monotherapy. arm 5: Participants with MET+ T790M positive Non-small Cell Lung Cancer (NSCLC) received a Tepotinib recommended Phase 2 dose 500 mg once daily along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
Interventions: intervention 1: Tepotinib intervention 2: Gefitinib intervention 3: Pemetrexed intervention 4: Cisplatin intervention 5: Carboplatin
Intervention descriptions: intervention 1: Tepotinib was administered at a dose range of 300 or 500 milligram (mg) (Phase 1b) and the recommended phase II dose (RP2D) determined in the Phase 1b in Phase II orally once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment. RP2D was determined as per safety monitoring committee (SMC) discretion. intervention 2: Gefitinib was administered at a dose of 250 mg orally as once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment. intervention 3: Pemetrexed was administered at a dose of 500 milligram per square meter (mg/m\^2) as intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered. intervention 4: Cisplatin was administered at a dose of 75 mg/m\^2 as intravenous infusion over 2 hours on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered. intervention 5: Carboplatin was administered intravenously on Day 1 of each 21-day cycle at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.

Protocol documents:
Prot_001.pdf: 
Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
1/154
Clinical Trial Protocol
Clinical Trial Protocol Number
EMR200095-006
Title
A Phase Ib/II Multicenter, Randomized, Open Label
Trial 
to 
Compare 
Tepotinib 
(MSC2156119J)
Combined with Gefitinib Versus Chemotherapy as 
Second-line Treatment in Subjects with MET 
Positive, Locally Advanced or Metastatic Non-small 
Cell Lung Cancer (NSCLC) Harboring EGFR 
Mutation and Having Acquired Resistance to Prior 
EGFR-Tyrosine 
Kinase 
Inhibitor 
(EGFR-TKI) 
Therapy
Short Title
Tepotinib with Gefitinib in Subjects with Locally 
Advanced or Metastatic NSCLC (INSIGHT)
Trial Phase
Ib/II
IND Number
EudraCT Number
2016-001604-28
Coordinating Investigator
 
Sponsor
For all countries except USA and Japan:
Merck KGaA
Frankfurter Strasse 250
64293 Darmstadt, Germany
For sites in the USA:
EMD Serono Research & Development Institute, Inc.
45A Middlesex Turnpike
Billerica, MA 01821-3936, USA
For sites in Japan:
Merck Serono Co., Ltd
Arco Tower. 1-8-1 Shimomeguro
Meguro-ku. Tokyo 153-8926. Japan
'RFXPHQW1R
2EMHFW1R
CCI
CCI
CCI
PPD


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
2/154
Medical Responsible
Merck KGaA
Tel: 
Fax: 
Clinical Trial Protocol Version
27 November 2017 / Version 8.0 (Global)
Replaces Version
30 September 2016 / Version 7.0
(Global) 
(Amendment no. 6)
Current 
Clinical 
Trial 
Protocol 
Amendment
27 November 2017 / Amendment no. 7 (Global)
-
 -
This document is the property of Merck KGaA, Darmstadt, Germany, or one of its subsidiaries. 
It is intended for restricted use only and may not – in full or part – be passed on, reproduced, 
published or used without express permission of Merck KGaA, Darmstadt, Germany, or its 
subsidiaries. Copyright© 2017 by Merck KGaA, Darmstadt, Germany, or its subsidiaries. All 
rights reserved.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
PPD
PPD
PPD


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
3/154
Previous Protocol Amendments
Protocol amendments included in this protocol:
!
Amendment no. 1 (Substantial); 
15 April 2014 (Global)
!
Amendment no. 2 (Substantial); 
05 February 2015 (Global)
!
Amendment no. 3 (Substantial); 
15 June 2015 (Global)
!
Amendment no. 4 (Substantial); 
15 February 2016 (Global)
!
Amendment no. 5 (Substantial); 
08 April 2016 (Global; not distributed in Asia to 
study 
sites, ethic committees and health 
authorities, but submitted to FDA for input on 
regulatory requirements 
of 
assay 
for 
patient 
selection)
!
Amendment no. 6 (Substantial); 
30 September 2016 (Global)
!
Amendment no. 7 (Substantial);
27 November 2017 (Global).
'RFXPHQW1R

2EMHFW1R

CCI
CCI


PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
CCI
CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
5/154
Further Sponsor Responsible Persons
Biostatistician
Name, academic 
degree
Function
Institution
Merck KGaA
Address
Frankfurter Strasse 250, 64293 Darmstadt, Germany
Telephone number
E-mail address
Clinical Trial Leader
Name, academic 
degree
Function
Institution
Merck KGaA
Address
Frankfurter Strasse. 250, 64293 Darmstadt, Germany
Telephone number
Fax number
E-mail address
'RFXPHQW1R

2EMHFW1R

CCI
CCI
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
6/154
Principal Investigator Signature
Trial Title
A Phase Ib/II Multicenter, Randomized, Open 
Label Trial to Compare Tepotinib (MSC2156119J)
Combined with Gefitinib Versus Chemotherapy as 
Second-line Treatment in Subjects with MET 
Positive, Locally Advanced or Metastatic Non-
small Cell Lung Cancer (NSCLC) Harboring EGFR 
Mutation and Having Acquired Resistance to Prior 
EGFR-Tyrosine Kinase Inhibitor (EGFR-TKI) 
Therapy
Clinical Trial Protocol 
Version/Date
27 November 2017 / Version 8.0
IND Number
EudraCT Number
2016-001604-28
Center Number
Principal Investigator
I, the undersigned, am responsible for the conduct of the trial at this site and affirm that:
I understand and will conduct the trial according to the clinical trial protocol, any approved 
protocol amendments, ICH Good Clinical Practice (ICH Topic E6 GCP) and all applicable 
Health Authority requirements and national laws.
I will not deviate from the clinical trial protocol without prior written permission from the 
Sponsor and prior review and written approval from the Institutional Review Board or 
Independent Ethics Committee, except where necessary to prevent immediate danger to 
the subject.
I understand that some regulatory Health Authorities require the Sponsors of clinical trials to 
obtain and supply, when required, details about the Investigators’ ownership interests in the 
Sponsor or Investigational Product and information regarding any financial ties with the 
Sponsor. The Sponsor will use any such information that is collected solely for the purpose of 
complying with the regulatory requirements. I therefore agree to supply the Sponsor with any 
necessary information regarding ownership interest and financial ties (including those of my 
spouse and dependent children), and to provide updates as necessary.
_____________________________________
____________________________
Signature
Date of Signature
Name, academic qualifications
Position (job title)
Address of Institution
Telephone number
Fax number
E-mail address
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
7/154
Table of Contents
Signature Page
..............................................................................................................4
Table of Contents
..............................................................................................................7
Table of Tables
............................................................................................................10
Table of Figures
............................................................................................................11
List of Abbreviations .........................................................................................................12
1
Synopsis..............................................................................................16
2
Sponsor, Investigators and Trial Administrative Structure ................28
3
Background Information.....................................................................29
3.1
Tepotinib-Summary of Nonclinical and Clinical Studies...................29
3.1.1
Nonclinical Evaluation .......................................................................29
3.1.2
Clinical Experience.............................................................................30
3.2
Rationale for the Study Design...........................................................32
3.3
Risk Benefit Assessment ....................................................................32
4
Trial Objectives ..................................................................................33
4.1
Primary Objectives .............................................................................33
4.2
Secondary Objectives .........................................................................34
4.3
Exploratory Objectives .......................................................................34
5
Investigational Plan ............................................................................35
5.1
Overall Trial Design and Plan ............................................................35
5.2
Discussion of Trial Design .................................................................40
5.2.1
Inclusion of Special Populations ........................................................42
5.3
Selection of Trial Population..............................................................42
5.3.1
Inclusion Criteria ................................................................................42
5.3.2
Exclusion Criteria...............................................................................44
5.4
Criteria for Subject Withdrawal..........................................................46
5.4.1
Withdrawal from the Trial..................................................................46
5.4.2
Withdrawal from Trial Therapy..........................................................47
5.5
Premature Discontinuation of the Trial ..............................................48
5.6
Replacement of Discontinued Subjects ..............................................48
5.7
Definition of End of Trial...................................................................49
6
Investigational Medicinal Product(s) and Other Drugs Used in 
the Trial...............................................................................................49
6.1
Description of Investigational Medicinal Product(s)..........................49
6.2
Dosage and Administration ................................................................50
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
8/154
6.2.1
Dose escalation Assessment Process (Phase Ib).................................51
6.2.2
Safety Monitoring Committee............................................................53
6.2.3
Definition of DLT...............................................................................53
6.2.4
Missed Doses and Dose Adjustment ..................................................55
6.2.5
Intrasubject Dose Escalation...............................................................57
6.3
Assignment to Dose Level (Phase Ib) or Phase II..............................57
6.4
Other Drugs to be used in the Trial ....................................................57
6.4.1
Comedications for Phase II.................................................................58
6.4.2
Pemetrexed .........................................................................................59
6.4.3
Cisplatin..............................................................................................60
6.4.4
Carboplatin .........................................................................................60
6.5
Concomitant Medications and Therapies ...........................................61
6.5.1
Permitted Medicines...........................................................................61
6.5.2
Non-permitted Medicines and Procedures..........................................61
6.6
Packaging and Labeling......................................................................62
6.7
Preparation, Handling and Storage.....................................................63
6.8
Investigational Medicinal Product Accountability.............................63
6.9
Assessment of Investigational Medicinal Products Compliance........64
6.10
Method of Blinding.............................................................................64
6.11
Emergency Unblinding.......................................................................64
6.12
Treatment of Overdose .......................................................................64
6.13
Medical Care of Subjects after End of Trial.......................................65
7
Trial Procedures and Assessments......................................................65
7.1
Schedule of Assessments....................................................................65
7.1.1
Informed Consent ...............................................................................65
7.1.2
Screening Period.................................................................................65
7.1.3
Treatment Period ................................................................................66
7.1.4
Post-treatment Follow-up Visit...........................................................72
7.1.5
Survival Follow-up (Phase II Only) ...................................................74
7.2
Demographic and Other Baseline Characteristics ..............................74
7.3
Assessment of Efficacy.......................................................................74
7.4
Assessment of Safety..........................................................................76
7.4.1
Adverse Events ...................................................................................76
7.4.2
Pregnancy and In Utero Drug Exposure.............................................81
7.4.3
Laboratory Assessments .....................................................................82
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
9/154
7.4.4
Vital Signs, Physical Examinations, and Other Assessments.............85
7.5
Pharmacokinetics................................................................................85
7.5.1
Body Fluids.........................................................................................86
7.5.2
Pharmacokinetic Calculations ............................................................86
7.6
Biopsies, Biomarkers, and Pharmacogenomics..................................87
7.6.1
Tumor Biopsies...................................................................................88
7.6.2
Tumor Tissue Biomarkers ..................................................................89
7.6.3
Blood Biomarkers...............................................................................89
7.6.4
Exploratory Pharmacogenomic Gene Analysis in Blood...................90
7.7
Health Related Quality of Life Assessments......................................90
7.7.1
Lung Cancer Symptom Scale .............................................................90
7.7.2
EORTC QLQ-C30..............................................................................91
8
Statistics..............................................................................................92
8.1
Sample Size ........................................................................................92
8.2
Randomization....................................................................................92
8.3
Endpoints............................................................................................93
8.3.1
Primary Endpoints ..............................................................................93
8.3.2
Secondary Endpoints ..........................................................................93
8.3.3
Exploratory Endpoints........................................................................94
8.4
Analysis Sets.......................................................................................95
8.5
Description of Statistical Analyses.....................................................96
8.5.1
General Considerations.......................................................................96
8.5.2
Analysis of Primary Endpoints...........................................................98
8.5.3
Analysis of Secondary Endpoints.......................................................99
8.5.4
Analysis of Safety.............................................................................103
8.5.5
Analysis of Quality of Life...............................................................103
8.5.6
Analyses of Further Endpoints .........................................................106
8.6
Interim Analysis and Data Monitoring Committee ..........................106
9
Ethical and Regulatory Aspects........................................................107
9.1
Responsibilities of the Investigator ..................................................107
9.2
Subject Information and Informed Consent .....................................107
9.3
Subject Identification and Privacy....................................................108
9.4
Emergency Medical Support and Subject Card................................109
9.5
Clinical Trial Insurance and Compensation to Subjects...................109
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
10/154
9.6
Independent Ethics Committee or Institutional Review Board........110
9.7
Health Authorities.............................................................................110
10
Trial Management.............................................................................111
10.1
Case Report Form Handling.............................................................111
10.2
Source Data and Subject Files..........................................................111
10.3
Investigator Site File and Archiving.................................................112
10.4
Monitoring, Quality Assurance and Inspection by Health 
Authorities ........................................................................................112
10.5
Changes to the Clinical Trial Protocol..............................................113
10.6
Clinical Trial Report and Publication Policy....................................113
10.6.1
Clinical Trial Report.........................................................................113
10.6.2
Publication........................................................................................113
11
References.........................................................................................113
12
Appendices .......................................................................................116
Appendix A
Schedule of Assessments in Phase Ib ...............................................117
Appendix B
Schedule of Assessments in Phase II................................................120
Appendix C
Response Evaluation Criteria in Solid Tumors (RECIST) 
Version 1.1........................................................................................124
Appendix D
Eastern Cooperative Oncology Group Performance Status 
(ECOG PS) .......................................................................................134
Appendix E
New York Heart Association (NYHA) Criteria ...............................135
Appendix F
Blood Sampling Schedule for PK/Pd ...............................................136
Appendix G
Blood Samples Volumes...................................................................137
Appendix H
Scoring System for MET Immunohistochemistry............................138
Appendix I
Gefitinib AE Management Guidelines .............................................139
Appendix J
Dose Modification for Gefitinib.......................................................142
Appendix K
Lung Cancer Symptom Scale (LCSS): Subject Scale ......................144
Appendix L
EORTC QLQ-C30 (Version 3.0)......................................................146
Appendix N
Contraceptive Guidance and Women of Childbearing Potential......153
Table of Tables
Table 7.1
Hematology and Coagulation Parameters ..........................................83
Table 7.2
Biochemistry Parameters....................................................................84
Table 7.3
Urinalysis Parameters .........................................................................84
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
11/154
Table of Figures
Figure 5.1
Phase Ib Design (“3+3” Dose Escalation Cohorts) ............................36
Figure 5.2
Trial Design for Phase II.....................................................................38
Figure 5.3
Treatment Duration in Phase II...........................................................39
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
12/154
List of Abbreviations
Abbreviation
Definition
ADME
Absorption, Distribution, Metabolism, and Elimination
AE
Adverse Event
AESI
Adverse Events of Special Interest
ALT
Alanine Aminotransferase
aPTT
Activated Partial Thromboplastin Time
ASBI
Average Symptomatic Burden Index
AST
Aspartate Aminotransferase
AUC0-∞
Area under the Curve from Time Zero to Infinity
AUC0-t
Area under the Curve from Time Zero to Time T
AUC0-tau
Area under the Curve Within 1 Dosing Interval
AUCextra
Area under the Curve Excreted
BCRP
Breast Cancer Resistance Protein
BUN
Blood Urea Nitrogen
BSA
Body Surface Area
Cavg
Average Plasma Concentration
CFDA
Chinese Food and Drug Administration
CHF
Congestive Heart Failure
CI
Confidence Interval
CL/F
Apparent Body Clearance of the Drug from Plasma
Clast
Calculated Plasma Concentration at the Last Sampling Time Point 
Cmax
Maximum Concentration 
c-Met
Mesenchymal-Epithelial Transition Factor Gene
Cmin
Minimum Concentration 
CNS
Central Nervous System
CR
Complete Response
CRO
Contract Research Organization
CT
Computed Tomography
CTCAE
Common Terminology Criteria for Adverse Events
CV
Coefficient of Variation (%)
CrCl
Creatinine Clearance
DBP
Diastolic Blood Pressure
DLT
Dose-Limiting Toxicity
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
13/154
Abbreviation
Definition
DNA
Deoxyribonucleic Acid
ECG 
Electrocardiogram
ECOG 
Eastern Cooperative Oncology Group
eCRF
Electronic Case Report Form
EGFR 
Epidermal Growth Factor Receptor
EGFRm+
EGFR-TKI Sensitizing Mutation
EGFR-TKI
EGFR-Tyrosine Kinase Inhibitors
EORTC QLQ-C30
European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire Core 30
FDG-PET
Fluorodeoxyglucose Positron Emission Tomography
FFPE
Formalin-Fixed Paraffin-Embedded 
FIM
First-In-Man
GCN
c-Met Gene Copy Number
GCP
Good Clinical Practice
GGT
Gamma-Glutamyl Transpeptidase 
GMP
Good Manufacturing Practice
HGF
Hepatocyte Growth Factor
HRQoL
Health-Related Quality of Life
IB
Investigator’s Brochure
ICF
Informed Consent Form
ICH
International Council for Harmonization
IDMC 
Independent Data Monitoring Committee
IEC
Independent Ethics Committee
IHC
Immunohistochemistry
IMP
Investigational Medicinal Product
INR
International Normalized Ratio
IRB
Institutional Review Board
IRC
Independent Review Committee
ISH
In Situ Hybridization
ITT
Intent-to-Treat
IVRS
Interactive Voice Response System
LCSS
Lung Cancer Symptom Scale
LLQ
Lower Level of Quantification
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
14/154
Abbreviation
Definition
LVEF
Left Ventricular Ejection Fraction
MedDRA
Medical Dictionary for Regulatory Activities
MET+
MET Diagnostic-positive (status)
MFI
Mean Fluorescence Intensity
MRI
Magnetic Resonance Imaging
MTD
Maximum Tolerated Dose
NCI
National Cancer Institute
NSCLC 
Non-Small Cell Lung Cancer
NYHA
New York Heart Association
OCT
Organic Cation Transporter
OR
Objective Response
OS
Overall Survival
PD
Progressive Disease
Pd
Pharmacodynamics
PET
Positron Emission Tomography
PFS 
Progression Free Survival
Pgp
P-glycoprotein
PK
Pharmacokinetics
PR
Partial Response
PRO
Patient-Reported Outcome
PS
Performance Status
PT
Prothrombin Time
QD
Once Daily
QoL
Quality of Life
RBC
Red Blood Cells
RECIST
Response Evaluation Criteria in Solid Tumors
RP2D 
Recommended Phase II Dose
SAE
Serious Adverse Event
SAP
Statistical Analysis Plan
SBP
Systolic Blood Pressure
SD
Stable Disease
SMC
Safety Monitoring Committee
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
15/154
Abbreviation
Definition
SmPC
Summary of Product Characteristics
SOC
System Organ Class
StD 
Standard Deviation
SUSAR
Suspected Unexpected Serious Adverse Reaction
t1/2
Apparent Terminal Half-Life
TEAE
Treatment-Emergent Adverse Event
TKI
Tyrosine Kinase Inhibitor
tmax
Time to Maximum Concentration
TTSP
Time-to-Symptom Progression
ULN
Upper Limit of Normal
VAS
Visual Analogue Scale
V/F
Volume of Distribution 
Vss/F
Volume of Distribution at Steady State
Vz/F
Apparent Volume of Distribution Associated to the Terminal Phase
WBC
White Blood Cells
λz
Apparent Terminal Rate Constant
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
16/154
1
Synopsis
Trial title
A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare 
Tepotinib (MSC2156119J)
Combined with Gefitinib Versus 
Chemotherapy as Second-line Treatment in Subjects with MET 
Positive, Locally Advanced or Metastatic Non-small Cell Lung 
Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired 
Resistance to Prior EGFR-Tyrosine Kinase Inhibitor (EGFR-TKI) 
Therapy
Short Title: Tepotinib (MSC2156119J) with Gefitinib in Subjects with
Locally Advanced or Metastatic NSCLC (INSIGHT)
Trial number
EMR200095-006
Sponsor
For all countries except USA and Japan:
Merck KGaA
Frankfurter Strasse 250
64293 Darmstadt, Germany
For sites in the USA:
EMD Serono Research & Development Institute, Inc.
45A Middlesex Turnpike
Billerica, MA 01821-3936, USA
For sites in Japan:
Merck Serono Co., Ltd
Arco Tower. 1-8-1 Shimomeguro 
Meguro-ku. Tokyo 153-8926. Japan
Phase
Ib/II
IND Number
EudraCT Number
2016-001604-28
Trial 
center(s)/country(ies)
Phase Ib: Selected sites in mainland China, South Korea, Taiwan, and 
other Asian countries
Phase II: 51 sites worldwide
Planned trial period
(first enrollment-last 
subject out)
December 2013 to June 2018
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
17/154
Trial objectives
Primary Objectives
Phase Ib 
! To determine the recommended Phase II dose (RP2D) of 
tepotinib when used in combination with gefitinib (at the 
approved standard dose of 250 mg) when administered orally 
once daily (QD) over a 21-day cycle in subjects with MET 
diagnostic-positive status (MET+) advanced NSCLC.
Phase II
! To evaluate whether the efficacy in terms of progression free 
survival (PFS) of second-line tepotinib in combination with 
gefitinib is superior to pemetrexed+cisplatin/carboplatin in 
subjects with T790M negative, MET+ locally advanced or 
metastatic NSCLC harboring an epidermal growth factor receptor 
(EGFR) mutation and having acquired resistance to first-line
EGFR-TKI therapy including gefitinib, erlotinib, icotinib or 
afatinib. 
Secondary objectives
Phase Ib
! To characterize the pharmacokinetics (PK) of tepotinib when 
given in combination with gefitinib; 
! To characterize the PK of gefitinib when given in combination 
with tepotinib;
! To assess the safety and tolerability of tepotinib in combination 
with gefitinib; 
! To evaluate preliminary antitumor activity of tepotinib in 
combination with gefitinib. 
Phase II
! To evaluate the safety and tolerability of tepotinib in combination 
with gefitinib;
! To evaluate the efficacy of tepotinib in combination with 
gefitinib in T790M negative, MET+ subjects;
! To evaluate the antitumor activity of tepotinib in combination 
with gefitinib in T790M positive, MET+ subjects in a separate 
single-arm cohort (mainland China sites only);
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
18/154
! To assess patient-reported outcomes (PROs) with respect to 
quality of life (QoL), as measured by the European Organization 
for Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30 (EORTC QLQ-C30, Version 3.0), and 
time-to-symptom progression (TTSP), as measured by Lung 
Cancer Symptom Scale (LCSS).
Exploratory Objectives
Phase Ib 
! To assess biomarkers that may correlate with antitumor activity, 
including,
but 
not 
limited 
to,
markers 
of
the 
Mesenchymal-Epithelial 
Transition 
Factor 
Gene 
(c-Met)
pathway activation (eg, hepatocyte growth factor [HGF] levels, 
and c-Met mutations), and other relevant oncogenic pathways.
Phase II
! To investigate biomarkers of c-Met pathway activation and other 
relevant oncogenic pathways in serum and tumor tissue and their 
potential correlation with prognosis and the activity of tepotinib
in combination with gefitinib;
Trial design and plan
Phase Ib 
The Phase Ib stage of the study comprises 2 parts, the standard “3+3” 
dose escalation cohorts, and an additional cohort for subjects from the 
mainland China sites. 
This Phase Ib part that contains the “3+3” dose escalation cohorts is a 
multicenter, open label, dose escalation phase. A standard “3+3” dose 
escalation design with a dose escalation and a dose confirmation phase 
will be used. The criteria for dose escalation and de-escalation rules 
are based on the occurrence of dose-limiting toxicities (DLTs) during 
Cycle 1. Other clinically relevant safety issues, as well as emerging 
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
19/154
PK data, should also be considered as necessary when making dosing 
decisions. A Safety Monitoring Committee (SMC) will perform 
periodic safety review and will be responsible for making the decision 
to escalate (or de-escalate) the dose level after all subjects in the 
preceding cohort have completed the first cycle of treatment and 
subject data during this cycle have been evaluated.
The anticipated dose cohorts of tepotinib are 300 and 500 mg QD. 
Gefitinib will be coadministered at standard dose (250 mg QD).
Rich PK sampling will be performed in Phase Ib to characterize the 
PK of tepotinib and gefitinib.
In addition, and separate from the “3+3” trial cohorts, up to 3
evaluable subjects will be enrolled in a separate cohort at one dose 
level below the RP2D at selected sites in mainland China.
Phase II 
The Phase II stage of the study also comprises two parts, randomized
part and non-randomized part. 
The randomized part is a multicenter, open label, active-control part 
to evaluate the efficacy and safety of tepotinib+gefitinib compared to 
that of pemetrexed+cisplatin/carboplatin in T790M negative, MET+ 
subjects. This part will be conducted once the RP2D for 
tepotinib+gefitinib has been defined in Phase Ib. A total of 
approximately 156 eligible subjects were planned to be enrolled. From 
study start to approval of Protocol Version 7.0, subjects were 
randomized at a 1:1 ratio
to either the experimental arm 
(tepotinib+gefitinib) or the control arm (pemetrexed+cisplatin). From 
the approval of Protocol Version 7.0 onwards, subjects were
randomized at a 2:1 ratio
to either the experimental arm 
(tepotinib+gefitinib) 
or 
the 
control 
arm 
(pemetrexed+cisplatin/carboplatin).
The 
Sponsor
subsequently 
decided to halt enrollment. The sites were notified about the 
enrollment halt on 25 May 2017. The last subject was randomized on 
12 June 2017. Until then 55 subjects had been randomized.
The Sponsor’s decision to halt further enrollment is due to the 
difficulties experienced in identifying subjects who meet the 
eligibility criteria of the trial. In spite of increased efforts, the 
enrollment rate did not improve to an extent that would allow for 
completion of the trial in a reasonable time frame. The decision is not 
based on any safety concerns. Accordingly, the benefit-risk ratio for 
all subjects continuing the trial remains unchanged.
The primary endpoint, PFS in the randomized part, and the secondary 
efficacy endpoints based on tumor response, will be assessed by 
Investigator/site radiologist using the Response Evaluation Criteria in 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
20/154
Solid Tumors (RECIST), Version 1.1. In addition, an Independent 
Review Committee (IRC) will evaluate tumor response independently
for both parts (ie, randomized and non-randomized). 
In addition to and separate from the randomized part of the trial in 
T790M negative and MET+ subjects, the safety and efficacy of 
tepotinib+gefitinib
will be evaluated in a single-arm cohort 
(non-randomized part) of up to 15 subjects with MET+ T790M 
positive NSCLC (mainland China sites only). For this single-arm 
cohort, the Sponsor may conduct administrative interim analyses at 
time points that are not specified in the protocol for internal planning 
purposes. By the time of the enrollment halt, all 15 subjects with 
MET+ T790M positive NSCLC had been enrolled.
For both parts (ie, randomized and non-randomized), an Independent
Data Monitoring Committee (IDMC) will monitor the efficacy and 
safety data. 
 
 
 
Planned number of 
subjects
Phase Ib: Approximately 15 to 18 subjects following a “3+3” dose 
escalation design, and an additional up to 3 evaluable subjects from 
the mainland China sites.
Phase II:
! Approximately 156 subjects were planned to be enrolled in the 
randomized part with T790M negative and MET+ status. The 
Sponsor subsequently decided to halt enrollment. The sites were 
notified about the enrollment halt on 25 May 2017. The last 
subject was randomized on 12 June 2017. Until then 55 subjects 
had been randomized.
! Up to 15 subjects in the single-arm cohort with T790M positive
and MET+ status (mainland China sites only). By the time of the 
enrollment halt, all 15 subjects with MET+ T790M positive 
NSCLC had been enrolled.
Schedule of visits and 
assessments
Subjects will be screened for up to 28 days prior to study treatment. 
Informed consent will be obtained prior to performing any trial 
assessment.
In Phase Ib, subjects will receive tepotinib in combination with 
gefitinib 
QD
until 
progressive 
disease 
(PD)/intolerable 
toxicities/withdrawal from treatment. 
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
21/154
In the randomized part of Phase II from study start to approval of 
Protocol Version 7.0, subjects were randomized at a 1:1 ratio stratified 
by type of MET+ and prior EGFR-TKI treatment to receive either 
tepotinib+gefitinib QD or pemetrexed+cisplatin. From the approval of 
Protocol Version 7.0 onwards, subjects were randomized at a 2:1 ratio 
to either the tepotinib+gefitinib or pemetrexed+cisplatin/carboplatin
using the same stratification factors as described above. Treatment 
will be discontinued for PD, intolerable toxicity, or withdrawal from 
the treatment. In addition, for subjects in the control arm not receiving 
pemetrexed continuation maintenance, the maximal number of 
pemetrexed+cisplatin/carboplatin is 6 cycles.
In the single-arm cohort
of Phase II, subjects will receive
tepotinib+gefitinib QD. Treatment will be discontinued for PD, 
intolerable toxicity, or withdrawal from the treatment.
In individual cases, treatment beyond progression may be considered 
for subjects on tepotinib+gefitinib. Cases that may be considered for 
treatment 
beyond 
progression 
include 
subjects 
with 
slow 
(“smoldering”) progression after an initial partial response 
(PR)/complete response (CR), provided there are no clinical 
symptoms and no new lesions. If, in selected subjects, the Investigator
wants to continue the treatment beyond progression although new 
lesion(s) have been documented, this must be discussed and agreed 
with the Sponsor, and documented in the appropriate designated 
electronic case report form (eCRF) section. The Investigator has to 
ensure that all safety data are collected, as per protocol, in the same 
manner as before progression, with the exception of the QoL 
questionnaires, which shall not be collected for this subject group. 
RECIST 
Version 1.1 
radiographical 
assessment 
will 
follow 
institutional practice guidelines, however, tumor assessment 
information will not be recorded in the eCRF and there will be no 
further documentation collected for any new lesion and/or clinical 
symptoms of PD after first PD.
Discontinuation of treatment beyond PD is at the discretion of the 
treating physician. If the subject develops new lesions or clinical 
symptoms, the benefit of continuing treatment with the study drugs 
should be discussed with the Sponsor. Please refer to Section 5.4.2. 
For analysis of the primary endpoint, only the first progression event 
is used.
Subjects who stop all trial treatments will have an End-of-Treatment 
visit within 14 days of the last dose, the completion of treatment cycle, 
or the day when it is determined to permanently discontinue the study 
treatment. A Safety Follow-up visit will occur at 30 ± 3 days after the 
last dose for safety monitoring. If a subject withdraws from the 
treatment for reasons other than PD, additional follow-up visits for 
tumor assessments will be performed until disease progression, or the 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
22/154
end of the trial, whichever comes first. In Phase II, there will also be 
survival follow-up assessments to collect subjects’ survival 
information every 3 months ± 2 weeks until death or the end of the 
trial, whichever comes first.
Following the enrollment halt, subjects were offered the option to 
continue the trial following the current protocol after discussion with 
their Investigator. Subjects in prescreening/screening and who were 
eligible had been offered to be enrolled in the trial. Subjects who 
decided to continue treatment continued on their originally allocated 
treatment, at their most recent dose according to the protocol. Safety 
monitoring and data collection will continue without modification 
through to the end of the trial.
Diagnosis and main 
inclusion and 
exclusion criteria
Note: only main inclusion and exclusion criteria are listed below; for 
a full list of criteria, refer to the protocol Section 5.3.1 and 
Section 5.3.2. 
Main Inclusion Criteria
Phase Ib
a)
Histologically or cytologically confirmed advanced NSCLC, 
regardless of histology subtype, which failed on gefitinib for 
reasons other than toxicity or compliance;
b)
Availability of a fresh or archived pretreatment tumor biopsy 
(excluding fine needle aspiration and cytology samples). For 
subjects who have had at least 1 prior anticancer treatment, a 
biopsy obtained between failure of the most recent anticancer 
treatment and enrollment is mandatory;
c)
MET+ status, as determined by the central laboratory, ie, c-Met 
overexpression as determined by immunohistochemistry (IHC)
(ie, IHC 2+ or IHC 3+);
d)
Eastern Cooperative Oncology Group (ECOG) performance 
status (PS) of 0 or 1.
Phase II 
a)
Locally 
advanced 
or 
metastatic
NSCLC 
other 
than 
predominantly squamous histology
(confirmed by either 
histology or cytology);
b)
Activating mutation of the EGFR receptor (documented, or as 
determined by the central laboratory);
c)
Acquired resistance on first-line EGFR-TKI therapy including 
gefitinib, erlotinib, icotinib, or afatinib;
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
23/154
d)
EGFR T790M status (as determined by the central laboratory, 
using a validated PCR test);
!
T790M negative status for the randomized part
!
T790M positive
status for the single-arm cohort
(mainland China sites only)
e)
Availability of a fresh or archived tumor tissue (excluding fine 
needle aspiration and cytology samples) obtained between 
documentation of acquired resistance to EGFR-TKI therapy 
including gefitinib, erlotinib, icotinib, or afatinib and enrollment 
is mandatory;
f)
MET+ status, as determined by the central laboratory, ie, c-Met 
overexpression as determined by IHC (ie, IHC 2+ or IHC 3+) 
and/or c-Met amplification and/or increased c-Met gene copy 
number (GCN), both determined by ISH;
g)
ECOG PS of 0 or 1.
Exclusion Criteria (Phase Ib and Phase II)
a)
Estimated life expectancy < 3 months;
b)
Inadequate bone marrow, liver or renal functions;
c)
Prior chemotherapy, biological therapy, radiation therapy, or 
other investigational anticancer therapy (not including palliative 
radiotherapy at focal sites) within 21 days prior to the first dose 
of trial treatment (Phase Ib only);
d)
Prior systemic anticancer treatment with chemotherapy or other 
agents targeting the
EGFR pathway excluding gefitinib, 
erlotinib, icotinib, and afatinib for advanced NSCLC (one course 
of chemotherapy regimen for [neo]adjuvant purpose, or one 
course of chemoradiation for Stage IIIa disease is allowed)
(Phase II only).
Investigational 
Medicinal Product(s): 
dose/mode of 
administration/ 
dosing schedule
Phase Ib: For “3+3” dose escalation cohorts, tepotinib will be 
administered orally at 300 or 500 mg (or potentially, at a lower dose 
level, depending on the decision of the SMC) QD, in combination with 
gefitinib at 250 mg.
For the additional up to 3 evaluable subjects from the mainland China 
sites, tepotinib will be administered orally one dose level below the 
RP2D QD, in combination with gefitinib at 250 mg. 
Phase II: Tepotinib will be administered orally at the RP2D QD, in 
combination with gefitinib at 250 mg.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
24/154
Reference 
therapy(ies): 
dose/mode of 
administration/dosing 
schedule
Subjects in Phase II in the control arm of the randomized part will be 
treated on Day 1 of each 21-day cycle. The subjects will receive 
pemetrexed at 500 mg/m2, administered as an intravenous infusion 
over 10 minutes.
The Investigator is free to choose either pemetrexed+cisplatin or 
pemetrexed+carboplatin for the individual subject. Cisplatin will be 
administered at 75 mg/m2, typically as an intravenous infusion over 2
hours,
beginning approximately 30 minutes after the end of 
pemetrexed administration. At the Investigator’s discretion, 
carboplatin will be administered at either AUC5 or AUC6 as an 
intravenous infusion over 1 hour, beginning about 30 minutes after the 
end of pemetrexed administration.
These 
are 
common 
administration 
protocols. 
For 
further 
administration details, Investigators are requested to check / take into 
account current medical and local administration guidelines /
treatment protocols as well as respective SmPCs and to discuss 
upfront with the Sponsor the treatment regimens they wish to select. 
Planned treatment 
duration per subject
Phase Ib and Phase II: In both phases, subjects may continue to 
receive tepotinib+gefitinib QD until PD, intolerable toxicity, or 
withdrawal from treatment.
In individual cases, treatment beyond progression may be considered 
for subjects on tepotinib+gefitinib. Discontinuation of treatment 
beyond PD is at the discretion of the treating physician. If the subject 
develops new lesions or clinical symptoms, the benefit of continuing 
treatment with the study drugs should be discussed with the Sponsor.
Phase II: In the control arm, pemetrexed+cisplatin/carboplatin will be 
administered on Day 1 of each cycle for:
!
Either up to 6 cycles, or 
!
4 cycles of pemetrexed+cisplatin/carboplatin followed by 
pemetrexed maintenance.
Primary endpoints
The primary endpoints for each part of the trial are as follows:
Phase Ib: 
! Incidence of subjects experiencing at least 1 DLT in Cycle 1. (ie,
21 days after the first dose of trial medication);
! Incidence and type of other adverse events (AEs).
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
25/154
Phase II:
! PFS in the randomized part, assessed by Investigator/site 
radiologist according to RECIST Version 1.1. 
PFS time is defined as the time, in months, from randomization 
to either the first observation of documented PD per RECIST 
Version 1.1 or occurrence of death due to any cause within 
84 days of either randomization or the last tumor assessment.
Secondary 
endpoint(s)
The secondary endpoints of the trial are as follows.
Secondary endpoints related to safety:
! Drug exposure;
! Incidence and type of Treatment-Emergent Adverse Events 
(TEAEs), toxicity grades as per National Cancer Institute 
Common 
Terminology 
Criteria 
for 
Adverse 
Events 
(NCI-CTCAE, Version 4.0); treatment-related TEAEs, serious 
AEs (SAEs), treatment-related SAEs, TEAEs with toxicity 
Grade ≥ 3, treatment-related TEAEs ≥3, and TEAEs leading to 
permanent treatment discontinuation;
! Incidence and reasons for deaths within 30 (±3) days after the last 
dose of study drug;
! Safety laboratory tests graded by NCI-CTCAE (Version 4.0);
! Vital signs, 12-lead electrocardiogram (ECG) changes, physical 
examination, including change in body weight, and ECOG PS.
Other secondary endpoints include:
! PFS assessed by IRC in the randomized part of Phase II;
! PFS assessed by Investigator and IRC in the single-arm cohort of 
Phase II;
In the single-arm cohort, PFS time is defined as the time, in 
months, from the first administration of the trial treatment to 
either the first observation of documented PD per RECIST 
Version 1.1 or occurrence of death due to any cause within 
84 days of either the first administration of the trial treatment or 
the last tumor assessment.
! Overall survival (OS) time, defined as the time, in months, from 
randomization/the first administration of the trial treatment to the 
date of death in randomized part of Phase II/single-arm cohort of 
Phase II;
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
26/154
! Tumor response as measured by objective response (OR) and 
disease control based on RECIST Version 1.1;
! PK (Phase Ib only): AUC0-t, AUC0-tau, Cmax, Cavg, Cmin, tmax, 
AUC0-∞, CL/F, Vz/F, Vss/F, λz and t1/2 (when appropriate); 
! Health-related quality of life (HRQoL) endpoints (Phase II only)
will be assessed using the EORTC QLQ-C30 (Version 3.0), and 
LCSS questionnaires.
Exploratory 
endpoints
! Exploratory biomarkers include biomarkers that may correlate 
with antitumor activity, including, but not limited to, markers of 
c-Met pathway activation (eg, HGF levels, and c-Met mutations), 
other relevant oncogenic pathways.
Statistical methods 
(includes sample size 
calculation)
Sample Size Calculation:
In Phase Ib, the total number of subjects planned in the “3+3” dose 
escalation cohorts is approximately 15 to 18, on the basis of the “3+3” 
dose escalation method with 2 dose cohorts: 3 or 6 in the dose 
escalation cohort and a potential for 3 or 12 subjects in the dose 
confirmation cohort (if dose de-escalation does not occur). The final 
sample size depends on the number of subjects who experience DLTs
at each dose level, emerging safety and available PK data, and the 
decision from the SMC meeting.
In addition, separately from the “3+3” dose escalation cohorts, up to 
3 evaluable subjects will be enrolled in the mainland China sites.
In the randomized Phase II part, the initial sample size planning 
required 111 PFS events (assessed by Investigator) to ensure 80% 
power with a two-sided significance level of 10% for rejecting the null 
hypothesis of equal treatment effect between treatment arms, 
assuming a true hazard ratio of 0.6. Assuming a median PFS time of 
5 months in subjects in the control arm, a hazard ratio of 0.6 represents 
a 3.3 months increase, resulting in a median PFS time of 8.3 months 
for the experimental arm. A total of 156 subjects were planned to be 
randomized 
to 
receive 
tepotinib+gefitinib 
or 
pemetrexed+cisplatin/carboplatin. From study start to approval of 
Protocol Version 7.0, subjects were randomized at a 1:1 ratio to 
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
27/154
receive tepotinib+gefitinib or pemetrexed+cisplatin. From the 
approval of Protocol Version 7.0 onwards, subjects were randomized 
at 
a 
2:1 
ratio 
to 
receive 
either 
tepotinib+gefitinib 
or 
pemetrexed+cisplatin/carboplatin. 
The Sponsor subsequently decided to halt enrollment. The sites were 
notified about the enrollment halt on 25 May 2017. The last subject 
was randomized on 12 June 2017. Until then 55 subjects had been 
randomized.
In the single-arm cohort of Phase II with MET+ T790M positive
subjects, up to 15 subjects were planned to be enrolled (mainland 
China sites only). By the time of the enrollment halt, all 15 subjects 
with MET+ T790M positive NSCLC had been enrolled.
Statistical Analyses:
The primary analysis of the Phase II part will be conducted once all 
subjects have either been treated for at least 6 months, died or have 
prematurely discontinued trial treatment for any reason, whichever 
comes first.
For the randomized Phase II part, the primary analyses will test the 
equality of PFS time, as assessed by Investigator, between treatment 
arms, based on the intent-to-treat (ITT) population, applying a 
two-sided stratified log-rank test at a significance level of 10% and 
taking into account for the stratification factors
used for 
randomization, type of MET+ and prior EGFR-TKI.
Through Phase Ib and Phase II, continuous variables will be tabulated 
using the following summary statistics: number of non-missing 
values, mean, standard deviation (StD), median, the 25th and 75th
percentiles, and the minimum and maximum values. Confidence 
intervals (CIs) will be presented where appropriate. Categorical 
variables will be tabulated using frequencies and percentages.
An IDMC will be established for periodic evaluations of the clinical 
trial to ensure continued subject safety as well as the validity and 
scientific merit of the study. More detailed information can be found 
in Section 8.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
28/154
2
Sponsor, Investigators and Trial Administrative Structure
Merck KGaA, Darmstadt, Germany (for all countries except USA and Japan), EMD Serono 
Research & Development Institute, Inc. (for USA), and Merck Serono Co., Ltd (for Japan) will 
be the Sponsor of this clinical trial of mesenchymal-epithelial transition factor gene (c-Met) 
inhibitor, tepotinib. Pemetrexed, cisplatin and carboplatin will be supplied to 51 sites 
worldwide by the respective study center or by the Sponsor, according to local laws and 
regulations. Tepotinib and gefitinib will be provided centrally by the Sponsor. The Sponsor
will perform quality audits.
The Coordinating Investigator 
 
 
, represents all Investigators for decisions and 
discussions regarding this trial, consistent with the International Council for Harmonization 
(ICH) Topic E6 Good Clinical Practice (GCP; hereafter referred to as ICH GCP). The 
Coordinating Investigator will provide expert medical input and advice relating to trial design 
and execution and is responsible for the review and signoff of the clinical trial report. 
Signature pages for the Protocol Lead and the Coordinating Investigator as well as a list of 
Sponsor responsible persons are on pages 4 and 5 of this protocol.
The contract research organization (CRO) responsible for the conduct of the trial (including 
trial management, monitoring, biostatistics, and data management) will be 
 
 
will undertake the operational aspects of this trial. Details of any transferred 
trial-related duty and function to 
and associated procedures are defined in writing in 
a Project Addendum.
A Safety Monitoring Committee (SMC) (see Section 6.2.2) will perform periodic reviews to 
evaluate the safety of the subjects who follow “3+3” dose escalation method in Phase Ib. 
Details of the safety monitoring process will be specified in a dedicated SMC charter.
The SMC will not be responsible for safety evaluation of the up to 3 evaluable subjects in the 
additional cohort of subjects from the mainland China sites of Phase Ib. Sponsor experts 
including, but not limited to, medical responsible, safety responsible and pharmacokineticist, 
as well as the coordinating Investigator, will review the safety profile of the up to 3 evaluable 
subjects in the additional cohort. See details in Section 5.1.
An Independent Data Monitoring Committee (IDMC) (see Section 8.6) will perform periodic 
reviews to evaluate the safety of the subjects participating in Phase II. Details of the data 
monitoring process will be specified in a dedicated IDMC charter. The first IDMC review took 
place after dosing of about 25% of the subjects. As the Sponsor decided to halt enrollment no 
further IDMC reviews will take place.
An Independent Review Committee (IRC) will conduct a blinded review of the images of all 
subjects participating in Phase II part using the Response Evaluation Criteria in Solid Tumors
(RECIST) Version 1.1 based on a separate charter outlining details of the review process.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
PPD
PPD
PPD


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
29/154
3
Background Information
Lung cancer remains the leading cause of cancer death world-wide. Approximately 85% of the 
subjects have non-small-cell lung cancer (NSCLC), most of these subjects present with 
advanced stage disease (not amenable to curative intent). Novel targeted therapies that interfere 
with specific molecular signaling pathways have emerged as a new standard option for selected 
subjects with epidermal growth factor receptor (EGFR) mutation, including the oral EGFR-
tyrosine kinase inhibitors (EGFR-TKI) gefitinib, erlotinib, icotinib, and afatinib. EGFR-TKIs 
inhibit the intracellular tyrosine kinase domain of the EGFR and therefore block the signal 
transduction pathways implicated in the proliferation and survival of cancer cells (1).
Among all the mechanisms identified for the development of resistance, the main reason is a 
secondary mutation in the EGFR gene (T790M mutation) and amplification of the c-Met 
proto-oncogene. In about 50% of cases, resistance is due to the occurrence of a secondary 
mutation in EGFR (ie, T790M mutation) (2).
Amplification of c-Met was initially reported to account for up to 20% of tyrosine kinase 
inhibitor (TKI) acquired resistance subjects. In more recent studies, however, c-Met 
amplification 
has 
been 
identified 
in 
only 
5% 
of 
specimens 
(3). 
c-Met 
overexpression/amplification and EGFR T790M mutation are two independent mechanisms of 
acquired drug resistance in NSCLC subjects progressing on EGFR-TKI treatment. The 
likelihood of progressing subjects to respond to tepotinib is, therefore, higher in MET 
diagnostic-positive (MET+) subjects which are negative for T790M. This occurs by a different 
molecular pathway from T790M (4). c-Met protein expression and c-Met gene mutation may,
also, be abnormal in NSCLC, and are associated with poor prognosis (5). 
Therefore, the inhibition of the c-Met pathway has become a potential novel therapeutic 
strategy in NSCLC. 
3.1
Tepotinib-Summary of Nonclinical and Clinical Studies
Tepotinib (MSC2156119J) is a potent, highly selective c-Met inhibitor with a favorable 
pharmacokinetic (PK) profile in humans allowing once daily (QD) dosing. It inhibits growth 
and induces regression of hepatocyte growth factor (HGF)-dependent and HGF-independent 
susceptible tumor models, and is currently under investigation in several trials. Refer to the 
current Investigator’s Brochure (IB) for further information regarding the nonclinical and 
clinical programs and guidance for the Investigator.
3.1.1
Nonclinical Evaluation
Nonclinical 
studies 
indicate 
that 
tepotinib
is 
a 
highly 
selective 
adenosine 
triphosphate-competitive c-Met inhibitor, which effectively inhibits c-Met signaling in tumors. 
Tepotinib exhibited marked inhibitory activity on the growth of mouse tumors and of human 
tumor xenografts and frequently led to complete regression of established tumors. This 
antitumor effect was observed in 2 types of clinically relevant models: 1) tumor cells in which 
c-Met activation was ligand independent, ie, tumors harboring c-Met amplification or 
activating mutation; 2) tumors in which c-Met and HGF were co-expressed, thereby creating 
an autocrine positive feedback loop. 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
30/154
Results of the nonclinical safety pharmacological studies conducted in compliance with the 
ICH Guideline 7A/7B suggest a favorable nonclinical safety profile for tepotinib.
On the basis of presently available results of the animal in vivo and in vitro studies, there are 
no reservations from a toxicological point of view against studying tepotinib in cancer subjects.
3.1.2
Clinical Experience
Until 30 September 2016, five clinical trials were completed:
1.
Three clinical pharmacology trials in 79 healthy volunteers (EMR200095-002, 
EMR200095-007 and MS200095-0012) and
2.
Two Phase I trials in 161 subjects with different advanced solid tumors (EMR200095-001 
and EMR200095-003).
Four trials in subjects with indications hepatocellular carcinoma (EMR200095-004 and 
EMR200095-005) and NSCLC (EMR200095-006 and MS200095-0022) are ongoing.
Healthy volunteers (see 1. above) well tolerated a single or up to 3 single doses of tepotinib at 
different dose levels up to 500 mg. All treatment-emergent adverse events (TEAEs) were mild 
to moderate, except one Grade 3 asymptomatic lipase elevation in 1 subject. Treatment 
emergent adverse events did not show a pattern across the 3 trials. No serious adverse events 
(SAEs) were reported and no subjects died. No clinically significant findings with regard to 
laboratory parameters, vital signs and ECG, including QTcF values were noted. 
In subjects with solid tumors (see 2. above), tepotinib was generally well tolerated at different 
dose levels up to 1400 mg QD. The most frequent (≥15%) TEAEs, irrespective of a 
relationship to tepotinib, were fatigue, decreased appetite, constipation, peripheral edema, 
nausea, vomiting, hypoalbuminemia and abdominal pain. The most frequent (≥5%) TEAEs 
with toxicity Grade ≥3 were fatigue and pulmonary embolism and the most frequently (≥3%) 
reported SAEs were abdominal pain, constipation, nausea and small intestinal obstruction 
ascites. No death was considered to be related to trial treatment. With the exception of 
lipase/amylase elevations, no safety findings with regard to laboratory tests, vital signs and 
ECG were noted. 
First clinical experience from EMR200095-001, EMR200095-003 and the safety run-in Phase 
Ib part of EMR200095-004, EMR200095-005 and EMR200095-006 provided first signs of 
clinical efficacy of tepotinib supporting its further clinical development in hepatocellular 
carcinoma and NSCLC and other potential indications.
A more detailed description of the safety and efficacy of tepotinib from completed and ongoing 
trials is provided in the Investigator’s Brochure.
3.1.2.1
Clinical Experience in Asian Population
In the Japanese Phase I trial EMR200095-003 a total of 12 subjects were enrolled and received 
at least one dose of study drug; 3 subjects each received 215 mg and 300 mg p.o. QD, and 
6 subjects received 500 mg p.o. QD. 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
31/154
No DLT was observed in any of the subjects treated with study medication. 
Treatment-emergent AEs of any grade were reported in 11 (92%) of 12 subjects; 
treatment-related TEAEs were reported in 5 (42%) subjects. The most frequently reported 
TEAEs (≥30% of all subjects or ≥4 subjects) by preferred term were constipation and 
decreased appetite in 6 subjects, each (50%), nausea in 5 (42%) subjects, and fatigue, 
hypoalbuminemia, edema peripheral, and vomiting in 4 (33%) subjects, each. Common 
treatment-related TEAEs were amylase increased, lipase increased, hypoalbuminemia, fatigue 
and dysgeusia in 2 subjects each.
Grade ≥3 TEAEs were reported in total of 7 (58%) subjects. Grade 3 TEAEs were ascites, 
decreased appetite, dyspnea, urinary tract obstruction, and hyponatremia. Grade 4 TEAEs were 
lipase increased, altered state of consciousness and dyspnea. Of these, treatment-related 
Grade ≥3 TEAEs were Grade 4 lipase increased in 2 subjects and Grade 3 hyponatremia in 
1 subject.
Serious AEs were reported in total of 4 (33%) subjects: altered state of consciousness, dyspnea, 
and decreased appetite and malaise. Apart from altered state of consciousness, all SAEs 
reported were recovered/resolved. In addition, 1 subject had serious dyspnea that was ongoing 
at death (25 days after last study treatment) due to progressive disease. All SAEs reported in 
this study were considered unrelated to the treatment by the Investigator.
No subject had TEAEs resulting in permanent treatment discontinuation. Grade 4 lipase 
increased occurred in 2 subjects and was considered treatment-related.  
No notable change was observed in laboratory tests over time except for decrease in mean 
corpuscular hemoglobin (MCH) and mean corpuscular volume (MCV). National Cancer 
Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade 3 or 4 
laboratory parameters were lymphocyte ratio (lower than lower limit of normal range = low), 
alkaline phosphatase (ALP), γ-glutamyl transferase (γ-GTP), glucose (higher than upper limit 
of normal range = high), sodium (low), and triacylglycerol lipase.
No clinically notable abnormalities or abnormal changes were found in vital signs and other 
safety observations.
Currently available data does not indicate an impact on QTc by tepotinib. High variability 
within and between subjects in QTc observed in the First-In-Man (FIM) trial is likely due to 
co-morbidity, comedication and/or electrolyte disturbances in such a subject population with 
advanced cancers. Specific safety measures consisting of frequent electrocardiogram (ECG)
monitoring which, at some time points is paired with PK sampling, are included in the current 
trial.
The assessment of TEAEs, laboratory parameters, and ECG results does not indicate any 
differences in the safety profile for Asian subjects compared with non-Asian subjects. Although 
the conclusions are limited due to the small number of Asian subjects, the use of 500 mg 
tepotinib daily in clinical trials may be justified in Asian subjects.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
32/154
3.2
Rationale for the Study Design
The FIM study identified the safety and tolerability of tepotinib monotherapy and the 
nonclinical studies demonstrated mechanism of dual inhibition of c-Met and EGFR pathways 
after acquired resistance to first-line EGFR-TKI treatment. 
In the randomized Phase II part of the present study, the antitumor activity of tepotinib will be 
evaluated in combination with an EGFR-TKI (gefitinib) and compared to standard 
chemotherapy (pemetrexed+cisplatin/carboplatin). The Phase Ib dose escalation part of the 
study, which precedes Phase II, is considered a safety run-in that will determine the proper 
dose of tepotinib in combination with EGFR-TKI (gefitinib). 
The non-randomized Phase II part will provide exploratory data on the combination of 
tepotinib and gefitinib in MET+ T790M positive tumors (mainland China sites only).
A detailed discussion of the trial design is provided in Section 5.2.
3.3
Risk Benefit Assessment
The risk-benefit relationship has been carefully considered in the planning of the trial. Based 
on the nonclinical and clinical data available to date, the conduct of the trial is considered 
justifiable using the dose(s) and dosage regimen(s) of the IMP as specified in this clinical trial 
protocol. 
In the ongoing and completed trials, tepotinib shows a favorable safety profile. For 
monotherapy, a RP2D of 500 mg QD has been determined. This RP2D is defined as a 
biologically active dose, based on PK/Pd modeling and supported by data on target inhibition 
from paired tumor biopsies, rather than as a safety defined MTD. However, since the RP2D of 
tepotinib administered with an EGFR-TKI as combination therapy has not been determined, a 
safety run-in phase will start dose escalation at 300 mg, thereby allowing for an additional 
safety step before exposing subjects to the full RP2D.
Available evidence suggests that c-Met overexpression/amplification is associated with 
acquired resistance in NSCLC subjects progressing on EGFR-TKI treatment. Analysis of 
progressing tumors revealed they are likely a mixture of EGFR-TKI sensitive clones and 
resistant clones. EGFR-TKI sensitive clones are very susceptible to EGFR-TKI, but rarely 
eradicated, re-administration or continuation of EGFR-TKI can therefore effectively suppress 
the expansion of drug sensitive clones (7). Thus, simultaneous inhibition of both pathways 
holds the promise to overcome this resistance (Section 5.2). Moreover, in a single-arm 
Phase Ib/II trial, the addition of INC280 (a highly selective c-Met inhibitor) to gefitinib showed 
promising clinical activity in MET+ NSCLC subjects resistant to EGFR-TKIs, which supports 
the therapeutic potential of c-Met-targeting agents (8). 
In an effort to further improve benefit-risk ratio of the trial, only subjects with MET+ tumors 
will be enrolled (both in Phase Ib and Phase II), this enable to investigate the efficacy and 
safety of the compound in the most relevant population and turned out further exposure to non-
targeted population.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
33/154
Since gefitinib is not active on the T790M mutation, the likelihood of progressing subjects to 
respond to tepotinib is expected to be higher in MET+ subjects who are negative for T790M 
and this will therefore be the target population for the randomized part of the Phase II trial. 
Doublet chemotherapy consisting of pemetrexed+cisplatin ensures the benefit of subjects 
randomized to the control arm in Phase II as this chemotherapeutic regimen is the most active 
platinum doublet in subjects with NSCLC (9), and magnitude of benefit has been confirmed in 
EGFR-TKI sensitizing mutation (EGFRm+) subjects in another Phase III trial (10). Carboplatin 
has a similar effect on progression free survival but a different toxicity profile when compared 
with cisplatin (11). Although carboplatin showed a tendency for a smaller response compared 
to cisplatin, this difference diminished when both platinum compounds were compared in 
combination treatments. Multiple clinical trials have shown a beneficial role for maintenance 
therapy in select groups. Pemetrexed maintenance will be an option for subjects who have not 
progressed 
after 
the 
completion 
of 
4 
cycles 
of 
chemotherapy 
with 
pemetrexed+cisplatin/carboplatin, in line with the current guideline and clinical practice (12, 
13).
Overall, in the ongoing and completed trials, tepotinib was well tolerated (refer to the current
IB). Asymptomatic elevation of pancreatic enzymes are an important risk associated with the
administration of tepotinib and have been reported for a number of other TKIs with molecular 
targets other than c-Met (eg, sunitinib, imatinib, sorafenib). Potential risks associated with 
study drug application from nonclinical studies are hepatobiliary toxicity and drug-drug 
interaction with P-glycoprotein (Pgp) inducing or inhibiting drugs as well as Breast Cancer 
Resistance Protein (BCRP), OATP1B1, OCT1, OCT2, MATE1 and MATE2 transported 
drugs. 
As long as safety measures described in the protocol are strictly followed, it is reasonable to 
believe that the potential benefit of tepotinib in addition to gefitinib outweighs its risk;
furthermore, there will be an SMC assessing the ongoing safety in Phase Ib and an IDMC 
which continues to regularly monitor safety in Phase II.
The trial shall be discontinued in the event of any new findings that indicate a relevant 
deterioration of the risk-benefit relationship that would render continuation of the trial 
unjustifiable.
This clinical trial will be conducted in compliance with the clinical trial protocol, Good Clinical 
Practice (ICH Topic E6, GCP), the Japanese ministerial ordinance on GCP and any additional
applicable regulatory requirements.
4
Trial Objectives
4.1
Primary Objectives
The primary objectives are: 
Phase Ib 
! To determine the RP2D of tepotinib when used in combination with gefitinib (at the 
approved standard dose of 250 mg) when administered orally QD over a 21-day cycle in 
subjects with MET+ advanced NSCLC. 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
34/154
Phase II
!
To evaluate whether the efficacy in terms of progression free survival (PFS) of 
second-line 
tepotinib
in 
combination 
with 
gefitinib 
is 
superior 
to 
pemetrexed+cisplatin/carboplatin in subjects with T790M negative, MET+ locally 
advanced or metastatic NSCLC harboring an EGFR mutation and having acquired 
resistance to first-line EGFR-TKI therapy including gefitinib, erlotinib, icotinib, or 
afatinib.
4.2
Secondary Objectives
Phase Ib
! To characterize the PK of tepotinib when given in combination with gefitinib; 
! To characterize the PK of gefitinib when given in combination with tepotinib;
! To assess the safety and tolerability of tepotinib in combination with gefitinib; 
! To evaluate preliminary antitumor activity of tepotinib in combination with gefitinib. 
Phase II
! To evaluate the safety and tolerability of tepotinib in combination with gefitinib;
! To evaluate the efficacy of tepotinib in combination with gefitinib in T790M negative, 
MET+ subjects;
! To evaluate the antitumor activity of tepotinib in combination with gefitinib in T790M 
positive, MET+ subjects in a separate single-arm cohort (mainland China sites only);
! To assess patient-reported outcomes (PROs) with respect to quality of life (QoL), as
measured by the European Organization for Research and Treatment of Cancer Quality of 
Life Questionnaire Core 30 (EORTC QLQ-C30, Version 3.0), and time-to-symptom 
progression (TTSP), as measured by Lung Cancer Symptom Scale (LCSS).
4.3
Exploratory Objectives
The exploratory objectives are: 
Phase Ib
! To assess biomarkers that may correlate with antitumor activity, including, but not limited 
to, markers of the c-Met pathway activation (eg, HGF levels, and c-Met mutations), and 
other relevant oncogenic pathways.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
35/154
Phase II
! To investigate biomarkers of c-Met pathway activation and other relevant oncogenic 
pathways in serum and tumor tissue and their potential correlation with prognosis and the 
activity of tepotinib in combination with gefitinib;
5
Investigational Plan
5.1
Overall Trial Design and Plan
Phase Ib 
The Phase Ib stage of the study comprises 2 parts, the standard “3+3” dose escalation cohorts,
and an additional cohort for subjects from the mainland China sites.
“3+3” Dose Escalation Cohorts
The Phase Ib part that contains the “3+3” dose escalation cohorts is a multicenter, open label
part to determine the RP2D of tepotinib in combination with gefitinib in subjects with MET+,
advanced NSCLC.
A standard “3+3” dose escalation design with a dose escalation and a dose confirmation phase 
will be used. In principle, the criteria for dose escalation and de-escalation rules are based on 
the occurrence of DLTs during Cycle 1. However, other clinically relevant safety issues, as 
well as emerging PK data should also be considered as necessary when making dosing 
decisions. A SMC will be responsible for making the decision to escalate (or de-escalate) the 
dose level after all subjects in the preceding cohort have completed the first cycle of treatment 
and all subjects’ data during this cycle have been evaluated.
The first dose level of tepotinib (300 mg QD) has been set to be 1 dose level lower than the 
RP2D from the FIM trial (500 mg QD). Therefore, the anticipated dose cohorts of tepotinib in 
this trial are 300 and 500 mg. Gefitinib will be coadministered at the standard dose (250 mg
QD).
The criteria for decisions concerning dose escalation or de-escalation are discussed in detail in 
Section 6.2.1. Dose escalation beyond the target RP2D of tepotinib will not be pursued unless 
there is reasonable concern that it might not be biologically active and if the safety data do not 
preclude further dose escalation. The SMC (Section 6.2.2) may also elect to evaluate a lower 
dose. Rich PK sampling will be performed to characterize the PK of tepotinib and gefitinib 
when given as combination therapy.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
36/154
Treatment Duration
There will be a screening period of up to 28 days prior to study treatment to assess subjects’ 
eligibility except for MET status. Some subjects may have a prescreening period which extends 
beyond 28 days for the determination of MET status. Eligible subjects will be enrolled into the 
trial and then enter the treatment period. Subjects will receive tepotinib in combination with 
gefitinib QD. Subjects who stop treatment with both components of the combination therapy 
will have an End-of-Treatment visit within 14 days of the last dose, the completion of treatment 
cycle, or the day when it is determined to permanently discontinue the study treatment.
A 30-day Safety Follow-up visit will occur at 30 ± 3 days after the last dose. If a subject 
withdraws from the treatment for reasons other than progressive disease (PD), additional 
follow-up visits for tumor assessments will be performed until progression.
The trial design is presented graphically in Figure 5.1.
Figure 5.1
Phase Ib Design (“3+3” Dose Escalation Cohorts)
MSC2156119J = tepotinib; sts=subjects
Chinese (Mainland) Subject Cohort
Up to 3 evaluable subjects will be enrolled in the mainland China sites separately and will be 
tested at tepotinib one dose level below the RP2D QD. An additional cohort for subjects from 
the mainland China sites is included to meet a request from the Chinese Food and Drug 
Administration (CFDA) following clinical trial amendment review. The aim of this cohort is 
to collect preliminary data of the safety and PK of tepotinib administered in combination with 
gefitinib in subjects from mainland China sites. All subjects in this cohort will be evaluated 
with the same criteria as the other subjects in the dose escalation cohort. Subjects who are not 
fully evaluable will be replaced (Section 5.6). The Sponsor experts (see Section 2) as well as 
the coordinating Investigator will take the responsibility of evaluating safety and available PK 
data at the last subject’s completion of Cycle 1. If any subject experiences an event listed in 
Section 6.2.3, and if this event is classified as related to tepotinib, this may trigger a decision 
of the treating physician and the coordinating Investigator to enroll more subjects, after 
discussing with the Sponsor. The safety data from the additional cohort of subjects from the 
mainland China sites will not be used for DLT evaluation and/or RP2D/MTD determination. 
MSC2156119J 300mg
Gefitinib 250mg
3+3 subjects
3+9 subjects
MSC2156119J 500mg
Gefitinib 250mg
Stage IV NSCLC sts
Failed on gefitinib
MET+
Dose Confirmation Phase 
Dose Escalation Phase 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
37/154
Phase II 
The Phase II stage of the study also comprises two parts, randomized part and non-randomized
part (single-arm cohort). This phase will be conducted once the RP2D for tepotinib+gefitinib 
has been defined in Phase Ib.
The randomized part is a multicenter, open label, active-control part to evaluate the efficacy 
and safety of tepotinib+gefitinib compared to that of pemetrexed+cisplatin/carboplatin in 
T790M negative, MET+ subjects. Subjects with MET+ and T790M negative locally advanced 
or metastatic NSCLC who harbor the EGFR mutation and have acquired resistance to first-line
EGFR-TKI therapy including gefitinib, erlotinib, icotinib, or afatinib will be enrolled in this 
part of the trial.
A total of approximately 156 eligible subjects were planned to be enrolled in the randomized 
part. From study start to approval of Protocol Version 7.0, subjects were randomized at a 1:1 
ratio to either the experimental arm (tepotinib+gefitinib) or the control arm 
(pemetrexed+cisplatin). From the approval of Protocol Version 7.0 onwards, subjects were
randomized at a 2:1 ratio to either the experimental arm (tepotinib+gefitinib) or the control arm 
(pemetrexed+cisplatin/carboplatin). They were stratified by type of MET+ (protein 
overexpression immunohistochemistry [IHC] 2+ vs. protein overexpression IHC 3+ vs. gene 
amplification and/or increased c-Met gene copy number (GCN), both by in situ hybridization 
[ISH]; see Appendix H) and prior EGFR-TKI treatment (gefitinib vs. erlotinib vs. icotinib vs. 
afatinib). Subjects who have the co-existence of amplification and/or increased c-Met GCN as 
well as overexpression were included in the amplification and/or increased c-Met GCN group.
The Sponsor subsequently decided to halt enrollment. The sites were notified about the 
enrollment halt on 25 May 2017. The last subject was randomized on 12 June 2017. Until then 
55 subjects had been randomized.
The Sponsor’s decision to halt further enrollment is due to the difficulties experienced in 
identifying subjects who meet the eligibility criteria of the trial. In spite of increased efforts, 
the enrollment rate did not improve to an extent that would allow for completion of the trial in 
a reasonable time frame. The decision is not based on any safety concerns. Accordingly, the 
benefit-risk ratio for all subjects continuing the trial remains unchanged.
Following the enrollment halt, subjects were offered the option to continue the trial following 
the current protocol after discussion with their Investigator. Subjects in prescreening/screening 
and who were eligible had been offered to be enrolled in the trial. Subjects who decided to 
continue treatment continued on their originally allocated treatment, at their most recent dose 
according to the protocol. Safety monitoring and data collection will continue without 
modification through to the end of the trial.
In addition to and separate from the randomized part of the trial in T790M negative and MET+
subjects, the safety and efficacy of tepotinib+gefitinib will be evaluated in a single-arm 
(non-randomized) cohort of up to 15 subjects with MET+ T790M positive NSCLC (mainland 
China sites only). By the time of the enrollment halt, all 15 subjects with MET+ T790M 
positive NSCLC had been enrolled. The rationale for inclusion of this cohort is provided in 
Section 5.2. For this single-arm cohort, the Sponsor may conduct administrative interim 
analyses at time points that are not specified in the protocol for internal planning purposes.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
38/154
The primary endpoint, PFS in the randomized part, and the secondary efficacy endpoints based 
on tumor response, will be assessed by the Investigator/site radiologist using RECIST, 
Version 1.1. In addition, an IRC will evaluate tumor response independently for both parts (ie, 
randomized and non-randomized), of which the results will serve as sensitivity analysis at the 
end of the trial. 
For both parts (ie, randomized and non-randomized), an IDMC will monitor the efficacy and 
safety data. 
 
 
 
For both parts (ie, randomized and non-randomized), at specified time points (Appendix A, 
Appendix B), subjects will be asked to complete QoL questionnaires, including LCSS 
(Appendix K), EORTC QLQ-C30 (Appendix L), and 
 evaluations by 
themselves. Subjects will need to complete the QoL questionnaires at the investigational center 
prior to the initiation of any other trial activities (including RECIST Version 1.1 assessments) 
or active treatments, and prior to any contact with the Investigator. The design of Phase II is 
summarized in Figure 5.2. 
Figure 5.2
Trial Design for Phase II 
Abbreviations: EGFR: epidermal growth factor receptor; EGFRm+: EGFR-TKI sensitizing mutation; R: randomization; 
Pem-Cis/Carb: pemetrexed+cisplatin/carboplatin (pemetrexed plus either cisplatin or carboplatin).
Treatment Duration
There will be an up to 28 day screening period to assess subject eligibility prior to 
randomization/the first administration of the study treatment, except for MET and T790M 
status. Some subjects may have a prescreening period which extends beyond 28 days for the 
determination of MET and T790M status. Eligible subjects will receive either
tepotinib+gefitinib QD, or pemetrexed+cisplatin/carboplatin for:
!
Either up to 6 cycles of pemetrexed+cisplatin/carboplatin, or 
!
4 cycles of pemetrexed+ cisplatin/carboplatin followed by pemetrexed maintenance.
Treatment will discontinue upon PD, intolerable toxicity, withdrawal from the treatment, or, 
for subjects in the control arm not receiving pemetrexed maintenance only, the completion of 
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
39/154
up to 6 cycles of chemotherapy with pemetrexed+cisplatin/carboplatin. In individual cases, 
treatment beyond progression may be considered for subjects on tepotinib+gefitinib. Please 
refer to Section 5.4.2. 
Subjects who stop treatment with all trial treatment will have an End-of-Treatment visit within 
14 days of the last dose, the completion of treatment cycle, or the day when it is determined to 
permanently discontinue the study treatment. A 30-day Safety Follow-up visit will occur at 
30 ± 3 days after the last dose for safety monitoring. If a subject withdraws from the treatment 
for reasons other than PD, additional follow-up visits for tumor assessments will be performed 
until they have PD. There will also be survival follow-up assessments to collect subjects’ 
survival information every 3 months ± 2 weeks until death or the end of the trial, whichever 
comes first.
Subjects who experience PD after having completed 6 cycles of chemotherapy or who 
prematurely have to stop their chemotherapy or who cannot continue their experimental or 
maintenance treatment due to toxicity or other reasons as specified in Section 5.4.2 will either 
have an End-of-Treatment visit within 14 days of the last dose, or at the completion of the 
respective treatment cycle, or the day when it is determined to permanently discontinue the 
study. 
A schematic of the flow of events for each subject is displayed in Figure 5.3.
Figure 5.3
Treatment Duration in Phase II
Note: for subjects who receive tepotinib+gefitinib in Phase II, treatment beyond progression may be considered. 
First Day 
of the Cycle
Last Day 
of the Cycle
Screening
-28 to -1 days
End-of-
Treatment 
Visit
30-day Safety 
Follow-up 
Visit
Survival
Follow-up 
Day
1
Day
21
Day
1
Day
21
Day
X+30
Day
21
Day
1
Q3 Months
X+30
+90 (∀2 weeks)
Day
X
Cycle 3
21 days
Cycle 2
21 days
30-day Safety 
Follow-up Period
30 ∀3 days
Cycle 1
21 days
Tepotinib+gefitinib is administered once 
daily, pemetrexed+cisplatin/carboplatin is 
administered on Day 1 of each cycle
!After Cycle 1, subjects in the 
tepotinib+gefitinib group will continue 
treatment until PD, intolerable toxicity, or 
withdrawal from treatment. Subjects in the 
pemetrexed+cisplatin/ carboplatin group 
will receive either up to 6 cycles of 
treatment or 4 cycles of treatment 
followed by pemetrexed maintenance.
!Day X = Day of last dose = the day subject discontinues both 
components of the combined regimen.
!Subjects who withdraw for reasons other than PD (or who 
either complete up to 6 cycles or 4 cycles followed by 
pemetrexed maintenance in the control arm) will have 
additional follow-up visits for tumor assessment until 
progression.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
40/154
5.2
Discussion of Trial Design
In the completed and ongoing trials, tepotinib shows a favorable safety profile. For 
monotherapy, a RP2D of 500 mg QD has been determined in the FIM study. This RP2D is 
defined as a biologically active dose, based on PK/Pd modeling and supported by data on target 
inhibition from paired tumor biopsies, rather than as a safety defined MTD. However, since 
the RP2D of tepotinib together with an EGFR-TKI as combination therapy has not been 
determined, a safety run-in phase will start dose escalation at 300 mg, thereby allowing for an 
additional safety step before exposing subjects to the full RP2D.
In this study, subjects will receive combination therapy of tepotinib+gefitinib. Based on the 
available drug metabolism and PK data from both compounds, no major drug-drug interaction 
is expected, however, PK of both compounds will still be evaluated in Phase Ib. Meanwhile, 
taking into account the potential difference in drug metabolism and PK in Asian ethnicity, 
de-escalating to the second lower level, will be open for SMC decision by carefully considering 
PK and safety data explored in preceding cohorts.
Doses exceeding 500 mg QD will not be pursued unless there is a reasonable concern that 
500 mg QD might not be biologically active in Asian subjects and the safety and/or PK data 
do not preclude further dose escalation. Continuous QD administration of tepotinib for 21 
consecutive days was determined, after consideration of nonclinical data and the FIM trial as 
the most appropriate treatment regimen for this trial. 
In the current plan, the highest dose level of tepotinib is set at 500 mg, which is in line with the 
RP2D defined in the FIM study. The definition of the RP2D (ie, 500 mg) in the FIM study was 
based on the following criteria and considerations (refer to the current IB):
1.
Based on the results from a nonclinical PK/Pd and tumor growth model, the analysis of 
target inhibition phospho-c-Met in on-treatment subject biopsies, and from a population 
PK model, the 500 mg QD dose achieves target inhibition ≥95% and results in sufficiently 
high steady state (trough) exposure levels in ≥90% of subjects to induce activity in tumors 
with varying degrees of sensitivity to c-Met inhibition. Further support for this 
recommendation can be found in the current IB.
2.
The SMC evaluated results from an expanded cohort of 14 subjects that were treated with 
500 mg tepotinib QD administered over a 21-day cycle. No DLTs were observed in the 12 
evaluable subjects. Of the 2 subjects who were not evaluable, 1 subject was replaced due 
to the AE of Grade 2 bacteremia (assessed by the Investigator as not related to tepotinib) 
and the other subject was replaced due to disease progression.
3.
The 500 mg QD dose is, therefore, considered to be safe and in the biologically active 
range and will be used as the target dose level (ie, RP2D) in subsequent clinical trials with 
tepotinib. 
In-house data and published evidence suggest the simultaneous inhibition of both pathways is 
necessary for subjects with MET+ tumors, and that these subjects require treatment combining 
both a c-Met and an EGFR inhibitor (14, 15). In tumors from subjects with acquired resistance 
to EGFR-TKI, the original activating mutation is still found in addition to the T790M resistance 
mutation, indicating that the original oncogenic driver is still present and therefore requires 
continued inhibition. It is hypothesized that the tumor may evade therapeutic pressure from 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
41/154
single pathway inhibition by switching the signaling to the other pathway. In house nonclinical 
data which demonstrated activity of tepotinib and EGFR-TKI combination regimen in MET+, 
T790M negative xenograft models after acquired resistance also provide compelling evidence. 
Based on the knowledge mentioned above, monotherapy with tepotinib or EGFR-TKI alone as 
active control is not justified.
In subjects with good performance status (PS) and acquired resistance to EGFR-TKI, the 
current standard treatment is platinum-based doublet chemotherapy (12). The majority of 
subjects with NSCLC harboring EGFR mutation have a non-squamous histology. The available 
evidence indicates that cisplatin in combination with pemetrexed is a preferred option for this 
histological subtype. Studies have indicated better survival and favorable safety profile when 
compared with gemcitabine+cisplatin (16). Moreover, some clinical trials in an EGFRm+ 
population have used pemetrexed+cisplatin as active control (17); thus, using this doublet 
regimen facilitates the verification of external validity in the future and allows for easier 
indirect comparison across trials.
This study will enroll subjects who are MET+. Initial scientific evidence (31) indicates that 
even tumors with relatively small MET gene copy number gains can develop resistance to 
EGFR TKIs, though remaining sensitive to c-Met inhibitors. Therefore, MET+ is defined as 
c-Met overexpression and/or c-Met amplification and/or increased c-Met GCN. Although there 
is little doubt on the driving role of c-Met amplification in the acquired resistance to EGFR 
inhibition, the role that c-Met overexpression plays in this field remains less established. 
However, in a single-arm Phase Ib/II trial, the addition of INC280 (a highly selective c-Met 
inhibitor) to gefitinib showed promising clinical activity in MET+ NSCLC subjects resistant 
to EGFR-TKIs. This suggests that c-Met overexpression (IHC2+, 3+) is predictive of benefit 
from the dual inhibition of c-Met and EGFR pathways (18). We hypothesize that c-Met 
overexpression is another indicator of c-Met pathway activation leading to acquired resistance 
to EGFR inhibition, and that it thus warrants being regarded as a potential predictive biomarker 
for dual inhibition of c-Met and EGFR pathways in this setting.
As previously mentioned, the T790M mutation has been identified as playing an important role 
and is frequently detected in EGFR-TKI acquired resistance. Growing evidence also indicates 
that the T790M mutation is associated with better prognosis. In-house nonclinical data indicate 
that a cell line carrying the T790M mutation was sensitive to EGFR and c-Met dual inhibition 
(cetuximab+tepotinib), suggesting that T790M mutation subjects may still benefit from this 
dual inhibition. However, there is scant data to predict how tepotinib+gefitinib may perform in 
subjects with the T790M mutation. If both c-Met overexpression/amplification and T790M 
mutation are present in the same subject, the contribution of each of the two resistance 
mechanisms to the overall resistant phenotype is currently unknown. 
Therefore, the initial trial design considered enrollment of a broad population of subjects
progressing on the first generation EGFR-TKI gefitinib. However, recent data from third 
generation EGFR-TKIs (AZD9291/CO-1686) on T790M positive subjects who have failed a 
first generation EGFR-TKI showed impressive efficacy (objective response rate 58% - 64%)
(19, 20). Therefore, several large global Phase III trials with a strong focus on the Asian region 
are ongoing. Since these trials may lead to a change in the standard of care in T790M positive 
subjects, and, thus, in the composition of the control arm in controlled studies, it has been 
decided to focus the randomized part of the present study on subjects who have failed EGFR-
TKI therapy including gefitinib, erlotinib, icotinib, and afatinib and are T790M negative. 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
42/154
In conclusion, only T790M negative subjects will be randomized to chemotherapy in the 
present study, but, in order to collect preliminary data on safety and antitumor activity in 
T790M positive subjects, up to 15 subjects with T790M mutation will be treated with 
tepotinib+gefitinib in a single-arm cohort (mainland China sites only).
5.2.1
Inclusion of Special Populations
Not applicable.
5.3
Selection of Trial Population
5.3.1
Inclusion Criteria
Phase Ib
For inclusion in Phase Ib, all of the following inclusion criteria must be fulfilled:
1. Histologically or cytologically confirmed advanced NSCLC, regardless of histology 
subtype, which failed on gefitinib for reasons other than toxicity or compliance;
2. Availability of a fresh or archived pretreatment tumor biopsy (excluding fine needle 
aspiration and cytology samples). For subjects who have had at least 1 prior anticancer 
treatment, a biopsy obtained between failure of the most recent anticancer treatment 
and enrollment is mandatory (details of tumor tissue collection are described in 
Section 7.6.2);
3. MET+ status, as determined by the central laboratory, ie, c-Met overexpression as 
determined by IHC (ie, IHC 2+ or IHC 3+) and/or c-Met amplification as determined 
by ISH;
4. Signed, written informed consent by subject or legal representative prior to any 
study-specific screening procedure;
5. Male or female, ≥18 years of age (or minimum age of legal consent consistent with 
local regulations, if minimum is > 18 years of age);
6. Measurable disease in accordance with RECIST Version 1.1;
7. Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
Phase II 
For inclusion in Phase II, all of the following inclusion criteria must be fulfilled:
1. Locally advanced or metastatic NSCLC other than predominantly squamous histology
(confirmed by either histology or cytology);
2. Activating mutation of the EGFR receptor (documented, or as determined by the central 
laboratory);
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
43/154
3. EGFR T790M status after acquired resistance to first line EGFR-TKI therapy including 
gefitinib, erlotinib, icotinib, or afatinib treatment (as determined by the central 
laboratory, using a validated PCR test);
!
T790M negative status for the randomized part
!
T790M positive status for the single-arm cohort (mainland China sites only)
4. Acquired resistance using the Jackman criteria (21) on first-line EGFR-TKI therapy
including gefitinib, erlotinib, icotinib, or afatinib, subjects must meet both of the 
following 2 criteria defined as following:
a.
Radiological documentation of disease progression while on continuous 
treatment with first-line gefitinib, erlotinib, icotinib, or afatinib within the last 
30 days prior to disease progression (refer to Section 7.3 for additional 
information):
i. Evidence of central nervous system (CNS) recurrence only while on 
first-line gefitinib, erlotinib, icotinib, or afatinib is not considered as 
acquired resistance;
b. Prior objective clinical benefit defined by either partial or complete radiological 
response, or durable SD (SD should last > 6 months) after initiation of first-line 
gefitinib, erlotinib, icotinib, or afatinib;
5. Availability of a fresh or archived tumor tissue (excluding fine needle aspiration and 
cytology samples) obtained between documentation of acquired resistance to gefitinib,
erlotinib, icotinib, or afatinib (as defined in inclusion criterion 4) and enrollment is 
mandatory (details of tumor tissue collection are described in Section 7.6.2);
6. MET+ status, as determined by the central laboratory, ie, c-Met overexpression as 
determined by IHC (ie, IHC 2+ or IHC 3+) and/or c-Met amplification and/or increased 
c-Met GCN, both determined by ISH (defined in Section 7.6.2);
7. Signed, written informed consent by subject or legal representative prior to any 
study-specific screening procedure;
8. Male or female, ≥18 years of age (or minimum age of legal consent consistent with 
local regulations, if minimum is > 18 years of age);
9. Measurable disease in accordance with RECIST Version 1.1;
10. ECOG PS of 0 or 1;
11. Eligible to start doublet chemotherapy consisting either of pemetrexed+cisplatin or 
pemetrexed+carboplatin.
12. Interval between documentation of radiological PD on first-line gefitinib, erlotinib, 
icotinib, or afatinib and first dose of study drug shall not exceed 60 days.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
44/154
5.3.2
Exclusion Criteria
Phase Ib 
Subjects are not eligible for Phase Ib if they fulfill any of the following exclusion criteria:
Cancer Related
1.
Symptomatic metastasis of brain and/or CNS, uncontrolled with antiepileptics and 
requiring steroids, unless treated and stable without steroids for at least 10 days within 
4 weeks prior to the first dose of trial treatment;
2.
Any unresolved toxicity more than NCI-CTCAE (Version 4.0) Grade 2 from previous 
anticancer therapy;
3.
Estimated life expectancy < 3 months;
4.
Need for transfusion within 14 days prior to the first dose of trial treatment;
5.
Prior chemotherapy, biological therapy, radiation therapy, or other investigational 
anticancer therapy (not including palliative radiotherapy at focal sites) within 21 days prior 
to the first dose of trial treatment.
Laboratory Values and Organ Function
1.
Inadequate hematological function:
!
Hemoglobin < 8.5 g/dL
!
Neutrophils < 1.5 × 109/L
!
Platelets < 100 × 109/L;
2.
Inadequate liver function:
!
Total bilirubin > 1.5 × upper limit of normal (ULN)
!
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 3 × ULN;
For subjects with liver metastases:
!
Total bilirubin > 1.5 × ULN
!
AST/ALT > 5 × ULN
3.
Known pre-existing interstitial lung disease;
4.
Inadequate renal function:
!
Renal impairment as evidenced by serum creatinine # 1.5 × ULN, or creatinine 
clearance (CrCl) < 60 mL/min calculated by the Cockcroft-Gault formula (24 
hour CrCl might be requested by the Investigator for confirmation, if calculated 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
45/154
CrCl is < 60 mL/min. In such case, subjects with 24 hour CrCl < 60 mL/min 
should be excluded)
CrCl (mL/min) =
[140 – age (year) x weight (kg)]
{x 0.85 for female subjects}
72 x serum creatinine (mg/dL)
5.
Subjects who have ongoing medical history of acute pancreatitis and/or chronic 
pancreatitis, with concomitant elevated lipase and/or amylase, clinical symptoms, and/or 
imaging studies that are indicative of the diagnosis (subjects in mainland China only) .
General 
1.
Impaired cardiac function
!
Left ventricular ejection fraction (LVEF) < 45% defined by echocardiography 
(a screening LVEF assessment without history of congestive heart failure [CHF]
is not required)
!
Serious arrhythmia
!
Unstable angina pectoris
!
CHF New York Heart Association (NYHA) III and IV (Appendix E)
!
Myocardial infarction within the last 12 months prior to trial entry
!
Signs of pericardial effusion;
2.
Hypertension uncontrolled by standard therapies (not stabilized to <150/90 mmHg);
3.
Contraindication to the administration of gefitinib;
4.
Medical history of liver fibrosis/cirrhosis;
5.
Past or current history of neoplasm other than NSCLC, except for curatively treated 
non-melanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively 
treated and with no evidence of disease for at least 5 years;
6.
Medical history of difficulty swallowing, malabsorption, or other chronic gastrointestinal 
disease, or conditions that may hamper compliance and/or absorption of the tested product;
7.
Major surgery within 28 days prior to Day 1 of trial treatment;
8.
Known human immunodeficiency virus positivity;
9.
Substance abuse, active infection, or other acute or chronic medical or psychiatric 
condition or laboratory abnormalities that might increase the risk associated with study 
participation at the discretion of Investigators;
10. Female subjects who are pregnant or lactating, or men and women of reproductive 
potential not willing or not able to employ a highly effective method of birth 
control/contraception to prevent pregnancy until the end of study. A highly effective 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
46/154
method of contraception is defined as those, alone or in combination, that results in a low 
failure rate (ie, less than 1% per year) when used consistently and correctly (see Appendix
N). This requirement begins 2 weeks before receiving the first trial treatment and ends 3
months after receiving the last treatment;
11. Known hypersensitivity to any of the trial treatment ingredients;
12. Legal incapacity or limited legal capacity;
13. Any other reason that, in the opinion of the Principal Investigator, precludes the subject 
from participating in the trial;
14. Participation in another interventional clinical trial (except those subjects who were solely 
involved in other trials where the investigation product was gefitinib, erlotinib, icotinib, or 
afatinib) within the 30 days prior to randomization/first dose.
Phase II 
Subjects are not eligible for Phase II if they fulfill any Phase Ib exclusion criteria listed above. 
Additional exclusion criteria, listed below, apply to Phase II only.
General
Any 
contraindication 
to 
the 
administration 
of 
either 
pemetrexed+cisplatin
or 
pemetrexed+carboplatin.
Cancer Related
1.
Prior systemic anticancer treatment with eg. chemotherapy or any other agents excluding 
gefitinib, erlotinib, icotinib, and afatinib for advanced NSCLC (one course of 
chemotherapy regimen for [neo]adjuvant purpose, or one course of chemoradiation for 
Stage IIIa disease is allowed);
2.
Prior treatment with other agents targeting the HGF/c-Met pathway.
5.4
Criteria for Subject Withdrawal
5.4.1
Withdrawal from the Trial
Subjects are free to discontinue the trial at any time without giving a reason. A subject must be 
withdrawn in the event of:
! Withdrawal of the subject’s consent,
! Participation in any other trial using an investigational drug or intervention during the 
subject’s participation in this trial.
If a subject fails to attend scheduled trial assessments, the Investigator must determine the 
reasons and the circumstances as completely and accurately as possible.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
47/154
In case of premature withdrawal from the trial, every effort should be made to complete the 
investigations scheduled for the End-of-Treatment visit, focusing on the most relevant 
assessments. The appropriate electronic case report form (eCRF) section must be completed.
If a subject withdraws consent from the 
 assessments, they may
continue on the trial.
5.4.2
Withdrawal from Trial Therapy
Withdrawal from trial therapy is defined as permanently discontinuing study treatment in the 
event of any of the following:
! Occurrence of an exclusion criterion which is clinically relevant and affects the subject’s 
safety, in the judgment of the Investigator and/or Sponsor;
! AEs, if discontinuation of trial treatment is desired or considered necessary by the
Investigator and/or subject;
! Dose delay time is more than 21 days at the permitted lowest dose due to any reason;
! Pregnancy;
! Noncompliance with administration of tepotinib, gefitinib or chemotherapy, as defined in 
Section 6.2.4;
! Initiation of a new systemic anticancer therapy as described in Section 6.5.2;
! Documented progression of the disease (but see following paragraphs for treatment 
beyond progression).
In individual cases, treatment beyond progression may be considered for subjects on 
tepotinib+gefitinib. Cases that may be considered for treatment beyond progression include 
subjects with slow (“smoldering”) progression after an initial partial response (PR)/complete 
response (CR), provided there are no clinical symptoms and no new lesions. If, in selected 
subjects, the Investigator wants to continue the treatment beyond progression although new 
lesion(s) have been documented, this must be discussed and agreed with the Sponsor, and 
documented in the appropriate designated eCRF section. The Investigator has to ensure that all 
safety data are collected, as per protocol, in the same manner as before progression.
RECIST Version 1.1 radiographical assessment will follow institutional practice guidelines, 
however, tumor assessment information will not be recorded in the eCRF and there will be no 
further documentation collected for any new lesion and/or clinical symptoms of PD after first 
PD.
Discontinuation of treatment beyond PD is at the discretion of the treating physician. If the 
subject develops new lesions or clinical symptoms, the benefit of continuing treatment with the 
study drugs should be discussed with the Sponsor.
For analysis of the primary endpoint, only the first progression event is used.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
48/154
If subjects withdraw from treatment without documented PD, every effort should be made to 
continue tumor assessments until objective PD, start of new anticancer treatment or withdrawal 
of consent.
Subjects who stop treatment with both components of the combination therapy will have an 
End- of-Treatment visit within 14 days of the last dose, the completion of treatment cycle, or 
the day when it is determined to permanently discontinue the study treatment.
5.5
Premature Discontinuation of the Trial
The whole trial may be discontinued prematurely in the event of any of the following:
! New information leading to an unfavorable risk-benefit judgment of tepotinib+gefitinib, 
for example:
o Evidence of inefficacy;
(Note: evidence of inefficacy may arise from this trial or from other trials; unfavorable 
safety findings may arise from clinical or nonclinical examinations, eg, toxicology.)
o Safety findings that preclude further continuation of the trial.
! Sponsor’s decision that continuation of the trial is unjustifiable for medical or ethical 
reasons;
! Poor enrollment making completion of the trial within an acceptable time frame unlikely;
! Discontinuation of development of tepotinib.
Health Authorities and Independent Ethics Committees (IECs)/Institutional Review Boards 
(IRBs) will be informed about the discontinuation of the trial in accordance with applicable 
regulations.
The whole trial may be terminated or suspended upon request of Health Authorities.
5.6
Replacement of Discontinued Subjects
Subjects withdrawn from Phase Ib may be replaced if they are not fully evaluable for the 
assessment of the primary endpoints. “Not fully evaluable” is defined as:
! Subjects who discontinue the trial prematurely during Cycle 1 for reasons other than a 
DLT. Such reasons could include, for example, withdrawal of consent, not meeting the 
eligibility criteria, noncompliance with follow-up, early disease progression, or unrelated 
AEs;
! Subjects who do not receive at least 80% (ie, < 17 treatment days) of planned cumulative 
doses of tepotinib+gefitinib during Cycle 1, for reasons other than AEs or DLTs.
Subjects withdrawn in Phase II will not be replaced.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
49/154
5.7
Definition of End of Trial
The end of the trial is defined as the time point in Phase II part when the last subject 
discontinued treatment and completed the subsequent safety follow-up visit.
The Sponsor decided to halt enrollment. The sites were notified about the enrollment halt on 
25 May 2017. The last subject was randomized on 12 June 2017. Until then 55 of 156 subjects 
with MET+ T790M negative NSCLC planned to be enrolled had been randomized. By that 
time, all 15 subjects planned to be enrolled in the single-arm cohort (mainland China sites only) 
of up to 15 subjects with MET+ T790M positive NSCLC had been included in the study. 
Following the enrollment halt, subjects were offered the option to continue the trial following 
the current protocol after discussion with their Investigator. Subjects who decided to continue 
treatment continued on their originally allocated treatment, at their most recent dose according 
to the protocol. Safety monitoring and data collection will continue without modification 
through to the end of the trial.
6
Investigational Medicinal Product(s) and Other Drugs 
Used in the Trial
The term “Investigational Medicinal Product” or “IMP” refers to the investigational drug 
undergoing trial, ie, tepotinib and gefitinib. Subjects in both Phase Ib and Phase II will take 
tepotinib in combination with gefitinib. The active comparators in Phase II is pemetrexed 
infusion followed by infusion with cisplatin or carboplatin. 
NOTE: Other medications and fluids are given as part of supportive care or to accompany the 
administration of pemetrexed and cisplatin or carboplatin. While some general information is 
discussed in this protocol, this document is not a comprehensive source of information 
regarding the use of pemetrexed and cisplatin or carboplatin. Please refer to the prescription 
information/summary of product characteristics (SmPC) and other reference sources for 
questions relating to pemetrexed, cisplatin, carboplatin, and accompanying medication. 
6.1
Description of Investigational Medicinal Product(s)
Tepotinib,
is supplied as 100 mg and 25 mg
film-coated tablets.
The percentage of active ingredient in the white, round, film-coated tablet is approximately 
26%. 
 
 
 
All excipients used are of compendial grade. 
Supplier’s certificates show that there is no transmissible spongiform encephalopathy risk.
Gefitinib (Iressa®) is provided as a 250 mg tablet and is ready for use. The actual appearance 
and composition of the product may depend on the respective marketed products sourced for 
the participating countries.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
50/154
6.2
Dosage and Administration
Phase Ib
For each dose cohort, a fixed dose and administration will be applied. The assigned dose of 
tepotinib will be administered daily, supplied as 100 mg (and 25 mg, if applicable) film-coated 
tablets. Tepotinib will be administered with gefitinib (250 mg).
For “3+3” dose escalation cohorts, the first dose level of tepotinib will be 300 mg QD, which 
is 1 level lower than the target dose of RP2D (500 mg QD) from the FIM trial. The planned 
second dose level will be 500 mg QD. However, depending on the safety profile and emerging 
PK data of tepotinib+gefitinib, a lower dose of tepotinib may be investigated. 
For additional up to 3 evaluable subjects from the mainland China sites, tepotinib will be 
administered orally one dose level below the RP2D, in combination with gefitinib at 250 mg. 
Subjects will take their assigned doses of tepotinib and gefitinib orally, in the morning
approximately at the same time, immediately after breakfast, with a full glass of water 
(approximately 200 mL) every day of each 21 day treatment cycle. 
Subjects will be instructed to swallow the tepotinib tablets whole and to avoid biting or 
breaking the tablets, or attempting to dissolve in water before taking them.
On days when PK samples are to be drawn, subjects should be instructed to attend the trial visit 
in a fasted state, with no breakfast and prior to taking their dose of tepotinib and gefitinib. After 
a predose PK blood sample is drawn, the assigned dose of tepotinib and gefitinib should be 
taken following breakfast. No further food should be consumed until 2 hours after the dose 
(water is allowed).
Phase II
For the single-arm and the experimental arm in the randomization part, tepotinib (at the RP2D 
determined in Phase Ib) will be administered orally with gefitinib (250 mg) QD with food in 
the morning approximately at the same time, immediately after breakfast, with a full glass of 
water (approximately 200 mL). If the dosing on scheduled time is missed, tepotinib and/or 
gefitinib should be taken with the next meal, if possible; however, an administration time delay 
> 12 hours on the current day should not be performed. Subjects will take tepotinib and 
gefitinib continuously throughout the 21 day cycle.
All subjects in the randomization part of Phase II are permitted to receive folic acid and B12 
intramuscular injection during screening period. After randomization, only subjects in the 
control arm will continue comedications for pemetrexed (eg, vitamin B12 and folic acid, see 
Section 6.4.1). A corticosteroid should be administered on the day prior to, day of, as well as 
on the day following pemetrexed administration to reduce treatment-related dermatologic 
toxicity (Section 6.4.1.1). Subjects should receive pretreatment and posttreatment hydration for 
cisplatin. All comedications will be administered per local package insert/SmPC. 
For the control arm of the randomization part, subjects will receive pemetrexed 500 mg/m2 as 
an intravenous infusion over 10 minutes. Cisplatin 75 mg/m2 will be administered as an 
intravenous infusion over 2 hours beginning approximately 30 minutes after the end of 
pemetrexed administration. 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
51/154
Based on the subject’s medical condition the Investigator may also choose carboplatin instead 
of cisplatin in combination with pemetrexed. In addition, the Investigator may decide for a 
carboplatin dose of either AUC5 or AUC6. Generally carboplatin is administered as an 
intravenous infusion over 1 hour, beginning about 30 minutes after the end of pemetrexed 
administration. The Investigator is allowed to change the platinum component, ie, from 
cisplatin to carboplatin and vice versa, during the trial based on the subject’s medical condition.
Subjects in the control arm will be treated on Day 1 of each 21 day cycle for up to 6 cycles of 
pemetrexed+cisplatin/carboplatin or 4 cycles of pemetrexed+cisplatin/carboplatin followed by 
pemetrexed maintenance, in line with the SmPC for pemetrexed, cisplatin, or carboplatin, 
respectively. Pemetrexed 500 mg/m2 as maintenance monotherapy will also be administered 
on Day 1 of each 21-day cycle following the completion of 4 cycles of doublet chemotherapy 
with the same administration method stated previously.
Common protocols for the administration of pemetrexed, cisplatin, and carboplatin are 
mentioned above. However, for further administration details, Investigators are also requested 
to check / take into account current medical and local administration guidelines / treatment 
protocols, as well as respective SmPCs.
On days when PK samples are to be drawn, subjects who receive tepotinib+gefitinib should be 
instructed to attend the trial visit in a fasted state, with no breakfast and prior to taking their 
dose of study medication. After a predose PK blood sample is drawn, the assigned doses of 
tepotinib and gefitinib should be taken following breakfast. No further food should be 
consumed until 2 hours after the dose (water is allowed).
6.2.1
Dose escalation Assessment Process (Phase Ib)
For “3+3” dose escalation cohorts, the trial will adopt the classical “3+3” dose escalation design
consisting of a dose escalation phase and a dose confirmation phase. Dose escalation (or 
potentially dose de-escalation) decisions are based on the occurrence of DLTs (defined in 
Section 6.2.3) during Cycle 1 in the first 3 to 6 subjects. Other clinically relevant safety issues 
and emerging PK data should also be considered when making a decision.
Dose Escalation Phase
For the first dose cohort (tepotinib 300 mg/day + gefitinib 250 mg/day):
! If no subject out of the first 3 experiences a DLT during Cycle 1, dose escalation will 
proceed to the higher dose cohort (500 mg);
! If 1 subject out of the first 3 experiences a DLT during Cycle 1, 3 additional subjects will 
be enrolled at 300 mg; 
o
if none of the additional 3 subjects experiences a DLT; dose escalation will 
proceed to the higher dose cohort (500 mg), or
o
if 1 or more of the additional 3 subjects experiences a DLT, the dose will be 
identified as intolerable, and the SMC will determine whether to step down to a 
lower dose level or discontinue the study. This decision will be made by a 
consideration of the DLTs, other clinically relevant safety issues, and emerging 
PK data;
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
52/154
! If 2 or more subjects out of the first 3 experience a DLT during Cycle 1, the dose will be 
identified as intolerable, and the SMC will determine whether to step down to a lower 
dose level or discontinue the study. This decision will be made by a consideration of the 
DLTs, other clinically relevant safety issues, and emerging PK data.
For the second dose cohort (tepotinib 500 mg/day + gefitinib 250 mg/day):
! If no subject of the first 3 treated at 500 mg experiences a DLT during Cycle 1, the SMC 
may decide to enroll 9 additional subjects at the same dose level for a total of 12 subjects. 
! If 1 subject out of first 3 experiences a DLT during Cycle 1, 3 additional subjects will be 
enrolled at the same dose cohort; 
o
if none of the additional 3 subjects experiences a DLT; 6 additional subjects will 
be enrolled at the same dose cohort, or
o
if 1 or more of the additional 3 subjects experience a DLT, the dose will be de-
escalated to the lower dose level;
! If 2 or more subjects out of the first 3 experience a DLT during Cycle 1, the dose will be 
de-escalated to the lower dose level.
Dose Confirmation Phase
After the dose has been determined by the SMC, the cohort at that dose level will be expanded 
to up to 12 subjects by recruiting an additional 6 to 9 subjects (final subject number depends
on those subjects already treated in the dose escalation phase) to confirm the RP2D. A SMC 
meeting will be held after all 12 subjects have completed Cycle 1. In addition, recruitment will 
be stopped and an ad hoc SMC meeting will be convened if at any time 33% of subjects or 
more experience a DLT:
! If 33% or more of up to 12 subjects experience DLTs at the second (500 mg) dose cohort; 
the dose will be de-escalated to a lower dose level (300 mg), or
! If 33% or more of up to 12 subjects experience DLTs at the first dose cohort (300 mg); 
the dose will be identified as intolerable, the SMC will determine whether to step down to 
a lower dose level or discontinue the study by considering other clinically relevant safety 
issues and emerging PK data.
! If less than 33% of up to 12 subjects experience DLTs at either dose cohort, the dose level 
will be identified as RP2D.
Dose De-escalation 
For dose de-escalation at tepotinib 300 mg/day, 1 step down to a lower dose level is permitted 
at the discretion of the SMC by considering DLTs, other safety concerns, and available PK 
data.
For dose de-escalation at tepotinib 500 mg/day, 2 steps down to 300 mg and a further decrease 
to a lower dose level are permitted at the discretion of SMC by considering DLTs, other safety 
concerns, and available PK data. 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
53/154
6.2.2
Safety Monitoring Committee
During Phase Ib, for subjects in the “3+3” dose escalation cohorts, data pertaining to all 
suspected unexpected serious adverse reactions (SUSARs) and potential DLTs will be sent to 
the SMC on a continual basis. SMC mandatory members will be identified before trial initiation 
and will include 1 or more Investigator(s), the Medical Responsible, a pharmacokineticist, and 
a safety representative from the Sponsor. Ad hoc members will be consulted as needed and 
may include, but are not restricted to, the biostatistician, or the treating Investigator in the case 
of particular safety findings.
In Phase Ib, the SMC will be responsible for making the decision of dose escalation (or 
de-escalation) to a new dose level or expansion of enrollment at the same dose level after all 
subjects in the preceding cohort have completed Cycle 1 and all events during this cycle have 
been fully evaluated. 
When 3 subjects have completed Cycle 1 at each dose cohort, new enrollment to this trial is 
paused in each of the dose cohorts. A full safety data set (all AEs, laboratory data, ECG data,
and vital signs) and available PK data will be submitted to the SMC, which evaluates the data 
and confirms the DLT incidence. Depending on the incidence of DLTs, the SMC will 
determine whether to recruit additional subjects, or de-escalate to next dose level, or 
discontinue the study. The details of this process will be described in the SMC Charter.
The ad hoc SMC meetings can be performed at any time in case a safety concern should arise.
Dose de-escalation rules as described in Section 6.2.1 will be followed by the SMC. 
Further information describing a scope of work and procedures for the SMC will be provided 
in the SMC Charter, and a separate statistical analysis plan (SAP) for the SMC will be 
established prior to the start of recruitment.
6.2.3
Definition of DLT 
The period of DLT observation is during Cycle 1 for each subject. 
Using the NCI-CTCAE (Version 4.0), a DLT is defined as any of the following toxicities that 
occur at any dose level and judged to be related to tepotinib by the Investigator and/or the 
Sponsor:
! Grade 4 neutropenia for more than 7 days;
! Grade ≥3 febrile neutropenia for more than 1 day;
! Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with non-traumatic bleeding;
! Grade ≥3 uncontrolled nausea/vomiting and/or diarrhea despite adequate and optimal 
treatment;
! Grade ≥3 any non-hematological AE, except the aforementioned gastrointestinal events 
and alopecia; however, a DLT is defined specifically for the following cases:
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
54/154
o Grade ≥3 liver AE requiring a recovery period of more than 7 days to the baseline or to 
Grade 1 (This criterion is not limited to the liver function tests. Other liver AE eg, jaundice 
or hepatic encephalopathy suggestive of liver failure should be also considered);
o Grade # 3 lipase and/or amylase elevation with confirmation of pancreatitis, either based 
on clinical or radiological signs will be considered as DLT. An isolated lipase and/or 
amylase elevation of # Grade 3 without clinical or radiological evidence of pancreatitis 
will not be classified as DLT (for related topics, see below “Asymptomatic Elevation of 
Serum Lipase and/or Amylase”).
Asymptomatic Elevation of Serum Lipase and/or Amylase
If an asymptomatic lipase/amylase elevation of Grade # 3 occurs during Cycle 1, the subject 
will undergo clinical evaluation for the presence of signs and symptoms typical of acute 
pancreatitis and for other risk factors for pancreatitis. In addition, a CT scan and/or magnetic 
resonance imaging (MRI) of the abdomen will be performed to assess the pancreas. The 
Sponsor (or delegate) will be notified of the outcome of the CT/MRI. Dosing with trial 
treatment will continue during the evaluation period unless the clinical evaluation indicates 
pancreatitis. However, the continuation of trial treatment for the subject will be individually 
discussed with the Sponsor (or delegate) on a subject by subject basis.
All cases of asymptomatic lipase and/or amylase elevations of Grade # 3 will be reported as 
Adverse Events of Special Interest (AESI) to the Sponsor (or delegate) in an expedited fashion 
(see Section 7.4.1.1). 
If there are no clinical or radiological signs indicative of pancreatitis, dosing with 
tepotinib+gefitinib will continue and the pancreatic enzyme elevation occurring during Cycle 1
will not be classified as a DLT. 
Asymptomatic lipase/amylase elevations may occur during or beyond Cycle 1, and 3 different 
scenarios are forecasted:
! Persistent asymptomatic lipase/amylase elevation at the same grade of Grade # 3;
! Recurrent asymptomatic elevation of Grade # 3, after an initial Grade # 3 elevation with 
subsequent resolution; and
! Asymptomatic lipase/amylase elevation of Grade # 3 with persistent elevation at the same 
grade, followed by subsequent further increase in grade.
In all cases, the subject will undergo clinical evaluation for the presence of signs and symptoms 
typical of acute pancreatitis and for other risk factors for pancreatitis. A gastrointestinal consult 
should be requested and additional investigations (eg, repeated abdominal CT scan) should be 
considered, as appropriate. The case will be discussed with the Sponsor (or delegate). 
Treatment with tepotinib+gefitinib may be continued during the evaluation period, at the 
discretion of the treating physician and depending on the circumstances of the individual case. 
If there is no clinical or radiological evidence of pancreatitis, treatment with tepotinib+gefitinib
should be continued, particularly if there is a potentially positive benefit for the individual 
subject. Evaluation of potential clinical benefit will be based on evidence from the literature, 
nonclinical models, and/or current experience with tepotinib+gefitinib in the subject or other 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
55/154
subjects with this tumor type. Otherwise, treatment with tepotinib+gefitinib should be 
discontinued.
6.2.4
Missed Doses and Dose Adjustment 
Subjects who miss more than approximately 20% of doses planned during Cycle 1
(ie, > 4 days) for reasons other than adverse drug reactions or DLTs will not be fully evaluable 
for the assessment of the primary endpoints of Phase Ib. These subjects will be replaced with
new subjects for assessment of DLT. 
The overall safety assessment will be performed based on the full data set from all subjects 
who take at least 1 dose of any trial medication.
Subjects will not make up any missed dose unless the entire tablet is seen if vomiting occurs 
immediately after administration of the study drug. An administration time delay ≤12 hours 
compared to the scheduled administration time is permitted; however, if the time delay is 
> 12 hours, study drug should not be administered on the current day.
Dose Reduction
If intolerable toxicities are observed and judged by Investigator to be related to either or both 
components of combination therapy, dose reduction of either or both components will be 
permitted, depending on the type and severity of toxicity encountered (based on NCI-CTCAE
Version 4.0), provided that criteria for subject withdrawal from study treatment have not been 
met.
Tepotinib
Dose reductions of 1 or 2 levels may be applied, depending on the RP2D identified from the 
Phase Ib part. If 500 mg is identified as the RP2D of tepotinib in combination with gefitinib, 
and the subject has a toxicity at that dose, the dose may be reduced on a case-by-case basis to 
300 mg. It should be noted that if such a situation arises, the Investigator should notify the 
Sponsor immediately and inform on a case-by-case basis, providing the reason for dose 
reduction. In case the Investigator needs to consider further dose reduction in response to 
toxicity, the Investigator should notify the Sponsor prior to modifying the dose further to a 
lower dose level of 200 mg.
The following dose reduction guidelines for tepotinib
are recommended. Clinical 
circumstances which are not covered by below criteria may be grounds for dose modification.
For all situations pertaining to dose reduction, the Investigators should notify the Sponsor on a 
case-by-case basis, providing the reason for dose reduction.
Under the following circumstances, the tepotinib dose should be temporarily interrupted until 
the AE recovers to Grade 1 (or less) or to baseline values. Following the interruption, subjects 
can be re-challenged at the next lower dose level, as described above.
! Grade 4 neutropenia for more than 7 days;
! Grade ≥3 febrile neutropenia for more than 1 day;
! Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with non-traumatic bleeding;
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
56/154
! Grade ≥3 uncontrolled nausea/vomiting and/or diarrhea despite adequate and optimal 
treatment for more than 3 days;
! Grade ≥ 3 any nonhematological AE, except the aforementioned gastrointestinal events 
and alopecia; however, the following cases are specifically defined:
o
Grade ≥ 3 liver AE requiring a recovery period of more than 7 days to return to 
the baseline grade or to Grade 1 (or less);
o
Grade ≥ 3 lipase and/or amylase elevation with confirmation of pancreatitis (for 
related topics, see above “Asymptomatic Pancreatic Enzyme Elevation”)
o
Recurrence of Grade ≥2 AEs after re-challenging despite adequate and optimal 
treatment of the AE.
Under the following circumstances, the dosing should be continued in combination with the 
appropriate supportive treatment:
! Grade 1 AE;
! Well tolerated Grade 2 AEs;
! Lipase and/or amylase elevation without confirmation of pancreatitis.
For the other circumstances not previously mentioned, the dose may be interrupted temporarily 
until recovery to Grade 1 (or less) or baseline grade and the same dose could be restarted after 
recovery.
Gefitinib
The Investigators may modify the dose schedule of gefitinib in response to any clinically 
relevant AE with a causal relationship with gefitinib. The dose schedule adjustment of gefitinib 
should follow its package insert. A table with general guidance for dose modification for 
common AEs related to gefitinib is provided in Appendix J. General recommendations for the 
management of diarrhea and skin toxicities related to gefitinib are provided in Appendix I. 
Pemetrexed, cisplatin, or carboplatin
Investigators may follow local package insert/SmPC, their own clinical judgment and their 
own institutional guidelines for dose modifications of pemetrexed, and cisplatin or 
carboplatin.
Dose Interruption
Subjects may discontinue 1 component of trial therapy and continue the other if, in the opinion 
of the Investigator; the subject may derive benefit from treatment. The Investigator must 
discuss this with the Sponsor on a case by case basis.
AEs assessed by the Investigators to be exclusively related to the subject’s underlying disease 
or medical condition/concomitant treatment are not considered in the decisions for dose 
reduction.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
57/154
Treatment beyond PD
Refer to Sections 5.4.2 and 7.1.3.9.
6.2.5
Intrasubject Dose Escalation
In Phase Ib, subjects will stay at their assigned dose level (except for dose modification due to 
tolerability issues) throughout their treatment period, unless there is a sufficient reason to allow 
intrasubject dose escalation. Only subjects who tolerate treatment well in prior cycles at their 
assigned dose levels will be considered as candidates for intrasubject dose escalation, and dose 
escalations may occur only after these subjects have the first tumor assessment. Any 
intrasubject dose escalation must be agreed to by the Sponsor on a case-by-case basis.
AEs reported after intrasubject dose escalation will not be included in the DLT assessment and 
will not be used for the definition of RP2D. In analyses and summaries, data from these subjects 
will be analyzed based on assigned dose. 
Intrasubject dose escalation to a higher dose level beyond RP2D will not be permitted after the 
RP2D is defined.
No intrasubject dose escalation is permitted in Phase II.
6.3
Assignment to Dose Level (Phase Ib) or Phase II
Subject Allocation
Phase Ib is planned to be conducted at selected sites in mainland China, South Korea, Taiwan,
and other Asian countries. Subjects will be assigned sequentially to the available dose cohort.
At the time of Amendment 7 approval, Phase II was being conducted in 51 sites worldwide.
Randomization of the randomized part of Phase II will be performed centrally by using an 
interactive voice response system (IVRS). Up to 15 T790M positive and MET+ subjects will 
be assigned in a single-arm cohort (mainland China sites only) by using an IVRS.
Subject Number
! The subject numbers will be assigned in the appropriate format and will reflect study 
number, site number and subject number. 
Subject numbers will not be reassigned to other subjects or reused in this trial. If a subject is 
replaced, the replacement will be enrolled with a unique subject number.
6.4
Other Drugs to be used in the Trial
In addition to the treatment with tepotinib and commercially available gefitinib in Phase Ib and 
Phase II, commercially available pemetrexed in combination with either cisplatin or 
carboplatin will be the active comparators in Phase II. The actual appearance and composition 
of the product may depend on the respective marketed products sourced for the participating 
countries.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
58/154
6.4.1
Comedications for Phase II
For subjects who receive pemetrexed in combination with either cisplatin or carboplatin in the 
randomized part of Phase II, as with most cytotoxic regimens, these drugs are preceded and 
accompanied by supportive care. Some important supportive care measures are described 
below.
NOTE: As comedications for pemetrexed (oral folic acid, vitamin B12 intramuscular injection) 
will need to be delivered in the week before first delivery of chemotherapy, this comedication 
is permitted in all subjects after signing the informed consent form (ICF) and before 
randomization/the first administration of the trial treatment. After that, only subjects in the 
control arm of the randomized part will continue comedications for pemetrexed.
6.4.1.1
Comedications for Pemetrexed
Vitamin Supplementation
All subjects in the randomized part of Phase II are permitted to receive folic acid and first B12
intramuscular injection during screening period, as noted in the section above. After 
randomization/first administration of the trial treatment, only subjects in the control arm in the 
randomized part of Phase II will continue comedications for pemetrexed (eg., vitamin B12 and 
folic acid). All comedications will be administered per local package insert/SmPC. 
Subjects should receive oral folic acid or a multivitamin containing folic acid on a daily basis. 
For the week (ie, 7 days) preceding the first dose of IMP/active comparator, there should be at 
least 5 doses of folic acid. In the control arm, dosing should continue for the full course of the 
treatment, and for 3 weeks (ie, 21 days) following the last dose of pemetrexed to be 
administered. 
Subjects should receive vitamin supplementation with vitamin B12 intramuscular injection to 
reduce hematologic and gastrointestinal toxicity. Subjects should be given an intramuscular 
injection of vitamin B12 (1000 μg) in the week preceding the first dose of IMP/active
comparator, 3 weeks after the first vitamin B12 intramuscular injection (in Cycle 1), and then 
around every 9 weeks for subjects in the control arm. The vitamin B12 administered orally 
cannot substitute the vitamin B12 intramuscular administration.
Corticosteroid administration
A corticosteroid should be administered on the day prior to, day of, as well as on the day 
following pemetrexed administration to reduce treatment-related dermatologic toxicity. The 
amount of corticosteroid to be administered should be equivalent to, for example, 4 mg of 
dexamethasone. The corticosteroid should be administered orally twice a day.
6.4.1.2
Comedications for Cisplatin
See local package insert/SmPC for details on dosing regarding comedications for subjects in 
the control arm for cisplatin. 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
59/154
Pretreatment hydration 
For pretreatment hydration, local package insert/SmPC for cisplatin will be followed. For 
example, subjects should receive pretreatment hydration with 1-2 L of fluid to be infused for 
8-12 hours prior to cisplatin administration to initiate diuresis. Additionally, adequate 
subsequent hydration should be ensured to maintain diuresis for the first 24 hours following 
administration (refer to Section 6.4.3).  
Pre-emesis
The administration of the antiemetic treatment should follow the recommendations given in 
the Consensus Statement of the Antiemetic Subcommittee of the Multinational Association of 
Supportive Care in cancer (MASCC, 22).
6.4.1.3
Comedications for Carboplatin
See local package insert/SmPC for details on dosing regarding comedications for subjects in 
the control arm for carboplatin. 
Pre-emesis
The administration of the antiemetic treatment should follow the recommendations given in 
the Consensus Statement of the Antiemetic Subcommittee of the Multinational Association of 
Supportive Care in cancer (MASCC, 22).
6.4.2
Pemetrexed
General instructions for pemetrexed: 
! Pemetrexed dosing should be performed in accordance with its product labeling and use at 
the site.
! Pemetrexed will be administered on Day 1 of each 21-day cycle at a dose of 500 mg/m2. 
! Pemetrexed is typically diluted in 100 mL normal saline and administered via IV infusion 
over 10 minutes. It should not be administered with calcium-containing IV fluids such as 
Lactated Ringer's solution.
! Pemetrexed will be centrally labeled and supplied by the Sponsor or prescribed by the 
Investigator, according to local laws. 
! Body surface area (BSA) should be calculated based on a standard formula—such as the 
Mosteller formula (23) :
BSA (m²) = ([Height(cm) x Weight(kg)]/3600 )½     eg, BSA = square root( (cm*kg)/3600)
or in inches and pounds:     BSA (m²) = ( [Height(in) × Weight(lbs)]/ 3131)½
! Pemetrexed dose modifications should be conducted according to the locally approved 
product label.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
60/154
6.4.3
Cisplatin
General instructions for cisplatin: 
! Cisplatin dosing should be performed in accordance with its product labeling and use at the 
site.
! Subjects should be well hydrated before receiving cisplatin. 
! Subjects must receive adequate antiemetic treatment prior to receiving cisplatin.
! Cisplatin will be centrally labeled and supplied by the Sponsor or prescribed by the 
Investigator, according to local laws. 
! Cisplatin infusion should start approximately 30 minutes after completion of the pemetrexed 
infusion.
! Cisplatin will be administered on Day 1 of each 21-day cycle at a dose of 75 mg/m2, for up 
to 6 cycles or, in case of pemetrexed continuation maintenance, for 4 cycles followed by 
pemetrexed maintenance (for BSA calculation see Section 6.4.2). 
! Cisplatin is typically diluted in 250 mL normal saline and administered via IV infusion over 
120 minutes.
! Cisplatin dose modifications will be conducted according to its locally approved product 
label.
! In addition, prior to each dose of cisplatin, monitoring for hearing loss via audiometry 
should be performed, as clinically indicated.
6.4.4
Carboplatin
General instructions for carboplatin: 
! Carboplatin dosing should be performed in accordance with its product labeling and use at 
the site.
! Subjects must receive adequate antiemetic treatment prior to receiving carboplatin.
! Carboplatin will be centrally labeled and supplied by the Sponsor or prescribed by the 
Investigator, according to local laws. 
! Carboplatin will be administered on Day 1 of each 21-day cycle at a dose of AUC5 or AUC6 
at the discretion of the Investigator. 
! Carboplatin is typically diluted in 5% glucose or 0.9% sodium chloride and administered 
via IV infusion over 60 minutes.
! The Calvert formula used to determine individual carboplatin dosage: 
[Note: With the Calvert formula, the total dose of carboplatin is calculated in mg, not mg/m2.]
Dose (mg) = target AUC (mg/mL x min) x [GFR mL/min + 25]
Generally the Cockcroft Gault calculation can be used to calculate creatinine clearance/GFR. 
However care should be taken if creatinine level is not felt to truly reflect renal function as in 
extremes of BSA. Creatinine clearance should be capped at 125 mL/min for carboplatin 
dosing as recommended by FDA (24). In this respect a maximum carboplatin dose (mg) = 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
61/154
target AUC (mg·min/mL) x (150 mL/min), for example for a target AUC = 5, the maximum 
dose is 5 x 150 = 750 mg.
! Carboplatin dose modifications should be conducted according to its locally approved 
product label. 
6.5
Concomitant Medications and Therapies
6.5.1
Permitted Medicines
Any medication (other than those excluded by the clinical trial protocol) that are considered 
necessary for the subjects’ welfare and will not interfere with the trial medication may be given 
at the Investigator’s discretion.
The Investigator will record all concomitant medications/procedures taken by the subject 
during the trial, from the date of signature of informed consent, in the appropriate section of 
the eCRF. Any additional concomitant therapy that becomes necessary during the trial and any 
change to concomitant drugs must be recorded in the corresponding section of the eCRF, noting 
the name, dose, duration and indication of each drug.
In order to avoid disease flare, it is highly recommended to continue first-line EGFR-TKI 
treatment (with gefitinib, erlotinib, icotinib, or afatinib) after documented disease progression 
until the day before first dose of chemotherapy or first dose of tepotinib/gefitinib.
The following are permitted:
!
Concomitant medications that have a narrow therapeutic window and are known to be 
transported by Pgp (eg, rivaroxaban, apixaban, ranolazine, talinolol, digoxin), BCRP
(eg, rosuvastatin), or OCT1 are permitted, but should be used with caution.
!
Concomitant medications that are known to inhibit Pgp (eg, itraconazole, telaprevir, 
clarithromycin, ketoconazole, and conivaptan) are permitted but should be used with 
caution.
The Investigator may decide not to include a subject in the trial, if the subject cannot withdraw 
a drug that is advised to be used with caution as defined above. If the Investigator decides to 
enroll a subject who is treated with a drug that should be used with caution, close safety 
monitoring is advised. 
6.5.2
Non-permitted Medicines and Procedures
Any additional concomitant therapy that becomes necessary during the trial and any change to 
concomitant drugs must be recorded in the corresponding section of the eCRF, noting the name, 
dose, duration, and indication of each drug.
The following are not permitted during the trial: 
! Any other approved or investigational systemic anticancer treatment including, but not 
limited to, Traditional Chinese Medicine, chemotherapy, biological response modifiers, 
hormones, or immunotherapy;
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
62/154
! Given gefitinib administration, concomitant use of known potent CYP3A4 inducers, such 
as phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort should only take 
place with caution;
! Drug(s), for which the package insert/SmPC includes a contraindication for Pgp (eg, 
dabigatran, aliskiren, colchicine), BCRP, OCT1, OCT2 and Multidrug and Toxin Extrusion 
protein (MATE) 1 inhibiting drugs, must not be combined with tepotinib;
! Drug(s) that are known to induce Pgp and thereby may decrease efficacy of Tepotinib such 
as drugs known to induce Pgp (eg, avasimibe, carbamazepine, phenytoin, rifampin, Saint 
John’s Wort);
! Any drug contraindicated for administration of gefitinib, pemetrexed, cisplatin, or 
carboplatin;
! Simultaneous participation in another clinical treatment study protocol;
! Experimental or systemic anticancer therapy, except for localized radiotherapy for pain 
control provided the localized radiotherapy does not compromise tumor assessments of 
target lesions
! Initiation of a new systemic anticancer therapy for any reason, except as stated above, must 
result in withdrawal of the subject from the treatment. If a subject requires a non-permitted 
medication more than 21 days other than an anticancer drug, this treatment may be allowed 
at the discretion of Investigator, if warranted by the subject’s medical condition. The subject 
should be advised to contact the Investigator before starting the non-permitted medicine, 
and should not take tepotinib concurrently.
6.6
Packaging and Labeling
Packaging and labeling will be in accordance with Manufacture of Investigational Medicinal 
Products (Annex 13, Volume 4), applicable local regulatory requirements, and applicable Good 
Manufacturing Practice (GMP) Guidelines.
Tepotinib tablets will be supplied in aluminum-aluminum blisters. A blister sheet contains 
tablets of 100 mg (and 25 mg if applicable) tepotinib suitable to support the dose escalation 
setting of the trial. The blisters will be packed in a suitable carton box which is labeled with 
(but not limited to) the following required information: trial number, number of tablets per box, 
storage condition, the word “for clinical trial use,” batch number, and the Sponsor’s name.
Gefitinib (Iressa®) is provided as 250 mg tablets and is ready for use. Gefitinib will be packed 
in a suitable carton box which is labeled with (but not limited to) the following required 
information: trial number, number of tablets per box, storage condition, the word “for clinical 
trial use,” batch number, and the Sponsor’s name. Pemetrexed (Alimta®) is provided as 100 or 
500 mg powder for preparation of a concentrate for solution for infusion. Cisplatin and 
carboplatin are provided as generic products.
Pemetrexed, cisplatin and carboplatin will be supplied by the study center or by the Sponsor, 
according to local laws and regulations.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
63/154
6.7
Preparation, Handling and Storage
The pharmacy or designee will receive tepotinib, gefitinib, pemetrexed, cisplatin, and 
carboplatin labeled and packaged according to the local regulatory requirements and storage 
requirements. Tepotinib and the co-administered marketed gefitinib are formulated as tablets
and are ready for use. The responsible pharmacist will dispense the necessary amount of 
tepotinib and gefitinib until the next visit to each subject. Pemetrexed, cisplatin, and carboplatin
are supplied as marketed formulations, which, depending on the type of formulation, require
further preparation before infusion. This preparation will be carried out by a certified 
pharmacist or by adequately trained personnel on behalf of the Investigator. Detailed guidance 
will be provided in a MOP.
The drug supplies will be recorded in a drug inventory and stored in a locked cabinet, protected 
from environmental extremes until use in the trial.
 For the storage conditions of gefitinib,
pemetrexed, cisplatin, and carboplatin please refer to information provided with the medication.
Any deviation from the recommended storage conditions should be immediately reported to 
the Sponsor, and the medication should not be used until authorization has been received from 
the Sponsor.
6.8
Investigational Medicinal Product Accountability
The pharmacist/delegate who is assigned by the Principal Investigator of the trial site is 
responsible for ensuring accountability for IMP (tepotinib and gefitinib) and/or active 
comparator (pemetrexed, cisplatin, or carboplatin), including reconciliation of drugs and 
maintenance of drug records.
After the conclusion of the trial contract with the site, the Sponsor (or designee) may deliver 
the IMP to the assigned pharmacist/delegate at the trial site.
! Upon receipt of IMP/active comparator, the pharmacist/delegate will check for accurate 
delivery and acknowledge receipt by signing (or initialing) and dating the documentation 
provided by the Sponsor and returning it to the Sponsor. A copy will be retained for the 
Investigator Site File or Pharmacy File.
! The dispensing of IMP/active comparator will be carefully recorded on the appropriate drug 
accountability forms provided by the Sponsor/CRO and an accurate accounting will be 
available for verification by the Sponsor/CRO monitor at each monitoring visit.
! IMP/active comparator accountability records will include:
o Confirmation of IMP/active comparator delivery to the trial site;
o The inventory at the site of IMP/active comparator provided by the Sponsor and prepared 
at the site;
o The use of each dose by each subject (diaries for subjects who receive tepotinib+gefitinib; 
infusion records for the control arm of the randomized part in Phase II);
o Disposition of unused IMP/active comparator;
o Dates, quantities, batch numbers, expiry dates and (for IMP/active comparator prepared 
at the site) formulation, as well as the subjects’ trial numbers;
'RFXPHQW1R

2EMHFW1R

&&,
&&,
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
64/154
! The assigned pharmacist/delegate should maintain records adequately document:
o That the subjects were provided the doses specified by the clinical trial
protocol/amendment(s);
o That all IMP/active comparator provided by the Sponsor was fully reconciled.
Unused IMP/active comparator must not be discarded or used for any purpose other than the 
present trial. IMP/active comparator that has been dispensed to a subject must not be 
re-dispensed to a different subject.
The Sponsor/CRO monitor will periodically collect the IMP/active comparator accountability 
forms and will check all returns (both unused and used containers) authorizing their destruction 
by the trial site.
6.9
Assessment 
of 
Investigational 
Medicinal 
Products 
Compliance
For those in Phase Ib and subjects who receive tepotinib+gefitinib in Phase II, each subject will 
record on a diary card the number and dosage of tepotinib and gefitinib taken daily and the 
time the tablets were taken. This diary card will be returned to the Investigator site at each visit.
Subjects should be instructed to bring with them to each visit both opened and unopened 
tepotinib+gefitinib packages, in order to allow the assessment of compliance with trial 
treatment. The tepotinib+gefitinib administration must be recorded as applicable.
Pemetrexed, cisplatin, and carboplatin are administered as intravenous infusions. The 
administration of these products must be recorded. 
6.10
Method of Blinding
Not applicable, both Phase Ib and Phase II will be carried out in an open label manner.
6.11
Emergency Unblinding
Not applicable.
6.12
Treatment of Overdose
An overdose is defined as any dose greater than the daily dose level at which the subject is 
being treated. Any overdose must be recorded in the trial medication section of the eCRF.
For monitoring purposes, any case of overdose, whether or not associated with an AE (serious 
or non-serious), must be reported to the Sponsor’s Global Drug Safety department in an 
expedited manner using the appropriate reporting form (see Section 7.4.1.4).
In case of an overdose that needs to be treated, the Investigator should use his/her clinical 
judgment for the management of the overdose.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
65/154
6.13
Medical Care of Subjects after End of Trial
After a subject has completed the trial or has withdrawn early, usual treatment will be 
administered, if required, in accordance with the trial site’s standard of care and generally 
accepted medical practice, and depending on the subject’s individual medical needs.
7
Trial Procedures and Assessments
Trial periods and assessments apply to both Phase Ib and Phase II, except where noted.
7.1
Schedule of Assessments 
A chart of all treatment visits and assessments are presented in Appendix A and Appendix B. 
Details of the visits and assessments performed are provided in their respective sections. 
Assessments will be performed on an outpatient basis. However, hospitalization may be needed 
on PK sampling days in Phase Ib as well as prior to administration of pemetrexed+cisplatin or 
pemetrexed+carboplatin on Day 1 of each treatment cycle in Phase II. In addition, if clinically 
indicated, subjects may be hospitalized for evaluation at the discretion of the Investigator.
7.1.1
Informed Consent
Prior to performing any trial assessments not part of the subject’s routine medical care, the 
Investigator should ensure that the subject or the subject’s legal representative has provided 
written informed consent(s) according to the procedure described in Section 9.2. A separate 
written informed consent is required for those subjects who go through the prescreening period 
to determine MET and/or T790M status.
7.1.2
Screening Period
Subjects who have a prescreening to determine MET and/or T790M status must sign a separate
ICF before any prescreening study procedures will be performed. Demographic data, medical 
history, and disease history will be collected in addition to MET and/or T790M status during 
prescreening.
Screening procedures must be performed within 28 days prior to study treatment of Phase Ib
and Phase II, except for MET and T790M status (if applicable). Some subjects may have a 
prescreening period which extends beyond 28 days for the determination of MET and T790M 
status (if applicable). Screening procedures include the following: physical examination, 
demography, height, medical history including EGFR mutation status, weight, vital signs, 
pretreatment tumor biopsy, 12-lead ECG, ECOG PS, laboratory assessments (laboratory 
assessments should be repeated if the last assessment is more than 7 days prior to the planned 
date for the first dose, and  must be performed by the central laboratory), recording of 
concomitant medications/procedures and assessments of AEs from the time of consent, and 
tumor imaging to evaluate each subjects’ eligibility for participation in the trial. A screening 
ICF must be obtained before any screening procedures.
Phase Ib and Phase II
Assessments include the following:
! Eligibility evaluation (review of inclusion/exclusion criteria);
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
66/154
! Demography (see Section 7.2) and height (cm);
! Medical history, including EGFR mutation status;
! Pretreatment tumor biopsy (see Section 7.6.1);
! Physical examination/weight (kg);
! ECOG PS (see Section 7.4.4.2);
! Vital signs (see Section 7.4.4.3); 
! 12-lead ECG (see Section 7.4.4.4);
! Chest X-ray (not necessary if thoracic CT performed);
! Hematology and coagulation (see Section 7.4.3.1);
! Biochemistry (see Section 7.4.3.2);
! Urinalysis (see Section 7.4.3.3);
! Serum pregnancy test for female subjects of child bearing potential;
! Complete tumor assessment of all lesions by radiographic or other modality (using 
RECIST Version 1.1) based on CT/MRI of the chest, abdomen, and pelvis to evaluate 
disease in these locations. CT/MRI of the head will be performed for subjects who have 
or are suspected to have CNS metastases (see Section 7.3);
! AE assessment;
! Concomitant medications/procedures.
Randomization must be performed after all inclusion and exclusion criteria have been checked 
and patient eligibility has been confirmed. The study treatment should be given on the day of 
randomization or the day following the randomization day.
7.1.3
Treatment Period 
Phase Ib: Tepotinib+gefitinib will be coadministered QD over a 21 day cycle until 
PD/intolerable toxicity/withdrawal from treatment.
Phase II: 
Subjects 
will 
be 
treated 
with 
either
tepotinib+gefitinib 
QD
or 
pemetrexed+cisplatin/carboplatin on Day 1 of each cycle (for up to 6 cycles or 4 cycles 
followed 
by 
pemetrexed 
maintenance).
After 
completion 
of 
4 
cycles 
of 
pemetrexed+cisplatin/carboplatin, pemetrexed monotherapy may be given on Day 1 of the 
subsequent cycles at the Investigator’s discretion. Treatment will discontinue upon PD, 
intolerable toxicity, withdrawal from the treatment, or, for subjects in the control arm not 
receiving pemetrexed maintenance only,
the completion of up
to
6 cycles of 
pemetrexed+cisplatin/carboplatin. In individual cases, treatment beyond progression may be 
considered for subjects on tepotinib+gefitinib. Discontinuation of treatment beyond PD is at
the discretion of the treating physician. If the subject develops new lesions or clinical symptoms, 
the benefit of continuing treatment with the study drugs should be discussed with the Sponsor. 
Please refer to Section 5.4.2.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
67/154
For subjects in the control arm, weight, hematology, biochemistry, and ECG should be 
performed within 3 days prior to treatment administration except for Cycle 1, unless stated 
otherwise.
! In Phase Ib, assessments and visits within ± 3 day time frame is permitted beginning with
Cycle 3.
! In Phase II, assessments and visits within ± 3 day time frame is permitted beginning with
Cycle 2.
7.1.3.1
Cycle 1, Day 1
Phase Ib 
On Cycle 1, Day 1, the following assessments/treatment administrations will be performed: 
! Drug dispensation;
! Vital signs
! Physical Examination/weight; ECOG PS; hematology and coagulation; biochemistry; 
urinalysis (only if screening assessments were performed > 7 days prior to Day 1);
! 12-lead ECG (predose [within 30 minutes prior to dose] and 4 hours ± 12 minutes
postdose, 10 hours ± 30 minutes postdose, and 24 hours postdose [within 30 minutes prior 
to next dose]);
! PK blood samples (predose and 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose);
! Tumor biopsy (excluding fine needle aspiration and cytology samples) optional, for 
subjects which did not provide a second pass at screening time point (also optional) for 
confirmation of target inhibition;
! Exploratory markers in plasma (predose only);
! AE assessment;
! Concomitant medications/procedures.
Phase II
Assessments will include the same assessments as in Phase Ib but with the following changes:
! ECOG PS; hematology and coagulation; biochemistry; and urinalysis on Cycle 1, Day 1 
will not be performed;
! Complete the QoL questionnaires prior to the initiation of any other trial activities 
(including RECIST Version 1.1 assessments) or active treatments, and prior to any contact 
with the Investigator (see Section 7.7) on Cycle 1, Day 1;
! 12-lead ECG (predose [within 30 minutes prior to dose] in the control (chemotherapy)
arm, predose [within 30 minutes 
] and 4 hours ± 10 minutes
postdose [
 4-hour postdose sampling] in subjects who 
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
68/154
receive tepotinib+gefitinib); ECGs will be collected in triplicate at the predose and 4 hour 
time points;
7.1.3.2
Cycle 1, Day 2
Phase Ib 
The following assessments and examinations will be performed: 
! Physical examination/weight;
! Vital signs; 
! Hematology and coagulation;
! Biochemistry;
! AE assessment;
! Concomitant medications/procedures.
Phase II: 
No assessments and examinations will be performed. 
7.1.3.3
Cycle 1, Day 8
Phase Ib and Phase II
The following assessments will be performed on Cycle 1, Day 8: 
! Physical examination/weight;
! Vital signs; 
! Hematology and coagulation; 
! Biochemistry;
! AE assessment;
! Concomitant medications/procedures.
7.1.3.4
Cycle 1, Day 15 
Phase Ib and Phase II
The following assessments will be performed on Cycle 1, Day 15: 
! Vital signs;
! Physical examination/weight;
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
69/154
! 12-lead ECG (predose [within 30 minutes prior to dose] and 4 hours ± 10 minutes
postdose, 10 hours ± 30 minutes postdose, and 24 hours postdose [within 30 minutes prior 
to next dose] in Phase Ib; predose only [ECGs collected in triplicate within 30 minutes 
prior to dose] in Phase II);
! PK blood samples (predose and 0.25, 0.5, 1, 2, 4, 8, 10 and 24 hours postdose [Phase Ib
only]);
! Tumor biopsy (excluding fine needle aspiration and cytology samples) for confirmation 
of target inhibition (optional);
! Hematology and coagulation; 
! Biochemistry;
! AE assessment;
! Concomitant medications/procedures.
7.1.3.5
Cycle 2, Day 1
Phase Ib
The following assessments/treatment administrations will be performed on Cycle 2 Day 1: 
! Drug dispensation;
! Physical examination/weight;
! Vital signs;
! 12-lead ECG (predose only [within 30 minutes prior to dose]);
! Exploratory markers in plasma (optional, predose only);
! Hematology and coagulation; 
! Biochemistry; 
! Urinalysis;
! ECOG PS;
! AE assessment;
! Concomitant medications/procedures. 
Phase II
Assessments include all assessments in Phase Ib, but with the following changes:
! 12-lead ECG (predose [within 30 minutes prior to dose] in the control [chemotherapy] 
arm, predose [within 30 minutes 
] and 4 hours ± 10 minutes 
postdose [
 4-hour postdose sampling] in subjects who 
receive tepotinib+gefitinib); ECGs will be collected in triplicate at the predose and 4 hour 
time points;
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
70/154
! Sparse PK sampling (within 60 minutes prior to dose and 1.5 hours ± 10 minutes and
4 hours ± 10 minutes postdose after ECG collection in subjects who receive 
tepotinib+gefitinib).
7.1.3.6
Cycle 2, Day 8
Phase Ib
On Cycle 2, Day 8 in Phase Ib, the following assessments will be performed: 
! Physical examination/weight;
! Vital signs; 
! Hematology and coagulation;
! Biochemistry;
! AE assessment;
! Concomitant medications/procedures.
Phase II
No assessments will be performed on Cycle 2, Day 8 in Phase II.
7.1.3.7
Cycle 2, Day 15
Phase Ib
On Cycle 2, Day 15 in Phase Ib, the following assessments will be performed: 
! Physical examination/weight;
! Vital signs;
! Hematology and coagulation;
! Biochemistry;
! AE assessment;
! Concomitant medications/procedures.
Phase II
No assessments will be performed on Cycle 2, Day 15.
7.1.3.8
Cycles ≥3, Day 1
Phase Ib and Phase II:
On Cycles ≥3, Day 1 in both Phase Ib and Phase II, the following assessments/treatment 
administrations will be performed:
! Phase II only: Complete the QoL questionnaires prior to the initiation of any other trial 
activities (including RECIST Version 1.1 assessments) or active treatments, and prior to 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
71/154
any contact with the Investigator (see Section 7.7), on Day 1 of odd numbered cycles 
(Cycles 3, 5, 7, 9, 11, 13, 15, 17 and every 4 cycles thereafter until PD).
! Drug dispensation;
! Physical examination/weight;
! Vital signs;
! ECOG PS;
! 12-lead ECG (predose only [within 30 minutes prior to dose]; starting at Cycle 3, then
performed every third cycle [Cycle 6, 9, 12, etc.] or as clinically indicated);
! Exploratory markers in plasma (Day 1 of Cycles 2, 4, 6, 8, 10 and 12 predose only, in 
subjects signing separate ICF);
! Hematology and coagulation;
! Biochemistry;
! Urinalysis;
! AE assessment;
! Concomitant medications/procedures; 
! Tumor Assessment: A complete tumor assessment of all lesions using RECIST Version 
1.1 will be performed on Day 1 of odd-numbered cycles (Cycles 3, 5, 7, 9, 11, 13, 15, 17, 
and every 4 cycles thereafter until PD).
7.1.3.9
Treatment Beyond Progressive Disease
In individual cases, treatment beyond progression may be considered for subjects on 
tepotinib+gefitinib. Cases that may be considered for treatment beyond progression include 
subjects with slow (“smoldering”) progression after an initial partial response (PR)/complete 
response (CR), provided there are no clinical symptoms and no new lesions. If, in selected 
subjects, the Investigator wants to continue the treatment beyond progression although new 
lesion(s) have been documented, this must be discussed and agreed with the Sponsor, and 
documented in the appropriate designated eCRF section. The Investigator has to ensure that all 
data are collected as required for Cycles ≥3, Day 1 (see Section 7.1.3.8), in the same manner 
as before progression, with the exception of the QoL questionnaires, which shall not be 
collected for this subject group, and tumor assessments. RECIST Version 1.1 radiographical 
assessment will follow institutional practice guidelines, however, tumor assessment 
information will not be recorded in the eCRF and there will be no further documentation 
collected for any new lesion and/or clinical symptoms of PD after first PD.
Discontinuation of treatment beyond PD is at the discretion of the treating physician. If the 
subject develops new lesions or clinical symptoms, the benefit of continuing treatment with the 
study drugs should be discussed with the Sponsor. Please refer to Section 5.4.2. For analysis 
of the primary endpoint, only the first progression event is used. 
7.1.3.10
End-of-Treatment Visit
An End-of-Treatment visit should be conducted within 14 days of the last dose of study
treatment, the completion of treatment cycle, or the day when it is determined to permanently 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
72/154
discontinue the study treatment. If the subject discontinues from the study at a scheduled visit, 
the End-of-Treatment assessment can be performed on that day. A subject will have an End-
of-Treatment visit only if they withdraw from treatment with both components of the 
combination therapy.
Note, for Phase II part of the study, at the End-of-Treatment visit, prior to the initiation of any 
other trial activities (including RECIST Version 1.1 assessments) or active treatments, and 
prior to any contact with the Investigator, subjects will need to complete the QoL 
questionnaires (see Section 7.7).
The following assessments will be performed at the End-of-Treatment visit if the last 
assessments were performed > 7 days prior to the visit. These will include:
! Vital signs;
! Physical examination/weight;
! ECOG PS;
! 12-lead ECG;
! Hematology and coagulation;
! Biochemistry;
! Urinalysis.
Other Assessments should also be performed at the End-of-Treatment visit:
! Exploratory markers in plasma;
! Tumor biopsy (Optional, whenever possible, the biopsy taken at progression on the last 
day of drug application [excluding fine needle aspiration and cytology samples] for 
determination of the MET status and analysis of potential resistance marker should be 
taken from the progressing lesion, provided that the lesion is accessible and there are no 
medical or safety reasons precluding a biopsy of the progressing lesion);
! Tumor assessment (For subjects whose last tumor assessment was performed ≥6 weeks 
before Cycle 17 and ≥12 weeks afterwards prior to this visit and has no radiological PD 
in previous visits);
! AE assessment;
! Concomitant medications/procedures;
! QoL assessment (Phase II only).
7.1.4
Post-treatment Follow-up Visit
30-Day Safety Follow-Up Visit (Phase Ib and Phase II)
The 30-day Safety Follow-up visit will be performed 30 ± 3 days after subject discontinues
both components of study treatment even if the subject starts on a new anticancer therapy.
Note, for Phase II part of the study, at the End-of-Treatment visit, prior to the initiation of any 
other trial activities (including RECIST Version 1.1 assessments), and prior to any contact with 
the Investigator, subjects will need to complete the QoL questionnaires. Subjects who terminate 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
73/154
their treatment early will be encouraged to return to the clinic for the 30-day safety follow-up 
visit. The following assessments will be performed:
! Physical examination/weight;
! Vital signs;
! ECOG PS;
! 12-lead ECG;
! Hematology and coagulation;
! Biochemistry;
! Urinalysis;
! Serum pregnancy test (for female subjects of child bearing potential)
! AE assessment;
! QoL assessment;
! Concomitant medications/procedures.
Ongoing or new AEs judged to be related to any trial medication will be followed until the 
event has resolved to the baseline grade, becomes stable, the subject is lost to follow-up, the 
subject withdraws consent, or it has been determined that the study treatment is not the cause 
of the AE, even if new anticancer treatment is initiated.
Additional Follow-Up Visits (Phase Ib and Phase II)
If a subject withdraws from the treatment for reasons other than PD, or, for subjects in the 
control arm not receiving pemetrexed maintenance only, the completion of up to 6 cycles of 
pemetrexed+cisplatin/carboplatin, tumor assessments will be performed every 6 weeks until 
Week 51 (Cycle 17) and every 12 weeks after Week 51 until radiologically documented PD, 
death, end of trial, or start of a new anticancer therapy, whichever occurs first.
Note, for Phase II part of the study, at the End-of-Treatment visit, prior to the initiation of any 
other trial activities (including RECIST Version 1.1 assessments), and prior to any contact with 
the Investigator, subjects will need to complete the QoL questionnaires
The following assessments should be performed:
! Tumor Assessment;
! Recording of any new anticancer therapy (a tumor assessment is mandatory before 
initiating the new therapy);
! QoL assessment. 
A ± 7 day time window is permitted for additional follow-up visits until Week 51 then a 
± 14 day time window is permitted thereafter. 
Trial Procedure Termination
Trial procedure termination could occur at the 30-day safety follow-up visit or at an additional 
follow-up visit, whichever comes later. The following information needs to be documented in 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
74/154
source documents, and will be recorded in the eCRF: the date of discontinuation from trial 
procedures, and the primary reason for discontinuation from trial procedures.
7.1.5
Survival Follow-up (Phase II Only)
Information about subject survival will be collected by telephone interview/clinic visit every 
3 months ∀2 weeks until death or the end of the trial, whichever comes first. Any new 
anticancer therapy given to the subject until death should be recorded. 
After discontinuation of survival follow-up, the Investigator must document the primary reason 
for a subject’s discontinuation from the survival follow-up in source document and record it in
the eCRF, accordingly. For subjects who are lost to follow-up, the Investigator should show 
due diligence by documenting in the source documents steps taken to contact the subject.
7.2
Demographic and Other Baseline Characteristics
Prior to the first dosing (Cycle 1, Day 1), all subjects will have Screening and Baseline 
examinations to ensure their eligibility. Before any examination, they will be informed about 
the trial aims, procedures, and possible risks of taking the study drugs and the Investigator will 
ensure that the subject or the subject’s legal representative has provided written informed 
consent, according to the procedure described in Section 9.2. 
The following Screening and Baseline assessments will be performed:
! Demographics: including date of birth, race, and gender. Height will also be recorded.
! Medical History: The medical history will include: 
o The starting and ending dates or duration of the medical incidences;
o Concomitant illnesses at screening, including chronic diseases or abnormal 
conditions;
o Previous relevant illnesses;
o Major relevant surgery not related to the cancerous condition, as well as other relevant 
prior procedures; 
o Smoking status.
! Oncology History: includes date of diagnosis, tumor type, histological type and location, 
tumor, lymph nodes, metastasis (tumor, lymph nodes, metastasis status) classification, 
staging information at the initial histological diagnosis, previous treatments (surgery, 
radiotherapy, and systemic therapies), current symptoms, and tumor involvement at the 
time of screening.
! Medication History of Oncology: includes the starting and ending dates of previous 
anticancer therapies, the best response to each treatment (including both prescription and 
over-the-counter medications) and other relevant tumor-related interventions. 
7.3
Assessment of Efficacy
Tumor Assessment (Tumor Response Assessment)
Tumor assessment will be performed according to RECIST Version 1.1 (see Appendix C).
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
75/154
The Baseline tumor assessment is scheduled to be performed during the Screening period (see 
Section 7.1.2). 
Computed tomography or MRI with contrast enhancement is recommended for tumor 
assessment. Imaging studies, including CT or MRI of the chest, abdomen and pelvis must be 
performed at Baseline in order to survey metastasis. At Baseline, the organs with metastatic 
disease and target and non-target lesions should be documented. CT/MRI of the head for 
subjects suggestive of CNS metastasis can be performed at Baseline. The bone scan and/or 
positron emission tomography (PET) could be considered for subjects suggestive of bone 
metastasis at baseline or when suspecting any bone metastasis during the study, however 
CT/MRI scan must be used for tumor assessment at the Baseline and at subsequent visits. The 
bone scan or PET cannot be used for tumor assessment.
Tumor response evaluations will be assessed by CT or MRI and other modalities at the end of 
every 2 cycles (every 4 cycles after Cycle 17). If the treatment cycle in the control or 
experimental arm is delayed, the scheduled tumor assessment should not be delayed and should 
still be performed every 6 weeks before Week 51 and every 12 weeks afterwards. This should 
include a complete assessment of all target and non-target lesions. In case of symptomatic 
progression, subjects should be evaluated by imaging studies thereafter. A CT or MRI must 
also be performed at the End-of-Treatment visit if subject’s last tumor assessment was 
performed ≥6 weeks before Cycle 17 and ≥12 weeks afterwards prior to this visit. Evaluation 
of lesions should be based on images obtained by either CT or MRI. The same method of 
assessment and the same technique should be used to characterize each identified and reported 
lesion at Baseline and during the trial. If a chest X-ray indicates metastatic disease while the 
subject is enrolled in this trial, a CT or MRI of the chest is required for confirmation. The 
assessment provided by the same physician or radiologist is recommended during the study.
All measurements should be recorded in metric notation. Tumor assessment will be performed 
according to RECIST Version 1.1 as described in Appendix C. In Phase Ib, tumor evaluations 
will be done by the Investigator and site radiologist.
For the determination of progression to evaluate PFS in the randomized part of Phase II, tumor 
evaluations will be done by the Investigator and site radiologist (as a primary endpoint) as well 
as by the IRC (as a secondary endpoint). 
For the determination of progression to evaluate PFS in the single-arm cohort of Phase II, tumor 
evaluations will be done by the Investigator and IRC.
If a subject drops out of the trial for a reason other than PD or death, further tumor assessments 
will be performed and the information will be used for PFS and other assessments based on 
tumor progression.
Subjects who withdraw from the trial for clinical or symptomatic deterioration before objective 
documentation of PD will be requested to undergo appropriate imaging to confirm PD. Every 
effort will be made to confirm a clinical diagnosis of PD by imaging. X-rays may only be taken 
for documentation of PD in case of clear evidence of PD on the chest X-ray, when CT or MRI 
are not feasible for medical reasons.
For subjects receiving treatment beyond PD, RECIST Version 1.1 radiographical assessment 
will follow institutional practice guidelines, however, tumor assessment information will not 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
76/154
be recorded in the eCRF and there will be no further documentation collected for any new 
lesion and/or clinical symptoms of PD after first PD.
7.4
Assessment of Safety
The safety profile of trial treatments will be assessed through the recording, reporting and 
analyzing of baseline medical conditions, AEs, AESIs, DLTs, physical examination findings 
including vital signs, ECG, and laboratory tests. 
Comprehensive assessment of any apparent toxicity experienced by the subject will be 
performed from the time of the subject’s signature of informed consent throughout the trial. 
The Investigator will report any AEs, whether observed by the Investigator or reported by the 
subject (see Section 7.4.1.2). The reporting period for AEs is described in Section 7.4.1.3.
7.4.1
Adverse Events
7.4.1.1
Adverse Event Definitions
Adverse Event
An AE is any untoward medical occurrence in a subject or clinical investigation subject 
administered a pharmaceutical product, which does not necessarily have a causal relationship 
with this treatment. An AE can therefore be any unfavorable and unintended sign (including 
an abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal product, whether or not considered related to the medicinal product. 
In cases of surgical or diagnostic procedures, the condition/illness leading to such a procedure 
is considered as the AE rather than the procedure itself.
The Investigator is required to grade the severity/intensity of each AE by referencing the 
NCI-CTCAE, Version 4.0 (publication date: 28 May 2009), a descriptive terminology that can 
be used for AE reporting.
A general grading (severity/intensity; hereafter referred to as severity) scale is provided at the 
beginning of the above referenced document, and specific event grades are also provided.
If a particular AE’s severity is not specifically graded by the guidance document, the 
Investigator is to use the general NCI-CTCAE definitions of Grade 1 through Grade 5 
following his or her best medical judgment.
The 5 general grades are:
Grade 1 or Mild
Grade 2 or Moderate
Grade 3 or Severe
Grade 4 or Life-threatening 
Grade 5 or Death 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
77/154
According to Sponsor convention, any clinical AE with severity of Grade 4 or 5 must also be 
reported as an SAE. However, a laboratory abnormality of Grade 4, such as anemia or 
neutropenia, is considered serious only if the condition meets one of the serious criteria 
described below.
If death occurs, the primary cause of death or event leading to death should be recorded and 
reported as a SAE. “Fatal” will be recorded as the outcome of this specific event and death will 
not be recorded as separate event. Only, if no cause of death can be reported (for example, 
sudden death, unexplained death), the death per se might be reported as an SAE. Investigators 
must also systematically assess the causal relationship of AEs to trial treatment (tepotinib
and/or gefitinib in Phase Ib and Phase II; cisplatin, carboplatin, and/or pemetrexed in Phase II) 
using the following definitions. 
Decisive factors for the assessment of causal relationship of an AE to the trial treatments 
include, but may not be limited to, temporal relationship between the AE and the trial 
treatments, known side effects of trial treatments, medical history, concomitant medication, 
course of the underlying disease, and trial procedures.
Not related: Not reasonably related to the trial treatment. The AE could not medically 
(pharmacologically/clinically) be attributed to the trial treatment under study in 
this clinical trial protocol. A reasonable alternative explanation must be available.
Related:
Reasonably related to the trial treatment. The AE could medically 
(pharmacologically/clinically) be attributed to the trial treatments under study in 
this clinical trial protocol. 
Abnormal Laboratory Findings and Other Abnormal Investigational Findings
Abnormal laboratory findings and other abnormal investigational findings (eg, an abnormal 
ECG trace) should not be reported as AEs unless they are associated with clinical signs and 
symptoms, lead to treatment discontinuation or are considered otherwise medically important 
by the Investigator. If a laboratory abnormality fulfills these criteria, the identified medical 
condition (for example, anemia, increased ALT) must be reported as the AE rather than the 
abnormal value itself.
Serious Adverse Event
An SAE is any untoward medical occurrence that at any dose:
! Results in death;
! Is life-threatening;
NOTE: The term “life-threatening” refers to an event in which the subject is at risk of death at 
the time of the event; not an event that hypothetically might have caused death if it was more 
severe.
! Requires inpatient hospitalization or prolongation of existing hospitalization;
! Results in persistent or significant disability/incapacity;
! Is a congenital anomaly/birth defect;
! Is otherwise considered as medically important.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
78/154
(NOTE: Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered as SAEs when, based upon appropriate medical judgment, 
they may jeopardize the subject or may require medical or surgical intervention to prevent one
of the outcomes listed above. Examples of such events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do 
not result in inpatient hospitalization, or the development of drug dependency or drug abuse).
For the purposes of reporting, any suspected transmission of an infectious agent via a trial 
treatment is also considered an SAE as described in Section 7.4.1.4.
Events that Do Not Meet the Definition of a SAE
Elective hospitalizations to administer, or to simplify trial treatment or trial procedures (eg, an 
overnight stay to facilitate chemotherapy and related hydration therapy application) are not 
considered as SAEs. However, all events leading to unplanned hospitalizations or unplanned 
prolongation of an elective hospitalization (eg, undesirable effects of any administered 
treatment) must be documented and reported as SAEs.
Events Not to Be Considered as AEs/SAEs
Medical conditions present at the initial trial visit that do not worsen in severity or frequency 
during the trial are defined as Baseline Medical Conditions, and are NOT to be considered AEs.
AE/SAEs Observed in Association with Disease Progression 
Progression of the disease/disorder being studied assessed by measurement of lesions on 
radiographs or other methods as well as associated clinical signs or symptoms (including 
laboratory abnormalities) should not be reported as an (S)AE, unless the patient’s general 
condition is more severe than expected and/or unless the outcome is fatal within the AE 
reporting period (as defined in Section 7.4.1.3). However, if adverse signs or symptoms occur 
in association with disease progression then these should be recorded as AEs or reported as 
SAEs, if they meet criteria for seriousness.
AEs of Special Interest
Subjects might experience asymptomatic elevations in serum pancreatic enzyme (lipase and 
amylase) and such enzyme elevations of Grade ≥3 are considered AESIs in this trial. 
When such AESI is not serious, a specific AESI form should be filled at the site and the Sponsor
must be notified immediately (within 24 hours). Reporting process of an AESI should follow 
the same process for reporting SAEs (see Section 7.4.1.4). 
Should the AESI be serious, a SAE Report Form, instead of the AESI Form should be filled 
and the procedure for reporting SAEs (see Section 7.4.1.4) should be followed. 
In addition to SAEs, all non-serious DLTs (Phase Ib) will be promptly reported by the 
Investigator using the AE section of the eCRF.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
79/154
7.4.1.2
Methods of Recording and Assessing Adverse Events
At each trial visit, the subject will be queried on changes in his/her condition. During the 
reporting period, any unfavorable changes in the subject’s condition will be recorded as AEs, 
whether reported by the subject or observed by the Investigator. 
Complete, accurate, and consistent data on all AEs experienced for the duration of the reporting 
period (defined below) will be reported on an ongoing basis in the appropriate section of the 
eCRF. All SAEs and all non-serious AESI must be additionally documented and reported using 
the appropriate Report Form as described in Section 7.4.1.4.
It is important that each AE report include a description of the event, its duration (onset and 
resolution dates, and times when it is important to assess the time of AE onset relative to the 
recorded treatment administration time), its severity, its causal relationship with the trial 
treatment, any other potential causal factors, any treatment given or other action taken 
(including dose modification or discontinuation of trial drug) and its outcome. In addition, 
serious cases should be identified and the appropriate seriousness criteria documented. If an 
AE constitutes a DLT this has to be documented accordingly.
Specific guidance can be found in the eCRF Completion and Monitoring Conventions provided 
by the Sponsor/designee.
7.4.1.3
Definition of the Adverse Event Reporting Period
The AE reporting period for safety surveillance begins when the subject is initially included in 
the trial (date of first signature of informed consent) and continues through the trial’s post 
treatment follow-up period, defined as 30 ± 3 days with a Safety Follow-up visit. If the “30-Day 
Safety Follow-up Visit” was not performed (eg, the subject could not come back to the site for 
a visit), a telephone interview should be performed to document any AEs that occurred in this 
time period. 
Any SAE assessed as related to trial treatment must be reported whenever it occurs, irrespective 
of the time elapsed since the last administration of trial treatment.
7.4.1.4
Procedure for Reporting Serious Adverse Events, Adverse 
Events of Special Interest and Dose Limiting Toxicities
Serious Adverse Events
In the event of any new SAE occurring during the reporting period, the Investigator must 
immediately (within a maximum 24 hours after becoming aware of the event) inform the 
Sponsor or its designee in writing. All written reports should be transmitted using the SAE 
Report Form, which must be completed by the Investigator following specific completion 
instructions.
In exceptional circumstances, an SAE (or follow-up information) may be reported by 
telephone. In these cases, a written report must be sent immediately thereafter by fax or e-mail.
The reporting procedures and timelines are the same for follow-up cases. Names, addresses, 
telephone and fax numbers for SAE reporting will be included in the trial specific SAE Report 
Form.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
80/154
Relevant pages from the eCRF may be provided in parallel (for example, medical history, 
concomitant drugs). Additional documents may be provided by the Investigator, if available 
(for example, laboratory results, hospital report, autopsy report). In all cases, the information 
provided on the SAE Report Form must be consistent with the data about the event recorded 
in the eCRF.
The Investigator must respond to any request for follow-up information (eg, additional 
information, outcome, final evaluation, other records where needed) or to any question the 
Sponsor/designee may have on the AE within the same timelines as those noted above for 
initial reports. This is necessary to ensure prompt assessment of the event by the 
Sponsor/designee and (as applicable) to allow the Sponsor/designee to meet strict regulatory 
timelines associated with expedited safety reporting obligations.
Requests for follow-up will usually be made by the responsible monitor, although in 
exceptional circumstances the Global Drug Safety department may contact the Investigator
directly to obtain further information or to discuss the event.
Adverse Events of Special Interest
In the event of a non-serious AESI, the Investigator will complete the AESI Report Form and 
send it to the Sponsor/designee within 24 hours after becoming aware of the event. Names, 
addresses, telephone and fax numbers for AESI reporting will be included on the Report Form. 
Serious AESIs have to be reported in an expedited manner as SAEs as outlined above. 
Dose Limiting Toxicities (Phase Ib)
Each event meeting the criteria of a DLT (see Section 6.2.3) has to be recorded in the eCRF 
within 24 hours after becoming aware of the event. Serious DLTs have to be reported in an 
expedited manner as SAEs as outlined above. 
7.4.1.5
Safety Reporting to Health Authorities, Independent Ethics 
Committees/ Institutional Review Boards and Investigators
The Sponsor will send appropriate safety notifications to Health Authorities in accordance with 
applicable laws and regulations.
Trials conducted in countries other than Japan:
The Investigator must comply with any applicable site-specific requirements related to the 
reporting of SAEs (particularly deaths) involving trial subjects to the IEC/IRB that approved 
the trial.
In accordance with ICH GCP guidelines, the Sponsor/designee will inform the Investigator of 
“findings that could adversely affect the safety of subjects, impact the conduct of the trial, or 
alter the IEC’s/IRB’s approval/favorable opinion to continue the trial.” In particular and in line 
with respective regulations, the Sponsor/designee will inform the Investigator of AEs that are 
both serious and unexpected and are considered to be related to the administered product 
(SUSARs). The Investigator should place copies of Safety Reports in the Investigator Site File. 
National regulations with regard to Safety Report notifications to Investigators will be taken 
into account.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
81/154
Trials to be conducted in Japan:
The Investigator must report SAEs (particularly deaths) in accordance with applicable site-
specific requirements to the IRB that approved the trial.
In accordance with ICH GCP and the Japanese ministerial ordinance on GCP, the 
Sponsor/designee will immediately inform all the trial Investigators and the Heads of the trial 
sites of “findings that could adversely affect the safety of subjects, impact the conduct of the 
trial or alter the IRB’s approval/favorable opinion to continue the trial.” In particular and in
line with respective applicable regulations, the Sponsor/designee will immediately inform all 
the trial Investigators and the Heads of the trial sites of AEs that are both serious and 
unexpected and are considered to be related to the administered product (“suspected 
unexpected serious adverse reactions” or SUSARs). In addition, according to applicable 
regulations, the Sponsor/designee will inform the trial Investigators and the Heads of the trial 
sites of all SAEs which were reported to the health authorities. In accordance with the Japanese 
regulatory requirements concerning safety reporting the Investigator should place copies of the 
Safety Reports in the Investigator Site File. The Head of the trial site should also maintain 
copies of safety reports appropriately.
When specifically required by regulations and guidelines, the Sponsor/designee will provide 
appropriate Safety Reports directly to the concerned lead IEC/IRB and will maintain records 
of these notifications. When direct reporting by the Sponsor/designee is not clearly defined by 
national or site-specific regulations, the Investigator will be responsible for promptly notifying 
the concerned IEC/IRB of any Safety Reports provided by the Sponsor/designee and of filing 
copies of all related correspondence in the Investigator Site File.
For trials covered by the European Directive 2001/20/EC, the Sponsor’s responsibilities 
regarding the reporting of SAEs/SUSARs/Safety Issues will be carried out in accordance with 
that directive and with the related detailed guidance.
7.4.1.6
Monitoring of Subjects with Adverse Events
AEs are recorded and assessed continuously throughout the study and are assessed for final 
outcome at the Post-treatment Follow-up Visit (30-Day Safety Follow-Up Visit). All SAEs and 
AESIs ongoing at the “30-Day Safety Follow-Up Visit” must be monitored and followed up 
by the Investigator until stabilization or until the outcome is known, unless the subject is 
documented as “lost to follow-up.” Reasonable attempts to obtain this information must be
made and documented. It is also the responsibility of the Investigator to ensure that any 
necessary additional therapeutic measures and follow-up procedures are performed. 
7.4.2
Pregnancy and In Utero Drug Exposure 
Only pregnancies considered by the Investigator as related to trial treatment (eg, resulting from 
a drug interaction with a contraceptive medication) are considered to be AEs. However, all 
pregnancies with an estimated conception date during the period defined in Section 7.4.1.3
must be recorded by convention in the AE page/section of the eCRF. The same rule applies to 
pregnancies in female subjects and to pregnancies in female partners of male subjects. The 
Investigator must notify the Sponsor/designee in an expedited manner of any pregnancy using 
the Pregnancy Report Form, which must be transmitted according to the same process as 
described for SAE reporting in Section 7.4.1.4. 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
82/154
Investigators must actively follow up, document, and report on the outcome of all these 
pregnancies, even if the subjects are withdrawn from the trial.
The Investigator must notify the Sponsor/designee of these outcomes using the Pregnancy 
Report Form. If an abnormal outcome occurs, the SAE Report Form will be used if the subject 
sustains an event and the Parent-Child/Fetus Adverse Event Report Form if the child/fetus 
sustains an event.
Any abnormal outcome must be reported in an expedited manner as described in 
Section 7.4.1.4, while normal outcomes must be reported within 45 days after delivery.
In the event of a pregnancy in a subject occurring during the course of the trial, the subject 
must be discontinued from trial medication immediately. The Sponsor/designee must be 
notified without delay and the subject must be followed as mentioned above.
7.4.3
Laboratory Assessments
Samples will be sent to a central laboratory for analysis, and these values will be imported into 
the eCRF on a regular basis. The Investigator may also use local laboratory results for safety 
evaluations and real time individual dose adjustments. If clinically significant discrepancies or 
differences are deemed necessary to repeat a test at the Investigator's discretion, the follow-up 
testing must be done by the central laboratory.
It is essential that the Sponsor/designee be provided with a list of laboratory normal ranges 
before shipment of the trial drug. Any change in laboratory normal ranges during the trial will 
additionally be forwarded to the Sponsor/designee. An amount of blood volume for laboratory 
assessments is shown in Appendix F.
7.4.3.1
Hematology and Coagulation
Hematology and coagulation assessments, as described in Table 7.1, will be performed during 
the course of this trial including the screening period (3 mL of blood for blood counts plus 
4.5 mL for coagulation tests for a total of 7.5 mL). 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
83/154
Table 7.1
Hematology and Coagulation Parameters
Parameter
Hemoglobin (Hb)
Hematocrit (Hct)
Red blood cell count (RBC)
Platelets
White blood cell (WBC) count 
Differential WBC
!
Neutrophils
!
Eosinophils
!
Basophils
!
Monocytes
!
Lymphocytes
!
Other
Prothrombin time (PT)
Activated thromboplastin time (aPTT)
International normalized ratio (INR)
Abbreviations: aPTT, activated partial thromboplastin time; Hb, hemoglobin; Hct, hematocrit; INR, international normalized 
ratio; PT, prothrombin time; RBC, red blood cells; WBC, white blood cells.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
84/154
7.4.3.2
Biochemistry
Biochemistry assessments, as described in Table 7.2, will be performed during the course of 
this trial including the screening period.
Table 7.2
Biochemistry Parameters
Parameter
Blood urea nitrogen (BUN)
Creatinine
ALT 
AST 
GGT 
Total bilirubin 
Direct fraction of bilirubin (if total bilirubin is abnormal)
Lipase
Amylase
Total protein
Albumin
Alkaline phosphatase
Creatinine clearancea
Sodium
Potassium
Calcium
Magnesium
Glucose
a.
If calculated creatinine clearance during screening is < 60 mL/min, 
then 24-hour urine creatinine clearance might be requested by the 
Investigator for confirmation of renal impairment; must be performed 
at the central laboratory.
7.4.3.3
Urinalysis
Urinalysis assessments (dipstick) for Phase Ib and Phase II are presented in Table 7.3. The 
dipstick urinalysis will be followed by microscopic examination if abnormal results are 
obtained.
Table 7.3
Urinalysis Parameters
Parameter
Blood
Glucose
Ketones
Leukocytes
Nitrites
pH
Proteins
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
85/154
7.4.4
Vital Signs, Physical Examinations, and Other Assessments
7.4.4.1
Physical Examinations
The physical examination will be identical to a general medical check-up comprising a whole 
body inspection (general appearance, skin/subcutaneous tissue, head, eyes, ears, nose, throat, 
neck, thyroid, respiratory, cardiovascular, peripheral vascular, lymphatic, lymph 
nodes/immunology, abdomen, musculoskeletal, neurological and psychiatric, palpation, 
percussion, and auscultation. Body weight (kg) should be recorded prior to treatment 
administration of chemotherapy. Any clinically significant abnormal findings or worsening of 
conditions previously recorded in the medical history must be documented in the eCRF.
7.4.4.2
ECOG PS
ECOG PS will be assessed according to the criteria described in Appendix D, at the times 
described in Appendix A and Appendix B. 
7.4.4.3
Vital Signs
Systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate (beats per minute), 
respiratory rate (breaths per minute), and body temperature (°C) will be measured in the study. 
SBP and DBP should be measured in seated position after 5 minutes resting (for individual 
subjects, measurements at different visits should be taken in the same position). On days when 
ECGs are also performed, vital signs should be taken after sitting for 5 minutes and 
immediately prior to each ECG recording. 
7.4.4.4
Electrocardiogram
A standard 12-lead ECG will be recorded after the subject has rested at least for 5 minutes in a 
supine position. At least 5 to 7 beats for each lead run. All ECGs are taken in triplicate with up 
to 2 minutes between each ECG, immediately after measurement of vital signs, to monitor the 
heart rhythm and PR, QRS, QT, RR, and QTc intervals. For both phases of the study, QTc 
intervals will be corrected using Fridericia’s formula (QTcF). For Phase II, QTc will be 
calculated in eCRF. Results of the ECG recordings will be included in the subject's eCRF.
7.5
Pharmacokinetics
For Phase Ib, plasma concentrations of tepotinib and gefitinib will be obtained on Day 1 and 
Day 15 of Cycle 1. Samples will be taken predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours 
postdose (the 24 hour postdose is equivalent to predose on Day 2 and Day 16, respectively).
Altogether 4 mL (2 mL for tepotinib and 2 mL for gefitinib) of whole blood will be collected 
for each PK time point.
 
 
 
 
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
86/154
For both Phase Ib and Phase II, the plasma concentration of tepotinib will be determined by a 
validated liquid chromatography-tandem mass spectrometry method. The validation of the 
method will be presented separately.
In Phase Ib, the plasma concentration of gefitinib will be determined by a validated liquid 
chromatography-tandem mass spectrometry method. The validation of the method will be 
presented separately.
A laboratory manual will provide detailed instructions on proper sample collection, 
centrifugation, and further processing to plasma, storage, and shipment of PK samples. The 
eCRF will contain provisions for recording the protocol-specified nominal time of each 
specimen, as well as the actual time and date that the specimen was obtained. Recording of the 
test results in the eCRF is not required.
7.5.1
Body Fluids
All predosing samples should be taken within 60 minutes before each treatment administration. 
In Phase Ib, whole blood (2 mL samples) will be collected in ethylenediamine tetracetic 
acid-coated tubes for tepotinib PK samples, and whole blood (2 mL samples) will be collected 
in heparin-coated tubes for gefitinib PK samples. In Phase II, whole blood (2 mL samples) PK 
samples will be taken for tepotinib only.
Details about the tumor and blood sampling and processing procedures, storage, and 
transportation will be provided in a separate laboratory manual. Values and changes over time 
in Pd and screening markers will be assessed during the trial. Sampling time points of blood 
samples are presented in Appendix A (Phase Ib) and Appendix B (Phase II) and detailed in 
Appendix F. Blood sample volumes are presented in Appendix G.
7.5.2
Pharmacokinetic Calculations
The following PK parameters will be calculated and summarized from the measured individual 
plasma concentrations of tepotinib and gefitinib using non-compartmental methods.
! Cmax: observed maximum plasma concentration;
! tmax: time to reach maximum plasma concentration;
! λz: apparent terminal rate constant determined by log-linear regression analysis of the 
measured plasma concentrations of the terminal log-linear phase;
! t1/2: apparent terminal half-life, calculated by ln2/λz;
! AUC0-∞: area under the plasma concentration versus time curve from time zero to infinity. 
AUC0-∞will be calculated by combining area under the curve from time zero to time t 
(AUC0-t)and area under the curve excreted (AUCextra). AUCextra represents an extrapolated 
value obtained by Clast/λz, where Clast is the calculated plasma concentration at the last 
sampling time point at which the measured plasma concentration is at or above the lower 
limit of quantification (LLQ). If the value of AUCextra provides more than 20% of AUC0-
∞, this parameter and all related parameters (eg, total body clearance of drug [CL] and 
volume of distribution associated to the terminal phase [Vz]) will be rejected as 
implausible and not included for further statistical analysis;
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
87/154
! AUC0-t: area under the plasma concentration versus time curve from time zero to the last 
sampling time (ie, t) at which the concentration is at or above the LLQ. AUC0-t will be 
calculated according to the mixed log-linear trapezoidal rule;
! AUC0-tau: area under the plasma concentration versus time curve within 1 dosing interval.
Further derived PK parameters will be calculated, when appropriate:
! CL/F: apparent body clearance of the drug from plasma, CL = Dose/AUC0-∞;
! Vz/F: apparent volume of distribution associated to the terminal phase, calculated by 
Dose/(AUC0-∞*λz);
! Vss/F: volume of distribution at steady state, CL, mean resident time.
The PK evaluation shall be carried out under the responsibility of the Sponsor.
The PK variables will be analyzed descriptively for each treatment and administration 
separately. Descriptive statistics include number of subjects, arithmetic mean, geometric mean, 
standard deviation (StD), standard error of the mean, median, minimum, maximum and 
coefficient of variation (CV in %). The drug concentration in plasma at each sampling time 
will be presented on the original scale for all subjects who participated in the trial. Values 
below LLQ will be taken as zero for descriptive statistics of concentrations. Individual plasma 
concentration-time profiles (linear and semi-logarithmic scale) will be plotted by treatment. 
Mean plasma concentrations per treatment and administration will be plotted with StD using 
schedule time points. The weight-normalized PK parameters will be calculated if it would be 
appropriate.
Formal statistical hypotheses will not be performed. All statistical tests will be performed in an 
explorative way. All analyses will be based on the PK analysis set. Details of the statistical 
analyses will be described in the SAP.
 
 
 
 
 
 
 
 
 
 
 
 
7.6
Biopsies, Biomarkers, and Pharmacogenomics
Details about the tumor and blood sampling and processing procedures, storage, and 
transportation will be provided in a separate laboratory manual. Values and changes over time 
in Pd and stratification markers will be assessed during the trial. Sampling time points of blood 
samples for PK/Pd are detailed in Appendix F. The storage period of tumor tissue and blood 
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
88/154
will be up to 12 years after the end of the trial. During this time, it is possible that the 
samples/data/medical information will be re-analyzed for meta-analyses, post hoc analyses, or 
other investigations in the scope of the project by the Sponsor. After this period, the samples 
will be destroyed by the Sponsor.
7.6.1
Tumor Biopsies
Pretreatment Biopsy
A pretreatment tumor biopsy (excluding fine needle aspiration and cytology samples) is 
mandatory in both the Phase Ib and Phase II parts.
For the Phase Ib, tumor tissue will be collected for MET status diagnosis. For subjects who 
experienced at least 1 anticancer treatment, the biopsy should be obtained between failure of 
the most recent anticancer treatment and enrollment.
For the Phase II, tumor tissue will be collected for MET status diagnosis, T790M mutation 
status determination (if no documented result is already available), as well as EGFR mutation 
status confirmation (if no documented result is already available). The new biopsy should be 
obtained between documentation of acquired resistance to first-line gefitinib, erlotinib, icotinib,
or afatinib and enrollment.
Whenever possible, the biopsy taken for determination of the MET status should be taken from 
the progressing lesion (primary or metastatic, whichever applies), provided that the lesion is 
accessible and there are no medical or safety reasons precluding a biopsy of the progressing 
lesion. Samples must be sent to the central laboratory prior to enrollment.
For pretreatment biopsy, 8 to 10 formalin-fixed paraffin-embedded (FFPE) sections (≥10% 
viable tumor cells) or paraffin block with tumor tissue (preferable) are required, the minimal 
number of required sections will be re-evaluated after the Phase Ib. For subjects without 
documented EGFR mutation in the Phase II part, 10 to 15 FFPE sections are required.
Optional Biopsies
The optional biopsies (excluding fine needle aspiration and cytology samples) include: 
! Additional pretreatment biopsy second pass in screening period or pre-dose on Cycle 1, 
Day 1;
! On-treatment biopsy;
! End-of-Treatment biopsy.
Paired tumor biopsies are not mandatory, but highly recommended for subjects with accessible 
tumors (highest priority in Phase Ib). Paired tumor biopsies should be taken before the 
treatment period (preferentially as second pass when biopsy for screening purposes is taken) 
and during the treatment period (can be taken any time between Cycle 1, Day 15 and the 
beginning of Cycle 3). If a tumor shows progression after initial response to tepotinib+gefitinib, 
a third biopsy is highly desirable when progression is diagnosed at the End-of-Treatment visit
(highest priority in Phase II). 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
89/154
For all subjects of Phase Ib and Phase II, the feasibility of a paired biopsy and End-of-
Treatment biopsy should be regularly reviewed and any reasonable effort should be made to 
obtain these additional biopsies.
Analysis of MET status and related markers will be performed on the tumor samples after 
consent has been obtained from the subjects. Tumor biopsies will be performed for analysis of 
specific markers (see Section 7.6.2).
7.6.2
Tumor Tissue Biomarkers
The pretreatment tumor biopsies (excluding fine needle aspiration and cytology samples) will 
be assessed to investigate the following:
1)
Selection biomarkers for both Phase Ib and Phase II: MET+ (cMET IHC for phase 
IB and cMET IHC and cMET FISH for the phase II)
MET+ status is based on:
c-Met overexpression determined by cMET IHC (IHC 2+ and IHC 3+)
and/or
Alterations of cMET gene copy numbers as determined by cMET ISH (ratio 
MET/CEN7≥ 2.0 and/or GCN ≥ 5).
cMET protein overexpression will be tested prospectively in Phase IB and Phase II.
c-Met amplification will be tested retrospectively in Phase Ib and prospectively in Phase II; 
technical details are specified in the laboratory manual.
2) 
Selection biomarkers for Phase II: Absence of the EGFR T790M mutation. 
T790M negative, MET+ subjects will be enrolled into the 2-arm randomized Phase II part of 
the trial and treated either with tepotinib + gefitinib or pemetrexed + cisplatin/carboplatin. 
In mainland China, an additional single-arm cohort of n=15 T790M positive, MET+ subjects 
will be enrolled and treated with tepotinib + gefitinib.
The EGFR T790M mutation status will be assessed by a central laboratory, using a validated 
PCR test. Technical details are specified in the laboratory manual. 
3) 
Exploratory biomarkers 
They will include, but will not be limited to, markers of c-Met pathway activation (eg, HGF 
levels, c-Met mutations), and other relevant oncogenic pathways.
7.6.3
Blood Biomarkers
Blood samples (20 mL) will be collected at pre-treatment, concurrent with treatment Cycles 1,
2, 4, 6, 8, 10, 12, as well as at the EOT visit. Blood samples will be obtained at tumor 
assessment visits.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
90/154
The aim of this sampling regimen is to facilitate molecular monitoring to study the relationship 
between molecular disease progression and clinical progression, a well-known benefit of the 
liquid biopsies. Liquid biopsy based molecular monitoring could be utilized as the basis for
clinical decision making in the future to greatly improve subjects’ treatment by reducing biopsy 
requirements.
Samples will be processed as appropriate or stored for exploration of potential new biomarkers 
based on future research or for new stratification biomarker identification by new technologies. 
 
 
7.7
Health Related Quality of Life Assessments
All subjects in Phase II are required to take part in all PRO assessments. The LCSS (see 
Appendix K), EORTC QLQ-C30 (see Appendix L), and 
 will be 
completed by the subject before any procedures are performed, and at the time points noted in 
the Schedule of Assessments described in Section 7.1 and Appendix B. Only countries/centers 
where validated local language(s) version of the subject scale of the questionnaires are
available, will take part in the PROs assessments.
The Sponsor will provide training for relevant personnel (eg, key Investigators, clinical 
research assistants) in the administration of the questionnaires, so that subjects fill in the 
questionnaires as completely and accurately as possible. It is important that the significance 
and relevance of the data are explained carefully to participating subjects so that they are 
motivated to comply with data collection (25).
Questionnaires will be handed to the subject and should be completed at the investigational 
center, in approx. 20 to 30 minutes, prior to the initiation of any other trial activities or active
treatments and prior to any contact with the Investigator. Efforts should be made at the 
investigational center (eg, by nominating a nurse) to ensure that fully completed questionnaires
are obtained from every subject at each scheduled time point, so as to not delay any clinical 
assessments. 
The measures are self-reported and the subject must complete the questionnaires in person and 
should not be given help from relatives/friends or clinic staff; help in interpreting the questions 
is not allowed. Subjects will be asked to fill in the questionnaires as completely and accurately 
as possible. 
In case local regulations stipulate requirements regarding confidentiality of questionnaire 
completion (ie, completed questionnaires not to be seen by the clinic staff), all appropriate 
arrangements will be made at the investigational center to ensure confidentiality.
7.7.1
Lung Cancer Symptom Scale
The LCSS is a validated questionnaire consisting of an observer scale and a subject scale 
(Appendix K) used to specifically measure symptom changes relevant to QoL for individuals 
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
91/154
undergoing treatment for lung cancer (26, 27, 28). In this trial, the subject scale will be used as
a tool to help to determine TTSP. The 9-item questionnaire used to document subject-reported 
outcomes for a variety of lung cancer associated symptoms will be used in this trial. The data 
derived provides a level of detail in determining clinical benefit that is unavailable from the 
review of other endpoints. 
The average symptomatic burden index (ASBI) will be used to determine differences in the 
two treatment arms in the randomized part of Phase II and to evaluate subjects in the single-
arm cohort. The ASBI is the mean of all six symptom scores treated as a single domain. TTSP 
will be defined as an increase (worsening) of the ASBI score of 10% of the scale breadth 
(10 mm on a scale of 0-100 mm) from the baseline score. 
If 3 or more items are missing, the subject will be considered non-evaluable at that time point. 
For each symptom score, the distance from the left boundary to the point where the subject has 
marked the line is measured in millimeters. The total scale length is 100 mm.
7.7.2
EORTC QLQ-C30
The EORTC QLQ-C30 (Appendix L) is a questionnaire developed to assess the QoL of cancer 
subjects. The EORTC QLQ-C30 (Version 3.0) is available in 81 languages and has been used 
in trials worldwide. It is cancer specific and consists of 5 functional scales (physical, role, 
cognitive, emotional, social), 4 symptom scales (fatigue, pain, nausea, vomiting), a global 
health status scale, and several single items (including dyspnea, loss of appetite, and insomnia). 
The questionnaire consists of 30 multiple choice questions.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
92/154
8
Statistics
8.1
Sample Size
In Phase Ib, the total number of subjects in the “3+3” dose escalation cohorts is approximately 
15 to 18, on the basis of the “3+3” dose escalation method with 2 dose cohorts: 3 or 6 in the 
dose escalation cohort and a potential for 3 or 12 subjects in dose confirmation cohort (if dose 
de-escalation does not occur). The final sample size depends on the number of subjects who 
experience DLTs at each dose level, safety and emerging available PK data and decision from 
the SMC meeting. In addition, separately from the “3+3” dose escalation cohorts, up to an 
additional 3 evaluable subjects will be enrolled in the mainland China sites.
In the randomization part of Phase II, the initial sample size planning required 111 PFS events 
(assessed by Investigator) to ensure 80% power with a two-sided significance level of 10% for 
rejecting the null hypothesis of equal treatment effect between treatment arms, assuming a true 
hazard ratio of 0.6. Assuming a median PFS time of 5 months in the control arm, a hazard ratio 
of 0.6 represents a 3.3 months increase, resulting in a median PFS time of 8.3 months for the 
experimental arm. With other assumptions: 1) accrual period of 39 months and follow-up 
period of 9 months; 2) randomization ratio of 2:1 (experimental vs. control arm); 3) overall 
drop-out rate of ~15%; 4) 1 non-binding futility analysis with futility boundary α0 = 0.81 was
planned to be performed after observation of 50% of PFS events. A total of approximately 
156 subjects were planned to be randomized to receive tepotinib+gefitinib or 
pemetrexed+cisplatin/carboplatin. From study start to approval of Protocol Version 7.0, 
subjects were randomized at a 1:1 ratio
to receive either tepotinib+gefitinib or 
pemetrexed+cisplatin. From the approval of Protocol Version 7.0 onwards, subjects were
randomized 
at 
a 
2:1 
ratio 
to 
receive 
either 
tepotinib+gefitinib 
or 
pemetrexed+cisplatin/carboplatin. The Sponsor subsequently decided to halt enrollment. The 
sites were notified about the enrollment halt on 25 May 2017. The last subject was randomized 
on 12 June 2017. Until then 55 subjects had been randomized.
In the single-arm cohort of Phase II, up to 15 subjects with T790M positive, MET+ status were 
planned to be enrolled (mainland China sites only). All subjects enrolled under clinical trial 
protocol Version 2.0 with T790M positive status and randomization to the experimental arm 
will count into this single-arm cohort as well, meaning that the number of 15 subjects will be 
reduced by these subjects, and T790M positive subjects enrolled under clinical trial protocol 
Version 2.0 and T790M positive subjects from the mainland China sites enrolled under clinical 
trial protocol Version 3.0 will be analyzed as one group.
By the time of the enrollment halt, all 15 subjects with MET+ T790M positive NSCLC had 
been enrolled.
8.2
Randomization
Randomization will only occur in the randomized part of Phase II and has been performed 
centrally by using an IVRS.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
93/154
From study start to approval of Protocol Version 7.0, eligible subjects were randomized at a 
1:1 ratio to receive either tepotinib+gefitinib or pemetrexed+cisplatin. From the approval of 
Protocol Version 7.0 onwards, subjects were randomized at a 2:1 ratio to receive either 
tepotinib+gefitinib or pemetrexed+cisplatin/carboplatin. A
stratified permuted block 
randomization procedure was employed using the following strata:
! Type of MET+: protein overexpression IHC2+ vs. protein overexpression IHC3+ vs. gene 
amplification and/or increased c-Met GCN, both by ISH.
! Prior EGFR-TKI treatment: Gefitinib vs. erlotinib vs. icotinib vs. afatinib.
Please note that subjects with the co-existence of protein over expression and gene 
amplification and/or increased c-Met GCN were included in the amplification and/or increased 
c-Met GCN stratum.
8.3
Endpoints
8.3.1
Primary Endpoints
The primary endpoints are: 
Phase Ib: 
! Incidence of subjects experiencing at least 1 DLT in Cycle 1 (ie, 21 days after the first 
dose of trial medication);
! Incidence and type of other AEs.
Phase II: 
! PFS assessed by Investigator in the randomized part of Phase II. PFS time is defined as 
the time (in months) from randomization to either the first observation of documented PD 
per RECIST Version 1.1 (as assessed by the Investigator) or occurrence of death due to 
any cause, whichever is latest, within 84 days of either randomization or the last tumor 
assessment.
Tumor assessments are performed according to RECIST Version 1.1 (see Appendix C).
8.3.2
Secondary Endpoints 
The safety endpoints will comprise:
! Drug exposure;
! Incidence and type of TEAEs, toxicity grades as per NCI-CTCAE (Version 4.0); 
treatment-related TEAEs, SAEs, treatment-related SAEs, TEAEs with toxicity Grade ≥ 3, 
treatment-related TEAEs ≥3, and TEAEs leading to permanent treatment discontinuation;
! Incidence and reasons for deaths within 30 (±3) days after the last dose of study drug;
! Safety laboratory tests graded by NCI-CTCAE (Version 4.0);
! Vital signs, 12-lead ECG changes, physical examination, including change in body weight, 
and ECOG PS.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
94/154
Other secondary endpoints include:
! PFS assessed by IRC in the randomized part of Phase II. PFS time is defined as the time 
(in months) from randomization to either the first observation of documented PD per 
RECIST Version 1.1 (as assessed by an IRC) or occurrence of death due to any cause 
within 84 days of either randomization or the last tumor assessment;
! PFS assessed by Investigator and IRC in single-arm cohort of Phase II. PFS time is defined 
as the time (in months) from the first administration of the trial treatment to either the first 
observation of documented PD per RECIST Version 1.1 (as assessed by the Investigator
and IRC) or occurrence of death due to any cause within 84 days of either the first 
administration of the trial treatment or the last tumor assessment.
! OS time: OS time is defined as the time (in months) from randomization/the first 
administration of the trial treatment to the date of death in the randomized part of Phase II/ 
the single-arm cohort of Phase II;
! Tumor response as measured by objective response (OR) and disease control based on 
RECIST Version 1.1. OR is defined as CR or PR as the best overall response according 
to local radiological assessments from randomization/the first administration of the trial 
treatment to the first observation of PD. Responses do not require confirmation according 
to RECIST Version 1.1; disease control is defined as CR, PR, or SD as the best overall 
response according to local radiological assessments from the date of randomization/the 
first administration of the trial treatment to the first observation of PD. In the case of SD, 
measurements must have met the SD criteria at least once after entry at a minimum interval
of 42 days after randomization/the first administration of the trial treatment;
! PK (Phase Ib only): AUC0-t, AUC0-tau, Cmax, average plasma concentration (Cavg), 
minimum concentration (Cmin), tmax, AUC0-∞, CL/F, Vz/F, Vss/F, λz and t1/2 (when 
appropriate);
! Health related quality of life (HRQoL) endpoints (Phase II only) will be assessed using 
EORTC QLQ-C30 (Version 3.0) and TTSP as measured by LCSS.
8.3.3
Exploratory Endpoints
Exploratory endpoints in this trial are: 
! Exploratory biomarkers include biomarkers that may correlate with antitumor activity, 
including, but not limited to, markers of c-Met pathway activation (eg, HGF levels, and 
c-Met mutations), other relevant oncogenic pathways.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
95/154
8.4
Analysis Sets
! All Screening Analysis Set: 
The All Screening Analysis Set includes all subjects who have provided the informed 
consent (ie, screening failures plus subjects enrolled). 
! DLT Analysis Set (Phase Ib part only): 
The DLT Analysis Set includes all subjects who experienced a DLT during Cycle 1, or did 
not experience a DLT, and completed at least 80% of planned treatment during the DLT 
observation period (21 days after the first dose administered). Subjects who have been 
replaced during the Cycle 1 will be excluded from the DLT Analysis set (for replacement 
criteria, see Section 5.6).
The DLT Analysis Set will be used for evaluation of the number of subjects experiencing 
any DLTs at the end of each cohort and for the assessment of the RP2D in Cycle 1. Subjects 
who have been replaced during the Cycle 1 or who belong to the additional cohort for 
subjects from the mainland China sites will be excluded from the DLT analysis set (for 
replacement criteria, see Section 5.6).
! Safety Analysis Set: 
In Phase Ib, the Safety Analysis Set includes all subjects who have received at least 1 dose 
of tepotinib or gefitinib. Subjects replaced for evaluation of DLT and subjects who are from 
mainland China sites will still be included in the Safety Analysis Set if they are treated at 
least once (ie, the above criteria is met). 
In Phase II, the Safety Analysis Set includes all subjects who have received at least 1 dose 
of tepotinib, gefitinib, pemetrexed, cisplatin, or carboplatin. 
In Phase Ib and Phase II, the Safety Analysis Set will be used for all summaries of safety 
data. Subjects will be allocated as treated.
In Phase Ib and the single-arm cohort of Phase II, the Safety Analysis Set will also be used 
for summaries of demographic and baseline characteristics.
! Intent-to-Treat (ITT) Analysis Set (Randomized part of Phase II only): 
The ITT Analysis Set consists of all subjects in randomized part of Phase II who were 
randomized to study treatment. Subjects will be allocated as randomized. 
The ITT will be used for summaries of demographic and baseline characteristics.
! QoL evaluable population (Phase II only): 
In the randomization part of Phase II, QoL evaluable population includes all ITT subjects 
with a baseline and at least one evaluable on-treatment QoL questionnaire.
In the single-arm cohort of Phase II, QoL evaluable population includes subjects in Safety 
Analysis Set with a baseline and at least one evaluable on-treatment QoL questionnaire.
! Subgroups of interest: 
Other subgroups are considered to be of interest to explore the treatment effect of 
tepotinib+gefitinib in an exploratory manner. These could include (depending on the actual 
size of the subgroups): 
o Age: < 65 years vs. ≥ 65 years;
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
96/154
o Gender: male vs. female;
o Type of MET: protein overexpression IHC2+ vs. protein overexpression IHC3+;
o Type of MET: gene amplification and/or increased c-Met GCN by ISH vs. neither gene 
amplification nor increased c-Met GCN;
o Histological subtype: adenocarcinoma vs. non-adenocarcinoma;
o Smoking history: never smokers vs. ever smokers.
! PK Analysis Set: 
All subjects who have received at least 1 dose of the tepotinib or gefitinib and who have 
provided at least 1 plasma concentration measurement of tepotinib or gefitinib after the first 
dose.
! Pd Analysis Set: 
All subjects who have received at least 1 dose of study drug and have the baseline and at 
least 1 post-baseline Pd/Biomarkers assessment.
8.5
Description of Statistical Analyses
8.5.1
General Considerations
As this study has 2 components, with 2 different objectives that will be investigated at different 
stages, the SAP will evolve over time to address the trial reporting needs.
Statistical analyses of the Phase Ib data will be carried out in a descriptive manner whereas 
Phase II has a confirmatory component when analyzing PFS time.
Statistical analyses will be performed using eCRF data in general. In Phase Ib, data will be 
analyzed after 21 days dosing of the last subject. The DLT population is the underlying data 
set for the MTD determination. In Phase Ib and Phase II, safety analyses will be performed 
according to the as-treated principle. Safety data will be descriptively analyzed on the Safety 
Analysis Set. AEs will be coded according to the current Medical Dictionary for Regulatory 
Activities (MedDRA) and reported by system organ class (SOC) and preferred term. The 
severity of AEs will be graded using NCI-CTCAE (Version 4.0) toxicity grades.
In Phase Ib and single-arm cohort of Phase II, efficacy analyses will be performed on the safety 
population. Safety Analysis Set will be primarily used in the analysis of baseline characteristic 
and efficacy. In the randomization part of Phase II, the analysis of efficacy endpoints in the 
ITT population requires a clinical cut-off date, which is determined by the date after the 
required number of events for the primary endpoint has been reported. 
In randomized part of Phase II, the ITT Analysis Set will be primarily used in the analysis of 
baseline characteristic and efficacy. Analyses on ITT population will consider subjects’ 
allocation to treatment arms as randomized.
In order to provide overall estimates of treatment effect, data will be pooled across centers. The 
factor center will not be considered in statistical models or for subgroup analyses because of 
high number of participating centers and the anticipated small number of subjects randomized 
in each center. 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
97/154
All statistical tests comparing treatment arms in the randomized part of Phase II will be 
performed two-sided using a significance level of α = 10%, unless otherwise stated. If 
confidence intervals (CIs) are to be calculated, they will be two-sided with a confidence 
probability of 90%, unless otherwise stated.
Continuous variables will be summarized using descriptive statistics, ie, number of subjects, 
mean, median, StD, 25th and 75th percentiles (Q1, Q3), minimum and maximum values. CIs will 
be presented where appropriate. 
Qualitative variables will be summarized by means of counts and percentages. Unless 
otherwise stated, the calculation of proportions will be based on the sample size of the 
population of interest. Counts of missing observations will be included in the denominator and 
presented as a separate category.
In general, in the randomized part of Phase II, the last measurement prior to or on the day of 
randomization will serve as the baseline measurement. In the Phase Ib and single-arm cohort
of Phase II, the last measurement prior to or on the day of the first administration of the trial 
treatment will serve as the baseline measurement.
The primary analysis of the Phase II part will be conducted once all subjects have either been 
treated for at least 6 months, died or have prematurely discontinued trial treatment for any 
reason, whichever comes first. 
The final analysis will be conducted once the last subject discontinued treatment and completed 
the subsequent safety follow-up visit.
Details of the statistical analyses will be defined in the SAP.
8.5.1.1
Protocol Deviations
All protocol deviations, including inclusion/exclusion criteria violations and deviations during 
the trial, will be listed, even if they are believed not to influence any of the results. The 
SMC/IDMC meetings will evaluate potential protocol deviations that could affect the 
MTD/RP2D determination (Phase Ib) and Phase II. The definition of protocol deviations will 
be specified in the SMC/IDMC’s charter or in the SMC/IDMC’s SAP.
8.5.1.2
Missing Data
Unless otherwise specified, missing data will not be imputed. For the derivation of new 
variables the following rules will apply:
Incomplete AE-related dates will be handled as follows:
! In case the onset date is completely missing or the onset is in the same year (if the onset 
year is available only) or the onset is in the same month and year (if the day is missing) as 
start of study treatment then the onset date will be replaced by the minimum of start of 
study treatment and AE resolution date;
! In all other cases the missing onset day or onset month will be replaced by 1;
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
98/154
! Incomplete stop dates will be replaced by the last day of the month (if day is missing only), 
if not resulting in a date later than the date of subject's death. In the latter case the date of 
death will be used to impute the incomplete stop date;
! In all other cases the incomplete stop date will not be imputed. 
For imputing missing parts of dates for the efficacy analyses the missing day in a date will be 
imputed as the fifteenth of the month, if month and year are documented. This also includes 
also dates of start of follow-up therapy. In all other cases missing or incomplete dates will not 
be imputed if not indicated otherwise.
In individual subject data listings the documented date as given in the eCRF will be reported. 
If applicable, imputed values will be presented, and the imputed information will be flagged.
8.5.2
Analysis of Primary Endpoints
8.5.2.1
Statistical Analysis of the Dose Escalation Cohort 
The DLT Analysis Set will be used for evaluation of the number of subjects experiencing any 
DLTs at the end of each cohort and for the assessment of the RP2D. 
For final statistical analysis, the number and proportion of subjects in the DLT population who 
experienced DLT during the Cycle 1 of treatment with tepotinib+gefitinib will be presented by 
dose level. Subject disposition will be reported for each dose level, and subject profiles will be 
presented. 
Listings and graphics of information which is relevant to the primary endpoint will be prepared 
for the SMC, for the purpose of determination of the MTD/RP2D of tepotinib+gefitinib, 
according to the content agreed and specified in the SMC’s charter. 
The MTD/RP2D will be determined as described in Section 6.2.1.
8.5.2.2
Statistical Analysis of Primary Endpoint of Phase II 
The primary endpoint of the randomized part of Phase II in this study is PFS as assessed by 
Investigator/site radiologist
according to RECIST Version 1.1. PFS (assessed by 
Investigator/site radiologist) time is defined as the time (in months) from randomization to 
either the first observation of documented PD per RECIST Version 1.1 or death in T790M
negative, MET+ subjects due to any cause within 84 days of either randomization or the last 
tumor assessment. If no progression or death is observed, or if death without previously 
documented PD is observed after more than 84 days of last tumor assessment without 
progression, the PFS time will be censored on the date of last tumor assessment or date of 
randomization, whatever occurs later. The 84-day time window represents 2 scheduled tumor 
assessments.
The primary analysis will test the equality of PFS time between treatment arms in the 
randomized part of Phase II, based on the ITT population, applying a two-sided stratified 
log-rank test at a significance level of α = 10%, taking into account for the strata used for 
randomization, ie, type of MET+ and prior EGFR-TKI.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
99/154
The following null hypothesis is tested:
H0: ∃A(t) = ∃B(t) versus H1: ∃A(t)=%∃B(t), % & 1,
where ∃(t) represents the hazard at time t and % the unknown constant of proportionality of 
hazards in the allocated treatment arms in the randomized part of Phase II (experimental and 
control arms).
The hazard ratio (including 90% CIs) of tepotinib+gefitinib compared to chemotherapy 
(pemetrexed+cisplatin/carboplatin) will be calculated by Cox's proportional hazards model 
stratified by type of MET+ and prior EGFR-TKI treatment.
Kaplan-Meier survival curves (product-limit estimates) will be presented by treatment arm 
together with a summary of associated statistics including the corresponding two-sided 
90% CIs. The CIs for the median will be calculated according to Brookmeyer and Crowley
(30), and CI for the survival function estimates at above defined time points will be derived 
directly from the Kaplan-Meier estimates. The estimate of the standard error will be computed 
using Greenwood's formula. 
8.5.3
Analysis of Secondary Endpoints
8.5.3.1
Progression-free Survival
In randomized part of Phase II, progression-free survival time (assessed by IRC) is defined as 
the time (in months) from randomization to either the first observation of PD or occurrence of 
death due to any cause within 84 days of either randomization or the last tumor assessment. If 
no progression or death is observed, or if death without previously documented PD is observed 
after more than 84 days of last tumor assessment without progression, the PFS time will be 
censored on the date of last tumor assessment or date of randomization, whatever occurs later. 
The 84-day time window represents time between 2 scheduled tumor assessments. 
The same survival analysis methods will be employed as for the primary endpoint, PFS 
assessed by Investigator, PFS assessed by IRC will be further explored considering pre-defined 
subgroups (see Section 8.4).
In the single-arm cohort of Phase II, progression-free survival time (assessed by Investigator
and IRC) is defined as the time (in months) from the first administration of the trial treatment 
to either the first observation of PD or occurrence of death due to any cause within 84 days of 
either the first administration of the trial treatment or the last tumor assessment. If no 
progression or death is observed, or if death without previously documented PD is observed 
after more than 84 days of last tumor assessment without progression, the PFS time will be 
censored on the date of last tumor assessment or date of the first administration of the trial 
treatment, whatever occurs later. The 84-day time window represents time between 2 scheduled 
tumor assessments. 
For PFS time in T790M positive, MET+ subjects (single-arm cohort of Phase II), it will be 
presented in subject listings and analyzed using the Kaplan-Meier method in the safety analysis 
set.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
100/154
8.5.3.2
Overall Survival (Phase II only)
In randomized part of Phase II, a preliminary analysis on OS may be performed when PFS, as 
assessed by Investigator is analyzed. Final OS analysis will be carried out when death has been 
reported in at least two-thirds of subjects. 
Overall survival will be measured as the time (in months) between the date of randomization 
and the date of death. The analysis will be performed on the basis of the ITT population. OS 
time (in months) is defined as:
(date of death or last date known to be alive – date of randomization + 1)/30.4375.
For subjects not known to be deceased at time of analysis, the time between date of 
randomization and date of last contact or date of lost to follow-up, will be calculated, and used 
as a censored observation in the analysis. If this date is after the data cut-off, then the subjects 
will be censored at the date of data cut-off.
Treatment arms will be compared, based on ITT population, applying two-sided stratified 
log-rank test at a significance level of α = 10% taking into account for strata used for 
randomization, type of MET+ and prior EGFR-TKI. 
The hazard ratio (including 90% CI) of tepotinib+gefitinib compared to chemotherapy 
(pemetrexed+cisplatin/carboplatin) will be calculated by Cox's proportional hazards model 
stratified by type of MET+ and prior EGFR-TKI treatment.
In the single-arm cohort of Phase II, OS will be measured as the time (in months) between the 
date of the first administration of the trial treatment and the date of death. The analysis will be 
performed on the basis of the Safety Analysis Set.
Furthermore, OS time in subjects from the single-arm cohort of Phase II will be presented in 
subject listings and analyzed using the Kaplan-Meier method in the Safety Analysis Set.
8.5.3.3
Antitumor Activity
OR and disease control will be evaluated based on the ITT population in randomized part of 
Phase II and the Safety Analysis Set in the Phase Ib and the single-arm cohort of Phase II. 
In the randomized part of Phase II, the OR rate is evaluated as the proportion of subjects having 
achieved CR or PR as the best overall response according to local radiological assessments 
from the date of randomization to the end of study treatment. Responses do not require 
confirmation according to RECIST Version 1.1.
In Phase Ib and single-arm cohort of Phase II, the OR rate is evaluated as the proportion of 
subjects having achieved CR or PR as the best overall response according to local radiological 
assessments from the date of the first administration of the trial treatment to the end of study 
treatment. Responses do not require confirmation according to RECIST Version 1.1.
The disease control rate is defined as the proportion of subjects having achieved CR, PR or SD 
as the best overall response according to local radiological assessments from randomization/the 
first administration of the trial treatment until the end of study treatment in the randomized part 
of Phase II/the single-arm cohort of Phase II and Phase Ib. In the case of SD, measurement 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
101/154
must have met the SD criteria at least once after study entry at a minimum interval of 42 days 
after randomization/the first administration of the trial treatment.
In randomized part of Phase II, the Cochran-Mantel-Haenszel test will be performed for 
analysis using the randomization strata, type of MET+ (protein overexpression IHC2+ vs. 
protein overexpression IHC3+ vs. gene amplification and/or increased c-Met GCN, both by 
ISH) and prior EGFR-TKI. The Cochran-Mantel-Haenszel will test the following 2-sided 
hypothesis:
H0: Ψ=1 versus H1: Ψ≠1
where Ψ defines the common odds ratio across all strata.
In general, the OR rate and disease control rate will be presented for each treatment arm in the 
randomized part and the single-arm cohort in the non-randomized part of Phase II, as well as 
each dose level of the “3+3” dose escalation cohorts and the additional mainland China cohort 
of Phase Ib, including the corresponding 90% Clopper-Pearson CIs.
Duration of response will be presented descriptively. 
Further exploratory analyses will be performed for the per-protocol population and predefined 
subgroup (see Section 8.4). 
8.5.3.4
Safety and Tolerability Analyses
The Safety Analysis Set will be used for summaries of demographic and baseline 
characteristics in Phase Ib and the single-arm cohort of Phase II, as well as for all summaries 
of safety data (except for DLT analysis) in both Phase Ib and Phase II. 
Safety analyses will be performed according to as-treated principle. Any TEAE will be 
summarized, ie, those events that are emergent during treatment having been absent 
pretreatment, or worsen relative to the pretreatment state and with onset dates occurring within 
the first dosing day of study treatment until 30 ± 3 days after the last dose of study treatment.
No formal statistical comparisons are planned.
The extent of exposure to tepotinib, gefitinib, pemetrexed, cisplatin, or carboplatin will be 
characterized by time on treatment (weeks), cumulative dose, dose intensity, relative dose 
intensity (actual cumulative dose/planned dose), number of dose reductions, and number of 
dose delays.
AEs will be coded according to the MedDRA. Severity of AEs will be graded using 
NCI-CTCAE (Version 4.0) toxicity grade. The incidence and type of AEs, SAEs, AESIs, study 
treatment-related AEs and SAEs, AEs of Grade ≥3 by NCI-CTCAE, study treatment-related 
AEs of Grade ≥3 by NCI-CTCAE (Version 4.0), AEs leading to death, study treatment-related 
AEs leading to death, and AEs leading to treatment discontinuation, will be summarized in 
total and for each treatment group according to MedDRA SOC and preferred terms. AE 
summaries will be prepared for Cycle 1 and the whole treatment period.
All deaths and deaths within 30 (±3) days after last dose of study treatment as well as reasons 
for death will be tabulated.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
102/154
Laboratory results will be classified according to NCI-CTCAE (Version 4.0). The worst 
on-treatment grades after the first dose of the study treatment will be summarized. Shifts in 
toxicity grades from treatment start to the highest grade will be displayed. Results for variables 
that were not part of the NCI-CTCAE (Version 4.0) will be presented as below, within and 
above the normal limits of the local laboratory. Only subjects with postbaseline laboratory 
values will be included in these analyses. The last measurement before study treatment will 
serve as the baseline measurement. Descriptive summaries of actual (absolute) laboratory 
values and changes from baseline will be presented. 
Changes in body weight from Baseline to measurements during the treatment phase will be 
classified according to the NCI-CTCAE (Version 4.0) criteria. The highest change from 
baseline will be summarized.
Clinically significant, abnormal findings from 12-lead ECG during treatment phase will be 
descriptively presented.
Changes from Baseline to worst on-treatment value will be summarized descriptively for the 
QTc interval (including absolute changes and categorical shifts).
Vital signs (body temperature, pulse rate, blood pressure, respiratory rate) recorded at Baseline 
will be descriptively presented.
Baseline results of the physical examination will be presented. Clinically significant, abnormal 
findings from the physical examination are to be reported as AEs. Separate summaries of the 
physical examination during and after treatment will therefore not be provided.
The ECOG PS will be summarized descriptively by visit.
Further details on safety analyses will be specified in the SAP.
Statistical Analyses for the Dose Escalation Decision
Within each dose level and upon completion of Cycle 1 of treatment by the last subject in the 
“3+3” dose escalation cohorts of Phase Ib, data from analyses will be presented to the SMC for 
a decision on dose escalation. These analyses will include safety data only from Cycle 1 and 
all safety data from subjects exposed to study combination above Cycle 1, including listings of 
AEs graded according to NCI-CTCAE (Version 4.0) and DLT, listings of laboratory data, vital 
signs, ECGs, as well as each subject’s demographics, disease history, and treatment compliance 
in Cycle 1. Any protocol deviation that could affect DLT will be monitored and reported at 
each SMC. The full data to be presented will be documented in detail in the SMC charter.
All subjects in the safety analysis set will be included in the listings. Subjects that have been 
replaced during Cycle 1 will be flagged.
8.5.3.5
Pharmacokinetics
Pharmacokinetic parameters for the Phase Ib and Phase II parts of the trial are described in 
Section 7.5.2. For PK evaluation of Phase Ib, individual plasma and mean (± StD) 
concentration time plots will be provided for each dose cohort using a linear and semi-
logarithmic scale. 
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
103/154
The plasma concentration data for tepotinib and gefitinib will be separately summarized 
descriptively per dose cohort and per time point. Descriptive statistics will include number of 
subjects, arithmetic mean, geometric mean, median, StD, minimum, and maximum values and 
CV in %. Mean plasma concentration-time profiles will be generated on both linear and semi-
logarithmic scales using time values as scheduled.
The derived PK parameters will be summarized descriptively per dose cohort. Descriptive 
statistics will include number of subjects (N), arithmetic mean, geometric mean, median, StD, 
minimum, and maximum values and CV in %.
The potential drug accumulation will be evaluated according to an appropriate manner. 
Additionally, the PK/Pd relationship may be explored. Pd variables might be chosen based on 
the trial outcome; efficacy, as well as safety variables might be considered. Further details on
PK analyses of Phase Ib will be provided in the SAP. 
 
 
 
 
The PK population includes all subjects who have received at least 1 dose of the tepotinib or 
gefitinib and who had at least 1 blood sample drawn that provide drug concentration data for 
PK evaluation. 
8.5.4
Analysis of Safety
See Section 8.5.3.4.
8.5.5
Analysis of Quality of Life 
8.5.5.1
General Considerations
The LCSS, EORTC QLQ-C30 (Version 3.0) and the 
 questionnaires are 
used in this study (see Appendix K, Appendix L and 
 respectively). 
Evaluability:
The analysis for PROs will be performed with the QoL evaluable population.
For QoL endpoints, subjects will be considered evaluable for LCSS, EORTC QLQ-C30 or 
 provided they have a baseline and at least one evaluable LCSS, EORTC QLQ-C30 
or 
 questionnaire, and are also included in the QoL evaluable population. 
To be considered evaluable at baseline, a questionnaire has to be filled in on Cycle 1 Day 1, 
before dosing. After Cycle 1 Day 1, to be considered evaluable in the treatment period, a 
questionnaire has to be completed on Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17 and every 4 
cycles thereafter until disease progression, and on the End-of-Treatment visit. Questionnaires 
filled in during the first 5 days after the beginning of a treatment cycle will be considered 
non-evaluable as these questionnaires would be primarily influenced by the acute side-effects 
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI
CCI
CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
104/154
of chemotherapy. In addition, questionnaires filled in “on-treatment”, but after the date of 
progression, will be considered non-evaluable. 
QoL questionnaires are expected from all subjects who remain on-treatment at the scheduled 
assessments. The patterns of completion of questionnaires will be explored to investigate the 
magnitude of missing data and to explore the extent of intermittent missing data and monotone 
missing data. The reasons for missing evaluable questionnaires will be presented by scheduled 
assessment time-point and treatment arm in the randomized part and the single-arm cohort. 
Additionally, no data of PRO will be collected for those subjects in Phase II who are allowed 
to continue the treatment beyond PD. 
Compliance will be defined for each assessment period and overall as follows:
! (number of subjects with at least one evaluable QoL questionnaires)
! % Compliance = 100 * (number of subjects with at least one evaluable QoL 
questionnaires)/
(number of subjects with at least one evaluable QoL questionnaire expected)
8.5.5.2
Time-to-Symptom Progression as Measured by the Lung 
Cancer Symptom Scale
As defined in Section 7.7.1, ASBI is the mean of the six symptom scores derived from the 
LCSS questionnaire. Symptom progression will be defined as an increase (worsening) of the 
ASBI score of 10% of the scale breadth (10 mm on a scale of 0-100 mm) from the baseline 
score on at least two consecutive assessments during the period when assessments are 
performed every 2 cycles and then every 4 cycles. Once the frequency of assessments is 
reduced to every 4 cycles, then an increase at only one assessment is required as proof of 
worsening.
TTSP will be defined as the time from date of Cycle 1 Day 1 until date of symptom progression. 
If symptom progression requires two consecutive assessments meeting the criteria of 
worsening, then the date of symptom progression will be taken as the date of the earlier of the 
two assessments. Subjects diagnosed with PD at time of death will be considered as having an 
uncensored TTSP defined as time between date of randomization/first administration of trial 
treatment and date of death.
For subjects without symptom progression still receiving treatment at the time of analysis, the 
date of the last LCSS assessment will be used to calculate TTSP and will be considered as a 
censored observation in the analysis. Subjects who have stopped trial treatment and who have 
not subsequently met the criteria for TTSP will be treated as censored observations at time of 
last follow-up LCSS assessment. Subjects dying from causes other than PD and who do not 
have symptom progression will be treated as censored observations at time of death.
Subjects who have missed two consecutive scheduled doses, without evaluable assessment for 
related visits and who were lost to follow-up thereafter will be considered as having clinically 
meaningful symptom progression. In that case, TTSP will be calculated from the date of 
Cycle 1 Day 1 until the date of the first missed administration of trial treatment.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
105/154
In randomized part of Phase II, the analysis of TTSP, to examine a potential clinically 
meaningful delay in symptom progression, will be based on a 2 sided log rank test comparison 
stratified by the type of MET+ and prior EGFR-TKI treatment.
The analysis of LCSS will be to determine the differences in the two treatment arms in the 
randomized part of Phase II: the proportion of subjects with symptomatic progression, the area 
under the curve, TTSP for the individual symptoms scores, TTSP for the summary symptoms 
score, time to worsening for global HRQoL.
Data from subjects in centers where a validated local language version of the LCSS is not used 
will not be included in the analysis of TTSP.
In single-arm cohort of Phase II, TTSP will be analyzed in a descriptive way.
8.5.5.3
EORTC QLQ-C30
The EORTC QLQ-C30 comprises 30 questions and provides a multi-dimensional assessment 
of QoL. Fifteen multi-items or single item scales were derived from the initial 30 items as per 
the EORTC QLQ-C30 Scoring Manual: 5 functional scales (physical functioning, role 
functioning, emotional functioning, cognitive functioning, social functioning), 3 symptom 
scales (fatigue, nausea and vomiting, pain), 6 symptom single item scales (dyspnea, insomnia, 
appetite loss, constipation, diarrhea, financial difficulties), and 1 global health status or QoL 
scale. All the scores will be derived from mutually exclusive sets of items, with scale scores 
ranging from 0 to 100 after a linear transformation. Higher scores for functioning scales and 
for the global health status or QoL scale indicate a higher level of functioning and a better QoL 
respectively, whereas higher scores in symptom scales represent a higher level of symptoms.
The analysis of EORTC QLQ-C30 scores will be based on descriptive statistics on changes 
from baseline scores for the multi-item scales and single item measures for each treatment arm
in the randomized part and the single-arm cohort of Phase II at each of the assessment points.
 
 
 
 
 
 
 
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
106/154
8.5.6
Analyses of Further Endpoints
8.5.6.1
Pharmacodynamics and Predictive Biomarkers
The exploratory biomarkers analysis set will include all subjects who have provided at least 
1 sample of blood and/or tumor biopsy. 
Exploratory biomarker (Pd markers and genetic alterations of relevant cancer genes) will be 
assessed in serum and tumor tissue and their potential correlation with prognosis and the 
activity of tepotinib in combination with gefitinib.
As exploratory endpoints, a statistical analysis of the biomarkers will be described in the SAP 
or in the specific Biomarkers SAP and the results of the analysis will be provided in a separate 
report.
 
 
 
 
 
8.6
Interim Analysis and Data Monitoring Committee
An IDMC will be formed from a group of three experts and will consist of at least 1 statistician 
and 1 oncologist who will not be participants in this trial. An IDMC charter and SAP will 
provide the details about the conduct of the IDMC meeting, frequency and decision making 
rules.
The IDMC will be responsible for periodic (as defined by the IDMC charter) evaluations of 
the clinical trial to ensure continued subject safety as well as the validity and scientific merit 
of the study. 
The designated independent statistician will provide the IDMC with the safety summaries 
periodically for review. The IDMC will give a recommendation regarding further conduct of 
the trial. The Sponsor management will take the final decision if the IDMC recommends to 
stop the trial. After the enrolment halt the requirements for an IDMC do no longer exist and no 
further IDMC meetings will be conducted.
In addition, the Sponsor may conduct administrative interim analyses in the single-arm (non-
randomized) cohort of up to 15 subjects with MET+ T790M positive NSCLC at time points 
that are not specified in the protocol for internal planning purposes.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
107/154
9
Ethical and Regulatory Aspects
9.1
Responsibilities of the Investigator
The Investigator is responsible for the conduct of the trial at his/her site. He/she will ensure 
that the trial is performed in accordance with the clinical trial protocol and with the ethical 
principles that have their origin in the Declaration of Helsinki, as well as with the ICH Note 
for Guidance on Good Clinical Practice (ICH Topic E6, 1996), the Japanese ministerial 
ordinance on GCP, and any other applicable regulatory requirements. In particular, the 
Investigator must ensure that only subjects who have given their informed consent are included 
into the trial.
In 1998, the US Food and Drug Administration (FDA) introduced a regulation (21 CFR, Part 
54) entitled “Financial Disclosure by Clinical Investigators”. For trials conducted in any 
country that could result in a product submission to the FDA for marketing approval and could 
contribute significantly to the demonstration of efficacy and safety of the IMP (named “covered 
trials” by the FDA), the Investigator and all sub-Investigators are obliged to disclose any 
financial interest which they, their spouses or their dependent children may have in the Sponsor
or the Sponsor’s product under study. This information is required during the trial and for 12 
months following completion of the trial.
9.2
Subject Information and Informed Consent
An unconditional prerequisite for a subject’s participation in the trial is his/her written informed 
consent. The subject’s written informed consent to participate in the trial must be given before 
any trial-related activities are carried out.
With the cooperation of the Sponsor, and in accordance with the Note for Guidance on Good 
Clinical Practice (ICH Topic E6, 1996), the Japanese ministerial ordinance on GCP (for study 
sites in Japan), and the ethical principles that have their origin in the Declaration of Helsinki, 
the Investigator will prepare the informed consent form and other written information to be 
used in obtaining informed consent from the trial subjects. The Sponsor should provide the 
Investigator with documents/information necessary for preparing the aforementioned written 
information and cooperate with the Investigator to prepare it. In addition to providing this 
written information to a potential subject, the Investigator or his/her designate will inform the 
subject of all pertinent aspects of the trial orally as well as in writing. The language used in the 
aforementioned oral and written information about the trial must be fully and readily 
understandable to lay persons. 
Before consent may be obtained, the Investigator should provide the prospective subject (or 
the prospective subject’s legally acceptable representative if applicable) with ample time and 
opportunity to inquire about details of the clinical trial and to decide whether or not to 
participate in the trial. In such cases, the Investigator or the trial collaborator giving 
supplementary explanation should answer all questions about the trial to the satisfaction of the 
prospective subject or legally acceptable representative.
Depending on national regulations, a person other than the Investigator may inform the subject 
and sign the ICF, as above.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
108/154
Where the information is provided by the Investigator, the ICF must be signed and personally 
dated by the subject and the Investigator. 
For trials conducted in Japan: The trial collaborator giving supplementary explanation, where 
applicable, should sign, seal and date the informed consent form.
The signed and dated declaration of informed consent will remain at the Investigator’s site, and 
must be safely archived by the Investigator so that the forms can be retrieved at any time for 
monitoring, auditing, and inspection purposes. A copy of the signed and dated information and 
ICF should be provided to the subject prior to participation.
Whenever important new information becomes available that may be relevant to the subject’s 
consent, the written subject information sheet and any other written information provided to 
subjects will be revised by the Sponsor and be submitted again to the IEC/IRB for review and 
favorable opinion. The agreed, revised information will be provided to each subject in the trial 
for signing and dating. The Investigator will explain the changes to the previous version.
 
 
 
 
 
9.3
Subject Identification and Privacy
A unique subject number will be assigned to each subject at inclusion, immediately after 
informed consent has been obtained. This number will serve as the subject’s identifier in the 
trial as well as in the clinical trial database.
The subject’s data collected in the trial will be stored under this number. Only the Investigator
will be able to link the subject’s trial data to the subject via an identification list kept at the site. 
The subject’s original medical data that are reviewed at the site during source data verification 
by the monitor, audits and Health Authority inspections will be kept strictly confidential.
Data protection and privacy regulations will be observed in capturing, forwarding, processing, 
and storing subject data. Subjects will be informed accordingly, and will be requested to give 
their consent on data handling procedures in accordance with national regulations.
 
 
 
 
 
 
 
 


CCI
CCI
CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
109/154
 
 
 
 
 
9.4
Emergency Medical Support and Subject Card
Subjects enrolled in this clinical trial will be provided with Emergency Medical Support cards 
during their trial participation, which will be furnished by the Sponsor. The Emergency 
Medical Support card is based on the need to provide clinical trial subjects with a way of 
identifying themselves as participating in a clinical trial, and subsequently to give health care 
providers access to the information about this participation that may be needed to determine 
the course of the subject’s medical treatment.
This service is designed to provide information to health care providers who are not part of the 
clinical trial; and this may include the possibility of emergency unblinding if needed, in case 
of blinded trials.
Clinical trial Investigators, who are already aware of the clinical trial protocol and treatment, 
have other means of accessing the necessary medical information for the management of 
emergencies occurring in their subjects.
The first point of contact for all emergencies will be the clinical trial Investigator caring for the 
affected subject. The Investigator agrees to provide his or her emergency contact information 
on the card for this purpose. If the Investigator is available when an event occurs, she/he will 
answer any questions. Any subsequent action (eg, unblinding) will follow the standard 
processes established for the Investigators.
In cases where the Investigator is not available, the Sponsor/designee provides the appropriate 
means to contact a Sponsor physician. This includes the provision of a 24 hour contact number 
at a call center, whereby the health care providers will be given access to the appropriate 
physician to assist with the medical emergency and to provide support for the potential 
unblinding of the subject concerned.
9.5
Clinical Trial Insurance and Compensation to Subjects
Insurance coverage shall be provided for each country participating to the trial. Insurance 
conditions shall meet good local standards, as applicable.
For trials conducted in Japan:
The Sponsor is entirely responsible for AEs that are associated with this trial and cause damage 
to the health of the subjects, except for AEs caused by an intentional and/or significant 
deviation on the part of the Investigator, the trial site, and/or the subject. The Sponsor takes out 
insurance to fulfill the responsibility.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
110/154
Insurance coverage will be provided for each country participating in the trial. Insurance 
conditions will meet good local standards, as applicable.
9.6
Independent Ethics Committee or Institutional Review 
Board
Prior to commencement of the trial at a given site, the clinical trial protocol will be submitted 
together with its associated documents to the responsible IEC/IRB for its favorable 
opinion/approval. The written favorable opinion/approval of the IEC/IRB will be filed in the 
Investigator Site File, and a copy will be filed in the Trial Master File at the Sponsor.
The trial must not start at a site before the Sponsor has obtained written confirmation of 
favorable opinion/approval from the concerned IEC/IRB. The IEC/IRB will be asked to 
provide documentation of the date of the meeting at which the favorable opinion/approval was 
given, and of the members and voting members present at the meeting. Written evidence of 
favorable opinion/approval that clearly identifies the trial, the clinical trial protocol version and 
the Subject Information and ICF version reviewed should be provided. Where possible, copies 
of the meeting minutes should be obtained.
Amendments to the clinical trial will also be submitted to the concerned IEC/IRB, before 
implementation in case of substantial changes (see Section 10.5). Relevant safety information 
will be submitted to the IEC/IRB during the course of the trial in accordance with national 
regulations and requirements.
For Japan sites:
The Sponsor initiates the trial at a site after obtaining written approval from the Head of the 
trial site based on favorable opinion/approval from the concerned IRB. The IRB will be asked 
to provide documentation of the date of the meeting at which the favorable opinion/approval 
was given, its membership list, and names of members who were present and voted at the 
meeting. Written favorable opinion/approval should clearly identify the trial, the clinical trial 
protocol version and the Subject Information and Informed Consent Form version that were 
reviewed at the meeting. Where possible, copies of the meeting minutes should also be 
obtained.
Plans for any substantial amendments to the clinical trial will also be submitted to the 
concerned IRB before they are implemented (see Section 10.5). Relevant safety information 
will be submitted to the IRB during the course of the trial in accordance with national 
regulations and requirements.
9.7
Health Authorities
The clinical trial protocol and any applicable documentation (eg, Investigational Medicinal 
Product Dossier, Subject Information, and ICF) will be submitted or notified to the Health 
Authorities in accordance with the regulations of the countries involved in the trial.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
111/154
10
Trial Management
10.1
Case Report Form Handling
The Investigator or designee will be responsible for entering trial data in the eCRF provided 
by the Sponsor. It is the Investigator’s responsibility to ensure the accuracy of the data entered 
in the eCRFs.
The data will be entered into a validated database. The data management department of the 
designated CRO, 
, will be responsible for data processing, in accordance with the 
defined data management procedures, under the supervision of the Sponsor. Database lock will 
occur once quality control procedures and quality assurance procedures (if applicable) have
been completed. PDF files of the eCRFs will be provided to the Investigators at the completion 
of the trial.
10.2
Source Data and Subject Files
The Investigator must keep a subject file (medical file, original medical records) on paper or 
electronically for every subject included in the trial. This file will contain the available 
demographic and medical information for the subject, and should be as complete as possible. 
In particular, the following data should be available in this file:
! Subject’s full name;
! Date of birth;
! Sex;
! Height;
! Weight;
! Medical history and concomitant diseases;
! Prior and concomitant therapies (including changes during the trial);
! Trial identification (Trial EMR200095-006);
! Date of subject’s inclusion into the trial (ie, date of giving informed consent);
! Subject number in the trial;
! Dates of the subject’s visits to the site;
! Any medical examinations and clinical findings predefined in the clinical trial protocol;
! All AEs observed in the subject;
! Date of subject’s end of the trial, and
! Date of and reason for early withdrawal of the subject from the trial or from IMP, if 
applicable.
It must be possible to identify each subject by using this subject file.
Additionally, any other documents containing source data must be filed. This includes original 
printouts of data recorded or generated by automated instruments, photographic negatives, 
'RFXPHQW1R

2EMHFW1R

CCI
CCI
PPD


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
112/154
X-rays, CT or MRI, ECG recordings, laboratory value listings, a subject diary for the 
compliance to IMP administration, etc. Such documents must bear at least the subject number 
and the date when the procedure was performed. Information should be printed by the 
instrument used to perform the assessment or measurement, if possible. Information that cannot 
be printed by an automated instrument will be entered manually. Medical evaluation of such 
records should be documented as necessary and the documentation signed and dated by the 
Investigator.
The following information described in the eCRF is regarded as the source data.
! Any Investigator’s comments,
! Subject number.
10.3
Investigator Site File and Archiving
The Investigator will be provided with an Investigator Site File upon initiation of the trial. This 
file will contain all documents necessary for the conduct of the trial and will be updated and 
completed throughout the trial. It must be available for review by the monitor, and must be 
ready for Sponsor audit, as well as for inspection by Health Authorities during and after the 
trial, and must be safely archived for at least 15 years (or per local requirements or as otherwise 
notified by the Sponsor) after the end of the trial. The documents to be archived include the 
Subject Identification List and the signed subject ICFs. If archiving of the Investigator Site File 
is no longer possible at the site, the Investigator must notify the Sponsor.
All original subject files (medical records) must be stored at the site (hospital, research institute, 
or practice) for the longest possible time permitted by the applicable regulations, and/or as per 
ICH GCP guidelines, whichever is longer. In any case, the Investigator (in Japan: a record 
retainer designated by the Head of the trial site) should ensure that no destruction of medical 
records is performed without the written approval of the Sponsor.
10.4
Monitoring, Quality Assurance and Inspection by Health 
Authorities
This trial will be monitored in accordance with the ICH Note for Guidance on Good Clinical 
Practice (ICH Topic E6, 1996), the Japanese ministerial ordinance on GCP, and any other 
applicable regulations. The site monitor will perform visits to the trial site at regular intervals.
Representatives of the Sponsor’s Quality Assurance unit or a designated organization, as well 
as Health Authorities, must be permitted to inspect all trial-related documents and other 
materials at the site, including the Investigator Site File, the completed eCRFs, the tepotinib, 
and the subjects’ original medical records/files.
The clinical trial protocol, each step of the data capture procedure, and the handling of the data, 
including the final clinical trial report, will be subject to independent Quality Assurance 
activities. Audits may be conducted at any time during or after the trial to ensure the validity 
and integrity of the trial data.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
113/154
10.5
Changes to the Clinical Trial Protocol
Changes to the clinical trial protocol will be documented in written protocol amendments. 
Major (substantial, significant) amendments will usually require submission to the Health 
Authorities and to the relevant IEC/IRB (For Japan: through the Head of the trial site) for 
approval or favorable opinion. In such cases, the amendment will be implemented only after 
(For Japan: written approval from the Head of the trial site based on) approval or favorable 
opinion has been obtained.
Minor (nonsubstantial) protocol amendments, including administrative changes, will be filed 
by the Sponsor and at the site. They will be submitted to the relevant IEC/IRB or to Health 
Authorities only where requested by pertinent regulations.
Any amendment that could have an impact on the subject’s agreement to participate in the trial 
requires the subject’s informed consent prior to implementation.
10.6
Clinical Trial Report and Publication Policy
10.6.1
Clinical Trial Report
After completion of the trial, a clinical trial report according to ICH Topic E3 will be written 
by the Sponsor in consultation with the Coordinating Investigator.
10.6.2
Publication
The first publication will be a publication of the results of the analysis of the primary endpoints 
that will include data from all trial sites.
The Investigator will inform the Sponsor in advance about any plans to publish or present data 
from the trial. Any publications and presentations of the results (abstracts in journals or 
newspapers, oral presentations, etc.), either in whole or in part, by Investigators or their 
representatives will require presubmission review by the Sponsor.
The Sponsor will not suppress or veto publications, but maintains the right to delay publication 
in order to protect intellectual property rights.
11
References
1. Loong HH, Wei J, Mok TS. Ethnic variation in response to EGFR inhibitors. Drug 
Discovery Today: Therapeutic Strategies. 2012 Autumn: 9(2–3):e61-66.
2. Brugger W, Thomas M. EGFR-TKI resistant non-small cell lung cancer (NSCLC): new 
developments and implications for future treatment. Lung Cancer. 2012 Jul;77(1):2-8.
3. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological 
evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 
2011 Mar;3(75): 75ra26. doi: 10.1126/scitranslmed.3002003.
4. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor 
receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the 
epidermal growth factor receptor pathway. Clin Lung Cancer. 2009 Jul;10(4):281-9.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
114/154
5. Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. 
Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S21-35.
6. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 
2011 Mar;53(3):1020-2.
7. Jang SH. Long Term Therapeutic Plan for Patients with Non-Small Cell Lung Cancer 
Harboring EGFR Mutation. Tuberc Respir Dis (Seoul). 2014 Jan;76(1):8-14.
8. Wu YL, Yang JCH, Kim DW, et al. Safety and efficacy of INC280 in combination with 
gefitinib (gef) in patients with EGFR-mutated (mut), MET+ NSCLC: A single-arm 
phase lb/ll study. ASCO Meeting Abstracts. 2014;32:8017.
9. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III Study Comparing Cisplatin Plus 
Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With 
Advanced-Stage Non–Small-Cell Lung Cancer. JCO July 20, 2008:3543-51.
10. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus 
pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J 
Clin Oncol. 2013 Sep 20;31(27):3327-34.
11. De Castria, TB, DeSilva, EM, Gois, AF, et al, 2013. Cisplatin versus Carboplatinin 
combination with third generation drugs for advanced non-small cell lung cancer. 
Cochrane Database Syst. Rev. 8, CD009256.
12. National Comprehensive Cancer Network Guidelines. http://www.nccn.com/cancer-
guidelines.html. Accessed 28 May 2015.
13. Coate LE, Shepherd FA. Maintenance therapy in advanced non-small cell lung cancer: 
evolution, tolerability and outcomes. Ther Adv Med Oncol. 2011 May; 3(3): 139–57.
14. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib 
resistance in lung cancer by activating ERBB3 signaling. Science. 2007 May 
18;316(5827):1039-43.
15. Tang Z, Du R, Jiang S, Wu C,  et al. Dual MET-EGFR combinatorial inhibition against 
T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer. 2008 Sep 
16;99(6):911-22.
16. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus 
gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with 
advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51.
17. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus 
pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J 
Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 
Jul 1. 
18. Spigel DR, Ervin TJ, R. Ramlau R, et al. Final efficacy results from OAM4558g, a 
randomized Phase II study evaluating MetMAb or placebo in combination with 
erlotinib in advanced NSCLC. J Clin Oncol 29:2011 (suppl; abstr 7505). 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
115/154
19. J.C. Yang, D. Kim, D. Planchard, Y, et al. Updated safety and efficacy from a phase I 
study of AZD9291 in patients (pts) with EGFR-TKI-resistant Non-Small Cell Lung 
Cancer (NSCLC). Developmental Therapeutics. Poster discussion. Abstract: 449PD. 
20. Sequist LV., Soria JC, Gadgeel SM, et al. First-in-human evaluation of CO-1686, an 
irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating 
and T790M). 2014 ASCO Annual Meeting. Abstract Number: 8010.
21. Jackman D, Pao W, Riely GJ, et al. Clinical Definition of Acquired Resistance to 
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell 
Lung Cancer. JCO Jan 10, 2010:357-360; published online on November 30, 2009.
22. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the 
prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of 
the Perugia consensus conference. Annals of Oncology. 2010; 21 (Supplement 5): 
v232-43. 
23. Mosteller RD. Simplified calculation of body surface area. N Engl J 
Med.1987;317(17):1098 (letter).
24. U.S Food and Drug Administration. Carboplatin dosing. Updated 11/27/2015.  
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/
CDER/ucm228974.htm.
25. Fallowfield L. Quality of Life: the objective measurement of subjective responses to 
cancer and its treatment. Cancer Topics.1987; 6: 99-100.
26. Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life assessment in individuals with lung 
cancer: Testing the lung cancer symptom scale (LCSS). Eur J Cancer 1993;29A:51-8.
27. Hollen PJ, Gralla RJ, Kris MG, et al. Measurement of quality of life in patients with 
lung cancer in multicenter trials of new therapies. Cancer 1994;73:2087-98.
28. Hollen PJ, Gralla RJ, Kris MG. An overview of the Lung Cancer Symptom Scale. In 
Gralla RJ, Moinpour CM (Eds). Assessing quality of life in patients with lung cancer: 
A guide for clinicians 1995:57-63. New York: NCM Publishers.
29. Van Hout B, Janssen M, Feng Y, et al. Interim scoring for the EQ 5D 5L: Mapping the 
EQ 5D 5L to EQ 5D 3L value sets. Value in Health. 2012; 15(5):708-15.
30. Brookmeyer R, Crowley J. A confidence interval for the median survival time. 
Biometrics. 1982; 38: 29-41.
31. Wu YL, Kim DW, Felip E, et al. Phase (Ph) II safety and efficacy results of a single-
arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-
mutated (mut), cMET-positive (cMET+) non-small cell lung cancer. J Clin Oncol 2016 
ASCO;34(15 suppl), abstract 9020.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
116/154
12
Appendices
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
117/154
Appendix A
Schedule of Assessments in Phase Ib
Screening aa
Treatment Period
EoT x
30-day 
Safety 
Follow-up 
Visit y
Additional 
Follow-Up 
Visit z
Cycle 1
Day
Cycle 2
Day
Cycle ≥3
Day w ±3d
DAY
-28 to -1
1
2
8±1d
15±1d
1±1d
8±1d
15±1d
1
≤14 d of the 
Last Dose
±3d
±7d/ ±14d
Written Informed Consent
X
Tepotinib+Gefitinib (IMP)
QD
Drug Dispensation
X
X
X
Demography bb, Height 
X
Medical History, Including EGFR Mutation 
Status bb
X
Tumor Tissue Collection cc and 
Determination of MET Status
X a, b
X b
X b
X b
Serum Pregnancy Test (If Applicable) c, cc
X
X
Chest X-Ray
X d
Physical Examination/Weight cc
X
X e
X
X
X
X
X
X
X
X f
X
ECOG PS cc
X
X e
X
X
X f
X
Vital Signs g, cc
X
X
X
X
X
X
X
X
X
X f
X
Adverse Events Assessment
X
X
X
X
X
X
X
X
X
X
X
Concomitant Medication/Procedure
X
X
X
X
X
X
X
X
X
X
X
12-lead ECG h, cc
X
X i
X i
Xi
X j
X f
X
Hematology and Coagulation k, cc
X
X e
X
X
X
X
X
X
X
X f
X
Biochemistry l, cc
X
X e
X
X
X
X
X
X
X
X f
X
Urinalysis m, cc
X
X e
X
X
X f
X
Tumor Assessment (RECIST Version 1.1)n, cc
X
X p
X q
X r
PK Blood Samples
X s
X s
Exploratory Markers in Plasma
X t
X u
X u
X t
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
118/154
Abbreviations: ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CNS, central nervous 
system; CT, computed tomography; ECG, electrocardiogram; EGFR, epidermal growth factor receptor; ECOG PS, Eastern Cooperative Oncology Group 
performance status; EoT, End-of-Treatment; FFPE, Formalin-fixed paraffin-embedded; GGT, gamma-glutamyl transpeptidase; ICF, informed consent form; IMP, 
investigational medicinal product; MRI, magnetic resonance imaging; PD, progressive disease; 
; PK, pharmacokinetic; PT, prothrombin 
time; QD, once daily; RECIST, Response Evaluation Criteria in Solid Tumors.
a.
Provision of a fresh or archived tumor biopsy (excluding fine needle aspiration and cytology samples). For subjects who experienced at least 1 anticancer treatment, biopsy 
obtained between failure of the most recent anticancer treatment and enrollment is mandatory. From the pretreatment biopsy, either FFPE tumor block (preferred) or 8 to 10 
unstained slides must be sent to the central laboratory prior to enrollment for determination of MET+ status. The tumor tissue sample should have at least 10% viable tumor 
cells for the central laboratory to perform assessments. An associated pathology report must also be sent with the sample. 
b.
Additional pre-treatment biopsy second pass in screening period or predose on Cycle 1, Day 1, on-treatment biopsy, and EoT biopsy. Paired tumor biopsies are not 
mandatory, but highly recommended for subjects with accessible tumors. Paired tumor biopsies should be taken before the treatment period (preferentially as second pass 
when biopsy for screening purposes is taken) and during the treatment period (can be taken any time between Cycle 1, Day 15 and the beginning of Cycle 3). If a tumor 
shows progression after initial response to tepotinib+gefitinib, a third biopsy is highly desirable when progression is diagnosed at the EoT.
c.
Only for women of childbearing potential, including those who have had a tubal ligation. 
d.
Not necessary if thoracic CT is performed.
e.
Only if screening assessments were performed ∋7 days prior to Day 1.
f.
Only if last assessments were performed ∋7 days prior to end of treatment.
g.
Vital signs (pulse rate, systolic and diastolic blood pressure, body temperature, respiratory rate) are to be taken after at least 5 minutes rest in seated position. If vital signs and 
ECGs are taken at the same time, vital signs are to be taken immediately prior to each ECG recording.
h.
All ECGs to be taken as 12-lead resting ECGs in triplicate with up to 2 minutes between each ECG. ECGs are to be taken after at least 5 minutes rest in supine position.
i.
ECG recordings in Cycle 1, Day 1 and Cycle 1, Day 15 will be performed at predose (within 30 minutes prior to dose) and 4 hours ± 12 minutes postdose, 10 hours 
± 30 minutes postdose, and 24 hours postdose (within 30 minutes prior to next dose). ECG recordings in Cycle 2, Day 1 will be performed at predose only (within 
30 minutes prior to dose).
j.
Predose only (within 30 minutes prior to dose) after Cycle 3, ECGs will be performed every third cycle (ie, Cycle 3, 6, 9, 12, etc.) or as clinically indicated.
k.
Hemoglobin, hematocrit, red blood cell count, white blood cell count, differential, platelets, and coagulation (PT, aPTT, and INR).
l.
BUN, creatinine, AST, ALT, GGT, total bilirubin (including direct fraction if total bilirubin is abnormal), lipase, amylase, total protein, albumin, alkaline phosphatase, 
creatinine clearance, sodium, potassium, calcium, magnesium and glucose.
m.
Urinalysis: dipstick followed by microscopic examination if abnormal results are obtained.
n.
Complete tumor assessment of all lesions by radiographic or other modality (using RECIST Version 1.1). CT or MRI of the chest, abdomen, and pelvis to evaluate disease in 
these locations. CT/MRI of the head at baseline for subjects who have or suspected to have CNS metastases. 
p.
To be performed on Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, and every 4 cycles thereafter until disease progression.
q.
Only if last tumor assessment was performed # 6 weeks before Cycle 17 and ≥ 12 weeks afterwards prior to end of treatment.
r.
To be performed every 6 weeks until Cycle 17 and every 12 weeks after Week 51 until radiologically documented PD, death, end of trial, or starting a new anticancer 
therapy, whichever occurs first. Chest CT/MRI, other scans to document all sites of disease.
s.
Plasma concentrations of tepotinib and gefitinib will be obtained on Day 1 and Day 15 of Cycle 1. Samples will be taken predose and at 0.25, 0.5, 1, 2, 4, 8, 10 and 24 hours 
postdose.
t.
Blood sample (Cycle 1 Day 1 [predose] and during EoT visit).
u.
The on-treatment blood samples should be taken at cycles 2, 4, 6, 8, 10, and 12, at Day 1 pre-dose.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
119/154
w.
All visits and assessments from Cycle 3 onwards may be performed ∀3 days to accommodate unforeseen delays, holidays, or vacations. 
x.
Performed within 14 days of the last dose of study drug, the completion of treatment cycle, or the day when it is determined to permanently discontinue the study treatment;
reason for treatment discontinuation should be recorded. If the subject discontinues from the study at a scheduled visit, the EoT assessment can be performed on that day. For 
subjects who withdraw from the treatment, only under the condition that subject stop administration for both components of the combination therapy, EoT visit is triggered. 
y.
Performed at 30 ± 3 days after the last treatment for all subjects who discontinue trial treatment permanently, including subjects who have completed an EoT visit. Reasons 
for study termination should be recorded if this visit is the last visit for subject. Ongoing or new AEs judged to be related to any trial medication will be followed until the 
event has resolved to the baseline grade, becomes stable, the subject is lost to follow-up, the subject withdraws consent, or it has been determined that the study treatment is 
not the cause of the AE, even if new anticancer treatment is initiated.
z.
Subjects who withdraw from the treatment for reasons other than PD have additional visits for tumor assessments. A ∀7 day time window is permitted for additional
follow-up visits until Week 51 then ∀2 weeks thereafter. Reasons for study termination should be recorded if this visit is the last visit for subject. Recording of any new 
anticancer therapy will be made (a tumor assessment is mandatory before initiating the new therapy), 
aa.
Subject eligibility evaluation (review of inclusion/exclusion criteria) will be checked. Some subjects may have a prescreening more than 28 days prior to first dose. Subjects 
who may have a prescreening to determine MET status must sign a prescreening ICF before any prescreening study procedures will be performed. MET status will be 
determined; and demographic data, medical history (including nicotine consumption), and disease history will be collected during the prescreening.
bb.
For some subjects who may have a prescreening ICF, this information will be recorded in prescreening.
cc.
Assessment can be repeated at the Investigator’s discretion at unscheduled visits to assess the safety and tolerability of the IMP (tepotinib+gefitinib). 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
120/154
Appendix B
Schedule of Assessments in Phase II
Screening ee
Treatment Period
EoT aa
30 Day 
Safety 
Follow-up 
Visit bb
Additional 
Follow-up 
Visit cc
Survival 
Follow-up dd
Cycle 1 Day
Cycle 2
Day z ±3d
Cycle≥3 
Day ±3d
DAY
–28 to –1
1
8 ±1d
15 ±1d
1
1
≤14 d of the 
Last Dose
±3d
±7d/±14d
Written Informed Consent
X
Randomization
Xhh
Comedication a
X a
Per local SmPC a
Pemetrexed+cisplatin/carboplatin (comparator) a
Day 1 of each cycle
Tepotinib+Gefitinib (IMP) 
QD
Drug Dispensation
X
X
X
Demography, Height 
X
Medical History, Including EGFR Mutation 
Status
X
Tumor Tissue Collection gg and Determination of 
MET+ and T790M Status
X b, c
X c
X c
X c
Serum Pregnancy Test (If Applicable) d, gg
X
X
Chest X-Ray
X e
Physical Examination/Weight gg
X f
X
X
X
X g
X g
X h
X
ECOG PS gg
X f
X
X
X h
X
Vital Signs i, gg
X f
X
X
X
X
X
X h
X
Adverse Events Assessment
X
X
X
X
X
X
X
X
Concomitant Medication/Procedure
X
X
X
X
X
X
X
X
12-lead ECG j, gg
X
X k
X l
Xg,k
X g,m
X h
X
Hematology and Coagulation n, gg
X f
X
X
X g
X g
X h
X
Biochemistry p, gg
X f
X
X
X g
X g
X h
X
Urinalysis q, gg
X f
X
X
X h
X
Tumor Assessment (RECIST Version 1.1) r, gg
X
X s
X t
X u
PK Blood Samples
X v
X v
Exploratory Markers in Plasma
X w
X
X
X w
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
121/154
Screening ee
Treatment Period
EoT aa
30 Day 
Safety 
Follow-up 
Visit bb
Additional 
Follow-up 
Visit cc
Survival 
Follow-up dd
Cycle 1 Day
Cycle 2
Day z ±3d
Cycle≥3 
Day ±3d
DAY
–28 to –1
1
8 ±1d
15 ±1d
1
1
≤14 d of the 
Last Dose
±3d
±7d/±14d
Subject survival and anticancer therapies
X
HRQoL questionnaires ff
X
X ff
X
X
X
Abbreviations: ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CNS, central nervous 
system; CT, computed tomography; ECG, electrocardiogram; EGFR, epidermal growth factor receptor; ECOG PS, Eastern Cooperative Oncology Group 
performance status; EoT, End-of-Treatment; FFPE, formalin-fixed paraffin-embedded; GGT, gamma-glutamyl transpeptidase; HRQoL, health related quality of 
life; ICF, informed consent form; IMP, investigational medicinal product; MRI, magnetic resonance imaging; PD, progressive disease; 
; 
PK, pharmacokinetic; PT, prothrombin time; QD, once daily; RECIST, Response Evaluation Criteria in Solid Tumors; SmPC, summary of product characteristics.
a.
Regarding the comedications for pemetrexed, cisplatin, or carboplatin (see Section 6.4.1), all subjects are permitted to receive folic acid and first B12 intramuscular injection 
during screening period. After randomization, only subjects in the control arm in Phase II will continue comedications for pemetrexed (eg., vitamin B12 and folic acid). All 
comedications will be administered per local package insert/SmPC. In the control arm, dosing for folic acid should continue for the full course of the treatment, and for 
3 weeks (ie, 21 days) following the last dose of pemetrexed to be administered. An intramuscular injection of vitamin B12 (1000 μg) will be administered around every 
9 weeks per local package insert/SmPC. Subjects should receive pretreatment and posttreatment hydration for cisplatin per local package insert/SmPC.
b.
Provision of a fresh or archived pretreatment tumor biopsy (excluding fine needle aspiration and cytology samples). For subjects experienced at least 1 anticancer treatment, 
biopsy obtained between failure of the most recent anticancer treatment and enrollment is mandatory. Test done after progression of gefitinib, erlotinib, icotinib, or afatinib
and more than 28 days prior to randomization/first administration of trial treatment is acceptable. From the pretreatment biopsy, either FFPE tumor block (preferred) or 10 to 
15 unstained slides must be sent to the central laboratory prior to enrollment for determination of MET+/T790M status. The tumor tissue sample should have at least 10% 
viable tumor cells for the central laboratory to perform assessments. An associated pathology report must also be sent with the sample. 
c.
Additional pre-treatment biopsy second pass in screening period or predose on Cycle 1, Day 1, on-treatment biopsy and EoT biopsy. Paired tumor biopsies are not 
mandatory, but highly recommended for subjects with accessible tumors. Paired tumor biopsies should be taken before the treatment period (preferentially as second pass 
when biopsy for screening purposes is taken) and during the treatment period (can be taken any time between Cycle 1, Day 15 and the beginning of Cycle 3). If a tumor 
shows progression after initial response to tepotinib+gefitinib, a third biopsy is highly desirable when progression is diagnosed at the EoT.
d.
Only for women of childbearing potential, including those who have had a tubal ligation.
e.
Not necessary if thoracic CT is performed.
f.
Should be repeated if the last assessment is more than 7 days prior to the planned date for first dose, and the laboratory assessment must be performed by the central 
laboratory.
g.
For control (chemotherapy) arm, weight, hematology, biochemistry, and ECG should be done within 3 days prior to treatment administration beginning with Cycle 2.
h.
Only if last assessments were performed ∋7 days prior to EoT.
i.
Vital signs (pulse rate, systolic and diastolic blood pressure, body temperature, respiratory rate) are to be taken after at least 5 minutes rest in seated position. If vital signs 
and ECGs are taken at the same time, vital signs should be taken immediately prior to each ECG recording. 
j.
All ECGs to be taken as 12-lead resting ECGs in triplicate with up to 2 minutes between each ECG. ECGs are to be taken after at least 5 minutes rest in supine position.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
122/154
k.
On Cycle 1, Day 1 and on Cycle 2, Day 1 in subjects who receive tepotinib+gefitinib, ECG will be taken predose (within 30 minutes prior to PK predose sampling) and at 
4 hours ± 10 minutes postdose [performed directly before PK 4-hour postdose sampling]. Predose only (within 30 minutes prior to dose) in control (chemotherapy) arm. 
ECGs will be collected in triplicate at the predose and 4 hour time points.
l.
Predose only (within 30 minutes prior to dose).
m.
Predose only (within 30 minutes prior to dose). After Cycle 3, ECGs will be performed every third cycle (ie, Cycle 3, 6, 9, 12, etc.) or as clinically indicated. 
n.
Hemoglobin, hematocrit, red blood cell count, white blood cell count, differential, platelets, and coagulation (PT, aPTT, and INR).
p.
BUN, creatinine, AST, ALT, GGT, total bilirubin (including direct fraction if total BR abnormal), lipase, amylase, total protein, albumin, alkaline phosphatase, creatinine 
clearance, sodium, potassium, calcium, magnesium and glucose.
q.
Urinalysis: dipstick followed by microscopic examination if abnormal results are obtained.
r.
Complete tumor assessment of all lesions by radiographic or other modality (using RECIST Version 1.1). CT or MRI of the chest, abdomen, and pelvis to evaluate disease in 
these locations. CT/MRI of the head at baseline for subjects who have or suspected to have CNS metastases.
s.
To be performed on Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, and every 4 cycles thereafter until disease progression. For subjects receiving treatment beyond PD, RECIST 
Version 1.1 radiographical assessment will follow institutional practice guidelines, however, tumor assessment information will not be recorded in the eCRF and there will 
be no further documentation collected for any new lesion and/or clinical symptoms of PD after first PD.
t.
Only if last tumor assessment was performed ≥ 6 weeks before Cycle 17 and ≥ 12 weeks afterwards prior to EoT.
u.
To be performed every 6 weeks until Cycle 17 and every 12 weeks after Week 51 until radiologically documented PD, death, end of trial, or starting a new anticancer 
therapy, whichever occurs first. Chest CT/MRI, other scans to document all sites of disease.
v.
Sparse PK sampling (total of 6 samples) will be performed at within 60 minutes prior to dose and at 1.5 ± 10 minutes and 4 hours ± 10 minutes postdose on Day 1 Cycle 1
and on Day 1 Cycle 2 in subjects who receive tepotinib+gefitinib. 
w.
Blood samples (Cycle 1 Day 1 [predose] and during EoT visit).
x.
The on-treatment blood samples should be taken at cycles 2, 4, 6, 8, 10, and 12, at Day 1 pre-dose.
z.
All visits and assessments from Cycle 2 onwards may be performed ∀3 days to accommodate unforeseen delays, holidays, or vacations. 
aa.
Performed within ≤14 days of the last dose of study drug, the completion of treatment cycle, or the day when it is determined to permanently discontinue the study treatment. 
Reason for treatment discontinuation should be recorded. If the subject discontinues from the study at a scheduled visit, the EoT assessment can be performed on that day. A 
subject will have an End-of-Treatment visit only if they withdraw from treatment with both components of the combination therapy. A subject will have an End-of-
Treatment visit only if he/she will withdraw from treatment with both components of the combination therapy.
bb.
Performed at 30 ± 3 days after the last treatment for all subjects who discontinue trial treatment permanently, including subjects who have completed an EoT visit. Ongoing 
or new AEs judged to be related to any trial medication will be followed until the event has resolved to the baseline grade, becomes stable, the subject is lost to follow-up, 
the subject withdraws consent, or it has been determined that the study treatment is not the cause of the AE, even if new anticancer treatment is initiated.
cc.
If a subject withdraws from the treatment for reasons other than PD, or, for subjects in the control arm not receiving pemetrexed maintenance only, the completion of up to 6 
cycles of pemetrexed+cisplatin/carboplatin, tumor assessments will be performed every 6 weeks until Week 51 (Cycle 17) and every 12 weeks after Week 51 until 
radiologically documented PD, death, end of trial, or start of a new anticancer therapy, whichever occurs first.
dd.
Information about subject survival will be collected by telephone interview/clinic visit every 3 months ± 2 weeks until death or the end of the trial, whichever comes first. 
Any new anticancer therapy given to the subject until death should be recorded.
ee.
Subject eligibility evaluation (review of inclusion/exclusion criteria) will be checked. Some subjects may have a prescreening more than 28 days prior to randomization/first 
administration of trial treatment. Subjects who may have a prescreening to determine MET and T790M status must sign a prescreening ICF before any prescreening study 
procedures will be performed. MET and T790M status will be determined; and demographic data, medical history (including nicotine consumption), and disease history will 
be collected during the prescreening.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
123/154
ff.
PROs (LCSS, EORTC QLQ-C30 and 
): the questionnaires will be completed on Day 1 of Cycles 1, 3, 5, 7, 9, 11, 13, 15, 17 and every 4 cycles thereafter until 
disease progression, and EOT. At the visits indicated, the questionnaires will be completed by the subject and prior to the initiation of any other trial activities (including 
RECIST Version 1.1 assessments) or active treatment. No PROs will be required for subjects receiving treatment beyond PD. 
gg.
Assessment can be repeated at the Investigator’s discretion at unscheduled visits to assess the safety and tolerability of the IMP/comparator. 
hh.
Study treatment should be given on the day of randomization or the day following the randomization day.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
124/154
Appendix C
Response Evaluation Criteria in Solid Tumors (RECIST) 
Version 1.1 
The text below was obtained from the following reference: Eisenhauer EA, Therasse P, Bogaerts 
J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised 
RECIST guideline (Version 1.1). European Journal of Cancer. 2009; 45: 228-247.
Definitions
Response and progression will be evaluated in this trial using the international criteria proposed 
by the RECIST Committee (Version 1.1). Changes in only the largest diameter (unidimensional 
measurement) of the tumor lesions are used in the RECIST criteria. Note: Lesions are either 
measurable or non-measurable using the criteria provided below. The term “evaluable” in 
reference to measurability will not be used because it does not provide additional meaning or 
accuracy.
Measurable Disease
Tumor lesions: Must be accurately measured in at least 1 dimension (longest diameter in the plane 
of measurement is to be recorded) with a minimum size of: 
10 mm by CT scan (irrespective of scanner type) and MRI (no less than double the slice thickness 
and a minimum of 10 mm) 
10 mm caliper measurement by clinical exam (when superficial) 
20 mm by chest X-ray (if clearly defined and surrounded by aerated lung) 
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph node 
must be ≥15 mm in short axis when assessed by CT scan (CT scan slice thickness recommended 
to be no greater than 5 mm). At baseline and in follow-up, only the short axis will be measured 
and followed.
Non-measurable Disease
All other lesions (or sites of disease), including small lesions (longest diameter ≥10 to < 15 mm 
with conventional techniques or <10 mm using spiral CT scan), are considered non-measurable 
disease. Leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast 
disease, lymphangitic involvement of skin or lung, abdominal masses/abdominal organomegaly 
identified by physical exam that is not measurable by reproducible imaging techniques are all non-
measurable.
Bone lesions:
Bone scan, PET scan, or plain films are not considered adequate imaging techniques to measure 
bone lesions. However, these techniques can be used to confirm the presence or disappearance 
of bone lesions.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
125/154
Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components, that 
can be evaluated by cross sectional imaging techniques such as CT or MRI can be considered 
as measurable lesions if the soft tissue component meets the definition of measurability 
described above.
Blastic bone lesions are non-measurable.
Cystic lesions:
Lesions that meet the criteria for radiographically defined simple cysts should not be considered 
as malignant lesions (neither measurable nor non-measurable) since they are, by definition, 
simple cysts.
Cystic lesions thought to represent cystic metastases can be considered as measurable lesions, if 
they meet the definition of measurability described above. However, if noncystic lesions are 
present in the same subject, these are preferred for selection as target lesions.
Lesions with prior local treatment:
Tumor lesions situated in a previously irradiated area, or in an area subjected to other local 
regional therapy, are usually not considered measurable unless there has been demonstrated 
progression in the lesion. Trial protocols should detail the conditions under which such lesions 
would be considered measurable.
Target Lesions
All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, should be 
identified as target lesions and recorded and measured at baseline. Target lesions should be 
selected on the basis of their size (lesions with the longest diameter), be representative of all 
involved organ, but in addition should be those that lend themselves to reproducible repeated 
measurements.
Lymph nodes merit special mention since they are normal anatomical structures which may be 
visible by imaging even if not involved by tumor. Pathological nodes which are defined as 
measurable and may be identified as target lesions must meet the criterion of a short axis of 
≥15 mm by CT scan. Only the short axis of these nodes will contribute to the baseline sum. The 
short axis of the node is the diameter normally used by radiologists to judge if a node is involved 
by solid tumor. Nodal size is normally reported as 2 dimensions in the plane in which the image is 
obtained (for CT scan this is almost always the axial plane; for MRI the plane of acquisition may 
be axial, saggital, or coronal). The smaller of these measures is the short axis. For example, an 
abdominal node which is reported as being 20 mm x 30 mm has a short axis of 20 mm and qualifies 
as a malignant, measurable node. In this example, 20 mm should be recorded as the node 
measurement. All other pathological nodes (those with short axis ≥10 mm but < 15 mm) should 
be considered non-target lesions. Nodes that have a short axis < 10 mm are considered non-
pathological and should not be recorded or followed.
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be 
included in the sum, then as noted above, only the short axis is added into the sum. The baseline 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
126/154
sum diameters will be used as reference to further characterize any objective tumor regression in 
the measurable dimension of the disease. 
Non-target Lesions
All other lesions (or sites of disease) including pathological lymph nodes should be identified as 
non-target lesions and should also be recorded at baseline. Measurements are not required and 
these lesions should be followed as ‘present’, ‘absent’, or in rare cases ‘unequivocal progression’ 
(more details to follow). In addition, it is possible to record multiple non-target lesions involving 
the same organ as a single item on the case record form (eg, ‘multiple enlarged pelvic lymph nodes’ 
or ‘multiple liver metastases’). 
Guidelines for Evaluation of Measurable Disease
All measurements should be recorded in metric notation, using calipers if clinically assessed. All 
baseline evaluations should be performed as close as possible to the treatment start and never more 
than 4 weeks before the beginning of the treatment.
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Imaging based evaluation should 
always be done rather than clinical examination unless the lesion(s) being followed cannot be 
imaged but are assessable by clinical exam.
Clinical lesions: Clinical lesions will only be considered measurable when they are superficial 
and ≥ 10 mm diameter as assessed using calipers (eg, skin nodules). For the case of skin lesions, 
documentation by color photography including a ruler to estimate the size of the lesion is 
suggested. As noted above, when lesions can be evaluated by both clinical exam and imaging, 
imaging evaluation should be undertaken since it is more objective and may also be reviewed at 
the end of the trial.
Chest X-ray: Chest CT is preferred over chest X-ray, particularly when progression is an 
important endpoint, since CT is more sensitive than X-ray, particularly in identifying new lesions. 
However, lesions on chest X-ray may be considered measurable if they are clearly defined and 
surrounded by aerated lung. 
CT, MRI: CT is the best currently available and reproducible method to measure lesions selected 
for response assessment. This guideline has defined measurability of lesions on CT scan based on 
the assumption that CT slice thickness is 5 mm or less. As is described in Appendix II of the 
original source article cited above, when CT scans have slice thickness greater than 5 mm, the 
minimum size for a measurable lesion should be twice the slice thickness. MRI is also acceptable 
in certain situations (eg, for body scans). 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
127/154
Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement. Ultrasound examinations cannot be reproduced in their entirety for 
independent review at a later date and, because they are operator dependent, it cannot be 
guaranteed that the same technique and measurements will be taken from 1 assessment to the next. 
If new lesions are identified by ultrasound in the course of the trial, confirmation by CT or MRI is 
advised. If there is concern about radiation exposure at CT, MRI may be used instead of CT in 
selected instances.
Endoscopy, laparoscopy: The utilization of these techniques for objective tumor evaluation is not 
advised. However, they can be useful to confirm complete pathological response when biopsies 
are obtained or to determine relapse in trials where recurrence following complete response or 
surgical resection is an endpoint.
Tumor markers: Tumor markers alone cannot be used to assess objective tumor response. If 
markers are initially above the upper normal limit, however, they must normalize for a subject to 
be considered in complete response. Because tumor markers are disease specific, instructions for 
their measurement should be incorporated into protocols on a disease specific basis. Specific 
guidelines for both CA-125 response (in recurrent ovarian cancer) and PSA response (in recurrent 
prostate cancer), have been published. In addition, the Gynecologic Cancer Intergroup has 
developed CA-125 progression criteria which are to be integrated with objective tumor assessment 
for use in first-line trials in ovarian cancer.
Cytology, histology: These techniques can be used to differentiate between PR and CR in rare 
cases if required by protocol (for example, residual lesions in tumor types such as germ cell tumors, 
where known residual benign tumors can remain). When effusions are known to be a potential AE 
of treatment (eg, with certain taxane compounds or angiogenesis inhibitors), the cytological 
confirmation of the neoplastic origin of any effusion that appears or worsens during treatment can 
be considered if the measurable tumor has met criteria for response or SD in order to differentiate 
between response (or SD) and PD.
Response Criteria
Evaluation of Target Lesions
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to < 10 mm.
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as 
reference the baseline sum diameters. 
Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking 
as reference the smallest sum on trial (this includes the baseline sum if that is the smallest on trial). 
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of 
at least 5 mm. (Note: the appearance of 1 or more new lesions is also considered progression). 
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on trial. 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
128/154
Lymph nodes. Lymph nodes identified as target lesions should always have the actual short axis 
measurement recorded (measured in the same anatomical plane as the baseline examination), even 
if the nodes regress to below 10 mm on trial. This means that when lymph nodes are included as 
target lesions, the ‘sum’ of lesions may not be zero even if complete response criteria are met, 
since a normal lymph node is defined as having a short axis of < 10 mm. Case report forms or 
other data collection methods may therefore be designed to have target nodal lesions recorded in 
a separate section where, in order to qualify for CR, each node must achieve a short axis < 10 mm. 
For PR, SD and PD, the actual short axis measurement of the nodes is to be included in the sum 
of target lesions.
Target lesions that become ‘too small to measure’. While on trial, all lesions (nodal and non-nodal) 
recorded at baseline should have their actual measurements recorded at each subsequent 
evaluation, even when very small (eg, 2 mm). However, sometimes lesions or lymph nodes which 
are recorded as target lesions at baseline become so faint on CT scan that the radiologist may not 
feel comfortable assigning an exact measure and may report them as being ‘too small to measure’. 
When this occurs it is important that a value be recorded on the eCRF. If it is the opinion of the 
radiologist that the lesion has likely disappeared, the measurement should be recorded as 0 mm. If 
the lesion is believed to be present and is faintly seen but too small to measure, a default value of 
5 mm should be assigned. (Note: It is less likely that this rule will be used for lymph nodes since 
they usually have a definable size when normal and are frequently surrounded by fat, such as in 
the retroperitoneum; however, if a lymph node is believed to be present and is faintly seen but too 
small to measure, a default value of 5 mm should be assigned in this circumstance as well). This 
default value is derived from the 5 mm CT slice thickness (but should not be changed with varying 
CT slice thickness). The measurement of these lesions is potentially non-reproducible; therefore, 
providing this default value will prevent false responses or progressions based upon measurement 
error. To reiterate, however, if the radiologist is able to provide an actual measure, that should be 
recorded, even if it is below 5 mm.
Lesions that split or coalesce on treatment. When non-nodal lesions ‘fragment’, the longest 
diameters of the fragmented portions should be added together to calculate the target lesion sum. 
Similarly, as lesions coalesce, a plane between them may be maintained that would aid in obtaining 
maximal diameter measurements of each individual lesion. If the lesions have truly coalesced such 
that they are no longer separable, the vector of the longest diameter in this instance should be the 
maximal longest diameter for the ‘coalesced lesion’.
Evaluation of Non-target Lesions
While some non-target lesions may actually be measurable, they need not be measured and instead 
should be assessed only qualitatively at the time points specified in the protocol. 
Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor 
marker level. All lymph nodes must be non-pathological in size (< 10 mm short axis). 
Non-CR/Non-PD: Persistence of 1 or more non-target lesion(s) and/or maintenance of tumor 
marker level above the normal limits.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
129/154
Progressive Disease (PD): Unequivocal progression (see comments below) of existing non-target 
lesions. (Note: the appearance of 1 or more new lesions is also considered progression). 
When the subject also has measurable disease. In this setting, to achieve ‘unequivocal progression’ 
on the basis of the non-target disease, there must be an overall level of substantial worsening in 
non-target disease such that, even in the presence of SD or PR in target disease, the overall tumor 
burden has increased sufficiently to merit discontinuation of therapy. A modest ‘increase’ in the 
size of 1 or more non-target lesions is usually not sufficient to quality for unequivocal progression 
status. The designation of overall progression solely on the basis of change in non-target disease 
in the face of SD or PR of target disease will therefore be extremely rare.
When the subject has only non-measurable disease. This circumstance arises in some Phase III 
trials when it is not a criterion of trial entry to have measurable disease. The same general concept 
apply here as noted above, however, in this instance there is no measurable disease assessment to 
factor into the interpretation of an increase in non-measurable disease burden. Because worsening 
in non-target disease cannot be easily quantified (by definition: if all lesions are truly non-
measurable), a useful test that can be applied when assessing subjects for unequivocal progression 
is to consider if the increase in overall disease burden based on the change in non-measurable 
disease is comparable in magnitude to the increase that would be required to declare PD for 
measurable disease: ie, an increase in tumor burden representing an additional 73% increase in 
‘volume’ (which is equivalent to a 20% increase diameter in a measurable lesion). Examples 
include an increase in a pleural effusion from ‘trace’ to ‘large’, an increase in lymphangitic disease 
from localized to widespread, or may be described in protocols as ‘sufficient to require a change 
in therapy’. If ‘unequivocal progression’ is seen, the subject should be considered to have had 
overall PD at that point. While it would be ideal to have objective criteria to apply to non-
measurable disease, the very nature of that disease makes it impossible to do so; therefore, the 
increase must be substantial.
New Lesions
The appearance of new malignant lesions denotes disease progression; therefore, some comments 
on detection of new lesions are important. There are no specific criteria for the identification of 
new radiographic lesions; however, the finding of a new lesion should be unequivocal: ie, not 
attributable to differences in scanning technique, change in imaging modality, or findings thought 
to represent something other than tumor (for example, some ‘new’ bone lesions may be simply 
healing or flare of pre-existing lesions). This is particularly important when the subject’s baseline 
lesions show partial or complete response. For example, necrosis of a liver lesion may be reported 
on a CT scan report as a ‘new’ cystic lesion, which it is not. 
A lesion identified on a follow-up trial in an anatomical location that was not scanned at baseline 
is considered a new lesion and will indicate PD. An example of this is the subject who has visceral 
disease at baseline and while on trial has a brain CT or MRI ordered which reveals metastases. 
The subject’s brain metastases are considered to be evidence of PD even if he/she did not have 
brain imaging at baseline.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
130/154
If a new lesion is equivocal, for example because of its small size, continued therapy and follow-
up evaluation will clarify if it represents truly new disease. If repeat scans confirm there is 
definitely a new lesion, then progression should be declared using the date of the initial scan.
While fluorodeoxyglucose positron emission tomography (FDG-PET) response assessments need 
additional trial, it is sometimes reasonable to incorporate the use of FDG-PET scanning to 
complement CT scanning in assessment of progression (particularly possible ‘new’ disease). New 
lesions on the basis of FDG-PET imaging can be identified according to the following algorithm:
a.
Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of PD based 
on a new lesion.
b. No FDG-PET at baseline and a positive FDG-PET at follow-up: If the positive FDG-PET at 
follow-up corresponds to a new site of disease confirmed by CT, this is PD. If the positive 
FDG-PET at follow-up is not confirmed as a new site of disease on CT, additional follow-up 
CT scans are needed to determine if there is truly progression occurring at that site (if so, the 
date of PD will be the date of the initial abnormal FDG-PET scan). If the positive FDG-PET 
at follow-up corresponds to a pre-existing site of disease on CT that is not progressing on the 
basis of the anatomic images, this is not PD.
Evaluation of Best Overall Response
The best OR is the best response recorded from the start of the trial treatment until the end of 
treatment taking into account any requirement for confirmation. On occasion, a response may not 
be documented until after the end of therapy, so protocols should be clear if post-treatment 
assessments are to be considered in determination of best OR. Protocols must specify how any 
new therapy introduced before progression will affect best response designation. The subject’s 
best OR assignment will depend on the findings of both target and non-target disease and will also 
take into consideration the appearance of new lesions. Furthermore, depending on the nature of 
the trial and the protocol requirements, it may also require confirmatory measurement. 
Specifically, in non-randomized trials where response is the primary endpoint, confirmation of PR 
or CR is needed to deem either 1 the ‘best OR’. 
The best OR is determined once all the data for the subject is known. Best response determination 
in trials where confirmation of complete or partial response IS NOT required: Best response in 
these trials is defined as the best response across all time points (for example, a subject who has 
SD at first assessment, PR at second assessment, and PD on last assessment has a best OR of PR). 
When SD is believed to be best response, it must also meet the protocol specified minimum time 
from baseline. If the minimum time is not met when SD is otherwise the best time point response, 
the subject’s best response depends on the subsequent assessments. For example, a subject who 
has SD at first assessment, PD at second and does not meet minimum duration for SD, will have a 
best response of PD. The same subject lost to follow-up after the first SD assessment would be 
considered inevaluable.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
131/154
Target Lesions
Non-target Lesions
New Lesions
Overall Response
CR*
CR
No
CR
CR
Non-CR/non-PD
No
PR
CR
Not Evaluated
No
PR
PR
Non-PD or not all evaluated
No
PR
SD
Non-PD or not all evaluated
No
SD
Non-PD
Not all evaluated
No
NE
PD
Any
Yes or No
PD
Any
PD
Yes or No
PD
Any
Any
Yes
PD
* CR = complete response; PR = partial response; SD = stable disease; and PD = progressive disease.
See text for more details.
Note:
When nodal disease is included in the sum of target lesions and the nodes decrease to ‘normal’ 
size (< 10 mm), they may still have a measurement reported on scans. This measurement should 
be recorded even though the nodes are normal in order not to overstate progression should it be 
based on increase in size of the nodes. As noted earlier, this means that subjects with CR may not 
have a total sum of ‘zero’ on the eCRF. 
In trials where confirmation of response is required, repeated ‘NE’ time point assessments may 
complicate best response determination. The analysis plan for the trial must address how missing 
data/assessments will be addressed in determination of response and progression. For example, in 
most trials, it is reasonable to consider a subject with time point responses of PR-NE-PR as a 
confirmed response.
Subjects with a global deterioration of health status requiring discontinuation of treatment without 
objective evidence of PD at that time should be reported as ‘symptomatic deterioration’. Every 
effort should be made to document objective progression even after discontinuation of treatment. 
Symptomatic deterioration is not a descriptor of an objective response; it is a reason for stopping 
trial therapy. 
Conditions that define ‘early progression, early death and inevaluability’ are trial specific and 
should be clearly described in each protocol (depending on treatment duration, treatment 
periodicity).
In some circumstances it may be difficult to distinguish residual disease from normal tissue. When 
the evaluation of CR depends upon this determination, it is recommended that the residual lesion 
be investigated (fine needle aspirate/biopsy) before assigning a status of CR. The use of FDG-PET 
may be used to upgrade a response to a CR in a manner similar to a biopsy in cases where a residual 
radiographic abnormality is thought to represent fibrosis or scarring. The use of FDG-PET in this 
circumstance should be prospectively described in the protocol and supported by disease specific 
medical literature for the indication. However, it must be acknowledged that both approaches may 
lead to false positive CR due to limitations of FDG-PET and biopsy resolution/ sensitivity.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
132/154
For equivocal findings of progression (eg, very small and uncertain new lesions; cystic changes or 
necrosis in existing lesions), treatment may continue until the next scheduled assessment. If at the 
next scheduled assessment, progression is confirmed, the date of progression should be the earlier 
date when progression was suspected.
Confirmatory Measurement/Duration of Response
Confirmation
In non-randomized trials where response is the primary endpoint, confirmation of PR and CR is 
required to ensure the responses identified are not the result of measurement error. This will also 
permit appropriate interpretation of results in the context of historical data where response has 
traditionally required confirmation in such trials. However, in all other circumstances, ie, in 
randomized trials (Phase II or III) or studies where stable disease or progression are the primary 
endpoints, confirmation of response is not required since it will not add value to the interpretation 
of the trial results. However, elimination of the requirement for response confirmation may 
increase the importance of central review to protect against bias, in particular in studies which are 
not blinded.
In the case of SD, measurements must have met the SD criteria at least once after trial entry at a 
minimum interval (in general not less than 6–8 weeks) that is defined in the trial protocol.
Duration of Overall Response
The duration of OR is measured from the time measurement criteria are first met for CR/PR 
(whichever is first recorded) until the first date that recurrent or progressive disease is objectively 
documented (taking as reference for progressive disease the smallest measurements recorded on 
trial).
The duration of overall complete response is measured from the time measurement criteria are first 
met for CR until the first date that recurrent disease is objectively documented. 
Duration of Stable Disease
Stable disease is measured from the start of the treatment (in randomized trials, from date of 
randomization) until the criteria for progression are met, taking as reference the smallest sum on 
trial (if the baseline sum is the smallest, this is the reference for calculation of PD).
The clinical relevance of the duration of stable disease varies in different studies and diseases. If 
the proportion of subjects achieving stable disease for a minimum period of time is an endpoint of 
importance in a particular trial, the protocol should specify the minimal time interval required 
between 2 measurements for determination of stable disease.
Note: The duration of response and stable disease as well as the progression-free survival are 
influenced by the frequency of follow-up after baseline evaluation. It is not in the scope of this 
guideline to define a standard follow-up frequency. The frequency should take into account many 
parameters including disease types and stages, treatment periodicity and standard practice. 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
133/154
However, these limitations of the precision of the measured endpoint should be taken into account 
if comparisons between trials are to be made.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
134/154
Appendix D
Eastern Cooperative Oncology Group Performance Status 
(ECOG PS)
Grade 
Description
0
Fully active, able to carry on all pre-disease performance without restriction
1
Restricted in physically strenuous activity but ambulatory and able to carry 
out work of a light or sedentary nature, eg, light housework, office work
2
Ambulatory and capable of all self-care but unable to carry out any work 
activities. Up and about more than 50% of waking hours
3
Capable of only limited self-care, confined to bed or chair more than 50% 
of waking hours
4
Completely disabled. Cannot carry on any self-care. Totally confined to
bed or chair
5
Dead
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin 
Oncol. 1982 Dec;5(6):649-55.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
135/154
Appendix E
New York Heart Association (NYHA) Criteria
Class
Description
I
No limitation: Ordinary physical activity does not cause undue fatigue, 
dyspnea, or palpitations.
II
Slight limitation of physical activity: Such subjects are comfortable at rest. 
Ordinary physical activity results in fatigue, palpitations, dyspnea, or 
angina.
III
Marked limitation of physical activity: Although subjects are comfortable 
at rest, less than ordinary physical activity will lead to symptoms.
IV
Inability to carry on physical activity without discomfort: Symptoms of 
congestive heart failure are present even at rest. With any physical activity, 
increased discomfort is experienced.
Source: Criteria Committee, New York Heart Association, Inc. Diseases of the heart and blood vessels. Nomenclature and 
criteria for diagnosis. 6th ed. Boston, Little, Brown and Co, 1964:114.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
136/154
Appendix F
Blood Sampling Schedule for PK/Pd
Phase Ib
Day
Time points
H = hours 
after dosing
PK
Pd/Biomarkers
Cycle
2 x 2 mL
20 mL
Day 1
Predosing
X
X
H 0.25
X
H 0.5
X
H 1
X
H 2
X
Cycle 1
H 4
X
H 8
X
H10
X
H 24
X
Day 15
Same time 
points as 
Day 1
X
All pre-dosing samples should be taken within 60 minutes before each treatment administration
Phase II
Cycle
Day
Time points
H = hours after dosing
PK
Pd/Biomarkers
2 mL
20 mL
Cycle 1
Day 1
Predosing
X
X
H 1.5
X
H 4
X
Cycle 2, 
Day 1
Same time points as Cycle 1
X
Cycle 2, 
4, 6, 8, 
10, 12 
and 
EoT
Day 1
Predosing
X
On days when PK samples are to be drawn, subjects should be instructed to attend the trial visit in a fasted state, with no 
breakfast and prior to taking their dose of study medication. After a predose PK blood sample is drawn, the assigned doses of
tepotinib and gefitinib should be taken following breakfast. No further food should be consumed until 2 hours after the dose 
(water is allowed).
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
137/154
Appendix G
Blood Samples Volumes
For Cycle 1
Sample Type
Volume of Blood (mL)
Cycle 1
Total
Day 1
Day 15
PK Phase Ib
36
36
72
PK Phase II
6
-
6
Pd/Biomarkers
20
-
20
Total (mL) Phase Ib
62
36
98
Total (mL) Phase II
32
-
32
An anticipated total blood sample volume of approximately 98 mL will be taken for Cycle 1 in Phase Ib.
An anticipated total blood sample volume of approximately 32 mL will be taken for Cycle 1 in Phase II.
For Cycle 2, 4, 6, 8, 10 and 12, End of Treatment
Sample type
Volume of blood (mL)
Cycle 2
Cycle ≥ 3
End of Treatment
Day 1
Day 1
Total(mL)
PK Phase II
6
-
-
6
Pd/Biomarkers *
20*
20*
20
60
Total (mL)
26
20
20
66
An anticipated total blood sample volume of approximately 66 mL will be taken for Cycle 2, Cycle 3, subsequent cycles and End 
of Treatment in both Phase Ib and Phase II.
*Seven on-treatment samples (1 cycle apart, ie, 1 in Cycle 2, 4, 6, 8, 10 and 12 and end of treatment in subjects signing separate 
ICF). 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
138/154
Appendix H
Scoring System for MET Immunohistochemistry
Diagnostic
Clinical Score
Scoring Criteria
Positive
3+
≥50% tumor cells with membrane and/or cytoplasmic 
staining with strong intensity
2+
≥50% tumor cells with membrane and/or cytoplasmic 
staining with moderate intensity
Negative
1+
≥50% tumor cells with membrane and/or cytoplasmic 
staining with weak intensity but < 50% tumor cells with 
moderate or high intensity
0
Samples with no staining, or with < 50% tumor cells with 
membrane and/or cytoplasmic staining (could be 
combination of any staining intensities)
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
139/154
Appendix I
Gefitinib AE Management Guidelines 
In all instances, it is recommended that subjects be instructed at time of starting drug therapy to 
call the Investigator/site if no improvement in symptoms has been observed after 24 hours of 
subject taking the recommended/optimal pharmacologic treatment.
Abbreviations:
BSA: Body Surface Area
ADL: Activities of Daily Living. 
Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using 
the telephone, managing money, etc. 
Self-care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, 
taking medications and not bedridden. (definitions per CTCAE Version 4.0) 
DIARRHEA
Subjects should be encouraged to drink 8 to 10 large glasses of clear liquids per day while on study 
in order to maintain adequate hydration
General dietary measures to limit impact of diarrhea could include:
Stop all lactose-containing products in subjects with evidence of lactose intolerance;
Eat frequent small meals if experiencing increased frequency of stools;
Consider low fat regimen enriched with bananas, rice, applesauce, and toast.
Diarrhea Management Guideline
Grade of Event Management / Next Dose
Grade 1: 
increase of 
< 4 stools per day 
over baseline;
Loperamide 4 mg at the first onset of diarrhea and then 2 mg every 2 hours 
until the subject is diarrhea-free for at least 12 hours. (During the night the 
subject may take 4 mg of loperamide every 4 hours).
Fluid intake of at least 2 L should be maintained to avoid dehydration: subjects 
are to drink 8-10 large glasses of clear liquids. Consideration for maintenance 
of electrolyte balance would include electrolyte-containing drinks, broth, and 
clear juices. 
Study Treatment: should be continued at same dose.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
140/154
Diarrhea Management Guideline
Grade of Event Management / Next Dose
Grade 2: 
increase of 
4-6 stools per day 
over baseline;
Loperamide as above, or consider use of diphenoxylate hydrochloride and 
atropine sulfate formula (eg, Lomotil(, Diarced(, Co-Phenotroope() at 
standard doses.
Fluid intake of at least 2 L should be maintained to avoid dehydration. 
Monitor subject closely and consider intravenous hydration. 
Study Treatment: If not improved to < Grade 1 within 24 hours despite use of 
loperamide, hold treatment until Grade 1. If diarrhea of > Grade 1 recurs after 
initial improvement, consider reduction of 1 dose level. 
Grade 3: 
increase of
#7 stools per day 
over baseline; or 
incontinence; or 
limiting self-care 
ADL: or 
hospitalization 
indicated
Oral therapy with diphenoxylate hydrochloride and atropine sulfate formula, 
or tincture of opium. 
Fluid intake of at least 2 L should be maintained, intravenously if necessary. 
Consider use of octreotide (Sandostatin) 100-150 )g subcutaneously twice 
daily with escalation to 500 )g three times daily.
Consider hospitalization if does not improve to Grade 2 within 24 hours, or in 
presence of fever, abdominal pain, etc.
Study Treatment: Hold therapy. Upon resolution to ∗Grade 1, resume therapy 
with consideration of reduction of 1 dose level
Grade 4: 
life-threatening
Maximal inpatient fluid and nutritional support, antibiotics as indicated in 
judgment of Investigator for fever, leukocytosis, marked dehydration, etc.
Study Treatment: Hold until ∗Grade 1. Mandatory dose reduction of 1 dose 
level
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
141/154
DERMATOLOGIC TOXICITY
Acneiform/ Papulopustular Rash:
Acneiform/ Papulopustular Rash Management Guideline
Grade of Event
Management
Grade 1:
< 10% body surface area (BSA) papules and 
/ or pustules (with or without symptoms of 
pruritus or tenderness)
Topical steroids *
And
Topical antibiotic bid
(clindamycin 1 - 2%, erythromycin 1% - 2%, 
metronidazole 1%)
Grade 2:
10 to 30% BSA papules and / or pustules 
(with or without symptoms of pruritus or 
tenderness), or psychosocial impact, or 
limited instrumental ADL
Oral antibiotic for at least 4 weeks
(doxycycline 100 mg bid, minocycline 100 mg
bid or oxytetracycline 500 mg bid);
Stop topical antibiotic if being used
And
Topical steroids *
Grade 3:
> 30% BSA papules and / or pustules (with 
or without symptoms of pruritus or 
tenderness);
or
limiting self-care ADL: 
or
associated with local super-infection with 
oral antibiotics indicated
Oral antibiotic for 4 weeks 
(doxycycline 100 mg bid, minocycline 100 mg
bid or oxytetracycline 500 mg bid)
If infection suspected (yellow crusts, purulent 
discharge, painful skin/nares):
switch oral antibiotic to broad spectrum/gram 
negative cover for at least 10 days
consider skin swab for bacterial culture, 
And
Topical steroids (continue)* Consider
dermatology consultation
* Moderate/Low strength steroids include: 
Triamcinolone acetonide 0.025% 
Desonide 0.05%
Alclometasone 0.05% cream
Fluticasone propionate 0.05% 
For subjects intolerant or allergic to tetracycline 
antibiotics, use an antibiotic with 
Staphylococcus coverage (eg, cephalexin, 
sulfamethoxazole/ trimethoprim)
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
142/154
Appendix J
Dose Modification for Gefitinib
AE/Grade
Gefitinib
Subjects should be instructed at time 
of starting drug therapy to call the 
Investigator/Site if no improvement 
in symptoms has been observed after 
24 hours of subject taking the 
recommended/optimal 
pharmacologic treatment.
Gefitinib dose frequency and discontinuation should 
follow local standard of care practice.
Depending upon local practice, subjects with toxicities 
which in the Investigator’s opinion are clearly related to 
gefitinib, may have their dosing held until toxicity 
resolution or may have their dosing frequency reduced in 
accordance with local standard of care practice
Grade 4 neutropenia for more than 
7 days
Grade ≥ 3 febrile neutropenia for 
more than 1 day;
Grade 4 thrombocytopenia or 
Grade 3 thrombocytopenia with 
bleeding;
No change in dose frequency
Grade ≥3 uncontrolled 
nausea/vomiting and/or diarrhea 
despite adequate and optimal 
treatment for more than 3 days 
Depending upon local practice, subjects with toxicities 
which in the Investigator’s opinion are clearly related to 
gefitinib, may have their dosing held until toxicity 
resolution or may have their dosing frequency reduced in 
accordance with local standard of care practice
Subjects with poorly tolerated diarrhea (sometimes 
associated with dehydration) drug reactions may be 
successfully managed by providing a brief (up to 14 days) 
therapy interruption followed by reinstatement of the 
250 mg daily dose.
Grade ≥ 3 any nonhematological 
AE, except the aforementioned 
gastrointestinal events and alopecia; 
Continue at Investigator discretion
Grade ≥ 3 liver AE requiring a 
recovery period of more than 7 days 
to return to the baseline grade or to 
Grade 2; 
Continue at Investigator discretion
Grade # 3 lipase and/or amylase 
elevation with confirmation of 
pancreatitis;
Continue at Investigator discretion
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
143/154
AE/Grade
Gefitinib
Clinically intolerable skin rash, acne 
or other skin symptoms
Depending upon local practice, subjects with toxicities 
which in the Investigator’s opinion are clearly related to 
gefitinib, may have their dosing held until toxicity 
resolution or may have their dosing frequency reduced in 
accordance with local standard of care practice.
Subjects with poorly tolerated skin adverse drug reactions 
may be successfully managed by providing a brief (up to 
14 days) therapy interruption followed by reinstatement 
of the 250 mg daily dose.
Acute onset or worsening of 
pulmonary symptoms (dyspnea, 
cough, fever)
Gefitinib therapy should be interrupted and a prompt 
investigation of these symptoms should occur. If 
Interstitial Lung Disease is confirmed, Gefitinib should 
be discontinued.
Eye symptoms
Subjects who develop onset of new eye symptoms such 
as pain should be medically evaluated and gefitinib 
therapy should be interrupted. After symptoms and eye 
changes have resolved, the decision should be made 
concerning reinstatement of the 250 mg daily dose.
Recurrence of Grade ≥ 2 AEs after 
re-challenging despite adequate and 
optimal treatment of the AE.
Continue at Investigator discretion
Grade 1 AE;
Well tolerated Grade 2 AEs;
Asymptomatic lipase and/or amylase 
elevation without confirmation of 
pancreatitis.
Continue at Investigator discretion
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
144/154
Appendix K
Lung Cancer Symptom Scale (LCSS): Subject Scale 
A sample of the English version of the LCSS is provided below. Local language version will be 
available for trial subjects.
Directions: Please place a mark along each line where it would best describe the symptoms of 
your lung cancer DURING THE PAST DAY (within the last 24 hours).
Example Question
How is the weather today?
As good as it 
could be
|________________________________________________________|
As bad as it 
could be
1. How is your appetite?
As good as it 
could be
|________________________________________________________|
As bad as it 
could be
2. How much fatigue do you have?
None
|________________________________________________________|
As much as it 
could be
3. How much coughing do you have?
None
|________________________________________________________|
As much as it 
could be
4. How much shortness of breath do you have?
None
|________________________________________________________|
As much as it 
could be
5. How much blood do you see in your sputum?
None
|________________________________________________________|
As much as it 
could be
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
145/154
6. How much pain do you have?
None
|________________________________________________________|
As much as it 
could be
7. How bad are your symptoms from lung cancer?
I have none
|________________________________________________________|
As bad as they 
could be
8. How much has your illness affected your ability to carry out normal activities?
Not at all
|________________________________________________________|
So much that I 
can do nothing 
for myself
9. How would you rate the quality of your life today?
Very high
|________________________________________________________|
Very low
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
146/154
Appendix L
EORTC QLQ-C30 (Version 3.0) 
A sample of the English version of the EORTC QLQ-C30 (Version 3.0) is provided below. Local 
language version will be available for trial subjects.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
147/154
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
148/154
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
149/154
 
 
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
150/154
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
151/154
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
152/154
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
153/154
Appendix N
Contraceptive Guidance and Women of Childbearing 
Potential
Definitions
Woman of Childbearing Potential 
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile. Permanent
sterilization methods include hysterectomy, bilateral 
salpingectomy, and bilateral oophorectomy.
Women in the following categories are not considered women of childbearing potential
1. Premenopausal female with 1 of the following:
! Documented hysterectomy
! Documented bilateral salpingectomy
! Documented bilateral oophorectomy
Note: Documentation can come from the site personnel’s: review of participant’s medical 
records, medical examination, or medical history interview.
2. Premenarchal 
3. Postmenopausal female
! Females who are postmenopausal (age-related amenorrhea ≥ 12 consecutive months and 
increased follicle-stimulating hormone [FSH] > 40 mIU/mL), or who have undergone 
documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy are exempt 
from pregnancy testing. If necessary to confirm postmenopausal status, FSH will be re-tested 
at Screening.
! Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt 
will be required to use one of the non-hormonal highly effective contraception methods if 
they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to 
allow confirmation of postmenopausal status before study enrollment.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Tepotinib (MSC2156119J)
Tepotinib with Gefitinib in Subjects with Locally Advanced or 
EMR200095-006
Metastatic NSCLC (INSIGHT)
154/154
Contraceptive Guidance
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of < 1% per year when used consistently and correctly. 
!
Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulationb
!
oral 
!
intravaginal 
!
transdermal 
!
Progestogen-only hormonal contraception associated with inhibition of ovulationb
!
oral 
!
injectable
Highly Effective Methods That Are User Independent 
!
Implantable progestogen-only hormonal contraception associated with inhibition of ovulationb
!
Intrauterine device (IUD)
!
Intrauterine hormone-releasing system (IUS)
!
bilateral tubal occlusion
!
Vasectomized partner 
(A vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual 
partner of the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional 
highly effective method of contraception should be used. 
!
Sexual abstinence 
(Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse 
during the entire period of risk associated with the study drug. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.) 
NOTES: 
a) Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with 
local regulations regarding the use of contraceptive methods for participants participating in clinical studies. 
b) Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of 
the contraceptive method. In this case another highly effective (not hormone based) method must be utilized during 
the treatment period and for at least 3 months after the last dose of study treatment.
'RFXPHQW1R

2EMHFW1R

CCI
CCI

SAP_000.pdf: 
7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





6WDWLVWLFDO$QDO\VLV3ODQ
&OLQLFDO7ULDO3URWRFRO
,GHQWLILFDWLRQ1R
(05
7LWOH
$3KDVH,E,,0XOWLFHQWHU5DQGRPL]HG2SHQ/DEHO7ULDOWR
&RPSDUH7HSRWLQLE06&-&RPELQHGZLWK*HILWLQLE
9HUVXV&KHPRWKHUDS\DV6HFRQGOLQH7UHDWPHQWLQ6XEMHFWV
ZLWK 0(7 3RVLWLYH /RFDOO\ $GYDQFHG RU 0HWDVWDWLF 1RQ
VPDOO&HOO/XQJ&DQFHU16&/&+DUERULQJ(*)50XWDWLRQ
DQG +DYLQJ $FTXLUHG 5HVLVWDQFH WR 3ULRU (*)57\URVLQH
.LQDVH,QKLELWRU(*)57.,7KHUDS\
7ULDO3KDVH
3KDVH,E
,QYHVWLJDWLRQDO0HGLFLQDO
3URGXFWV
7HSRWLQLEDQG*HILWLQLE
&OLQLFDO7ULDO3URWRFRO
9HUVLRQ
6HSWHPEHU9HUVLRQ
1RYHPEHU9HUVLRQORFDO-DSDQ
$SULO9HUVLRQ/RFDOIRU&DQDGD
6WDWLVWLFDO$QDO\VLV3ODQ
$XWKRU

6WDWLVWLFDO$QDO\VLV3ODQ
'DWHDQG9HUVLRQ
-XO\9HUVLRQ
6WDWLVWLFDO$QDO\VLV3ODQ
5HYLHZHUV


7ULDO%LRVWDWLVWLFLDQ



7KLVGRFXPHQWLVWKHSURSHUW\RI0HUFN.*D$'DUPVWDGW*HUPDQ\RURQHRILWVDIILOLDWHGFRPSDQLHV
,WLVLQWHQGHGIRUUHVWULFWHGXVHRQO\DQGPD\QRWLQIXOORUSDUWEHSDVVHGRQUHSURGXFHGSXEOLVKHGRUXVHGZLWKRXWH[SUHVV
SHUPLVVLRQRI0HUFN.*D$'DUPVWDGW*HUPDQ\RULWVDIILOLDWH
&RS\ULJKWE\0HUFN.*D$'DUPVWDGW*HUPDQ\RULWVDIILOLDWH$OOULJKWVUHVHUYHG
PPD
PPD
PPD
PPD


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 
6LJQDWXUH3DJH
6WDWLVWLFDO$QDO\VLV3ODQ(05
$3KDVH,E,,0XOWLFHQWHU5DQGRPL]HG2SHQ/DEHO7ULDOWR&RPSDUH7HSRWLELE&RPELQHGZLWK
*HILWLQLE9HUVXV&KHPRWKHUDS\DV6HFRQGOLQH7UHDWPHQWLQ6XEMHFWVZLWK0(73RVLWLYH/RFDOO\
$GYDQFHGRU0HWDVWDWLF1RQVPDOO&HOO/XQJ&DQFHU16&/&+DUERULQJ(*)50XWDWLRQDQG
+DYLQJ$FTXLUHG5HVLVWDQFH3ULRU(*)57\URVLQH.LQDVH,QKLELWRU(*)57.,7KHUDS\


%LRVWDWLVWLFLDQ
0HUFN.*D$
)UDQNIXUWHU6WUDVVH'DUPVWDGW*HUPDQ\













PPD
PPD
PPD
PPD
PPD
PPD
PPD


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 
7DEOHRI&RQWHQWV
 
6LJQDWXUH3DJH 
 
7DEOHRI&RQWHQWV 
 
/LVWRI$EEUHYLDWLRQVDQG'HILQLWLRQRI7HUPV 
 
0RGLILFDWLRQ+LVWRU\ 
 
3XUSRVHRIWKH6WDWLVWLFDO$QDO\VLV3ODQ 
 
6XPPDU\RI&OLQLFDO7ULDO)HDWXUHV 
 
6DPSOH6L]H5DQGRPL]DWLRQ 
 
2YHUYLHZRI3ODQQHG$QDO\VHV 
 
6HTXHQFHRI$QDO\VLV 
 
6DIHW\0RQLWRULQJ&RPPLWWHH 
 
'HILQLWLRQRI'/7 
 
)LQDO$QDO\VLV 
 
&KDQJHVWRWKH3ODQQHG$QDO\VHVLQWKH&OLQLFDO7ULDO3URWRFRO 
 
3URWRFRO'HYLDWLRQVDQG$QDO\VLV6HWV 
 
'HILQLWLRQRI3URWRFRO'HYLDWLRQV 
 
'HILQLWLRQRI$QDO\VLV6HWVDQG6XEJURXSV 
 
*HQHUDO6SHFLILFDWLRQVIRU6WDWLVWLFDO$QDO\VHV 
 
7ULDO6XEMHFWV 
 
'LVSRVLWLRQRI6XEMHFWVDQG'LVFRQWLQXDWLRQV 
 
3URWRFRO'HYLDWLRQV 
 
,PSRUWDQW3URWRFRO'HYLDWLRQV 
 
'HPRJUDSKLFVDQG2WKHU%DVHOLQH&KDUDFWHULVWLFV 
 
'HPRJUDSKLFV 
 
0HGLFDO+LVWRU\ 
 
'LVHDVH+LVWRU\ 
 
0HGLFDWLRQ+LVWRU\RI2QFRORJ\ 
 
%DVHOLQH%LRPDUNHUV0HDVXUHGLQ7XPRU7LVVXH 
 
%DVHOLQH%LRPDUNHU9DULDEOHV 
 
'HVFULSWLYH6XPPDULHVRI%DVHOLQH%LRPDUNHUV 
 
2WKHU%DVHOLQH&KDUDFWHULVWLFV 
 
3UHYLRXVRU&RQFRPLWDQW0HGLFDWLRQV3URFHGXUHV 


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 
3UHYLRXVDQGFRQFRPLWDQWPHGLFDWLRQV 
 
$QWL&DQFHU7UHDWPHQWDIWHU7UHDWPHQW7HUPLQDWLRQ 
 
7UHDWPHQW&RPSOLDQFHDQG([SRVXUH 
 
(QGSRLQW(YDOXDWLRQ 
 
3ULPDU\(QGSRLQW$QDO\VHV 
 
6HFRQGDU\(QGSRLQW$QDO\VHV 
 
7XPRUUHVSRQVH 
 
2WKHU(QGSRLQW$QDO\VHV 
 
'XUDWLRQRI5HVSRQVH 
 
7DUJHW/HVLRQ'LDPHWHU 
 
3KDUPDFRNLQHWLFV 
 
2Q7UHDWPHQW%LRPDUNHUVLQ7XPRU7LVVXH 
 
6DIHW\(YDOXDWLRQ 
 
$GYHUVH(YHQWV 
 
$OO$GYHUVH(YHQWV 
 
6HYHULW\ 
 
5HODWLRQVKLSWR6WXG\7UHDWPHQW 
 
$GYHUVH(YHQWV/HDGLQJWR7UHDWPHQW'LVFRQWLQXDWLRQ 
 
'HDWKV2WKHU6HULRXV$GYHUVH(YHQWVDQG2WKHU6LJQLILFDQW
$GYHUVH(YHQWV 
 
'HDWKV 
 
6HULRXV$GYHUVH(YHQWV 
 
$GYHUVH(YHQWVRI6SHFLDO,QWHUHVW 
 
&OLQLFDO/DERUDWRU\(YDOXDWLRQ 
 
9LWDO6LJQV 
 
(&*(YDOXDWLRQV 
 
3K\VLFDO([DPLQDWLRQ 
 
2WKHU6DIHW\$VVHVVPHQWV 
 
%HQHILW5LVN$VVHVVPHQW 
 
5HIHUHQFHV 
 
$SSHQGLFHV 
$33(1',; 
1(:<25.+($57$662&,$7,211<+$&5,7(5,$ 


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





$33(1',; 
$6<03720$7,&(/(9$7,212)6(580/,3$6(
$1'25$0</$6( 
$33(1',; 
352*5$00,1*&219(17,216)252873876 
$33(1',; 
/,672)/$%25$725<$66(660(176 
$33(1',; 
/$%25$725<5()(5(1&(5$1*(6 


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 
/LVWRI$EEUHYLDWLRQVDQG'HILQLWLRQRI7HUPV
$(
$GYHUVH(YHQW
$&6
$EQRUPDO&OLQLFDOO\6LJQLILFDQW
$1&6
$EQRUPDO1RW&OLQLFDOO\6LJQLILFDQW
$7&
$QDWRPLFDO7KHUDSHXWLF&KHPLFDO
$8&
$UHD8QGHUWKH&XUYH
$8&W
$UHD8QGHUWKH&RQFHQWUDWLRQWLPH&XUYHIURP7LPH=HURWR
WKH/DVW4XDQWLILDEOH&RQFHQWUDWLRQ
%25
%HVW2YHUDOO5HVSRQVH
&DY
$YHUDJH3ODVPD&RQFHQWUDWLRQ
&,
&RQILGHQFHLQWHUYDO
&/)
$SSDUHQW6\VWHPLF&OHDUDQFH
&PD[
0D[LPXP3ODVPD&RQFHQWUDWLRQ
&PLQ
0LQLPXP3ODVPD&RQFHQWUDWLRQ
&5
&RPSOHWH5HVSRQVH
&73
&OLQLFDO7ULDO3URWRFRO
&7
&RPSXWHG7RPRJUDSK\
&7&
&RPPRQ7R[LFLW\&ULWHULD
&7&$(
&RPPRQ7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV
'%3
'LDVWROLF%ORRG3UHVVXUH
'/7
'RVH/LPLWLQJ7R[LFLW\
'0
'DWD0DQDJHPHQW
H&5)
(OHFWURQLF&DVH5HSRUW)RUP
(&*
(OHFWURFDUGLRJUDP
(&2*
(DVWHUQ&RRSHUDWLYH2QFRORJ\*URXS
(27
(QGRI7UHDWPHQW
*HR&9
*HRPHWULF&RHIILFLHQWRI9DULDWLRQ
*HR0HDQ
*HRPHWULF0HDQ
+*)
+HSDWLF*URZWK)DFWRU


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





//24
/RZHU/LPLWRI4XDQWLILFDWLRQ
0HG'5$
0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV
05$8&W
0HWDEROLWHWR3DUHQW5DWLREDVHGRQ$8&W
05&PD[
0HWDEROLWHWR3DUHQW5DWLREDVHGRQ&PD[
05,
0DJQHWLF5HVRQDQFH,PDJLQJ
0:
0ROHFXODU:HLJKW
1&,
1DWLRQDO&DQFHU,QVWLWXWH
1(
1RW(YDOXDEOH
16&/&
1RQVPDOO&HOO/XQJ&DQFHU
3'
3URJUHVVLYH'LVHDVH


35
3DUWLDO5HVSRQVH
3.
3KDUPDFRNLQHWLF
37
3UHIHUUHG7HUP
37)
3HDN7URXJK)OXFWXDWLRQ5DWLRLQ
5DFF$8&
$FFXPXODWLRQ)DFWRUIRU$8&Ĳ
5DFF&PD[
$FFXPXODWLRQ)DFWRUIRU&PD[
5(&,67
5HVSRQVH(YDOXDWLRQ&ULWHULDLQ6ROLG7XPRUV
53'
5HFRPPHQGHG3KDVH,,'RVH
6$(
6HULRXV$GYHUVH(YHQWV
6$)
6DIHW\$QDO\VLV
6$3
6WDWLVWLFDO$QDO\VLV3ODQ
6%3
6\VWROLF%ORRG3UHVVXUH
6'
6WDEOH'LVHDVH
6(0
6WDQGDUG(UURURIWKH0HDQ
6,
,QWHUQDWLRQDO6\VWHPRI8QLWV
60&
6DIHW\0RQLWRULQJ&RPPLWWHH
62&
6\VWHP2UJDQ&ODVV
CCI


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





Ĳ
'RVLQJ,QWHUYDO
WODJ
7LPH3ULRUWRWKH)LUVW4XDQWLILDEOH&RQFHQWUDWLRQ
WPD[
7LPHRI0D[LPXP3ODVPD&RQFHQWUDWLRQ
7($(
7UHDWPHQW(PHUJHQW$GYHUVH(YHQW


8/24
8SSHU/LPLWRI4XDQWLILFDWLRQ
:+2
:RUOG+HDOWK2UJDQLVDWLRQ

CCI


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 
0RGLILFDWLRQ+LVWRU\
Unique 
Identifier for 
SAP Version 
Date of 
SAP Version 
Author 
Changes from the Previous Version 
0.1 
18NOV2013 
Not Applicable – First Version 
0.2 
23DEC2013 
Internal Review 
0.3 
14MAY2014 
Sponsor Feedback for cMET-004 SAP relevant 
sections 
0.4 
2014 
Rewrite to fit Merck Serono template;  
Remove cumulative presentations from all SMC 
meetings per cMET-004 sponsor decision 
1.0 
09Jun2016 
Rewrite to fit Merck Serono template; 
Update to protocol_V5 
2.0 
10July2017 
Update for dry run comments and protocol v7.0/7.1/7.2 
and, PK analysis, and biomarker analysis. Correction 
for parameter CTCAE grading 
 
3XUSRVHRIWKH6WDWLVWLFDO$QDO\VLV3ODQ
7KH SXUSRVH RI WKLV 6WDWLVWLFDO $QDO\VLV 3ODQ 6$3 LV WR GRFXPHQW WHFKQLFDO DQG GHWDLOHG
VSHFLILFDWLRQVIRUWKHVDIHW\PRQLWRULQJFRPPLWWHH60&DQGILQDODQDO\VLVRIGDWDFROOHFWHGIRU
WKH3KDVH,EVHFWLRQVRISURWRFRO(055HVXOWVRIWKHDQDO\VHVGHVFULEHGLQWKLV6$3
ZLOOEHLQFOXGHGLQWKH&OLQLFDO6WXG\5HSRUW&65$GGLWLRQDOO\WKHSODQQHGDQDO\VHVLGHQWLILHG
LQWKLV6$3ZLOOEHLQFOXGHGLQUHJXODWRU\VXEPLVVLRQVRUIXWXUHPDQXVFULSWV$Q\SRVWKRFRU
XQSODQQHGDQDO\VHVSHUIRUPHGWRSURYLGHUHVXOWVIRULQFOXVLRQLQWKH&65EXWQRWLGHQWLILHGLQWKLV
SURVSHFWLYH6$3ZLOOEHFOHDUO\LGHQWLILHGLQWKH&65
7KLV6$3LVEDVHGRQFOLQLFDOWULDOSURWRFRO&73YHUVLRQGDWHG6HSWHPEHUYHUVLRQ
ORFDO-DSDQGDWHG1RYHPEHUYHUVLRQORFDO&DQDGDGDWHG$SULO60&
FKDUWHUYHUVLRQGDWHG'HFDQGLVSUHSDUHGLQFRPSOLDQFHZLWK,&+(
 
6XPPDU\RI&OLQLFDO7ULDO)HDWXUHV
7ULDO
2EMHFWLYHV
3ULPDU\2EMHFWLYHV
• 7RGHWHUPLQHWKHUHFRPPHQGHG3KDVH,,GRVH53'RIWHSRWLQLEZKHQ
XVHGLQFRPELQDWLRQZLWKJHILWLQLEDWWKHDSSURYHGVWDQGDUGGRVHRI
PJZKHQDGPLQLVWHUHGRUDOO\RQFHGDLO\RYHUDGD\F\FOHLQVXEMHFWV
ZLWK0(7GLDJQRVWLFSRVLWLYHVWDWXV0(7DGYDQFHG16&/&
6HFRQGDU\2EMHFWLYHV
• 7RFKDUDFWHUL]HWKHSKDUPDFRNLQHWLFV3.RIWHSRWLQLEZKHQJLYHQLQ
FRPELQDWLRQZLWKJHILWLQLE
• 7RFKDUDFWHUL]HWKH3.RIJHILWLQLEZKHQJLYHQ LQFRPELQDWLRQZLWK
WHSRWLQLE
PPD


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





• 7RDVVHVVWKHVDIHW\DQGWROHUDELOLW\RIWHSRWLQLELQFRPELQDWLRQZLWK
JHILWLQLE
• 7RHYDOXDWHSUHOLPLQDU\DQWLWXPRUDFWLYLWLHVRIWHSRWLQLELQFRPELQDWLRQ
ZLWKJHILWLQLE
([SORUDWRU\2EMHFWLYHV
• 7R DVVHVV ELRPDUNHUV WKDW PD\ FRUUHODWH ZLWK DQWLWXPRU DFWLYLW\
LQFOXGLQJEXWQRWOLPLWHGWRPDUNHUVRIWKH0HVHQFK\PDO(SLWKHOLDO
7UDQVLWLRQ )DFWRU *HQH F0HW SDWKZD\ DFWLYDWLRQ HJ SKRVSKRF
0HWKHSDWRF\WHJURZWKIDFWRU>+*)@OHYHOVDQGF0HWPXWDWLRQVDQG
RWKHUUHOHYDQWRQFRJHQLFSDWKZD\V
7ULDOGHVLJQ
DQGSODQ
7KH3KDVH,EVWDJHRIWKHVWXG\FRPSULVHVSDUWVWKHVWDQGDUG³´GRVH
HVFDODWLRQ FRKRUWV DQG DQ DGGLWLRQDO FRKRUW IRUVXEMHFWV IURP WKH PDLQODQG
&KLQDVLWHV
7KLV 3KDVH,E SDUW WKDW FRQWDLQV WKH ³´ GRVH HVFDODWLRQ FRKRUWV LV D
PXOWLFHQWHU RSHQ ODEHO GRVH HVFDODWLRQ SKDVH $ VWDQGDUG ͆͇ GRVH
HVFDODWLRQGHVLJQZLWKDGRVHHVFDODWLRQDQGDGRVHFRQILUPDWLRQSKDVHZLOOEH
XVHG7KHFULWHULDIRUGRVHHVFDODWLRQDQGGHHVFDODWLRQUXOHVDUHEDVHGRQWKH
RFFXUUHQFHRIGRVHOLPLWLQJWR[LFLWLHV'/7VGXULQJ&\FOH2WKHUFOLQLFDOO\
UHOHYDQWVDIHW\LVVXHVDVZHOODVHPHUJLQJ3.GDWDVKRXOGDOVREHFRQVLGHUHG
DVQHFHVVDU\ZKHQPDNLQJGRVLQJGHFLVLRQV$6DIHW\0RQLWRULQJ&RPPLWWHH
60&ZLOOSHUIRUPSHULRGLFVDIHW\UHYLHZDQGZLOOEHUHVSRQVLEOHIRUPDNLQJ
WKHGHFLVLRQWRHVFDODWHRUGHHVFDODWHWKHGRVHOHYHODIWHUDOOVXEMHFWVLQWKH
SUHFHGLQJFRKRUWKDYHFRPSOHWHGWKHILUVWF\FOHRIWUHDWPHQWDQGVXEMHFWGDWD
GXULQJWKLVF\FOHKDYHEHHQHYDOXDWHG
7KH DQWLFLSDWHG GRVH FRKRUWV RI WHSRWLQLE DUH  DQG  PJ RQFH GDLO\
*HILWLQLEZLOOEHFRDGPLQLVWHUHGDWVWDQGDUGGRVHPJRQFHGDLO\
5LFK3.VDPSOLQJZLOO EHSHUIRUPHG LQ3KDVH,EWRFKDUDFWHUL]HWKH3.RI
WHSRWLQLEDQGJHILWLQLE
,QDGGLWLRQDQGVHSDUDWHIURPWKH³´WULDOFRKRUWVXSWRHYDOXDEOHVXEMHFWV
ZLOO EH HQUROOHG LQ D VHSDUDWH FRKRUW DW RQH GRVH OHYHO EHORZ WKH 53' DW
VHOHFWHGVLWHVLQPDLQODQG&KLQD
CCI


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





3ODQQHG
QXPEHURI
VXEMHFWV
$SSUR[LPDWHO\WRVXEMHFWVIROORZLQJD³´GRVHHVFDODWLRQGHVLJQDQG
DQDGGLWLRQDOXSWRHYDOXDEOHVXEMHFWVIURPWKHPDLQODQG&KLQDVLWHV
6FKHGXOHRI
YLVLWVDQG
DVVHVVPHQWV
6XEMHFWVZLOOEHVFUHHQHGIRUXSWRGD\VSULRUWRVWXG\WUHDWPHQW,QIRUPHG
FRQVHQWZLOOEHREWDLQHGSULRUWRSHUIRUPLQJDQ\WULDODVVHVVPHQW
6XEMHFWVZLOOUHFHLYHWHSRWLQLELQFRPELQDWLRQZLWKJHILWLQLERQFHGDLO\XQWLO
SURJUHVVLYHGLVHDVH3'LQWROHUDEOHWR[LFLWLHVZLWKGUDZDOIURPWUHDWPHQW
,Q LQGLYLGXDO FDVHV WUHDWPHQW EH\RQG SURJUHVVLRQ PD\ EH FRQVLGHUHG IRU
VXEMHFWV RQ WHSRWLQLEJHILWLQLE &DVHV WKDW PD\ EH FRQVLGHUHG IRU WUHDWPHQW
EH\RQGSURJUHVVLRQLQFOXGHVXEMHFWVZLWKVORZ³VPROGHULQJ´SURJUHVVLRQDIWHU
DQLQLWLDOSDUWLDOUHVSRQVH35FRPSOHWHUHVSRQVH&5SURYLGHGWKHUHDUHQR
FOLQLFDOV\PSWRPVUHODWHGWRXQGHUO\LQJFDQFHUGLVHDVHDQGQRQHZOHVLRQV$OO
FDVHVPXVWEHGLVFXVVHGDQGDJUHHGZLWKWKHVSRQVRUDQGGRFXPHQWHGLQWKH
DSSURSULDWH GHVLJQDWHG HOHFWURQLF FDVH UHSRUW IRUP H&5) VHFWLRQ 7KH
LQYHVWLJDWRUKDVWRHQVXUHWKDWDOOVDIHW\GDWDDUHFROOHFWHGDVSHUSURWRFROLQ
WKH VDPH PDQQHU DV EHIRUH SURJUHVVLRQ ZLWK WKH H[FHSWLRQ RI WKH 4R/
TXHVWLRQQDLUHVZKLFKVKDOO QRWEHFROOHFWHGIRUWKLVVXEMHFWJURXS5(&,67
9HUVLRQ  UDGLRJUDSKLFDO DVVHVVPHQW ZLOO IROORZ LQVWLWXWLRQDO SUDFWLFH
JXLGHOLQHVKRZHYHUWXPRUDVVHVVPHQWLQIRUPDWLRQZLOOQRWEHUHFRUGHGLQWKH
H&5)DQGWKHUHZLOOEHQRIXUWKHUGRFXPHQWDWLRQFROOHFWHGH[FHSW$(VIRUDQ\
QHZOHVLRQDQGRUFOLQLFDOV\PSWRPVRI3'DIWHUILUVW3'
'LVFRQWLQXDWLRQ RI WUHDWPHQW EH\RQG 3' LV EDVHG XSRQWKH GHYHORSPHQW RI
FOLQLFDOV\PSWRPVHPHUJHQFHRIQHZOHVLRQVRUWKHGLVFUHWLRQRIWKHWUHDWLQJ
SK\VLFLDQ)RUDQDO\VLVRIWKHSULPDU\HQGSRLQWRQO\WKHILUVWSURJUHVVLRQHYHQW
LVXVHG
6XEMHFWVZKRVWRSDOOWULDOWUHDWPHQWVZLOOKDYHDQ(QGRI7UHDWPHQWYLVLWZLWKLQ
GD\VRIWKHODVWGRVHWKHFRPSOHWLRQRIWUHDWPHQWF\FOHRUWKHGD\ZKHQLW
LVGHWHUPLQHGWRSHUPDQHQWO\GLVFRQWLQXHWKHVWXG\WUHDWPHQW$6DIHW\)ROORZ
XSYLVLWZLOORFFXUDWGD\VsGD\VDIWHUWKHODVWGRVHIRUVDIHW\PRQLWRULQJ
,IDVXEMHFWZLWKGUDZVIURPWKHWUHDWPHQWIRUUHDVRQVRWKHUWKDQ3'DGGLWLRQDO
IROORZ XS YLVLWV IRU WXPRU DVVHVVPHQWV ZLOO EH SHUIRUPHG XQWLO GLVHDVH
SURJUHVVLRQ
,QFOXVLRQ
DQG
H[FOXVLRQ
FULWHULD

,QFOXVLRQ&ULWHULD
)RU LQFOXVLRQ LQ 3KDVH,E DOO RI WKH IROORZLQJ LQFOXVLRQ FULWHULD PXVW EH
IXOILOOHG
 
+LVWRORJLFDOO\RUF\WRORJLFDOO\FRQILUPHGDGYDQFHG16&/&UHJDUGOHVVRI
KLVWRORJ\VXEW\SHZKLFKIDLOHGRQJHILWLQLEIRUUHDVRQVRWKHUWKDQWR[LFLW\
RUFRPSOLDQFH


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 
$YDLODELOLW\RIDIUHVKRUDUFKLYHGSUHWUHDWPHQWWXPRUELRSV\H[FOXGLQJ
ILQHQHHGOHDVSLUDWLRQDQGF\WRORJ\VDPSOHV)RUVXEMHFWVZKRKDYHKDG
DWOHDVWSULRUDQWLFDQFHUWUHDWPHQWDELRSV\REWDLQHGEHWZHHQIDLOXUHRI
WKHPRVWUHFHQWDQWLFDQFHUWUHDWPHQWDQGHQUROOPHQWLVPDQGDWRU\
 
0(7 VWDWXV DV GHWHUPLQHG E\ WKH FHQWUDO ODERUDWRU\ LH F0HW
RYHUH[SUHVVLRQ DV GHWHUPLQHG E\ LPPXQRKLVWRFKHPLVWU\ ,+& LH
,+&RU,+&DQGRUF0HWDPSOLILFDWLRQDVGHWHUPLQHGE\LQVLWX
K\EULGL]DWLRQ,6+
 
6LJQHGZULWWHQLQIRUPHGFRQVHQWE\VXEMHFWRUOHJDOUHSUHVHQWDWLYHSULRU
WRDQ\VWXG\VSHFLILFVFUHHQLQJSURFHGXUH
 
0DOHRUIHPDOHı\HDUVRIDJHRUPLQLPXPDJHRIOHJDOFRQVHQW
FRQVLVWHQWZLWKORFDOUHJXODWLRQVLIPLQLPXPLV!\HDUVRIDJH
 
0HDVXUDEOHGLVHDVHLQDFFRUGDQFHZLWK5(&,679HUVLRQ
 
(DVWHUQ&RRSHUDWLYH2QFRORJ\*URXS(&2*SHUIRUPDQFHVWDWXV36RI
RU
([FOXVLRQ&ULWHULD
6XEMHFWV DUH QRW HOLJLEOH IRU 3KDVH,E LI WKH\ IXOILOO DQ\ RI WKH IROORZLQJ
H[FOXVLRQFULWHULD
&DQFHU5HODWHG
 
6\PSWRPDWLF PHWDVWDVLV RI EUDLQ DQGRU &16 XQFRQWUROOHG ZLWK
DQWLHSLOHSWLFV DQG UHTXLULQJ VWHURLGV XQOHVV WUHDWHG DQG VWDEOH ZLWKRXW
VWHURLGVIRUDWOHDVWGD\VZLWKLQZHHNVSULRUWRWKHILUVWGRVHRIWULDO
WUHDWPHQW
 
$Q\XQUHVROYHGWR[LFLW\ PRUHWKDQ1DWLRQDO&DQFHU,QVWLWXWH&RPPRQ
7HUPLQRORJ\ &ULWHULD IRU $GYHUVH (YHQWV 1&,&7&$( 9HUVLRQ 
*UDGHIURPSUHYLRXVDQWLFDQFHUWKHUDS\
 
(VWLPDWHGOLIHH[SHFWDQF\PRQWKV
 
1HHG IRU WUDQVIXVLRQ ZLWKLQ GD\V SULRU WR WKH ILUVW GRVH RI WULDO
WUHDWPHQW
 
3ULRU FKHPRWKHUDS\ ELRORJLFDO WKHUDS\ UDGLDWLRQ WKHUDS\ RU RWKHU
LQYHVWLJDWLRQDODQWLFDQFHUWKHUDS\QRWLQFOXGLQJSDOOLDWLYHUDGLRWKHUDS\DW
IRFDOVLWHVZLWKLQGD\VSULRUWRWKHILUVWGRVHRIWULDOWUHDWPHQW
/DERUDWRU\9DOXHVDQG2UJDQ)XQFWLRQ


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 
,QDGHTXDWHKHPDWRORJLFDOIXQFWLRQ
• 
+HPRJORELQJG/
• 
1HXWURSKLOVî/
• 
3ODWHOHWVî/
 
,QDGHTXDWHOLYHUIXQFWLRQ
• 
7RWDOELOLUXELQ!îXSSHUOLPLWRIQRUPDO8/1
• 
$VSDUWDWH DPLQRWUDQVIHUDVH $67DODQLQH DPLQRWUDQVIHUDVH
$/7!î8/1
)RUVXEMHFWVZLWKOLYHUPHWDVWDVHV
• 
7RWDOELOLUXELQ!î8/1
• 
$67$/7!î8/1
 
.QRZQSUHH[LVWLQJLQWHUVWLWLDOOXQJGLVHDVH
 
,QDGHTXDWHUHQDOIXQFWLRQ
• 
5HQDO LPSDLUPHQW DV HYLGHQFHG E\ VHUXP FUHDWLQLQH ≥  î
8/1RUFUHDWLQLQHFOHDUDQFH&U&OP/PLQFDOFXODWHGE\
WKH&RFNFURIW*DXOWIRUPXODKRXU&U&OPLJKWEHUHTXHVWHG
E\WKHLQYHVWLJDWRUIRUFRQILUPDWLRQLIFDOFXODWHG&U&OLV
P/PLQ,QVXFKFDVHVXEMHFWVZLWKKRXU&U&OP/PLQ
VKRXOGEHH[FOXGHG
&U&OP/PLQ 
>±DJH\HDU[ZHLJKWNJ@
^[IRUIHPDOH`
[VHUXPFUHDWLQLQHPJG/
 
6XEMHFWVZKRKDYHRQJRLQJPHGLFDOKLVWRU\RIDFXWHSDQFUHDWLWLVDQGRU
FKURQLF SDQFUHDWLWLV ZLWK FRQFRPLWDQW HOHYDWHG OLSDVH DQGRU DP\ODVH
FOLQLFDO V\PSWRPV DQGRU LPDJLQJ VWXGLHV WKDW DUH LQGLFDWLYH RI WKH
GLDJQRVLVVXEMHFWVLQPDLQODQG&KLQDRQO\
*HQHUDO
 ,PSDLUHGFDUGLDFIXQFWLRQ
• /HIW YHQWULFXODU HMHFWLRQ IUDFWLRQ /9()   GHILQHG E\
HFKRFDUGLRJUDSK\ D VFUHHQLQJ /9() DVVHVVPHQW ZLWKRXW
KLVWRU\RIFRQJHVWLYHKHDUWIDLOXUH>&+)@LVQRWUHTXLUHG
• 6HULRXVDUUK\WKPLD
• 8QVWDEOHDQJLQDSHFWRULV
• &+) 1HZ <RUN +HDUW $VVRFLDWLRQ 1<+$ ,,, DQG ,9
$33(1',;
• 0\RFDUGLDO LQIDUFWLRQ ZLWKLQ WKH ODVW PRQWKV SULRUWRWULDO
HQWU\
• 6LJQVRISHULFDUGLDOHIIXVLRQ


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 +\SHUWHQVLRQ XQFRQWUROOHG E\ VWDQGDUG WKHUDSLHV QRW VWDELOL]HG WR
PP+J
 &RQWUDLQGLFDWLRQWRWKHDGPLQLVWUDWLRQRIJHILWLQLE
 0HGLFDOKLVWRU\RIOLYHUILEURVLVFLUUKRVLV
 3DVW RU FXUUHQW KLVWRU\ RI QHRSODVP RWKHU WKDQ 16&/& H[FHSW IRU
FXUDWLYHO\ WUHDWHG QRQPHODQRPD VNLQ FDQFHU LQ VLWX FDUFLQRPD RI WKH
FHUYL[RURWKHUFDQFHUFXUDWLYHO\WUHDWHGDQGZLWKQRHYLGHQFHRIGLVHDVH
IRUDWOHDVW\HDUV
 0HGLFDOKLVWRU\RIGLIILFXOW\VZDOORZLQJPDODEVRUSWLRQRURWKHUFKURQLF
JDVWURLQWHVWLQDOGLVHDVHRUFRQGLWLRQVWKDWPD\KDPSHUFRPSOLDQFHDQGRU
DEVRUSWLRQRIWKHWHVWHGSURGXFW
 0DMRUVXUJHU\ZLWKLQGD\VSULRUWR'D\RIWULDOWUHDWPHQW
 .QRZQKXPDQLPPXQRGHILFLHQF\YLUXVSRVLWLYLW\
 6XEVWDQFH DEXVH DFWLYH LQIHFWLRQ RURWKHU DFXWH RU FKURQLF PHGLFDO RU
SV\FKLDWULFFRQGLWLRQRUODERUDWRU\DEQRUPDOLWLHVWKDWPLJKWLQFUHDVHWKH
ULVNDVVRFLDWHGZLWKVWXG\SDUWLFLSDWLRQDWWKHGLVFUHWLRQRILQYHVWLJDWRUV
 )HPDOH VXEMHFWV ZKR DUH SUHJQDQW RU ODFWDWLQJ RU PHQ DQG ZRPHQ RI
UHSURGXFWLYHSRWHQWLDOQRWZLOOLQJRUQRWDEOHWRHPSOR\DKLJKO\HIIHFWLYH
PHWKRGRIELUWKFRQWUROFRQWUDFHSWLRQWRSUHYHQWSUHJQDQF\XQWLOWKHHQGRI
VWXG\$KLJKO\HIIHFWLYHPHWKRGRIFRQWUDFHSWLRQLVGHILQHGDVWKRVHDORQH
RULQFRPELQDWLRQWKDWUHVXOWVLQDORZIDLOXUHUDWHLHOHVVWKDQSHU
\HDU ZKHQ XVHG FRQVLVWHQWO\ DQG FRUUHFWO\ 7KLV UHTXLUHPHQW EHJLQV 
ZHHNVEHIRUHUHFHLYLQJWKHILUVWWULDOWUHDWPHQWDQGHQGVPRQWKVDIWHU
UHFHLYLQJWKHODVWWUHDWPHQW
 .QRZQK\SHUVHQVLWLYLW\WRDQ\RIWKHWULDOWUHDWPHQWLQJUHGLHQWV
 /HJDOLQFDSDFLW\RUOLPLWHGOHJDOFDSDFLW\
 $Q\RWKHUUHDVRQWKDWLQWKHRSLQLRQRIWKHSULQFLSDOLQYHVWLJDWRUSUHFOXGHV
WKHVXEMHFWIURPSDUWLFLSDWLQJLQWKHWULDO
 3DUWLFLSDWLRQLQDQRWKHULQWHUYHQWLRQDOFOLQLFDOWULDOH[FHSWWKRVHVXEMHFWV
ZKRZHUHVROHO\LQYROYHGLQRWKHUWULDOVZKHUHWKHLQYHVWLJDWLRQSURGXFW
ZDVJHILWLQLEHUORWLQLERUDIDWLQLEZLWKLQWKHGD\VSULRUWRILUVWGRVH



7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





,QYHVWLJDWLRQ
DO0HGLFLQDO
3URGXFWV
GRVHPRGHRI
DGPLQLVWUDWL
RQGRVLQJ
VFKHGXOH
)RU³´GRVHHVFDODWLRQFRKRUWVWHSRWLQLEZLOOEHDGPLQLVWHUHGRUDOO\DW
RUPJRUSRWHQWLDOO\DWDORZHUGRVHOHYHOGHSHQGLQJRQWKHGHFLVLRQRI
WKH60&RQFHGDLO\LQFRPELQDWLRQZLWKJHILWLQLEDWPJ
)RUWKHDGGLWLRQDOXSWRHYDOXDEOHVXEMHFWVIURPWKHPDLQODQG&KLQDVLWHV
WHSRWLQLEZLOOEHDGPLQLVWHUHGRUDOO\RQHGRVHOHYHOEHORZWKH53'RQFHGDLO\
LQFRPELQDWLRQZLWKJHILWLQLEDWPJ
3ODQQHG
WUHDWPHQW
GXUDWLRQSHU
VXEMHFW
6XEMHFWV PD\ FRQWLQXH WR UHFHLYH WHSRWLQLEJHILWLQLE RQFH GDLO\ XQWLO 3'
LQWROHUDEOHWR[LFLW\RUZLWKGUDZDOIURPWUHDWPHQW
,Q LQGLYLGXDO FDVHV WUHDWPHQW EH\RQG SURJUHVVLRQ PD\ EH FRQVLGHUHG IRU
VXEMHFWVRQWHSRWLQLEJHILWLQLE'LVFRQWLQXDWLRQRIWUHDWPHQWEH\RQG3'LVDW
WKHGLVFUHWLRQRIWKHWUHDWLQJSK\VLFLDQ,IWKHVXEMHFWGHYHORSVQHZOHVLRQVRU
FOLQLFDOV\PSWRPVWKHEHQHILWRIFRQWLQXLQJWUHDWPHQWZLWKWKHVWXG\GUXJV
VKRXOGEHGLVFXVVHGZLWKWKHVSRQVRU
3ULPDU\
HQGSRLQWV
• ,QFLGHQFHRIVXEMHFWVH[SHULHQFLQJDWOHDVW'/7LQ&\FOHLH
GD\VDIWHUWKHILUVWGRVHRIWULDOPHGLFDWLRQ
•
,QFLGHQFHDQGW\SHRIRWKHUDGYHUVHHYHQWV$(V
6HFRQGDU\
HQGSRLQWV
7KHVHFRQGDU\HQGSRLQWVRIWKHWULDODUHDVIROORZV
6HFRQGDU\HQGSRLQWVUHODWHGWRVDIHW\
• 'UXJH[SRVXUH
• ,QFLGHQFHDQGW\SHRI7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV7($(V
WR[LFLW\JUDGHVDVSHU1DWLRQDO&DQFHU,QVWLWXWH&RPPRQ7HUPLQRORJ\
&ULWHULD IRU $GYHUVH (YHQWV 1&,&7&$( YHUVLRQ  WUHDWPHQW
UHODWHG7($(VVHULRXV$(V6$(VWUHDWPHQWUHODWHG6$(V7($(V
ZLWKWR[LFLW\*UDGH ı WUHDWPHQWUHODWHG7($(V *UDGH ı DQG
7($(VOHDGLQJWRSHUPDQHQWWUHDWPHQWGLVFRQWLQXDWLRQ
• ,QFLGHQFHDQGUHDVRQVIRUGHDWKVZLWKLQGD\VDIWHUWKHODVWGRVHRI
VWXG\GUXJ
• 6DIHW\ODERUDWRU\WHVWVJUDGHGE\1&,&7&$(YHUVLRQ
• 9LWDO VLJQV OHDG HOHFWURFDUGLRJUDP (&* FKDQJHV SK\VLFDO
H[DPLQDWLRQLQFOXGLQJFKDQJHLQERG\ZHLJKWDQG(&2*36
2WKHUVHFRQGDU\HQGSRLQWVLQFOXGH


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





• 7XPRUUHVSRQVHDVPHDVXUHGE\REMHFWLYHUHVSRQVH25DQGGLVHDVH
FRQWUROEDVHGRQ5(&,679HUVLRQ
• 3.$8&W$8&WDX&PD[&DYJ&PLQWPD[$8&Ğ&/)9])9VV)
Ȝ]DQGWZKHQDSSURSULDWH
([SORUDWRU\
HQGSRLQWV
• ([SORUDWRU\ ELRPDUNHUV LQFOXGH ELRPDUNHUV WKDW PD\ FRUUHODWH ZLWK
DQWLWXPRUDFWLYLW\LQFOXGLQJEXWQRWOLPLWHGWRPDUNHUVRIF0HWSDWKZD\
DFWLYDWLRQHJSKRVSKRF0HW+*)OHYHOVDQGF0HWPXWDWLRQVRWKHU
UHOHYDQWRQFRJHQLFSDWKZD\V

 
6DPSOH6L]H5DQGRPL]DWLRQ
7KHWRWDOQXPEHURIVXEMHFWVLQWKH³´GRVHHVFDODWLRQFRKRUWVLVDSSUR[LPDWHO\WRRQ
WKHEDVLVRIWKH³´GRVHHVFDODWLRQPHWKRGZLWKGRVHFRKRUWVRULQWKHGRVHHVFDODWLRQ
FRKRUWDQGDSRWHQWLDOIRURUVXEMHFWVLQGRVHFRQILUPDWLRQFRKRUWLIGRVHGHHVFDODWLRQGRHV
QRWRFFXU7KHILQDOVDPSOHVL]HGHSHQGVRQWKHQXPEHURIVXEMHFWVZKRH[SHULHQFH'/7VDWHDFK
GRVHOHYHOVDIHW\DQGHPHUJLQJ3.GDWDDQGGHFLVLRQIURPWKH60&PHHWLQJ
,QDGGLWLRQVHSDUDWHO\IURPWKH³´GRVHHVFDODWLRQFRKRUWVXSWRDQDGGLWLRQDOHYDOXDEOH
VXEMHFWVZLOOEHHQUROOHGLQWKHPDLQODQG&KLQDVLWHV
5DQGRPL]DWLRQZLOOQRWRFFXULQERWKSDUWRI3KDVH,EVWXGLHV

 
2YHUYLHZRI3ODQQHG$QDO\VHV
,QDGGLWLRQWR³´'RVH(VFDODWLRQ&RKRUWVDQDGGLWLRQDOFRKRUWIRUVXEMHFWVIURPWKHPDLQODQG
&KLQDVLWHVLVLQFOXGHGWRPHHWDUHTXHVWIURPWKH&KLQHVH)RRGDQG'UXJ$GPLQLVWUDWLRQ&)'$
IROORZLQJ FOLQLFDO WULDO DPHQGPHQW UHYLHZ 8S WR HYDOXDEOH VXEMHFWV ZLOO EH HQUROOHG LQ WKH
PDLQODQG&KLQDVLWHVVHSDUDWHO\DQGZLOOEHWHVWHGDWWHSRWLQLERQHGRVHOHYHOEHORZWKH53'RQFH
GDLO\ 7KH DLP RI WKLV FRKRUW LV WR FROOHFW SUHOLPLQDU\ GDWDRI WKH VDIHW\ DQG 3. RI WHSRWLQLE
DGPLQLVWHUHGLQFRPELQDWLRQZLWKJHILWLQLELQVXEMHFWVIURPPDLQODQG&KLQDVLWHV
6WDWLVWLFDODQDO\VHVRIWKH3KDVH,EGDWDZLOOEHFDUULHGRXWLQDGHVFULSWLYHPDQQHUDQGZLOOEH
SHUIRUPHGXVLQJH&5)GDWDLQJHQHUDO'DWDZLOOEHDQDO\]HGDIWHU GD\VGRVLQJRIWKHODVW
VXEMHFW7KH'/7SRSXODWLRQLVWKHXQGHUO\LQJGDWDVHWIRUWKH07'GHWHUPLQDWLRQ6DIHW\DQDO\VHV
ZLOOEHSHUIRUPHGDFFRUGLQJWRWKHDVWUHDWHGSULQFLSOH6DIHW\GDWDZLOOEHGHVFULSWLYHO\DQDO\]HG
RQWKH6DIHW\$QDO\VLV6HW$(VZLOOEHFRGHGDFFRUGLQJWRWKH0HGLFDO'LFWLRQDU\IRU5HJXODWRU\
CCI


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





$FWLYLWLHV0HG'5$9HUVLRQDQGUHSRUWHGE\V\VWHPRUJDQFODVV62&DQGSUHIHUUHGWHUP
377KHVHYHULW\RI$(VZLOOEHJUDGHGXVLQJ1&,&7&$(9HUVLRQWR[LFLW\JUDGHV
(IILFDF\DQDO\VHVZLOOEHSHUIRUPHGRQWKH6DIHW\$QDO\VLV6HW7KHDQDO\VLVRIGHPRJUDSKLFVDQG
EDVHOLQHFKDUDFWHULVWLFVZLOOEHREWDLQHGIURPWKH6DIHW\$QDO\VLV6HW
 
6HTXHQFHRI$QDO\VLV
$6DIHW\0RQLWRULQJ&RPPLWWHH60&ZLOOEHUHVSRQVLEOHIRUPDNLQJWKHGHFLVLRQWRHVFDODWHRU
GHHVFDODWHWKHGRVHOHYHODIWHUDOOVXEMHFWVLQWKHSUHFHGLQJFRKRUWKDYHFRPSOHWHGWKHILUVWF\FOH
RIWUHDWPHQWDQGDOOVXEMHFWV¶GDWDGXULQJWKLVF\FOHKDYHEHHQHYDOXDWHG)LQDODQDO\VLVZLOOEH
SHUIRUPHGDIWHUFRPSOHWLRQRIWKHGRVHFRQILUPDWLRQSKDVH
7KH60&ZLOOQRWEHUHVSRQVLEOHIRUVDIHW\HYDOXDWLRQRIWKHXSWRHYDOXDEOHVXEMHFWVLQWKH
DGGLWLRQDOFRKRUWRIVXEMHFWVIURPWKHPDLQODQG&KLQDVLWHV6SRQVRUH[SHUWVLQFOXGLQJEXWQRW
OLPLWHG WR PHGLFDO UHVSRQVLEOH VDIHW\ UHVSRQVLEOH DQG SKDUPDFRNLQHWLFLVW DV ZHOO DV WKH
FRRUGLQDWLQJLQYHVWLJDWRUZLOOUHYLHZWKHVDIHW\SURILOHRIWKHXSWRHYDOXDEOHVXEMHFWVLQWKH
DGGLWLRQDOFRKRUW
 
6DIHW\0RQLWRULQJ&RPPLWWHH
)RUVXEMHFWV LQWKH³´GRVHHVFDODWLRQFRKRUWVGDWDSHUWDLQLQJWRDOO VXVSHFWHGXQH[SHFWHG
VHULRXVDGYHUVHUHDFWLRQV686$5VDQGSRWHQWLDO'/7VZLOOEHVHQWWRWKH6DIHW\0RQLWRULQJ
&RPPLWWHH60&RQDFRQWLQXDOEDVLV60&PDQGDWRU\PHPEHUVZLOOEHLGHQWLILHGEHIRUHWULDO
LQLWLDWLRQ DQG ZLOO LQFOXGH  RU PRUH LQYHVWLJDWRUV WKH 0HGLFDO 5HVSRQVLEOH D
SKDUPDFRNLQHWLFLVW DQG D VDIHW\ UHSUHVHQWDWLYH IURP WKH VSRQVRU $G KRF PHPEHUV ZLOO EH
FRQVXOWHGDVQHHGHGDQGPD\LQFOXGHEXWDUHQRWUHVWULFWHGWRWKHELRVWDWLVWLFLDQRUWKHWUHDWLQJ
LQYHVWLJDWRULQWKHFDVHRISDUWLFXODUVDIHW\ILQGLQJV
7KH60&ZLOOEHUHVSRQVLEOHIRUPDNLQJWKHGHFLVLRQRIGRVHHVFDODWLRQRUGHHVFDODWLRQWRD
QHZGRVHOHYHORUH[SDQVLRQRIHQUROOPHQWDWWKHVDPHGRVHOHYHODIWHUDOOVXEMHFWVLQWKHSUHFHGLQJ
FRKRUWKDYHFRPSOHWHG&\FOHDQGDOOHYHQWVGXULQJWKLVF\FOHKDYHEHHQIXOO\HYDOXDWHG
:KHQVXEMHFWVKDYHFRPSOHWHG&\FOHDWHDFKGRVHFRKRUWQHZHQUROOPHQWWRWKLVWULDOLVSDXVHG
LQHDFKRIWKHGRVHFRKRUWV$IXOOVDIHW\GDWDVHWDOO$(VODERUDWRU\GDWDHOHFWURFDUGLRJUDP
(&*GDWDDQGYLWDOVLJQVDQGDYDLODEOH3.GDWDZLOOEHVXEPLWWHGWRWKH60&ZKLFKHYDOXDWHV
WKHGDWDDQG FRQILUPVWKH'/7 LQFLGHQFH )RUWKHGHILQLWLRQRI D'/7UHIHUWR 6HFWLRQ
'HSHQGLQJ RQ WKH LQFLGHQFH RI '/7V WKH 60& ZLOO GHWHUPLQH ZKHWKHU WR UHFUXLW DGGLWLRQDO
VXEMHFWVRUGHHVFDODWHWRQH[WGRVHOHYHORUGLVFRQWLQXHWKHVWXG\7KHDGKRF60&PHHWLQJVFDQ
EHSHUIRUPHGDWDQ\WLPHLQFDVHDVDIHW\FRQFHUQVKRXOGDULVH
)XUWKHUGHWDLOVRIWKHVDIHW\PRQLWRULQJSURFHVVDUHVSHFLILHGLQWKHGHGLFDWHG60&FKDUWHUYHUVLRQ
GDWHG'HFHPEHU



7HSRWLQLE06&-
7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05
9HUVLRQ


 
'HILQLWLRQRI'/7
7KHSHULRGRI'/7REVHUYDWLRQLVGXULQJ&\FOHIRUHDFKVXEMHFW
8VLQJWKH1&,&7&$(9HUVLRQD'/7LVGHILQHGDVDQ\RIWKHIROORZLQJWR[LFLWLHVWKDW
RFFXUDWDQ\GRVHOHYHODQGMXGJHGWREHUHODWHGWR 7HSRWLQLE &RPELQHGZLWK*HILWLQLE E\WKH
LQYHVWLJDWRUDQGRUWKHVSRQVRU
*UDGHQHXWURSHQLDIRUPRUHWKDQGD\V
*UDGHıIHEULOHQHXWURSHQLDIRUPRUHWKDQGD\
*UDGHWKURPERF\WRSHQLDRU*UDGHWKURPERF\WRSHQLDZLWKQRQWUDXPDWLFEOHHGLQJ
*UDGHıXQFRQWUROOHGQDXVHDYRPLWLQJDQGRUGLDUUKHDGHVSLWHDGHTXDWHDQGRSWLPDOWUHDWPHQW
*UDGH ı DQ\ QRQKHPDWRORJLFDO $(H[FHSWWKHDIRUHPHQWLRQHGJDVWURLQWHVWLQDOHYHQWVDQG
DORSHFLDKRZHYHUD'/7LVGHILQHGVSHFLILFDOO\IRUWKHIROORZLQJFDVHV
o *UDGHıOLYHU$(UHTXLULQJDUHFRYHU\SHULRGRIPRUHWKDQGD\VWRWKHEDVHOLQHRUWR
*UDGH7KLVFULWHULRQLVQRWOLPLWHGWRWKHOLYHUIXQFWLRQWHVWV2WKHUOLYHU$(HJMDXQGLFH
RUKHSDWLFHQFHSKDORSDWK\VXJJHVWLYHRIOLYHUIDLOXUHVKRXOGEHDOVRFRQVLGHUHG
o *UDGH≥OLSDVHDQGRUDP\ODVHHOHYDWLRQZLWKFRQILUPDWLRQRISDQFUHDWLWLVHLWKHUEDVHG
RQ FOLQLFDO RU UDGLRORJLFDO VLJQV ZLOO EH FRQVLGHUHG DV '/7 $Q LVRODWHG OLSDVH DQGRU
DP\ODVHHOHYDWLRQRI≥*UDGHZLWKRXWFOLQLFDORUUDGLRORJLFDOHYLGHQFHRISDQFUHDWLWLV
ZLOOQRWEHFODVVLILHGDV'/7IRUUHODWHGWRSLFVVHH$33(1',;
 
)LQDO$QDO\VLV
$OOILQDODQDO\VHVLGHQWLILHGLQWKLV6$3ZLOOEHSHUIRUPHGE\

 IROORZLQJ VSRQVRU DXWKRUL]DWLRQ RI WKLV 6$3 GDWDEDVH ORFN DQG
VSRQVRUDXWKRUL]DWLRQRIWKHDQDO\VLVVHWV
$GDWDUHYLHZPHHWLQJZLOOEHKHOGSULRUWRGDWDEDVHORFN,QDGGLWLRQQRGDWDEDVHFDQEHORFNHG
XQWLOWKLV6$3KDVEHHQDSSURYHG
 
&KDQJHVWRWKH3ODQQHG$QDO\VHVLQWKH&OLQLFDO7ULDO3URWRFRO
7KH GRVLQJ DQG VDPSOLQJ VFKHPH LQ WKLV VWXG\ GRHV QRW DOORZ WKH UHOLDEOH HVWLPDWLRQ RI Ȝ]
FRQVLGHULQJ WKH DSSDUHQW WHUPLQDO KDOIOLIH RI WHSRWLQLE DQG LWV PHWDEROLWHV 7KHUHIRUH DOO 3.
SDUDPHWHUVGHSHQGHQWRQȜ]ZLOOQRWEHGHWHUPLQHGLH$8&$8&H[WUD&/)VLQJOHGRVH
W9])DQG9VV)
7KHELRPDUNHUDQDO\VLVVHWVZLOOQRWEHXVHG,QVWHDGDOOELRPDUNHUDQDO\VHVZLOOEHSHUIRUPHGRQ
WKH6DIHW\6HW)RUDOODQDO\VHVRIFDWHJRULFDOELRPDUNHUVDPLVVLQJFDWHJRU\ZLOOEHLQFOXGHGIRU
DOOVXEMHFWVZKHUHWKHELRPDUNHUZDVQRWGHWHUPLQHGRULVQRWHYDOXDEOH
PPD
PPD


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 
3URWRFRO'HYLDWLRQVDQG$QDO\VLV6HWV
 
'HILQLWLRQRI3URWRFRO'HYLDWLRQV
3URWRFROGHYLDWLRQVGHVFULEHKRZFORVHWKHVWXG\KDVEHHQFRQGXFWHGDFFRUGLQJWRWKHSURWRFRODV
H[SHFWHGSHU*&36RPHRIWKHVHGHYLDWLRQVPD\EHVLJQLILFDQWFRQWULEXWRUVWRDQDO\VLVELDV
,PSRUWDQWSURWRFROGHYLDWLRQVDUHDVXEVHWRISURWRFROGHYLDWLRQVWKDWPLJKWVLJQLILFDQWO\DIIHFWWKH
FRPSOHWHQHVVDFFXUDF\DQGRUUHOLDELOLW\RIWKHVWXG\GDWDRUWKDWPLJKWVLJQLILFDQWO\DIIHFWD
VXEMHFW
VULJKWVVDIHW\RUZHOOEHLQJ
7KHIROORZLQJEXWQRWOLPLWHGWRDUHGHILQHGDVLPSRUWDQWSURWRFROGHYLDWLRQV
• 6XEMHFWVWKDWDUHGRVHGRQWKHVWXG\GHVSLWHQRWVDWLVI\LQJWKHLQFOXVLRQFULWHULD
• 6XEMHFWVWKDWGHYHORSZLWKGUDZDOFULWHULDZKLOVWRQWKHVWXG\EXWDUHQRWZLWKGUDZQ
• 6XEMHFWVWKDWUHFHLYHWKHZURQJWUHDWPHQWRUDQLQFRUUHFWGRVH
• 6XEMHFWVWKDWUHFHLYHDQH[FOXGHGFRQFRPLWDQWPHGLFDWLRQ
• 'HYLDWLRQIURP*&3
,PSRUWDQW SURWRFRO GHYLDWLRQV ZLOO EH GHWHUPLQHG IRU DOO VXEMHFWV E\ HLWKHU VLWH PRQLWRULQJ RU
PHGLFDOUHYLHZ
$OOWKHLPSRUWDQWSURWRFROGHYLDWLRQVZLOOEHLQFOXGHGLQ6WXG\'DWD7DEXODWLRQ0RGHO6'70
GDWDVHWV7KH$QDO\VLV'DWD0RGHO$'D0GDWDVHWVZLOOEHGHULYHGIURP6'70DQGLQFOXGHDOO
LPSRUWDQWSURWRFROGHYLDWLRQV
$GDWDUHYLHZZLOOEHKHOGWRGLVFXVVDQGXSGDWHWKHGHILQLWLRQRILPSRUWDQWSURWRFROGHYLDWLRQV
SULRUWRGDWDEDVHORFN
 
'HILQLWLRQRI$QDO\VLV6HWVDQG6XEJURXSV
$OO6FUHHQLQJ$QDO\VLV6HW
7KH$OO6FUHHQLQJ$QDO\VLVVHWLQFOXGHVDOOVXEMHFWVZKRKDYHSURYLGHGWKHLQIRUPHGFRQVHQWLH
VFUHHQLQJIDLOXUHVSOXVVXEMHFWVHQUROOHG
'/7$QDO\VLV6HW
7KH'/7$QDO\VLV6HWLQFOXGHVDOOVXEMHFWVZKRH[SHULHQFHGD'/7GXULQJ&\FOHRUGLGQRW
H[SHULHQFHD'/7DQGFRPSOHWHGDWOHDVWRISODQQHGWUHDWPHQWGXULQJWKH'/7REVHUYDWLRQ
SHULRGGD\VDIWHUWKHILUVWGRVHDGPLQLVWHUHG6XEMHFWVZKRGLVFRQWLQXHWKHWULDOSUHPDWXUHO\
GXULQJ&\FOHIRUUHDVRQVRWKHUWKDQD'/7DQGGRQRWUHFHLYHDWOHDVWLHWUHDWPHQW
GD\VRISODQQHGFXPXODWLYHGRVHVRIWHSRWLQLEJHILWLQLEGXULQJ&\FOHIRUUHDVRQVRWKHUWKDQ
$(VRU'/7VZLOOEHUHSODFHG
7KH'/7$QDO\VLV6HWZLOOEHXVHGIRUHYDOXDWLRQRIWKHQXPEHURIVXEMHFWVH[SHULHQFLQJDQ\
'/7VDWWKHHQGRIHDFKFRKRUWDQGIRUWKHDVVHVVPHQWRIWKH53'LQ&\FOH6XEMHFWVZKRKDYH


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





EHHQUHSODFHGGXULQJWKH&\FOHRUZKREHORQJWRWKHDGGLWLRQDOFRKRUWIRUVXEMHFWVIURPWKH
PDLQODQG&KLQDVLWHVZLOOEHH[FOXGHGIURPWKH'/7DQDO\VLVVHW
6DIHW\$QDO\VLV6HW6$)
7KH 6$) VHW LQFOXGHVDOO VXEMHFWVZKRKDYHUHFHLYHGDWOHDVW GRVHRI WHSRWLQLE RUJHILWLQLE
6XEMHFWVUHSODFHGIRUHYDOXDWLRQRI'/7DQGVXEMHFWVZKRDUHIURPPDLQODQG&KLQDVLWHVZLOOVWLOO
EHLQFOXGHGLQWKH6$)VHWLIWKH\DUHWUHDWHGDWOHDVWRQFH
,QDGGLWLRQWRVDIHW\DQDO\VLVWKHHIILFDF\DQDO\VLVZLOOEHDQDO\]HGXVLQJDOOVXEMHFWVLQWKH6$)
VHW
3.$QDO\VLV6HW
7KH3.$QDO\VLV6HWLQFOXGHVDOOVXEMHFWVZKRKDYHUHFHLYHGDWOHDVWRQHGRVHRIWHSRWLQLEDQG
ZKRKDGDWOHDVWRQHSRVWGRVHEORRGVDPSOHGUDZQWKDWSURYLGHVGUXJFRQFHQWUDWLRQGDWDIRU3.
HYDOXDWLRQDQGZDVQRWLPSDFWHGE\DSURWRFROGHYLDWLRQRURWKHUHYHQWHJYRPLWLQJZLWKLQWKH
WLPHIUDPHRIWHSRWLQLEPHGLDQWPD[HWFDIIHFWLQJ3.7KLVDQDO\VLVVHWZLOOEHXVHGIRU
VXPPDULHVRIWKH3.GDWDIRUWHSRWLQLEDQGLWVPHWDEROLWHVDVZHOODVIRUJHILWLQLE,IDVXEMHFW
XQGHUJRHVDWHSRWLQLEGRVHFKDQJH DIWHU&\FOH'D\WKHLU3.GDWDIRUERWKWHSRWLQLE DQG
JHILWLQLEWUHDWPHQWZLOOQRORQJHUEHLQFOXGHGLQWKH3.$QDO\VLV6HWIURPWKHWLPHRIWKHFKDQJH
$OO3.GDWDZLOOEHLQFOXGHGLQOLVWLQJVUHJDUGOHVVRIZKHWKHURUQRWWKH\DUHLQFOXGHGLQWKH3.
DQDO\VLVVHW
)RU EDVHOLQH ELRPDUNHU DQDO\VHV WKH 6DIHW\ $QDO\VLV 6HW ZLOO EH XVHG )RU DOO DQDO\VHV RI
FDWHJRULFDOELRPDUNHUVPLVVLQJFDWHJRULHVZLOOEHLQFOXGHGIRUDOOVXEMHFWVZKHUHELRPDUNHUUHVXOWV
DUH QRWDYDLODEOH,IDSSOLFDEOHWZRPLVVLQJFDWHJRULHVZLOO EHDSSOLHGWRGLVWLQJXLVKEHWZHHQ
VXEMHFWVZKHUHWKHELRPDUNHUZDVQRWGHWHUPLQHGDQGWKRVHZKHUHWKHELRPDUNHUGDWDZDVQRW
HYDOXDEOH

 
*HQHUDO6SHFLILFDWLRQVIRU6WDWLVWLFDO$QDO\VHV
'DWDKDQGOLQJDIWHUFXWRIIGDWH
,QJHQHUDOLIDFXWRIIGDWHLVVHWGDWDREWDLQHGDIWHUWKHFXWRIIZLOOQRWEHGLVSOD\HGLQDQ\OLVWLQJV
RUXVHGIRUVXPPDU\VWDWLVWLFVHJODERUDWRU\YDOXHVRIVDPSOHVWDNHQDIWHUGDWDFXWRII$(ZLWK
RQVHWGDWHDIWHUGDWDFXWRIIGHDWKHWFZLOOQRWEHLQFOXGHGLQDQ\DQDO\VLVRUOLVWLQJ,QSDUWLFXODU
WKHIROORZLQJVWHSVZLOOEHWDNHQWRGHULYHDQGUHSRUWVRPHH&5)GDWDWKDWPLJKWEHSRWHQWLDOO\
DIIHFWHGE\WKHFXWRIIGDWH
• ,IWKHVWDUWGDWHRIDYLVLWRUDSULRUFRQFRPLWDQWDQGSRVWPHGLFDWLRQSURFHGXUHWUHDWPHQW
RUDQDGYHUVHHYHQWLVEHIRUHRURQWKHFXWRIIGDWHDQGWKHVWRSGDWHLVDIWHUWKHFXWRIIGDWH
WKHVWRSGDWHLQWKHGHULYHGGDWDVHWVZLOOEHVHWWRWKHFXWRIIGDWHDQG
o )RUWKHPHGLFDWLRQSURFHGXUHWUHDWPHQWLWZLOOEHFRQVLGHUHGLQWKHVWDWXVRIRQJRLQJ


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





o )RUWKHDGYHUVHHYHQWLWVRXWFRPHZLOOEHFRQVLGHUHGDVRQJRLQJ
• ,IWKHODVWNQRZQDOLYHGDWHLVDIWHUWKHFXWRIIGDWHWKHGDWHZLOOEHXSGDWHGWRWKHFXWRII
GDWH
• ,IWKHGHDWKGDWHLVDIWHUWKHFXWRIIGDWHWKHGHDWKGDWHZLOOEHVHWWRPLVVLQJDQGWKHODVW
NQRZQDOLYHGDWHZLOOEHXSGDWHGWRWKHFXWRIIGDWH
'HILQLWLRQRIUHIHUHQFHVWDUWGDWHHQGGDWHVDQGVWXG\GD\
5HIHUHQFHVWDUWGDWHVKRXOGFRLQFLGHZLWK&\FOH'D\DQGLVGHILQHGDVWKHGD\RQZKLFKWKH
ILUVWGRVHRIVWXG\WUHDWPHQWZDVWDNHQE\WKHVXEMHFW
5HIHUHQFHHQGGDWHLVGHILQHGDVWKHGD\RIWKHODVWGRVHRIVWXG\WUHDWPHQW
6WXG\'D\ZLOOEHFDOFXODWHGIURPWKHUHIHUHQFHVWDUWGDWHDQGZLOOEHXVHGWRVKRZVWDUWVWRSGD\
RIDVVHVVPHQWVDQGHYHQWV
• ,IWKHGDWHRIWKHHYHQWLVRQRUDIWHUWKHUHIHUHQFHGDWHWKHQ6WXG\'D\ GDWHRIHYHQW±
UHIHUHQFHGDWH
• ,IWKHGDWHRIWKHHYHQWLVSULRUWRWKHUHIHUHQFHGDWHWKHQ6WXG\'D\ GDWHRIHYHQW±
UHIHUHQFHGDWH
,QWKHVLWXDWLRQZKHUHWKHHYHQWGDWHLVSDUWLDORUPLVVLQJWKHGDWHZLOODSSHDUSDUWLDORUPLVVLQJLQ
WKHOLVWLQJVDQGVWXG\GD\DQGDQ\FRUUHVSRQGLQJGXUDWLRQVZLOOEHSUHVHQWHGDVPLVVLQJ5XOHV
RIKDQGOLQJPLVVLQJGDWHVUHOHYDQWWRHIILFDF\ZLOOVSHFLILHGLQWKHVXEVHTXHQWVHFWLRQV
5HWHVWVXQVFKHGXOHGYLVLWVDQGHDUO\WHUPLQDWLRQGDWD
,Q JHQHUDO IRU E\YLVLW VXPPDULHV GDWD UHFRUGHG DW WKH QRPLQDO YLVLW ZLOO EH SUHVHQWHG
8QVFKHGXOHG PHDVXUHPHQWVZLOO QRW EH LQFOXGHG LQ E\YLVLW VXPPDULHVEXWZLOOFRQWULEXWHWR
EHVWZRUVWFDVHYDOXHZKHUHUHTXLUHGHJVKLIWWDEOH
,QWKHFDVHRIDUHWHVWVDPHYLVLWQXPEHUDVVLJQHGWKHZRUVWDYDLODEOHPHDVXUHPHQWIRUWKDWYLVLW
ZLOOEHXVHGIRUE\YLVLWVXPPDULHV6FHQDULRVZKHUHE\VXEMHFWVKDYHDUHWHVWZLOOEHORRNHGDWRQ
DFDVHE\FDVHEDVLVZLWKGLVFXVVLRQZLWKWKHPHGLFDOWHDPWRGHFLGHZKLFKPHDVXUHPHQWVKRXOG
EHXVHG
(DUO\WHUPLQDWLRQGDWDZLOOEHPDSSHGWRWKHQH[WDYDLODEOHYLVLWQXPEHUIRUE\YLVLWVXPPDULHV
/LVWLQJVZLOOLQFOXGHDOOVFKHGXOHGXQVFKHGXOHGUHWHVWDQGHDUO\GLVFRQWLQXDWLRQGDWD
'HILQLWLRQRIEDVHOLQH
8QOHVVRWKHUZLVHVSHFLILHGEDVHOLQHLVGHILQHGDVWKHODVWQRQPLVVLQJPHDVXUHPHQWWDNHQSULRUWR
UHIHUHQFHVWDUWGDWHLQFOXGLQJXQVFKHGXOHGDVVHVVPHQWV,QWKHFDVHZKHUHWKHODVWQRQPLVVLQJ
PHDVXUHPHQW DQG WKH UHIHUHQFH VWDUW GDWH FRLQFLGH WKDW PHDVXUHPHQW ZLOO EH FRQVLGHUHG DV
EDVHOLQHEXW$(VDQGPHGLFDWLRQVFRPPHQFLQJRQWKHUHIHUHQFHVWDUWGDWHZLOOEHFRQVLGHUHGSRVW
EDVHOLQH


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





(QGRIWUHDWPHQW
8QOHVV RWKHUZLVH VSHFLILHG HQG RI WUHDWPHQW (27 LV GHILQHG DV WKH HDUOLHVW QRQPLVVLQJ
PHDVXUHPHQWWDNHQDIWHUUHIHUHQFHHQGGDWH(27PHDVXUHPHQWVLQJHQHUDOVKRXOGEHUHFRUGHGDW
WKH³(QGRI7UHDWPHQW´YLVLW
'HILQLWLRQRIRQWUHDWPHQWYDOXH
2QWUHDWPHQWGDWDUHIHUVWRDVVHVVPHQWYDOXHVFROOHFWHGDIWHUWKHILUVWVWXG\GUXJDGPLQLVWUDWLRQRI
DQ\WULDOGUXJDQGZLWKLQGD\VLQFOXVLYHDIWHUWKHODVWVWXG\GUXJDGPLQLVWUDWLRQ
&DOFXODWLRQRIGXUDWLRQ
'XUDWLRQZLOOEHFDOFXODWHGE\WKHGLIIHUHQFHRIVWDUWDQGVWRSGDWHLIQRWRWKHUZLVHVSHFLILHG
&RQYHUVLRQIDFWRUV
7KHIROORZLQJFRQYHUVLRQIDFWRUVZLOOEHXVHGWRFRQYHUWGD\VLQWRPRQWKVRU\HDUVPRQWK 
GD\V\HDU GD\V
0LVVLQJGDWD
8QOHVVRWKHUZLVHVSHFLILHGPLVVLQJGDWDZLOOQRWEHLPSXWHG)RUWKHGHULYDWLRQRIQHZYDULDEOHV
WKHIROORZLQJUXOHVZLOODSSO\
,QFRPSOHWH$(UHODWHGGDWHVZLOOEHKDQGOHGDVIROORZV
• ,QFDVHWKHRQVHWGDWHLVFRPSOHWHO\PLVVLQJRUWKHRQVHWLVLQWKHVDPH\HDULIWKHRQVHW
\HDULVDYDLODEOHRQO\RUWKHRQVHWLVLQWKHVDPHPRQWKDQG\HDULIWKHGD\LVPLVVLQJDV
VWDUWRIVWXG\WUHDWPHQWWKHQWKHRQVHWGDWHZLOOEHUHSODFHGE\WKHPLQLPXPRIVWDUWRI
VWXG\WUHDWPHQWDQG$(UHVROXWLRQGDWH
• ,QDOORWKHUFDVHVWKHPLVVLQJRQVHWGD\RURQVHWPRQWKZLOOEHUHSODFHGE\
• ,QFRPSOHWHVWRSGDWHVZLOOEHUHSODFHGE\WKHODVWGD\RIWKHPRQWKLIGD\LVPLVVLQJRQO\
LIQRWUHVXOWLQJLQDGDWHODWHUWKDQWKHGDWHRIVXEMHFW
VGHDWK,QWKHODWWHUFDVHWKHGDWHRI
GHDWKZLOOEHXVHGWRLPSXWHWKHLQFRPSOHWHVWRSGDWH
• ,QDOORWKHUFDVHVWKHLQFRPSOHWHVWRSGDWHZLOOQRWEHLPSXWHG
)RULPSXWLQJPLVVLQJSDUWVRIGDWHVIRUWKHHIILFDF\DQDO\VHVWKHPLVVLQJGD\LQDGDWHZLOOEH
LPSXWHGDVWKHILIWHHQWKRIWKHPRQWKLIPRQWKDQG\HDUDUHGRFXPHQWHG7KLVDOVRLQFOXGHVDOVR
GDWHVRIVWDUWRI IROORZXSWKHUDS\,QDOORWKHUFDVHV PLVVLQJRULQFRPSOHWHGDWHVZLOO QRWEH
LPSXWHGLIQRWLQGLFDWHGRWKHUZLVH
,Q LQGLYLGXDOVXEMHFWGDWDOLVWLQJVWKHGRFXPHQWHGGDWHDVJLYHQ LQWKHH&5)ZLOO EHUHSRUWHG
HJBB0D\LQFDVHRIGD\PLVVLQJEXWPRQWKDQG\HDUDYDLODEOH1RLPSXWHGYDOXHVZLOO
EHSUHVHQWHGLQWKH&OLQLFDO7ULDO5HSRUW,QDOORWKHUVXEMHFWGDWDOLVWLQJVLPSXWHGYDOXHVZLOOEH
SUHVHQWHG,QWKRVHOLVWLQJVLPSXWHGGDWHRIGHDWKODVWGDWHNQRZQWREHDOLYHVWDUWRI$(DQG
UHODWLRQVKLSRI$(WRVWXG\WUHDWPHQWZLOOEHIODJJHG


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





0LVVLQJVWDWLVWLFVHJZKHQWKH\FDQQRWEHFDOFXODWHGVKRXOGEHSUHVHQWHGDV³QG´)RUH[DPSOH
LIQ WKHPHDVXUHRIYDULDELOLW\VWDQGDUGGHYLDWLRQFDQQRWEHFRPSXWHGDQGVKRXOGEHSUHVHQWHG
DV³QG´
:LQGRZLQJFRQYHQWLRQV
1RYLVLWZLQGRZLQJZLOOEHSHUIRUPHGIRUWKLVVWXG\
6WDWLVWLFDOWHVWVDQGVLJQLILFDQFHOHYHO
$OOGDWDZLOOEHGHVFULEHGXVLQJSUHVHQWDWLRQVRIGHVFULSWLYHVWDWLVWLFVRQO\1RIRUPDOVWDWLVWLFDO
DQDO\VHVZLOOEHFRQGXFWHGLQWKLVVWXG\DQGVLJQLILFDQFHOHYHOLVQRWDSSOLFDEOH
6RIWZDUHYHUVLRQ
$OO DQDO\VHV ZLOO EH FRQGXFWHG XVLQJ 6$6 

YHUVLRQRUKLJKHU
3RROLQJRIFHQWHUV
%HFDXVHRIWKHKLJKQXPEHURISDUWLFLSDWLQJFHQWHUVDQGWKHDQWLFLSDWHGVPDOOQXPEHURIVXEMHFWV
LQHDFKFHQWHUGDWDZLOOEHSRROHGDFURVVFHQWHUV&HQWUHSRROLQJZLOOEHFDUULHGRXWDFURVVDOO
FHQWHUVIRUXVHLQVWDWLVWLFDOVXPPDULHVIRUWKLVVWXG\
([DPLQDWLRQRIVXEJURXSV
1RIRUPDOVXEJURXSVXPPDULHVZLOOEHSUHVHQWHGLQWKLVVWXG\
3UHVHQWDWLRQRIFRQWLQXRXVDQGTXDOLWDWLYHYDULDEOHV
$SSHQGL[VKRZVFRQYHQWLRQVIRUSUHVHQWDWLRQRIGDWDLQRXWSXWV
7KHWHPSODWHVSURYLGHGZLWKWKLV6$3GHVFULEHWKHSUHVHQWDWLRQVIRUWKLVVWXG\DQGWKHUHIRUHWKH
IRUPDW DQG FRQWHQW RI WKH VXPPDU\ WDEOHV ILJXUHV DQG OLVWLQJV WR EH SURYLGHG E\


&RQWLQXRXV YDULDEOHV ZLOO EH VXPPDUL]HG XVLQJ WKH IROORZLQJ GHVFULSWLYH VWDWLVWLFV XQOHVV
RWKHUZLVHVSHFLILHGVHH6HFWLRQ
• QXPEHURIVXEMHFWV1QXPEHURIVXEMHFWVZLWKQRQPLVVLQJYDOXHV
• PHDQVWDQGDUGGHYLDWLRQDQGPHGLDQ
• WK3HUFHQWLOHWK3HUFHQWLOH44
• PLQLPXPDQGPD[LPXP
• &,VZLOOEHSUHVHQWHGZKHUHDSSURSULDWH
4XDOLWDWLYHYDULDEOHVZLOOEHVXPPDUL]HGE\FRXQWVDQGSHUFHQWDJHV
PPD
PPD


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





8QOHVVRWKHUZLVHVWDWHGWKHFDOFXODWLRQRISURSRUWLRQVZLOOEHEDVHGRQWKHVDPSOHVL]HRIWKH
SRSXODWLRQRILQWHUHVW&RXQWVRIPLVVLQJREVHUYDWLRQVZLOOEHLQFOXGHGLQWKHGHQRPLQDWRUDQG
SUHVHQWHGDVDVHSDUDWHFDWHJRU\

 
7ULDO6XEMHFWV
7KH VXEVHFWLRQV LQ WKLV VHFWLRQ LQFOXGH VSHFLILFDWLRQV IRU UHSRUWLQJ VXEMHFW GLVSRVLWLRQ DQG
WUHDWPHQWWULDO GLVFRQWLQXDWLRQV $GGLWLRQDOO\ SURFHGXUHV IRU UHSRUWLQJ SURWRFRO GHYLDWLRQV DUH
SURYLGHG
 
'LVSRVLWLRQRI6XEMHFWVDQG'LVFRQWLQXDWLRQV
Population: All Screening Analysis Set 
$OOVXEMHFWVZKRSURYLGHLQIRUPHGFRQVHQWZLOOEHDFFRXQWHGIRULQWKLVVWXG\6XEMHFWGLVSRVLWLRQ
DQGZLWKGUDZDOVZLOOEHSUHVHQWHG
6XEMHFWVZLOOUHPDLQLQWKHVWXG\XQWLOGHDWKSURJUHVVLRQGLVHDVHORVVWRIROORZXSRUZLWKGUDZDO
RIFRQVHQW6XEMHFWVDUHIUHHWRZLWKGUDZIURPWKHVWXG\DWDQ\WLPHZLWKRXWJLYLQJWKHLUUHDVRQV
7KHIROORZLQJZLOOEHVXPPDUL]HGRYHUDOODQGSHUWUHDWPHQWJURXSZKHQDSSOLFDEOH
• 7RWDOQXPEHURIVXEMHFWVVFUHHQHG$OOVFUHHQHGVXEMHFWV
• 1XPEHU RI VFUHHQ IDLOXUH VXEMHFWV RYHUDOO DQG JURXSHG E\ SULPDU\ UHDVRQ IRU VFUHHQ
IDLOXUHDQGQXPEHURIVXEMHFWVDOORFDWHGWRWUHDWPHQW
• 1XPEHURIVXEMHFWVZKRGLVFRQWLQXHGWKHWUHDWPHQWDIWHUDOORFDWHGWRWUHDWPHQWJURXSHG
E\GRVHOHYHODQGPDLQUHDVRQVHSDUDWHO\IRUHDFKWUHDWPHQWFRPSRQHQW
• 1XPEHURIVXEMHFWVZKRGLVFRQWLQXHGWKHWULDODIWHUDOORFDWHGWRWUHDWPHQWJURXSHGE\GRVH
OHYHODQGPDLQUHDVRQ
 
3URWRFRO'HYLDWLRQV
Population: Safety Analysis Set  
$OOSURWRFROGHYLDWLRQVLQFOXGLQJLQFOXVLRQH[FOXVLRQFULWHULDGHYLDWLRQVDQGGHYLDWLRQVGXULQJWKH
WULDOZLOOEHOLVWHGHYHQLIWKH\DUHEHOLHYHGQRWWRLQIOXHQFHDQ\RIWKHUHVXOWV 
 
,PSRUWDQW3URWRFRO'HYLDWLRQV
7KHIROORZLQJRXWSXWVZLOOEHSURYLGHG
• 6XPPDU\RILPSRUWDQWSURWRFROGHYLDWLRQV



7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 
'HPRJUDSKLFVDQG2WKHU%DVHOLQH&KDUDFWHULVWLFV
Population: Safety Analysis Set 
'HPRJUDSKLFGDWDDQGRWKHUEDVHOLQHFKDUDFWHULVWLFVZLOOEHSUHVHQWHGXVLQJVXPPDU\VWDWLVWLFVIRU
FRQWLQXRXVYDULDEOHVDQGIUHTXHQF\WDEOHVIRUFDWHJRULFDOYDULDEOHV
 
'HPRJUDSKLFV
'HPRJUDSKLF FKDUDFWHULVWLFV ZLOO EH VXPPDUL]HG XVLQJ WKH IROORZLQJ LQIRUPDWLRQ IURP WKH
6FUHHQLQJ%DVHOLQH9LVLW&5)SDJHV
'HPRJUDSKLFFKDUDFWHULVWLFV
• $JH\HDUVVXPPDU\VWDWLVWLFV
• $JHLQFDWHJRULHV\HDUV! \HDUV! \HDUV
• 6H[PDOHIHPDOH
• 5DFH$VLDQRWKHU
• 5HJLRQ0DLQODQG&KLQD6RXWK.RUHD7DLZDQ6LQJDSRUH
• 1LFRWLQHXVH6PRNLQJVWDWXVQHYHUXVHGUHJXODUXVHURFFDVLRQDOXVHUIRUPHUXVHU
• (&2*36DWEDVHOLQH
9LWDO6LJQVDWEDVHOLQH
• +HLJKWFPVXPPDU\VWDWLVWLFV
• :HLJKWNJVXPPDU\VWDWLVWLFV
• %0,NJPVXPPDU\VWDWLVWLFV
6SHFLILFDWLRQVIRUFRPSXWDWLRQ
• $JH \HDUV GDWHRI JLYHQ LQIRUPHG FRQVHQW  GDWHRI ELUWK   SUHVHQWHGWR 
GHFLPDOSODFHGS
• %0,NJP ZHLJKWNJKHLJKWP
 
0HGLFDO+LVWRU\
7KH PHGLFDO KLVWRU\ ZLOO EH VXPPDUL]HG IURP WKH ³0HGLFDO +LVWRU\´ DQG ³0HGLFDO +LVWRU\
'HWDLOV´H&5)SDJHVXVLQJ0HG'5$YHUVLRQSUHIHUUHGWHUP37DVHYHQWFDWHJRU\DQG
0HG'5$V\VWHPRUJDQFODVV62&ERG\WHUPDV%RG\6\VWHPFDWHJRU\
2QJRLQJPHGLFDOKLVWRU\ZLOOEHGLVSOD\HGLQWHUPVRIIUHTXHQF\WDEOHVRUGHUHGE\SULPDU\62&
DQG37LQDOSKDEHWLFDORUGHU2QJRLQJPHGLFDOKLVWRULHVDUHWKHRQHVUHFRUGHGDV³RQJRLQJ´LQWKH
³0HGLFDO+LVWRU\'HWDLOV´H&5)IRUPRWKHUZLVHZLOOEHFODVVLILHGDVSUHYLRXVPHGLFDOFRQGLWLRQV
%RWKSUHYLRXVDQGRQJRLQJPHGLFDOKLVWRU\ZLOOEHOLVWHG


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 
'LVHDVH+LVWRU\
'LVHDVH KLVWRU\ LV FROOHFWHG RQ 'LVHDVH +LVWRU\ H&5) GDWD ,QIRUPDWLRQ RQ GLVHDVH KLVWRU\
FROOHFWHG DW WKH SUHWUHDWPHQW HYDOXDWLRQ YLVLW ZLOO EH SUHVHQWHG 6XPPDU\ VWDWLVWLFV ZLOO EH
SUHVHQWHGIRU
• 6LWHRI3ULPDU\WXPRXU
• 7LPHVLQFHLQLWLDOGLDJQRVLV\HDUV
• 7XPRU KLVWRSKDWKRORJLFF\WRORJLF W\SH VTXDPRXV DGHQRFDUFLQRPD ODUJH FHOO
EURQFKRDOYHRODURWKHU
• +LVWRORJLF WXPRU JUDGHGLIIHUHQWLDWLRQ ZHOO GLIIHUHQWLDWHG PRGHUDWHO\ GLIIHUHQWLDWHG
SRRUO\GLIIHUHQWLDWHGQRWDSSOLFDEOH
• 710FODVVLILFDWLRQDWLQLWLDOGLDJQRVLVDQGDWVWXG\HQWU\
• 0HWDVWDVLVVLWHVDWLQLWLDOGLDJQRVLVDQGDWVWXG\HQWU\
• (*)5JHQHWLFPXWDWLRQVWDWXVZLOGW\SHPXWDWHGQRWDYDLODEOHIHDVLEOH
• 700XWDWLRQ6WDWXV3RVLWLYH1HJDWLYH
6SHFLILFDWLRQVIRUFRPSXWDWLRQ
• 7LPHVLQFH LQLWLDOGLDJQRVLV\HDUV GDWHRI LQIRUPHGFRQVHQW ± GDWHRIGLDJQRVLV
SUHVHQWHGWRGHFLPDOSODFH
 
0HGLFDWLRQ+LVWRU\RI2QFRORJ\
3ULRU DQWLFDQFHUWKHUDS\DQGVXUJHU\ LQIRUPDWLRQ LQFOXGLQJGUXJWKHUDSLHVUDGLRWKHUDS\DQG
VXUJHULHVZLOOEHVXPPDUL]HG
6XPPDU\VWDWLVWLFVZLOOEHSUHVHQWHGIRU
• 3ULRUDQWLFDQFHUGUXJWKHUDS\
o $Q\SULRUDQWLFDQFHUGUXJWKHUDS\
o 7\SHRIV\VWHPLFWKHUDS\
o ,QWHQWRIWKHUDS\
o 3UHYLRXV7.,WKHUDSLHV
o /LQHRISUHYLRXV7.,WKHUDSLHV
o ,PPHGLDWHSULRU7.,WKHUDSLHV
o 3UHYLRXVFKHPRWKHUDSLHV
o %HVWUHVSRQVH
• 3ULRUDQWLFDQFHUUDGLRWKHUDS\
o $Q\SULRUDQWLFDQFHUUDGLRWKHUDS\
o 7\SHRIWKHUDS\


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





o ,QWHQWRIWKHUDS\
o %HVWUHVSRQVH
• 3ULRUDQWLFDQFHUVXUJHU\
o $Q\SULRUDQWLFDQFHUVXUJHU\
o 1XPEHURISULRUDQWLFDQFHUVXUJHULHV
o 7KHVXUJHU\ZDVFXUDWLYHLQLQWHQW\HVQR
o 2XWFRPHRIVXUJHU\
0HGLFDWLRQKLVWRU\IRUSULRUDQWLFDQFHUWKHUDS\DQGVXUJHU\LQIRUPDWLRQLQFOXGLQJGUXJWKHUDSLHV
UDGLRWKHUDS\DQGVXUJHULHVZLOOEHOLVWHGVHSDUDWHO\
6SHFLILFDWLRQIRUFRPSXWDWLRQ
3UHYLRXV7.,WKHUDSLHVDUHWKRVHFROOHFWHGE\³3ULRU$QWL&DQFHU'UXJ7KHUDSLHV'HWDLOV´H&5)
DQGOLVWHGLQEHORZWDEOHSHUWKHUHYLHZRIWKHPRVWFXUUHQWGDWDEDVH
6'70&0&0'(&2'
6'70&0&0757
5HSRUWHGWR2XWSXWV
VDPHDV&0'(&2'E\GHIDXOW
$)$7,1,%
$IDWLQLE

(5/27,1,%
(UORWLQLE

(5/27,1,%+<'52&+/25,'(
7DUFHYD
(5/27,1,%
*(),7,1,%
*HILWLQLE

,UHVVD

,UHVVD*HILWLQLE

,19(67,*$7,21$/'58*
$8<
$8<

$=' 7KLUG JHQHUDWLRQ
(*)57.,
$='

$=' 7KLUG JHQHUDWLRQ
(*57.,
$='
,1&
,1&
&0'(&2' ZLOO EH UHSRUWHG E\ GHIDXOW 7KH GUXJV ZLWK GLIIHUHQW QDPHV EXW ZLWK VDPH
FDWHJRU\ ZRXOG EH PHUJHG WRJHWKHU IRU H[DPSOH &0'(&2'  µµ(5/27,1,%¶ RU
µ(5/27,1,% +<'52&+/25,'(¶ ZLOO EH FRPELQHG LQWR RQH FDWHJRU\ µ(5/27,1,%¶
'UXJVZLWKRXWFRPPHUFLDOQDPHVXFKDV&0'(&2' µ,19(67,*$7,21$/'58*¶WKH
PRGLILHGH&5)UHSRUWHGQDPHZLOOEHXVHGIRUFDWHJRULHV
/LQHVRISUHYLRXV7.,DQWLFDQFHUWKHUDSLHVDUHWKRVHOLQHVFROOHFWHGE\³3ULRU$QWL&DQFHU'UXJ
7KHUDSLHV 'HWDLOV´ H&5) DQG FRQWDLQLQJ RQH RU PRUH 7., WKHUDSLHV 7KH VHTXHQFH QXPEHU
6'70&0&0*53,'IRUWKHODVWSUHYLRXV7.,OLQHZLOOEHFDWHJRUL]HGDQGVXPPDUL]HG
$QLPPHGLDWHSULRU7.,WKHUDS\LVWKHRQHZKLFKPHHWVWKHFRUUHVSRQGLQJOLQHLVWKHODVWRQH
UHSRUWHGLQWKH³3ULRU$QWL&DQFHU'UXJ7KHUDSLHV'HWDLOV´H&5)WKHWKHUDS\LVD7.,WKHUDS\




7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





3UHYLRXVFKHPRWKHUDSLHVDUHWKRVHFROOHFWHGE\³3ULRU$QWL&DQFHU'UXJ7KHUDSLHV'HWDLOV´H&5)
ZLWKD&0'(&2'YDOXHOLVWHGDVEHORZSHUWKHUHYLHZRIWKHPRVWFXUUHQWGDWDEDVH
6'70&0&0'(&2'
6'70&0&0757
5HSRUWHGWR2XWSXWV
VDPHDV&0'(&2'E\GHIDXOW
&$5%23/$7,1
&DUERSODWLQ

FDUGRSODWLQ

&,63/$7,1
&,63/$7,1

'2&(7$;(/
GRFHWD[HO

7D[RWHUH

72;27(5(

(72326,'(
(WRSRVLGH

*(0&,7$%,1(
JHPFLWDELQH

*(0&,7$%,1(
+<'52&+/25,'(
*(07$1
*(0&,7$%,1(
*(0=$5
*(0&,7$%,1(
,5,127(&$1
,ULQRWHFDQ

3$&/,7$;(/
SDFOLWD[HO

7D[RO

3(0(75(;('
SHPHWUH[HG

3(0(75(;('',62',80
$OLPWD
3(0(75(;('
$OLPWDSHPHWUH[HG
3(0(75(;('
8)725$/
7HJDIXUXUDFLO

9,125(/%,1(
YLQRUHOELQH

9,125(/%,1(7$575$7(
1DYHOELQH
9,125(/%,1(
 
%DVHOLQH%LRPDUNHUV0HDVXUHGLQ7XPRU7LVVXH
$OOEDVHOLQHELRPDUNHUYDULDEOHVZLOOEHOLVWHG
 
%DVHOLQH%LRPDUNHU9DULDEOHV
 
%DVHOLQHWXPRUF0HW([SUHVVLRQ
7KHIROORZLQJVFRUHVZLOOEHSURYLGHGE\WKHSDWKRORJLVWEDVHGRQF0HWH[SUHVVLRQUDZGDWD
PHDVXUHGE\,+&LQSUHWUHDWPHQWRUDUFKLYHGWXPRUELRSVLHV
• 0HWVFRUHDWEDVHOLQHSRVVLEOHYDOXHV
,QJHQHUDOPHDVXUHPHQWVIODJJHGDVQRQHYDOXDEOHZLOOQRWEHWDNHQLQWRDFFRXQWIRUDQDO\VLV
 
%DVHOLQHWXPRUF0HW$PSOLILFDWLRQ
7KHIROORZLQJSDUDPHWHUVZLOOEHSURYLGHGIRU),6+DQDO\VLVRISUHWUHDWPHQWRUDUFKLYHGWXPRU
ELRSVLHV
• ),6+DQDO\VLV


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





o F0HW&(3FRS\QXPEHUUDWLR
o 0HDQJHQHFRS\QXPEHU
,QJHQHUDOPHDVXUHPHQWVIODJJHGDVQRQHYDOXDEOHZLOOQRWEHWDNHQLQWRDFFRXQWIRUDQDO\VLV
 
%DVHOLQHWXPRU+*)([SUHVVLRQ
7KH IROORZLQJ VFRUH ZLOO EH SURYLGHG E\ WKH SDWKRORJLVW EDVHG RQ +*) H[SUHVVLRQ UDZ GDWD
PHDVXUHGE\,+&LQSUHWUHDWPHQWRUDUFKLYHGWXPRUELRSVLHV
• &$)+*)+VFRUHDWEDVHOLQHFRQWLQXRXV
• +*)+VFRUHDWEDVHOLQHFRQWLQXRXV
,QJHQHUDOPHDVXUHPHQWVIODJJHGDVQRQHYDOXDEOHZLOOQRWEHWDNHQLQWRDFFRXQWIRUDQDO\VLV
7KHEDVHOLQH+*)+VFRUHVZLOOQRWEHDQDO\]HGIRUFRUUHODWLRQDVVRFLDWLRQWRHIILFDF\SDUDPHWHUV
0RUHRYHUWKH+*)+VFRUHVZLOOEHFDWHJRUL]HGLQWKHIROORZLQJZD\
• WKHYDULDEOHEDVHOLQH+*)+VFRUHJURXS>YVDQ\YDOXH@ZLOOKDYHWKHIROORZLQJOHYHOV
+VFRUH+VFRUH!+VFRUHQRWGRQH+VFRUHQRWHYDOXDEOH
 
'HVFULSWLYH6XPPDULHVRI%DVHOLQH%LRPDUNHUV
 
%DVHOLQHWXPRUF0HW([SUHVVLRQ
%DVHOLQH0HWVFRUHZLOOEHVXPPDUL]HGGHVFULSWLYHO\LQDIUHTXHQF\WDEOH
0RUHRYHUUDZF0HWH[SUHVVLRQGDWDZLOOEHSUHVHQWHGLQOLVWLQJV
 
%DVHOLQHWXPRUF0HW$PSOLILFDWLRQ6WDWXV
%DVHOLQH F0HW&(3 FRS\ QXPEHU UDWLR PHDQ JHQH FRS\ QXPEHU ZLOO EH VXPPDUL]HG
GHVFULSWLYHO\XVLQJVXPPDU\VWDWLVWLFV,QDGGLWLRQWKHIROORZLQJFDWHJRULHVZLOOEHVXPPDUL]HG
• 0HDQ*HQH&RS\1XPEHU! ! 
• F0HW&(3FRS\QXPEHUUDWLR! 
• ),6+6WDWXV),6+HLWKHU0HDQ*HQH&RS\1XPEHU! RUF0HW&(3FRS\QXPEHU
UDWLR! ),6+
0RUHRYHUF0HWDPSOLILFDWLRQGDWDZLOOEHSUHVHQWHGLQOLVWLQJV


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 
&RUUHODWLRQ EHWZHHQ WXPRU %DVHOLQH F0HW ([SUHVVLRQ DQG
$PSOLILFDWLRQ6WDWXV
7KHFRUUHODWLRQDVVRFLDWLRQEHWZHHQF0HWH[SUHVVLRQDQGDPSOLILFDWLRQVWDWXVZLOOEHDQDO\]HG
E\ SUHVHQWLQJ D FURVVWDEXODWLRQ WDEOH &URVVWDEXODWLRQ WDEOHV ZLOO RQO\ EH SUHVHQWHG E\ GRVH
OHYHOV
 
%DVHOLQHWXPRU+*)H[SUHVVLRQ6WDWXV
%DVHOLQH+*)VFRUH&$)+*)+VFRUHDQG&\WRSODVPLF+*)+VFRUHZLOOEHVXPPDUL]HG
GHVFULSWLYHO\XVLQJVXPPDU\VWDWLVWLFV
0RUHRYHUUDZ+*)IURPSUHWUHDWPHQWWXPRUELRSVLHVZLOOEHSUHVHQWHGLQOLVWLQJV
 
2WKHU%DVHOLQH&KDUDFWHULVWLFV
%DVHOLQHFKDUDFWHULVWLFVZLWKUHVSHFWWRKHPDWRORJ\DQGFRDJXODWLRQELRFKHPLVWU\XULQDO\VLVYLWDO
VLJQV(&*ZLOOEHSDUWRI6HFWLRQ

 
3UHYLRXVRU&RQFRPLWDQW0HGLFDWLRQV3URFHGXUHV
Population: Safety Analysis Set 
 
3UHYLRXVDQGFRQFRPLWDQWPHGLFDWLRQV
$OOWHUPVZLOOEHFRGHGXVLQJ:RUOG+HDOWK2UJDQL]DWLRQ:+2'UXJ'LFWLRQDU\YHUVLRQ0DUFK
 0HGLFDWLRQV ZLOO EH SUHVHQWHG XVLQJ WKH $QDWRPLFDO 7KHUDSHXWLF &KHPLFDO $7&
FODVVLILFDWLRQV\VWHPXQGHUOHYHODQGSUHIHUUHGQDPHV3URFHGXUHVZLOOEHUHSRUWHGE\V\VWHP
RUJDQFODVV62&DQGSUHIHUUHGWHUP37XVLQJ0HG'5$YHUVLRQ5HDVRQVIRUSUHYLRXV
PHGLFDWLRQVSURFHGXUHVZLOODOVREHSUHVHQWHG
0LVVLQJRUSDUWLDOGDWHVIRUPHGLFDWLRQVDQGSURFHGXUHVZLOOQRWEHLPSXWHG,QWKHFDVHZKHUHLW
LVQRWSRVVLEOHWRGHILQHDPHGLFDWLRQRUSURFHGXUHDVSULRURUFRQFRPLWDQWWKHHYHQWZLOO EH
FODVVLILHGE\WKHZRUVWFDVHLHFRQFRPLWDQW
• µ3UHYLRXV¶PHGLFDWLRQVRUSURFHGXUHVDUHWKRVHZKLFKVWDUWHGDQGVWRSSHGSULRUWRWKHILUVW
GRVHRIVWXG\WUHDWPHQW
• µ&RQFRPLWDQW¶PHGLFDWLRQVRUSURFHGXUHVDUHWKRVHZKLFK
o VWDUWHGSULRUWRRQRUDIWHUWKHILUVWGRVHRIVWXG\WUHDWPHQWDQGVWDUWHGQRODWHUWKDQ
GD\VIROORZLQJHQGRIVWXG\WUHDWPHQW
o $1'HQGHGRQRUDIWHUWKHGDWHRIILUVWGRVHRIVWXG\WUHDWPHQWRUZHUHRQJRLQJDWWKH
HQGRIWKHVWXG\
• µ3RVW¶PHGLFDWLRQVRUSURFHGXUHVDUHWKRVHZKLFKVWDUWHGPRUHWKDQGD\VIROORZLQJWKH
ODVWGRVHRIVWXG\WUHDWPHQW


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





$OOPHGLFDWLRQWUHDWPHQWSURFHGXUHVZLOOEHOLVWHG
 
$QWL&DQFHU7UHDWPHQWDIWHU7UHDWPHQW7HUPLQDWLRQ
1HZDQWLFDQFHUWKHUDS\ ZLOO EHUHFRUGHG IRUVXEMHFWVZKRGLVFRQWLQXH IURPWKHWUHDWPHQWIRU
UHDVRQV RWKHU WKDQ 3' DW WKH DGGLWLRQDO IROORZXS YLVLWV 7KH IROORZLQJ VXPPDULHV ZLOO EH
SUHVHQWHGIRUDQWLFDQFHUWUHDWPHQWDIWHUGLVFRQWLQXDWLRQ
• $Q\DQWLFDQFHUWUHDWPHQWDIWHUGLVFRQWLQXDWLRQ
• 7\SHRIV\VWHPLFWKHUDS\
• %HVWUHVSRQVH
$QWLFDQFHUWUHDWPHQWDIWHUWUHDWPHQWWHUPLQDWLRQZLOOEHOLVWHG

 
7UHDWPHQW&RPSOLDQFHDQG([SRVXUH
Population: Safety Analysis Set 
&RPSOLDQFHDQGH[SRVXUHWRERWKVWXG\WUHDWPHQWWHSRWLQLEDQGJHILWLQLEZLOOEHSUHVHQWHGIRUWKH
6$)VHWIRU&\FOHDVZHOODVRYHUDOO
6WXG\WUHDWPHQWWHSRWLQLEDQGJHILWLQLEDUHJLYHQRQFHGDLO\2'DQGLWLVDVVXPHGWKDWWKHVXEMHFW
VKRXOGWDNHPHGLFDWLRQIURPWKHPRUQLQJRI&\FOH'D\WKHYLVLWGD\DWZKLFKWKHLUPHGLFDWLRQ
LVLQLWLDOO\GLVSHQVHGWRWKHPRUQLQJEHIRUHWKHLUVFKHGXOHGPHGLFDWLRQUHWXUQGDWH
7KHGDWHRIILUVWWHSRWLQLEDQGJHILWLQLEDGPLQLVWUDWLRQZLOOEHWDNHQIURPWKHH&5)³7UHDWPHQW
$GPLQLVWUDWLRQ06&-'HWDLOV´DQG³7UHDWPHQW*HILWLQLE$GPLQLVWUDWLRQ'HWDLOV´IRUPV
UHVSHFWLYHO\ 7KH GDWH RI ODVW WHSRWLQLE DQG JHILWLQLE WUHDWPHQW ZLOO EH WDNHQ IURP WKH H&5)
³7UHDWPHQW7HUPLQDWLRQIRU06&-´DQG³7UHDWPHQW7HUPLQDWLRQIRU*HILWLQLE´IRUPV
UHVSHFWLYHO\
7KHH[WHQWRIFRPSOLDQFHDQGH[SRVXUHWRWHSRWLQLEDQGJHILWLQLEZLOOEHSUHVHQWHGE\WKHIROORZLQJ
VXPPDULHV
• 'XUDWLRQRIH[SRVXUHZHHNV
• &XPXODWLYHGRVHPJ
• 'RVHLQWHQVLW\PJGD\
• 5HODWLYHGRVHLQWHQVLW\
o 7KHEUHDNGRZQRIUHODWLYHGRVHLQWHQVLW\
 ! ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS LI SDWLHQWV KDYH PXOWLSOH
5HODWLYHGRVHLQWHQVLW\
• 7KHQXPEHURIGRVHUHGXFWLRQV


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





o 1XPEHU DQG SHUFHQWDJH RI SDWLHQWV ZLWK DW OHDVW RQH GRVH UHGXFWLRQ DV ZHOO DV D
EUHDNGRZQRIGRVHUHGXFWLRQVıZLOOEHVXPPDUL]HGE\WUHDWPHQWJURXS
o &XPXODWLYHGXUDWLRQRIGRVHUHGXFWLRQVGD\VZLOOEHVXPPDUL]HG
• 7KHQXPEHURIGRVHGHOD\VGRVHWHPSRUDU\GLVFRQWLQXDWLRQ
o 1XPEHU DQG SHUFHQWDJH RI SDWLHQWV ZLWK LQWHUUXSWHG VWXG\ GUXJ DGPLQLVWUDWLRQ DQG
PD[LPXPOHQJWKRIWHPSRUDU\GLVFRQWLQXDWLRQGD\VGD\VıGD\VLHWKH
ZRUVW FDVH ZLOO EH VXPPDUL]HG E\ WUHDWPHQW JURXS LI SDWLHQWV KDYH PXOWLSOH GRVH
WHPSRUDU\GLVFRQWLQXDWLRQV
o &XPXODWLYHGXUDWLRQRIGRVHWHPSRUDU\GLVFRQWLQXDWLRQGD\VZLOOEHVXPPDUL]HG
6SHFLILFDWLRQVIRUFRPSXWDWLRQ
• 'XUDWLRQRIH[SRVXUHGRVHUHGXFWLRQDQGGRVHGHOD\DUHQRWWDNHQLQWRDFFRXQWIRUWKH
FDOFXODWLRQRIGXUDWLRQRIH[SRVXUH
• &XPXODWLYHGRVH WKHVXPRIWKHWRWDOGRVDJHWKDWWKHVXEMHFWUHFHLYHGLQDWLPHSHULRG
• 'RVHLQWHQVLW\PJGD\ FXPXODWLYHGRVHPJGXUDWLRQRQH[SRVXUHGD\V
• 5HODWLYHGRVHLQWHQVLW\ DFWXDOGRVHPJSODQQHGGRVHPJ
• 'RVHUHGXFWLRQLVGHILQHGDVDFKDQJHWRDQRQ]HURGRVHOHYHOORZHUWKDQWKDWSODQQHGLQ
WKHSURWRFRO$FKDQJHIURPDOHVVWKDQSODQQHGQRQ]HURGRVHOHYHOWRDQRWKHUOHVVWKDQ
SODQQHGQRQ]HURGRVHOHYHOZLOOEHFRQVLGHUHGDVDQHZGRVHUHGXFWLRQ
• 'RVHGHOD\LVGHILQHGDVDFKDQJHWRGUXJLQWHUUXSWHGLH³´GRVHOHYHO

 
(QGSRLQW(YDOXDWLRQ
 
3ULPDU\(QGSRLQW$QDO\VHV
Population: DLT Analysis Set 
7KHSULPDU\REMHFWLYHRIWKLVVWXG\LVWRLQYHVWLJDWHWKHLQFLGHQFHRIVXEMHFWVH[SHULHQFLQJDWOHDVW
'/7ZLWKLQWKHILUVWWUHDWPHQWF\FOHLHGD\VDIWHUILUVWGRVH3OHDVHUHIHUVHFWLRQIRU
WKHGHILQLWLRQRI'/77KHSULPDU\HQGSRLQWLVWDNHQIURPWKH³$GYHUVH(YHQWV'HWDLOV´IRUPRQ
WKHH&5)DQGLVUHFRUGHGDV³,VWKLVDGYHUVHHYHQWDGRVHOLPLWLQJWR[LFLW\"´
,QDGGLWLRQWRWKH'/7HQGSRLQWWKHLQFLGHQFHDQGW\SHRIRWKHU$(VZLOODOVREHDVVHVVHG7KHVH
YDULDEOHVDUHDOVRWDNHQIURPWKH³$GYHUVH(YHQWV'HWDLOV´IRUP
1RLPSXWDWLRQIRUPLVVLQJGDWDZLOOEHSHUIRUPHGIRUWKH'/7YDULDEOH
7KHIROORZLQJZLOOEHSURYLGHGIRU'/7VGXULQJF\FOHLHILUVWGD\VIRUHDFKGRVHOHYHODQG
RYHUDOO
• ,QFLGHQFHVRI'/7V


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





• /LVWLQJRI'/7V
,QFLGHQFHDQGW\SHRIRWKHU$(VZLOOEHVSHFLILHGLQ6HFWLRQ
 
6HFRQGDU\(QGSRLQW$QDO\VHV
Population: Safety Analysis Set 
7XPRU DVVHVVPHQW ZLOO EH SHUIRUPHG DFFRUGLQJ WR WKH 5HVSRQVH (YDOXDWLRQ &ULWHULD LQ 6ROLG
7XPRUV5(&,67YHUVLRQ7KHEDVHOLQHWXPRUDVVHVVPHQWLVVFKHGXOHGWREHSHUIRUPHGGXULQJ
WKH VFUHHQLQJ SHULRG 7XPRU UHVSRQVH HYDOXDWLRQV ZLOO EH WKHQ EH DVVHVVHG E\ FRPSXWHG
WRPRJUDSK\&7RUPDJQHWLFUHVRQDQFHLPDJLQJ05,DQGRWKHUPRGDOLWLHVDWWKHHQGRIHYHU\
F\FOHV&\FOHVDQGHYHU\F\FOHVWKHUHDIWHUXQWLO3'
7XPRU DVVHVVPHQWV ZLOO EH SHUIRUPHG DW (27 IRU VXEMHFWV ZKRVH ODVW WXPRU DVVHVVPHQW ZDV
SHUIRUPHGıZHHNVEHIRUH&\FOHDQGıZHHNVDIWHUZDUGVSULRUWRWKLVYLVLWDQGKDVQR
UDGLRORJLFDO3'LQSUHYLRXVYLVLWV
7KHVHFRQGDU\HQGSRLQWDQDO\VHVDVVRFLDWHGWRVDIHW\DUHOLVWHGLQVHFWLRQ
6XPPDU\VWDWLVWLFVZLOOEHSUHVHQWHGIRUDOOSDUDPHWHUVOLVWHGEHORZIRUWKH6$)VHW
 
7XPRUUHVSRQVH
7XPRUUHVSRQVHDVPHDVXUHGE\REMHFWLYHUHVSRQVH25DQGGLVHDVHFRQWUROEDVHGRQ5(&,67
9HUVLRQ25LVGHILQHGDV&5RU35DVWKHEHVWRYHUDOOUHVSRQVHDFFRUGLQJWRORFDOUDGLRORJLFDO
DVVHVVPHQWV IURPWKH ILUVWDGPLQLVWUDWLRQRIWKHWULDOWUHDWPHQWWRWKH ILUVWREVHUYDWLRQRI3'
5HVSRQVHV GR QRW UHTXLUH FRQILUPDWLRQ DFFRUGLQJ WR 5(&,67 9HUVLRQ  GLVHDVH FRQWURO LV
GHILQHGDV&535RU6'DVWKHEHVWRYHUDOOUHVSRQVHDFFRUGLQJWRORFDOUDGLRORJLFDODVVHVVPHQWV
IURPWKHGDWHRIWKHILUVWDGPLQLVWUDWLRQRIWKHWULDOWUHDWPHQWWRWKHILUVWREVHUYDWLRQRI3',QWKH
FDVHRI6'PHDVXUHPHQWVPXVWKDYHPHWWKH6'FULWHULDDWOHDVWRQFHDIWHUHQWU\DWDPLQLPXP
LQWHUYDORIGD\VDIWHUWKHILUVWDGPLQLVWUDWLRQRIWKHWULDOWUHDWPHQW
,QDGGLWLRQWRDVXPPDU\RIEHVWRYHUDOOUHVSRQVHE\GRVHOHYHOIRUDOOVXEMHFWVVXPPDULHVZLOOEH
SURYLGHGE\WKHIROORZLQJEDVHOLQHELRPDUNHUV
• F0HWVFRUH
• 0HDQ*HQH&RS\1XPEHU! 
• F0HW&(3FRS\QXPEHUUDWLR! 
• ),6+6WDWXV),6+HLWKHU0HDQ*HQH&RS\1XPEHU! RUF0HW&(3FRS\QXPEHU
UDWLR! ),6+
 
2WKHU(QGSRLQW$QDO\VHV
Population: Safety Analysis Set 


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 
'XUDWLRQRI5HVSRQVH
7KHGXUDWLRQRIRYHUDOOUHVSRQVHLQPRQWKVLQVXEMHFWVZLWKD&5RU35LVGHILQHGDVWKHWLPHIURP
ILUVWDVVHVVPHQWRI&535WRWKHILUVWWLPHGLVHDVHSURJUHVVLRQRUGHDWKLVGRFXPHQWHG,IDVXEMHFW
KDV QRW SURJUHVVHG RU GLHG DWWKHWLPH RI DQDO\VLV WKH GXUDWLRQ RIREMHFWLYH UHVSRQVH ZLOO EH
FHQVRUHGRQWKHGDWHRIODVWGLVHDVHDVVHVVPHQW
7KHGXUDWLRQRIVWDEOHGLVHDVHLQPRQWKVLVGHILQHGDVWKHWLPHIURPWKH ILUVWGRVHWRWKHILUVW
RFFXUUHQFHRI3'RUGHDWK,IDVXEMHFWKDVQRWSURJUHVVHGRUGLHGDWWKHWLPHRIDQDO\VLVWKH
GXUDWLRQRI6'ZLOOEHFHQVRUHGRQWKHGDWHRIODVWGLVHDVHDVVHVVPHQW
7KHIROORZLQJVXPPDUL]HVZLOOEHUHSRUWHGLQWKLVVWXG\IRU6$)VHW
• 'XUDWLRQRIVWDEOHGLVHDVHZLWKRUZLWKRXWFHQVRULQJLQFOXGHG
• 'XUDWLRQRIRYHUDOOUHVSRQVHZLWKRUZLWKRXWFHQVRULQJLQFOXGHG
• 7KHQXPEHURIFHQVRUHGVXEMHFWV
7KHWLPHDQGGXUDWLRQRIUHVSRQVHSHUVXEMHFWZLOOEHGLVSOD\HGLQDVZLPPHUJUDSKLQVXEMHFWV
ZLWK&535)ODJVIRUF0HWVWDWXVDQGLPPHGLDWHSULRU(*)57.,WKHUDS\ZLOOEHSURYLGHG
 
7DUJHW/HVLRQ'LDPHWHU
7KHFKDQJHIURPEDVHOLQHLQWDUJHWOHVLRQGLDPHWHUZLOOEHVXPPDUL]HGXVLQJGHVFULSWLYHVWDWLVWLFV
7KHVXPRIWKHGLDPHWHUVZLOOEHXVHGIRUDOOWDUJHWOHVLRQVPHDVXUHGDWHDFKHYDOXDWLRQ 7KH
DEVROXWHFKDQJHIURPEDVHOLQHZLOODOVREHVXPPDUL]HG
7KHLQGLYLGXDOPD[LPDOSHUFHQWDJHUHGXFWLRQLQVXPRIWKHGLDPHWHUVUHODWLYHWREDVHOLQHZLOOEH
SUHVHQWHGRYHUDOOXVLQJD:DWHUIDOOSORWZKLFKZLOOLQFOXGHIODJVIRUF0HWVWDWXVDQGLPPHGLDWH
SULRU(*)57.,WKHUDS\
7KH SHUFHQW FKDQJH IURP EDVHOLQH RI VXP RI GLDPHWHUV LQ WDUJHW OHVLRQV DV ZHOO DV WKH ILUVW
SURJUHVVLYHGLVHDVHZLWKWKHW\SHRIWKHUDWLRQDOOHVLRQWDUJHWQRQWDUJHWQHZZLOOEHGLVSOD\HG
DJDLQVWWLPHSRLQWZHHNVLQDOLQHSORW7KHWLPHSRLQWRIDWXPRUDVVHVVPHQWLVGHILQHGDVWKH
HDUOLHVWVFDQGDWHRIWKHUHVSHFWLYHYLVLW7KHEDVHOLQHSHUFHQWFKDQJHLVFRQVLGHUHG³´RQGD\
)ODJVIRUF0HWVWDWXVDQGLPPHGLDWHSULRU(*)57.,WKHUDS\ZLOOEHSURYLGHG
 
3KDUPDFRNLQHWLFV
Population: PK Analysis Set 
7HSRWLQLEDQGPHWDEROLWH06&$DQG06&$FRQFHQWUDWLRQVLQSODVPDZLOOEH
OLVWHGDQGSUHVHQWHGLQWDEOHVDQGGHVFULSWLYHO\VXPPDUL]HGE\GRVHOHYHOGD\DQGVFKHGXOHGWLPH
SRLQW*HILWLQLEFRQFHQWUDWLRQVLQSODVPDZLOOEHOLVWHGDQGSUHVHQWHGLQWDEOHVDQGGHVFULSWLYHO\
VXPPDUL]HGE\ GD\DQG VFKHGXOHG WLPHSRLQW'HVFULSWLYHVWDWLVWLFVZLOO LQFOXGH 1DULWKPHWLF
PHDQVWDQGDUGGHYLDWLRQVWDQGDUGHUURURIWKHPHDQ6(0PHGLDQPLQLPXPPD[LPXPDQG
FRHIILFLHQWRIYDULDWLRQ&9)RUGHVFULSWLYHVWDWLVWLFVRIFRQFHQWUDWLRQGDWDYDOXHVEHORZWKH
ORZHU OLPLW RI TXDQWLILFDWLRQ //24 ZLOO EH DVVLJQHG YDOXHV DV GHILQHG LQ 6HFWLRQ 
'HVFULSWLYHVWDWLVWLFVRI3.SDUDPHWHUVZLOODGGLWLRQDOO\VKRZWKHJHRPHWULFPHDQ*HR0HDQWKH


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





JHRPHWULF&9SHUFHQWDJH*HR&9DQGWKHFRQILGHQFHLQWHUYDO&,IRUWKHJHRPHWULF
PHDQ
,QGLYLGXDOSODVPDFRQFHQWUDWLRQWLPHSURILOHVOLQHDUDQGVHPLORJDULWKPLFVFDOHVRIWHSRWLQLEDQG
LWVPHWDEROLWHVZLOOEHSORWWHGE\GRVHOHYHODQGGD\WKHVHSURILOHVLHDOOWKUHHDQDO\WHVZLOOEH
RYHUODLGLQRQHSORWSHUVXEMHFW,QGLYLGXDOSODVPDFRQFHQWUDWLRQWLPHSURILOHVOLQHDUDQGVHPL
ORJDULWKPLFVFDOHVRIJHILWLQLEZLOOEHSORWWHGE\GD\WKHVHSURILOHVLHERWKGD\VZLOOEHRYHUODLG
LQRQHSORWSHUVXEMHFW6SDJKHWWLSORWVRYHUOD\LQJDOOVXEMHFWV¶FRQFHQWUDWLRQWLPHSURILOHVOLQHDU
DQGVHPLORJDULWKPLFVFDOHVZLOOEHSORWWHGE\GRVHOHYHODQGGD\IRUHDFKRIWKHIRXUDQDO\WHV
VHSDUDWHO\ LH WHSRWLQLE DQG LWV PHWDEROLWHV DQG JHILWLQLE 0HDQ SODVPD FRQFHQWUDWLRQV RI
WHSRWLQLEDQGPHWDEROLWHV06&$DQG06&$RYHUODLGZLOODOVREHSORWWHGE\
GRVHOHYHODQGGD\RQOLQHDUVWDQGDUGGHYLDWLRQDQGVHPLORJDULWKPLFVFDOHVXVLQJVFKHGXOHG
WLPHSRLQWV0HDQFRQFHQWUDWLRQWLPHSURILOHVVHSDUDWHO\E\DQDO\WHDQGGRVHOHYHOZLOODOVREH
GLVSOD\HG IRU HDFK RI WKH IRXU DQDO\WHV LH WHSRWLQLE PHWDEROLWHV >06&$ DQG
06&$@DQGJHILWLQLERYHUOD\LQJERWK'D\DQG'D\LQRQHSORW
$WWKHGRVHOHYHOZKLFKLQFOXGHVWKHPDLQODQG&KLQHVHVXEJURXSGDWDZLOOEHVXPPDUL]HGIRU
&KLQHVH VXEMHFWV DORQH QRQ&KLQHVH VXEMHFWV DORQH DQG &KLQHVH DQG QRQ&KLQHVH VXEMHFWV
FRPELQHGLQDOOGHVFULSWLYHVXPPDU\WDEOHVDQGSORWVGHVFULEHGDERYH
$OLVWLQJRI3.EORRGVDPSOHFROOHFWLRQWLPHVE\LQGLYLGXDODVZHOODVGHULYHGVDPSOLQJGHYLDWLRQV
ZLOOEHSURYLGHG
3.SURILOHVRIWHSRWLQLEDQG LWVDFWLYHPHWDEROLWHV 06&$ 06&$IURPVWXG\
(05SKDVH,ESDUWZLOOEHDQDO\]HGMRLQWO\ZLWKGDWDIURPVWXGLHV(05
DQGE\DQRQOLQHDUPL[HGHIIHFWDSSURDFK7KHSODVPDFRQFHQWUDWLRQWLPH
SURILOHVDIWHUVLQJOHRUPXOWLSOHGRVHDGPLQLVWUDWLRQRIWHSRWLQLELQKHDOWK\YROXQWHHUVDQGVROLGWXPRU
SDWLHQWVZLOOEHHYDOXDWHGZLWKFRPSDUWPHQWPRGHOV&RYDULDWHVRIGHPRJUDSKLFVODEYDOXHVGLVHDVH
VWDWXVDQGFRPHGLFDWLRQZLOOEHWHVWHGLQRUGHUWRLGHQWLI\DQ\LQWULQVLFDQGH[WULQVLFIDFWRUVWKDWDUH
SUHGLFWLYHRI3.LQWHULQGLYLGXDOYDULDELOLW\0RUHGHWDLOVDUHJLYHQLQDVHSDUDWH'DWD$QDO\VLV3ODQ
IRU3RROHG3RSXODWLRQ3KDUPDFRNLQHWLF$QDO\VLV7KHUHVXOWVZLOOEHUHSRUWHGVHSDUDWHO\
 
3KDUPDFRNLQHWLF(QGSRLQWV
7KHIROORZLQJSKDUPDFRNLQHWLFHQGSRLQWVZLOOEHDQDO\]HG
• 3ODVPD3.SDUDPHWHUVRIWHSRWLQLEDQGPHWDEROLWHV06&$DQG06&$
DQGSODVPD3.SDUDPHWHUVRIJHILWLQLEWKHGHILQLWLRQRIWKHSDUDPHWHUVDQGWKHSODQQHG
DQDO\VLVLVGHVFULEHGLQWKHVXEVHTXHQWVHFWLRQV
 
(VWLPDWLRQRI,QGLYLGXDO3KDUPDFRNLQHWLF3DUDPHWHUV
3KDUPDFRNLQHWLFSDUDPHWHUVZLOOEHFDOFXODWHGE\WKH
3.JURXSXVLQJVWDQGDUGQRQ
FRPSDUWPHQWDOPHWKRGVDFWXDOHODSVHGVDPSOLQJWLPHVDQGWKHDFWXDODGPLQLVWHUHGGRVH7KH3.
SDUDPHWHUV OLVWHG EHORZ ZLOO EH FDOFXODWHG IRU WHSRWLQLE DQG PHWDEROLWHV 06&$ DQG
06&$DQGIRUJHILWLQLELQSODVPDZKHQDSSOLFDEOHEDVHGRQIUHTXHQW3.VDPSOLQJDV
DSSOLHGLQSKDVH,E3.SDUDPHWHUVZLOOEHVXPPDUL]HGE\3.DQDO\WHGRVHOHYHODQGGD\$WWKH
PPD


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





GRVHOHYHOUHFHLYHGE\WKH&KLQHVHVXEJURXSGDWDZLOOEHVXPPDUL]HGIRU&KLQHVHVXEMHFWVDORQH
QRQ&KLQHVHVXEMHFWVDORQHDQG&KLQHVHDQGQRQ&KLQHVHVXEMHFWVFRPELQHG

&PD[
0D[LPXPREVHUYHGFRQFHQWUDWLRQ
WPD[
7LPHRI&PD[
$8&W
$UHDXQGHUWKHFRQFHQWUDWLRQWLPHFXUYHIURPWLPH]HURWR
WKHODVWTXDQWLILDEOHFRQFHQWUDWLRQ
WODJ
WODJ LV WKH WLPH SULRU WR WKH ILUVW TXDQWLILDEOH QRQ]HUR
FRQFHQWUDWLRQIRU&\FOH'D\RQO\
&DY
7KH DYHUDJH FRQFHQWUDWLRQ DW VWHDG\ VWDWH FDOFXODWHG RQ
&\FOH'D\RQO\&DY $8&ĲĲ$8&WLIQHFHVVDU\
&PLQ
7KH PLQLPXP REVHUYHG FRQFHQWUDWLRQ GXULQJ D FRPSOHWH
GRVLQJLQWHUYDOFDOFXODWHGRQ&\FOH'D\RQO\
$8&Ĳ
7KHDUHDXQGHUWKHFRQFHQWUDWLRQWLPHFXUYHRYHUWKHGRVLQJ
LQWHUYDOIURP7 KSUHGRVHWR7 ĲK&DOFXODWHGXVLQJ
WKHPL[HGORJOLQHDUWUDSH]RLGDOUXOHOLQHDUXSORJGRZQ
)RU&\FOH'D\$8&ĲZLOOEHFDOFXODWHGDVDSDUWLDODUHD
ZLWKLQ WKH GHILQHG WLPH UDQJH )RU &\FOH 'D\ $8&τ
ZLOOEHFDOFXODWHGDWVWHDG\VWDWHIURPWKHSUHGRVHWLPHSRLQW
WRWKHGRVLQJLQWHUYDOWLPH$8&τZLOOEHFDOFXODWHGEDVHGRQ
WKHREVHUYHGFRQFHQWUDWLRQDWWKHDFWXDOREVHUYDWLRQWLPHDV
ORQJDVDFWXDOWLPHGHYLDWLRQLVOHVVWKDQDWτ,IDFWXDO
WLPHGHYLDWLRQLVHTXDOWRRUJUHDWHUWKDQ$8&τZLOOEH
UHSRUWHGDVPLVVLQJ
&/)
$SSDUHQW V\VWHPLF FOHDUDQFH FDOFXODWHG IRU WHSRWLQLE DQG
JHILWLQLERQO\DV'RVH$8&Ĳ&DOFXODWHGRQ&\FOH'D\
RQO\)RUWHSRWLQLE'RVHLVWKHWHSRWLQLEIUHHEDVHGRVHLH
DGMXVWHG IRU VDOW IRUP 7KH WHSRWLQLE IUHH EDVH GRVH LV
FDOFXODWHGDV$FWXDOGRVH0:IUHHEDVH0:VDOWZKHUH
0:IUHHEDVHLVWKHPROHFXODUZHLJKW0:RIIUHHEDVH
LHDQG0:VDOWLVWKH0:RIWKHK\GURFKORULGH
K\GUDWH VDOW LH  )RU JHILWLQLE WKH GRVH
DGPLQLVWHUHGLVWKHIUHHEDVHIRUPVRQRGRVHDGMXVWPHQWLV
UHTXLUHG
$8&W'RVH
'RVH1RUPDOL]HG $8&W FDOFXODWHG IRU WHSRWLQLE RQO\
1RUPDOL]HGXVLQJDFWXDOGRVHLHXQDGMXVWHGIRUVDOWIRUP


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





$8&Ĳ'RVH
'RVH1RUPDOL]HG $8&Ĳ FDOFXODWHG IRU WHSRWLQLE RQO\
1RUPDOL]HGXVLQJDFWXDOGRVHLHXQDGMXVWHGIRUVDOWIRUP
&PD['RVH
'RVH1RUPDOL]HG &PD[ FDOFXODWHG IRU WHSRWLQLE RQO\
1RUPDOL]HGXVLQJDFWXDOGRVHLHXQDGMXVWHGIRUVDOWIRUP
37)
7KHSHDNWURXJKIOXFWXDWLRQUDWLRZLWKLQDFRPSOHWHGRVLQJ
LQWHUYDODWVWHDG\VWDWHLQFDOFXODWHGRQ&\FOH'D\
RQO\37) &PD[&PLQ&DY

3RWHQWLDOGUXJDFFXPXODWLRQIRUWHSRWLQLEDQGLWVPHWDEROLWHVDQGIRUJHILWLQLEZLOOEHHYDOXDWHGE\
PHDQVRILQGLYLGXDODFFXPXODWLRQUDWLRVIRU$8&ĲDQG&PD[>5DFF$8&DQG5DFF&PD[UHVSHFWLYHO\@
WKDWZLOOEHFDOFXODWHGE\GLYLGLQJWKHYDOXHVREWDLQHGDIWHUPXOWLSOHGRVHLHRQ&\FOH'D\
E\WKHYDOXHVREWDLQHGDIWHUVLQJOHGRVHLH&\FOH'D\DQGVXPPDUL]HGGHVFULSWLYHO\IRUHDFK
GRVHOHYHO

,QGLYLGXDOPHWDEROLWHWRSDUHQWUDWLRVIRU$8&WDQG&PD[>05$8&WDQG05&PD[UHVSHFWLYHO\@
ZLOO EH FDOFXODWHG IRU WHSRWLQLE DQG LWV PHWDEROLWHV E\ GLYLGLQJ WKH YDOXH REWDLQHG IRU HDFK
PHWDEROLWH E\ WKH YDOXH REWDLQHG IRU WKH SDUHQW LH 06&$WHSRWLQLE DQG
06&$WHSRWLQLE DIWHU FRUUHFWLRQ IRU 0: GLIIHUHQFHV EHWZHHQ SDUHQW DQG PHWDEROLWH
0: RI WHSRWLQLE IUHH EDVH LV  0: RI 06&$ LV  DQG 0: RI
06&$LVVHSDUDWHO\IRUVLQJOHGRVHLH&\FOH'D\DQGPXOWLSOHGRVHLH
&\FOH'D\DQGVXPPDUL]HGGHVFULSWLYHO\IRUHDFKGRVHOHYHODQGGD\
7KH GRVLQJ DQG VDPSOLQJ VFKHPH LQ WKLV VWXG\ GRHV QRW DOORZ WKH UHOLDEOH HVWLPDWLRQ RI Ȝ]
FRQVLGHULQJ WKH DSSDUHQW WHUPLQDO KDOIOLIH RI WHSRWLQLE DQG LWV PHWDEROLWHV DQG JHILWLQLE
7KHUHIRUHDOO3.SDUDPHWHUVGHSHQGHQWRQȜ]ZLOOQRWEHGHWHUPLQHGLH$8&䌲$8&H[WUD
&/)VLQJOHGRVHW9])DQG9VV)
2WKHUSDUDPHWHUVPD\EHDGGHGDVDSSURSULDWH
7KHFDOFXODWLRQRIWKH$8&VZLOOEHSHUIRUPHGXVLQJWKHPL[HGORJOLQHDUWUDSH]RLGDOPHWKRG
OLQHDU XS ORJ GRZQ 7KH DFWXDO XQURXQGHG WLPH RI EORRG VDPSOLQJ ZLOO EH XVHG IRU 3.
HYDOXDWLRQ,QFDVHVZKHUHWKHDFWXDOVDPSOLQJWLPHLVPLVVLQJFDOFXODWLRQVZLOOEHSHUIRUPHG
XVLQJWKHVFKHGXOHGWLPH2WKHUZLVHWKHUHZLOOEHQRIXUWKHULPSXWDWLRQRIPLVVLQJGDWD7KH
SUHGRVH VDPSOHV ZLOO EH FRQVLGHUHG DV LI WKH\ KDG EHHQ WDNHQ VLPXOWDQHRXVO\ ZLWK WKH
DGPLQLVWUDWLRQ3ODVPDFRQFHQWUDWLRQVEHORZ//24EHIRUHWKHODVWTXDQWLILDEOHGDWDSRLQWZLOOEH
WDNHQDV]HURIRUFDOFXODWLQJWKH$8&LHHPEHGGHG%/4YDOXHVZLOOEHVHWWR]HUR3ODVPD
FRQFHQWUDWLRQVEHORZ//24DIWHUWKHODVWTXDQWLILDEOHGDWDSRLQWZLOOEHVHWWRµ]HUR¶
3. SDUDPHWHUV ZLOO EH HYDOXDWHG DQG OLVWHG IRU DOO VXEMHFWV ZKR SURYLGH VXIILFLHQW
FRQFHQWUDWLRQWLPHGDWD)RUPDOVWDWLVWLFDOK\SRWKHVHVKDYHQRWEHHQSODQQHGIRU3.SDUDPHWHUV
$Q\VWDWLVWLFDOWHVWVWKDWPLJKWEHSHUIRUPHGZLOOEHFRQVLGHUHGH[SORUDWRU\
)RUWHSRWLQLEDQGLWVPHWDEROLWHVGRVHSURSRUWLRQDOLW\ZLOOEHSUHVHQWHGJUDSKLFDOO\E\GD\DV
IROORZV
 
%R[SORWVIRUGRVHQRUPDOL]HG3.SDUDPHWHUV$8&Ĳ'RVHDQG&PD['RVHE\GRVHOHYHO


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 
6FDWWHUSORWVRQLQGLYLGXDO$8&ĲDQG&PD[YHUVXV'RVHRQDOLQHDUVFDOH
3.3DUDPHWHUVDUHWREHURXQGHGIRUUHSRUWLQJDVDSSURSULDWH,QH[SRUWGDWDVHWV3.SDUDPHWHUV
ZLOOEHSURYLGHGZLWKIXOOSUHFLVLRQDQGZLOOQRWEHURXQGHG
7KH3KRHQL[:LQ1RQOLQ1&$&RUH2XWSXWZLOOEHSURYLGHGLQDVHSDUDWHOLVWLQJ
 
2Q7UHDWPHQW%LRPDUNHUVLQ7XPRU7LVVXH
2QWUHDWPHQWWXPRUELRSV\LVVFKHGXOHGDWDQ\WLPHEHWZHHQ&\FOH'D\DQGWKHEHJLQQLQJ
RI&\FOH,IDWXPRUVKRZVSURJUHVVLRQDIWHULQLWLDOUHVSRQVHWR7HSRWLELEDILQDOELRSV\LVKLJKO\
GHVLUDEOHZKHQSURJUHVVLRQLVGLDJQRVHG
'XHWRRQWUHDWPHQWELRSVLHVDUHRSWLRQDODQGSUREDEO\QRRQWUHDWPHQWVDPSOHZDVSURYLGHGQR
DQDO\VLVZLOOEHDSSOLHGIRURQWUHDWPHQWELRPDUNHUVLQWXPRUWLVVXH
,IRQWUHDWPHQWUHVXOWLVDYDLODEOHLWZLOOEHSUHVHQWHGLQOLVWLQJRQO\

 
6DIHW\(YDOXDWLRQ
Population: Safety Analysis Set 
7KHVXEVHFWLRQVLQWKLVVHFWLRQLQFOXGHVSHFLILFDWLRQVIRUVXPPDUL]LQJVDIHW\HQGSRLQWVWKDWDUH
FRPPRQDFURVVFOLQLFDOWULDOVVXFKDVDGYHUVHHYHQWVODERUDWRU\WHVWVDQGYLWDOVLJQV
7KHSULPDU\HQGSRLQW'/7LVDVDIHW\HQGSRLQWUHIHUWR6HFWLRQIRUIXUWKHULQIRUPDWLRQ
6DIHW\ DQDO\VHV ZLOO EH SHUIRUPHG DFFRUGLQJ WR WKH DVWUHDWHG SULQFLSOH 6DIHW\ GDWD ZLOO EH
GHVFULSWLYHO\DQDO\]HGRQWKH6DIHW\$QDO\VLV6HW
 
$GYHUVH(YHQWV
$(VZLOO EHFRGHGDFFRUGLQJWRWKH0HGLFDO'LFWLRQDU\ IRU5HJXODWRU\ $FWLYLWLHV0HG'5$
9HUVLRQDQGUHSRUWHGE\V\VWHPRUJDQFODVV62&DQGSUHIHUUHGWHUP377KHVHYHULW\RI
$(VZLOOEHJUDGHGXVLQJ1&,&7&$(9HUVLRQWR[LFLW\JUDGHV7KHLQYHVWLJDWRUZLOOEH
UHVSRQVLEOHIRUDVVLJQLQJWKH&RPPRQ7R[LFLW\&ULWHULD&7&JUDGHVIRU$(V
7UHDWPHQW HPHUJHQW DGYHUVH HYHQWV 7($(V DUH GHILQHG DV $(V WKDW VWDUWHG RU ZRUVHQHG LQ
VHYHULW\ZLWKLQWKHILUVWGRVLQJGD\RIVWXG\WUHDWPHQWXQWLOGD\VLQFOXVLYHDIWHUWKHODVWGRVH
RIVWXG\WUHDWPHQW $(RFFXUULQJDIWHUWKHILUVWWUHDWPHQWZLOODOZD\V EHFRQVLGHUHGDV7($(
UHJDUGOHVV RI ZKHWKHU LWV RQVHW GDWH EH\RQG WKH  GD\V LI LW LV DVVHVVHG DV GUXJ UHODWHG E\
LQYHVWLJDWRU,QWKHFDVHZKHUHLWLVQRWSRVVLEOHWRGHILQHDQ$(DVEHLQJWUHDWPHQWHPHUJHQWRU
QRWWKH$(ZLOOEHFODVVLILHGDVWUHDWPHQWHPHUJHQWDVWKHPRVWFRQVHUYDWLYHDSSURDFK
7KHPHFKDQLVPVIRUKDQGOLQJLQFRPSOHWH$(UHODWHGGDWHVDUHGHVFULEHGLQ6HFWLRQ


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





,QFLGHQFHUDWHVIUHTXHQFLHVDQGSHUFHQWDJHVRILQGLYLGXDO$(VWKDWLVWKHQXPEHURIVXEMHFWV
H[SHULHQFLQJHYHQWV$(VLQHDFK37RU62&DQGWKHSURSRUWLRQUHODWLYHWRWKHQXPEHURIVXEMHFWV
LQWKH6$)VHWZLOOEHSUHVHQWHG
8QOHVVRWKHUZLVHVWDWHGDGYHUVHHYHQWVZLOOEHSUHVHQWHGE\62&DQG37LQDOSKDEHWLFDORUGHUDQG
DOVREURNHQGRZQIXUWKHUE\PD[LPXPVHYHULW\UHIHUWR6HFWLRQDQGUHODWLRQVKLSUHIHU
6HFWLRQWRVWXG\WUHDWPHQW
$OOOLVWLQJVZLOOLQFOXGHDOO7($(VDQG1RQ7($(V$OODQDO\VHVGHVFULEHGLQ6HFWLRQZLOO
EHEDVHGRQ7($(VLIQRWRWKHUZLVHVSHFLILHG
 
$OO$GYHUVH(YHQWV
7KHIUHTXHQF\WDEOHVLQZKROHWLPHSHULRGDVZHOODVLQFLGHQFHUDWHVRILQGLYLGXDO$(VZLOOEH
SUHSDUHGIRUIROORZV
• 7($(V
• 7HSRWLQLERU*HILWLQLEUHODWHG$(V
• 6HULRXV$(VUHIHUWR6HFWLRQ
• 7HSRWLQLERU*HILWLQLEUHODWHGVHULRXV$(V
• $(6,VUHIHUWR6HFWLRQ
• 7HSRWLQLERU*HILWLQLEUHODWHG$(6,V
• $(VE\1&,&7&$(VHYHULW\JUDGH
• 7HSRWLQLERU*HILWLQLEUHODWHG$(VE\1&,&7&$(VHYHULW\JUDGH
• $(VOHDGLQJWR7HSRWLQLERU*HILWLQLESHUPDQHQWWHPSRUDU\WHUPLQDWLRQUHIHUWR6HFWLRQ

• $(VOHDGLQJWRGHDWK
• 7HSRWLQLERU*HILWLQLEUHODWHGGHDWK
)XUWKHUPRUHWKHIROORZLQJRYHUDOOIUHTXHQF\WDEOHVZLOOEHSURYLGHG
• 7($(VE\VHYHULW\
• 5HODWLRQVKLSWR7HSRWLQLERU*HILWLQLE
• $FWLRQVWDNHQZLWK7HSRWLQLERU*HILWLQLE
• 2XWFRPHVRI7($(
 
6HYHULW\
6HYHULW\LVUHVSRQVHIRUWKHLWHP³7R[LFLW\JUDGH´RQWKH³$GYHUVH(YHQWV'HWDLOV´IRUPRIWKH
H&5)


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





,IDVXEMHFWUHSRUWVD7($(PRUHWKDQRQFHZLWKLQWKDW62&37WKH$(ZLWKWKHZRUVWFDVH
VHYHULW\ZLOOEHXVHGLQWKHFRUUHVSRQGLQJVHYHULW\VXPPDULHV
 
5HODWLRQVKLSWR6WXG\7UHDWPHQW
5HODWLRQVKLSWR7HSRWLQLERU*HILWLQLEZLOOEHLGHQWLILHGDVWKHUHVSRQVHWRWKHLWHP³5HODWLRQVKLS
ZLWK06&-´RU³5HODWLRQVKLSZLWK*HILWLQLE´RQWKH³$GYHUVH(YHQWV'HWDLOV´IRUPRI
WKHH&5)
 
$GYHUVH(YHQWV/HDGLQJWR7UHDWPHQW'LVFRQWLQXDWLRQ
7($(VOHDGLQJWRSHUPDQHQWGLVFRQWLQXDWLRQRI7HSRWLQLERU*HILWLQLEZLOOEHLGHQWLILHGDVWKRVH
UHFRUGVZLWKDUHVSRQVHRI³'UXJ:LWKGUDZDO´WRWKHLWHP³$FWLRQVWDNHQZLWK06&-´
RU³$FWLRQVWDNHQZLWK*HILWLQLE´RQWKH³$GYHUVH(YHQWV'HWDLOV´IRUPRIWKHH&5)  
7($(VOHDGLQJWRWHPSRUDU\GLVFRQWLQXDWLRQRI7HSRWLQLERU*HILWLQLEZLOOEHLGHQWLILHGDVWKRVH
UHFRUGVZLWKDUHVSRQVHRI³'UXJLQWHUUXSWHG´WRWKHLWHP³$FWLRQVWDNHQZLWK06&-´
RU³$FWLRQVWDNHQZLWK*HILWLQLE´RQWKH³$GYHUVH(YHQWV'HWDLOV´IRUPRIWKHH&5) 
 
'HDWKV2WKHU6HULRXV$GYHUVH(YHQWVDQG2WKHU6LJQLILFDQW
$GYHUVH(YHQWV
 
'HDWKV
$OOGHDWKVDQGGHDWKVZLWKLQGD\VDIWHUODVWGRVHRIVWXG\WUHDWPHQWDVZHOODVUHDVRQVIRUGHDWK
ZLOOEHWDEXODWHGEDVHGRQWKHLQIRUPDWLRQIURPWKH³'HDWK´IRUPRIWKHH&5)
6XPPDULHVZLOOEHSUHVHQWHGIRU
• 1XPEHURIGHDWKV
• 1XPEHURIGHDWKVZLWKLQGD\VDIWHUODVWGRVHRIWUHDWPHQW
• $XWRSV\3HUIRUPHG<HV1RRU8QNQRZQ
• 3ULPDU\UHDVRQIRUGHDWK'LVHDVHSURJUHVVLRQV$GYHUVHHYHQWUHODWHGWRVWXG\WUHDWPHQW
$GYHUVHHYHQWQRWUHODWHGWRVWXG\WUHDWPHQW2WKHURU8QNQRZQ
 
6HULRXV$GYHUVH(YHQWV
6HULRXVDGYHUVHHYHQWV6$(VDUHWKRVHHYHQWVZLWKDUHVSRQVHRI³<HV´IRUWKHLWHP³6HULRXV
$GYHUVH(YHQW´RQWKH³$GYHUVH(YHQWV'HWDLOV´IRUPRIWKHH&5)
 
$GYHUVH(YHQWVRI6SHFLDO,QWHUHVW
$GYHUVH (YHQWV RI 6SHFLDO ,QWHUHVW $(6, LV GHILQHG DV $(V RI DV\PSWRPDWLF OLSDVH DQGRU
DP\ODVHHOHYDWLRQVRI*UDGHı
/LVWLQJRIVXEMHFWVH[SHULHQFHGDQ\JUDGHHOHYDWLRQRIOLSDVHDP\ODVHZLOOEHSURYLGHG


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 
&OLQLFDO/DERUDWRU\(YDOXDWLRQ
8ULQDO\VLVDVVHVVPHQWV
'LSVWLFNXULQDO\VLVDVVHVVPHQWVZLOOEHFRQGXFWHGE\VLWHV6LWHVZLOOGHFLGHZKHWKHURUQRWVHQGLQJ
XULQHVDPSOHVWRFHQWUDOODERUDWRU\IRUPLFURVFRSLFH[DPLQDWLRQ
7KHIROORZLQJLQIRUPDWLRQZLOOEHSURYLGHG
• 'LSVWLFNXULQDO\VLVDVVHVVPHQWVRXWFRPHE\YLVLWQRUPDODEQRUPDO
• /LVWRIDEQRUPDOPLFURVFRSLFH[DPLQDWLRQILQGLQJV
%LRFKHPLVWU\KHPDWRORJ\DQGFRDJXODWLRQ
/DERUDWRU\YDOXHVLQFOXGLQJFRUUHVSRQGLQJQRUPDOUDQJHVIURPFHQWUDOODERUDWRU\ZLOOEHXVHG
IRUVXPPDU\VWDWLVWLFVDQGVKLIWWDEOHV2QO\VXEMHFWVZLWKSRVWEDVHOLQHODERUDWRU\YDOXHVZLOOEH
LQFOXGHGLQWKHVHDQDO\VHV'DWDZLOOEHSURYLGHGE\WKHFHQWUDOODERUDWRU\XVLQJWKH,QWHUQDWLRQDO
6\VWHPRI8QLWV6,DQGDOOSUHVHQWDWLRQVZLOOXVH6,XQLWV
4XDQWLWDWLYH ODERUDWRU\ PHDVXUHPHQWV UHSRUWHG DV ³ ;´ LH EHORZ WKH ORZHU OLPLW RI
TXDQWLILFDWLRQ//24RU³!;´LHDERYHWKHXSSHUOLPLWRITXDQWLILFDWLRQ8/24ZLOOEH
FRQYHUWHGWR;IRUWKHSXUSRVHRITXDQWLWDWLYHVXPPDULHVEXWZLOOEHSUHVHQWHGDVUHFRUGHGLHDV
³;´RU³!;´LQWKHOLVWLQJV
/DERUDWRU\UHVXOWVZLOOEHFODVVLILHGDFFRUGLQJWRWKH1&,&7&9HUVLRQ3OHDVHUHIHUWR
$SSHQGL[IRUJUDGDEOHSDUDPHWHUV$GGLWLRQDOODERUDWRU\UHVXOWVWKDWDUHQRWSDUWRI1&,&7&
ZLOOEHSUHVHQWHGDFFRUGLQJWRWKHFDWHJRULHVEHORZQRUPDOOLPLWVZLWKLQQRUPDOOLPLWVDQG
DERYHQRUPDOOLPLWVDFFRUGLQJWRWKHODERUDWRU\QRUPDOUDQJHV)RUGHWDLOVRIWKHUHIHUHQFH
UDQJHVIRUHDFKLQGLYLGXDOODERUDWRU\SDUDPHWHUUHIHUWR$SSHQGL[3DUDPHWHUVWKDWKDYHERWK
//24DQG8/2*ZLOOEHVSOLWLQWRKLJKDQGORZ)RUH[DPSOHJOXFRVHZLOOEHSUHVHQWHGE\
³JOXFRVHKLJK´DQG³JOXFRVHORZ´VHSDUDWHO\
4XDQWLWDWLYHGDWDZLOOEHH[DPLQHGIRUWUHQGVXVLQJGHVFULSWLYHVWDWLVWLFVPHDQ6'PHGLDQ4
4PLQLPXPDQGPD[LPXPRIDFWXDOYDOXHVDQGFKDQJHVIURPEDVHOLQHWRHDFKYLVLWRYHUWLPH
4XDOLWDWLYHGDWDEDVHGRQUHIHUHQFHUDQJHVZLOOEHGHVFULEHGDFFRUGLQJWRWKHFDWHJRULHVLH/RZ
1RUPDO+LJK7KHQXPEHURIVXEMHFWVZLWKFOLQLFDOODERUDWRU\YDOXHVEHORZZLWKLQRUDERYH
QRUPDOUDQJHVDWEDVHOLQHFRPSDUHGWRYDOXHVDWDQ\SRVWEDVHOLQHYLVLWZLOOEHWDEXODWHGIRUHDFK
YLVLWE\WUHDWPHQW6KLIWWDEOHVRIEDVHOLQHYHUVXVWKHZRUVWYDOXHZLOOEHSUHVHQWHG$EQRUPDOLWLHV
FODVVLILHGDFFRUGLQJWR1&,&7&$(WR[LFLW\JUDGLQJYHUVLRQZLOOEHGHVFULEHGXVLQJWKHZRUVW
JUDGH,QFDVHRIPLVVLQJGDWDDWWKHHQGRIWKHWUHDWPHQWSHULRGWKHODVWNQRZQSRVWEDVHOLQHYDOXH
ZLOOEHFDUULHGIRUZDUG
7KHIROORZLQJVXPPDULHVZLOOEHSURYLGHGIRUODERUDWRU\GDWD
• $FWXDODQGFKDQJHIURPEDVHOLQHE\YLVLWIRUTXDQWLWDWLYHPHDVXUHPHQWV
• ,QFLGHQFHRIWKHZRUVWRQWUHDWPHQWYDOXHDFFRUGLQJWRQRUPDOUDQJHFULWHULD


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





• 6KLIWIURPEDVHOLQHWRZRUVWRQWUHDWPHQWYDOXHDFFRUGLQJWRQRUPDOUDQJHFULWHULD
• 6KLIWIURPEDVHOLQHWRKLJKHVW1&,&7&JUDGH
/DERUDWRU\YDOXHVWKDWDUHRXWVLGHWKHQRUPDOUDQJHZLOODOVREHIODJJHGLQWKHGDWDOLVWLQJVDORQJ
ZLWKFRUUHVSRQGLQJQRUPDOUDQJHV$Q\RXWRIUDQJHYDOXHVWKDWDUHLGHQWLILHGE\WKHLQYHVWLJDWRU
DVEHLQJFOLQLFDOO\VLJQLILFDQWZLOOEHVKRZQLQDGDWDOLVWLQJ
 
9LWDO6LJQV
7KHIROORZLQJ9LWDO6LJQVPHDVXUHPHQWVZLOOEHUHSRUWHGIRUWKLVVWXG\
• %RG\7HPSHUDWXUHÛ&
• 3XOVH5DWHESP
• 6\VWROLF%ORRG3UHVVXUH6%3PP+JLQVHDWHGSRVLWLRQ
• 'LDVWROLF%ORRG3UHVVXUH'%3PP+JLQVHDWHGSRVLWLRQ
• 5HVSLUDWRU\5DWHEUHDWKVPLQ
• :HLJKWNJ
7KHIROORZLQJVXPPDULHVZLOOEHSURYLGHGIRUYLWDOVLJQVGDWD
• $FWXDODQGFKDQJHIURPEDVHOLQHE\YLVLWIRUTXDQWLWDWLYHPHDVXUHPHQWV
• :DWHUIDOOSORWIRUPD[LPXPSHUFHQWDJHLQFUHDVHGHFUHDVH
• &DWHJRULFDOFKDQJHIURPEDVHOLQHWRZRUVWFKDQJHIRUYLWDOVLJQVH[FOXGLQJZHLJKWZLOO
EHJURXSHGDVIROORZV
%RG\WHPSHUDWXUHLQFUHDVHIURP
EDVHOLQH
&&&
&! &
°&°&°&≥°&
3XOVHUDWHLQFUHDVHIURPEDVHOLQH
ESPıESP
≤ESP!±ESP!ESP
3XOVHUDWHGHFUHDVHIURPEDVHOLQH
ESPıESP
≤ESP!±ESP!ESP
6%3LQFUHDVHIURPEDVHOLQH
PP+JıPP+J
≤PP+J!±PP+J!PP+J
6%3GHFUHDVHIURPEDVHOLQH
PP+JıPP+J
≤PP+J!±PP+J!PP+J
'%3LQFUHDVHIURPEDVHOLQH
PP+JıPP+J
≤PP+J!±PP+J!PP+J
'%3GHFUHDVHIURPEDVHOLQH
PP+JıPP+J
≤PP+J!±PP+J!PP+J


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





5HVSLUDWLRQUDWHLQFUHDVHIURPEDVHOLQH
ESPıESP
≤ESP!±ESP!ESP
5HVSLUDWLRQUDWHGHFUHDVHIURPEDVHOLQH
ESPıESP
≤ESP!±ESP!ESP
• &DWHJRULFDOFKDQJHVLQERG\ZHLJKWIURPEDVHOLQHWRPHDVXUHPHQWVGXULQJWKHWUHDWPHQW
SKDVHFODVVLILHGDFFRUGLQJWRWKH1&,&7&$(YHUVLRQ
9DULDEOH




:HLJKW
*DLQ
IURP
EDVHOLQH
IURP
EDVHOLQH
IURP
EDVHOLQH
! IURP
EDVHOLQH
:HLJKW
/RVV
IURP
EDVHOLQH
IURP
EDVHOLQH
IURP
EDVHOLQH
! IURP
EDVHOLQH

 
(&*(YDOXDWLRQV
$OO(&*UHDGLQJVZLOOEHUHFRUGHGDVOHDGUHVWLQJ(&*VLQWULSOLFDWHV7KHDYHUDJHRIWKHVH
UHVXOWVZLOOEHXVHGIRULQFOXVLRQLQWKHUHSRUWLQJRIWKLVVWXG\IRUQXPHULFSDUDPHWHUV,IVRPHRI
WKHUHVXOWVDUHPLVVLQJWKHDYHUDJHRIDYDLODEOHUHVXOWVZLOOEHXVHG)RURUGLQDOFDWHJRULFDO(&*
DVVHVVPHQWUHVXOWWKHZRUVWUHVXOWDPRQJWKHUHVXOWVZLOOEHXVHG,IERWKDEQRUPDOZLWKFOLQLFDOO\
VLJQLILFDQWDQGDEQRUPDOZLWKRXWFOLQLFDOO\VLJQLILFDQWDSSHDUHGWKHZRUVWFDVHLVDEQRUPDOZLWK
FOLQLFDOO\VLJQLILFDQW5K\WKPZLOORQO\EHOLVWHG
7KHIROORZLQJ(&*SDUDPHWHUVZLOOEHUHSRUWHGIRUWKLVVWXG\EDVHGRQWKH6$)VHW
• 35,QWHUYDOPVHF
• 456,QWHUYDOPVHF
• 47F%,QWHUYDOPVHF
• 47F),QWHUYDOPVHF
• 55PVHF
• 2YHUDOO DVVHVVPHQW RI (&* 1RUPDO $EQRUPDO QRW FOLQLFDOO\ VLJQLILFDQW $EQRUPDO
FOLQLFDOO\VLJQLILFDQW
6SHFLILFDWLRQVIRUFRPSXWDWLRQ
ܳܶܿܨ (msec) =
ܳܶ (݉ݏ݁ܿ)
ටܴܴ (݉ݏ݁ܿ)/1000
య

7KHIROORZLQJVXPPDULHVZLOOEHSURYLGHGIRU(&*GDWD
• $FWXDODQGFKDQJHIURPEDVHOLQHE\YLVLWIRUTXDQWLWDWLYHPHDVXUHPHQWV
• )UHTXHQF\DQGSHUFHQWDJHVIRUUHVXOWRI(&*E\YLVLW


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





• &DWHJRULFDOVKLIWIURPEDVHOLQHWRZRUVWRQWULDOYDOXHIRU47F)WKHEDVHOLQHDQGWKHZRUVW
RQWULDOYDOXHZLOOEHJURXSHGDVIROORZV
3DUDPHWHU
%DVHOLQHFDWHJRU\
:RUVWRQWULDOYDOXH
47F)

 PV
! PV
! PV
!PV
 PV
! PV
! PV
!PV
• &DWHJRULFDOFKDQJHIURPEDVHOLQHWRZRUVWFKDQJHIRU47F)WKHEDVHOLQHDQGWKHZRUVW
FKDQJHIURPEDVHOLQHYDOXHZLOOEHJURXSHGDVIROORZV
3DUDPHWHU
%DVHOLQHFDWHJRU\
:RUVWFKDQJHIURPEDVHOLQH
47F)

1RUPDOLH PV
$EQRUPDOLH!PV

 PV
! PV
! PV
!PV
• ,QFLGHQFHRI47F)SURORQJDWLRQV
3DUDPHWHU
3URORQJDWLRQV
47F)
!PV
!PV
!PV
$EVROXWH47F)FKDQJH
!PV
!PV 
 
3K\VLFDO([DPLQDWLRQ
$ OLVWLQJ RI VXEMHFWV FRPSOHWLQJ SK\VLFDO H[DPLQDWLRQV UHVXOWV ZLOO EH SUHVHQWHG KRZHYHU
FOLQLFDOO\VLJQLILFDQWDQGDEQRUPDOILQGLQJVZLOOEHUHSRUWHGDV$(V
 
2WKHU6DIHW\$VVHVVPHQWV
7KH (DVWHUQ &RRSHUDWLYH 2QFRORJ\ *URXS (&2* 3HUIRUPDQFH 6WDWXV ZLOO EH VXPPDUL]HG
GHVFULSWLYHO\E\YLVLW
3UHJQDQF\WHVWGDWDZLOORQO\EHOLVWHG
 
%HQHILW5LVN$VVHVVPHQW
1RWDSSOLFDEOHIRUWKLVVWXG\





7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 
5HIHUHQFHV
,&+(*XLGHOLQHV
,&+(*XLGHOLQHV
&OLQLFDO6WXG\3URWRFRO(053KDVH,E,,
$QQRWDWHG6WXG\%RRNIRU6WXG\'HVLJQ(053KDVH,E(OHFWURQLF&5)
(LVHQKDXHU($7KHUDVVH3%RJDHUWV-6FKZDUW]/+6DUJHQW')RUG5HWDO1HZUHVSRQVH
HYDOXDWLRQFULWHULDLQVROLGWXPRUVUHYLVHG5(&,67JXLGHOLQHYHUVLRQ(XU-&DQFHU






7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 
$SSHQGLFHV
$33(1',; 1(:<25.+($57$662&,$7,211<+$&5,7(5,$
&ODVV
'HVFULSWLRQ
,
1R OLPLWDWLRQ 2UGLQDU\ SK\VLFDO DFWLYLW\ GRHV QRW FDXVH XQGXH IDWLJXH
G\VSQHDRUSDOSLWDWLRQV
,,
6OLJKWOLPLWDWLRQRISK\VLFDODFWLYLW\6XFKVXEMHFWVDUHFRPIRUWDEOHDWUHVW
2UGLQDU\SK\VLFDODFWLYLW\UHVXOWVLQIDWLJXHSDOSLWDWLRQVG\VSQHDRUDQJLQD
,,,
0DUNHGOLPLWDWLRQRISK\VLFDODFWLYLW\$OWKRXJKVXEMHFWVDUHFRPIRUWDEOHDW
UHVWOHVVWKDQRUGLQDU\SK\VLFDODFWLYLW\ZLOOOHDGWRV\PSWRPV
,9
,QDELOLW\ WR FDUU\ RQ SK\VLFDO DFWLYLW\ ZLWKRXW GLVFRPIRUW 6\PSWRPV RI
FRQJHVWLYHKHDUWIDLOXUHDUHSUHVHQWHYHQDWUHVW:LWKDQ\SK\VLFDODFWLYLW\
LQFUHDVHGGLVFRPIRUWLVH[SHULHQFHG
6RXUFH&ULWHULD&RPPLWWHH1HZ<RUN+HDUW$VVRFLDWLRQ,QF'LVHDVHVRIWKHKHDUWDQGEORRGYHVVHOV1RPHQFODWXUHDQG
FULWHULDIRUGLDJQRVLVWKHG%RVWRQ/LWWOH%URZQDQG&R


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





$33(1',; $6<03720$7,&(/(9$7,212)6(580/,3$6(
$1'25$0</$6(
,IDQDV\PSWRPDWLFOLSDVHDP\ODVHHOHYDWLRQRI*UDGH≥RFFXUVGXULQJ&\FOHWKHVXEMHFWZLOO
XQGHUJRFOLQLFDOHYDOXDWLRQIRUWKHSUHVHQFHRIVLJQVDQGV\PSWRPVW\SLFDORIDFXWHSDQFUHDWLWLV
DQG IRU RWKHU ULVN IDFWRUV IRU SDQFUHDWLWLV ,Q DGGLWLRQ D &7 VFDQ DQGRU PDJQHWLF UHVRQDQFH
LPDJLQJ05,RIWKHDEGRPHQZLOOEHSHUIRUPHGWRDVVHVVWKHSDQFUHDV7KHVSRQVRURUGHOHJDWH
ZLOOEHQRWLILHGRIWKHRXWFRPHRIWKH&705,'RVLQJZLWKWULDOWUHDWPHQWZLOOFRQWLQXHGXULQJ
WKH HYDOXDWLRQ SHULRG XQOHVV WKH FOLQLFDO HYDOXDWLRQ LQGLFDWHV SDQFUHDWLWLV +RZHYHU WKH
FRQWLQXDWLRQRIWULDOWUHDWPHQWIRUWKHVXEMHFWZLOOEHLQGLYLGXDOO\GLVFXVVHGZLWKWKHVSRQVRURU
GHOHJDWHRQDVXEMHFWE\VXEMHFWEDVLV
$OOFDVHVRIDV\PSWRPDWLF OLSDVHDQGRUDP\ODVHHOHYDWLRQVRI*UDGH ≥ ZLOO EHUHSRUWHGDV
$GYHUVH(YHQWVRI6SHFLDO,QWHUHVW$(6,WRWKHVSRQVRURUGHOHJDWHLQDQH[SHGLWHGIDVKLRQ
,I WKHUH DUH QR FOLQLFDO RU UDGLRORJLFDO VLJQV LQGLFDWLYH RI SDQFUHDWLWLV GRVLQJ ZLWK
06&-JHILWLQLE ZLOO FRQWLQXH DQG WKH SDQFUHDWLF HQ]\PH HOHYDWLRQ RFFXUULQJ GXULQJ
&\FOHZLOOQRWEHFODVVLILHGDVD'/7
$V\PSWRPDWLF OLSDVHDP\ODVHHOHYDWLRQV PD\RFFXUGXULQJRUEH\RQG&\FOHDQG GLIIHUHQW
VFHQDULRVDUHIRUHFDVWHG
• 3HUVLVWHQWDV\PSWRPDWLFOLSDVHDP\ODVHHOHYDWLRQDWWKHVDPHJUDGHRI*UDGH≥
• 5HFXUUHQWDV\PSWRPDWLFHOHYDWLRQRI*UDGH≥DIWHUDQLQLWLDO*UDGH≥HOHYDWLRQZLWK
VXEVHTXHQWUHVROXWLRQDQG
• $V\PSWRPDWLFOLSDVHDP\ODVHHOHYDWLRQRI*UDGH≥ZLWKSHUVLVWHQWHOHYDWLRQDWWKHVDPH
JUDGHIROORZHGE\VXEVHTXHQWIXUWKHULQFUHDVHLQJUDGH
,QDOOFDVHVWKHVXEMHFWZLOOXQGHUJRFOLQLFDOHYDOXDWLRQIRUWKHSUHVHQFHRIVLJQVDQGV\PSWRPV
W\SLFDORIDFXWHSDQFUHDWLWLVDQGIRURWKHUULVNIDFWRUVIRUSDQFUHDWLWLV$JDVWURLQWHVWLQDOFRQVXOW
VKRXOGEHUHTXHVWHGDQGDGGLWLRQDOLQYHVWLJDWLRQVHJUHSHDWHGDEGRPLQDO&7VFDQVKRXOGEH
FRQVLGHUHGDVDSSURSULDWH7KHFDVHZLOOEHGLVFXVVHGZLWKWKHVSRQVRURUGHOHJDWH7UHDWPHQW
ZLWK06&-JHILWLQLEPD\EHFRQWLQXHGGXULQJWKHHYDOXDWLRQSHULRGDWWKHGLVFUHWLRQRI
WKHWUHDWLQJSK\VLFLDQDQGGHSHQGLQJRQWKHFLUFXPVWDQFHVRIWKHLQGLYLGXDOFDVH
,I WKHUH
LV
QR FOLQLFDO RU UDGLRORJLFDO
HYLGHQFH RI SDQFUHDWLWLV WUHDWPHQW ZLWK
06&-JHILWLQLEVKRXOGEHFRQWLQXHGSDUWLFXODUO\LIWKHUHLVDSRWHQWLDOO\SRVLWLYHEHQHILW
IRUWKHLQGLYLGXDOVXEMHFW(YDOXDWLRQRISRWHQWLDOFOLQLFDOEHQHILWZLOOEHEDVHGRQHYLGHQFHIURP
WKHOLWHUDWXUHQRQFOLQLFDOPRGHOVDQGRUFXUUHQWH[SHULHQFHZLWK06&-JHILWLQLELQWKH
VXEMHFWRURWKHUVXEMHFWVZLWKWKLVWXPRUW\SH2WKHUZLVHWUHDWPHQWZLWK06&-JHILWLQLE
VKRXOGEHGLVFRQWLQXHG


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





$33(1',; 352*5$00,1*&219(17,216)252873876
2XWSXW&RQYHQWLRQV
2XWSXWVZLOOEHSUHVHQWHGDFFRUGLQJWRWKH
JHQHUDOJXLGHOLQHVDQGWHPSODWHIRURXWSXWV
FRQYHQWLRQV
'DWHV	7LPHV
'HSHQGLQJRQGDWDDYDLODEOHGDWHVDQGWLPHVZLOOWDNHWKHIRUP''000<<<<++0066
6SHOOLQJ)RUPDW
86(QJOLVK
3UHVHQWDWLRQRI9LVLWV
)RURXWSXWVYLVLWVZLOOEHUHSUHVHQWHGDVIROORZVDQGLQWKDWRUGHU
Long Name  
Short Name  
6FUHHQLQJ
6&5
&\FOH'D\
&'
&\FOH'D\
&'
&\FOH'D\
&'
&\FOH'D\
&'
&\FOH'D\
&'
&\FOH'D\
&'
&\FOH'D\
&'
&\FOH'D\
&'
&\FOH'D\
&'
«
«
&\FOH;'D\
&;'
6DIHW\)ROORZXS
6)8
/LVWLQJV
• $OOOLVWLQJVZLOOEHRUGHUHGE\WKHIROORZLQJXQOHVVRWKHUZLVHLQGLFDWHGLQWKHWHPSODWH
• 7UHDWPHQWUHFHLYHGE\DVFHQGLQJGRVHJURXS
PPD
PPD


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





• &HQWUH6XEMHFW,'
• 'DWHZKHUHDSSOLFDEOH
• )RUOLVWLQJVZKHUHVFUHHQIDLOXUHVXEMHFWVDUHLQFOXGHGWKHVHZLOODSSHDULQDFDWHJRU\DIWHUWKH
WUHDWPHQWJURXSVODEHOOHGµ6FUHHQ)DLOXUH¶





7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





$33(1',; /,672)/$%25$725<$66(660(176
+HPDWRORJ\DQG&RDJXODWLRQ3DUDPHWHUV
3DUDPHWHU
+HPRJORELQ+E
+HPDWRFULW+FW
5HGEORRGFHOOFRXQW
3ODWHOHWV
:KLWHEORRGFHOO:%&FRXQW
'LIIHUHQWLDO:%&
• 
1HXWURSKLOV
• 
(RVLQRSKLOV
• 
%DVRSKLOV
• 
0RQRF\WHV
• 
/\PSKRF\WHV
• 
2WKHU
3URWKURPELQWLPH37
$FWLYDWHGWKURPERSODVWLQWLPHD377
,QWHUQDWLRQDOQRUPDOL]HGUDWLR,15
%LRFKHPLVWU\
3DUDPHWHU
%ORRGXUHDQLWURJHQ%81
&UHDWLQLQH
$/7
$67
**7
7RWDOELOLUXELQ
'LUHFWIUDFWLRQRIELOLUXELQLIWRWDOELOLUXELQLVDEQRUPDO
/LSDVH
$P\ODVH
7RWDOSURWHLQ
$OEXPLQ
$ONDOLQHSKRVSKDWDVH
&UHDWLQLQHFOHDUDQFHD
6RGLXP
3RWDVVLXP
&DOFLXP
0DJQHVLXP
*OXFRVH
a. 
If calculated creatinine clearance during screening is < 60 mL/min, then 
24-hour urine creatinine clearance might be requested by the investigator 


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





for confirmation of renal impairment; must be performed at the central 
laboratory. 
• /DERUDWRU\SDUDPHWHUVZLWK&7&$(JUDGLQJDUH
/DE7HVW1DPH

*UDGH
*UDGH
*UDGH
*UDGH
&KHPLVWU\





7RWDO%LOLUXELQ
XPRO/
,QFUHDVH
!8/1
!8/1
!8/1
!8/1
$VSDUWDWH
$PLQRWUDQVIHUDVH
8/6*27
,QFUHDVH
![8/1
![8/1
![8/1
![8/1
$ODQLQH
$PLQRWUDQVIHUDVH
8/6*37
,QFUHDVH
![8/1
![8/1
![8/1
![8/1
6RGLXPPPRO//RZ
'HFUHDVH
//1
1$


6RGLXPPPRO/+LJK ,QFUHDVH
!8/1
!
!
!
&DOFLXPPPRO/
/RZ
$OEXPLQFRUUHFWHG
1RWWRWDOFDOFLXP
'HFUHDVH
//1



&DOFLXPPPRO/
+LJK
$OEXPLQFRUUHFWHG
1RWWRWDOFDOFLXP
,QFUHDVH
!8/1
!
!
!
0DJQHVLXPPPRO/
/RZ
'HFUHDVH
//1



0DJQHVLXPPPRO/
+LJK
,QFUHDVH
!8/1
1$
!
!
&UHDWLQLQHXPRO/
,QFUHDVH
!%/RU
8/1
!%/RU
8/1
!%/RU
8/1
!8/1
$OEXPLQJ/
'HFUHDVH
//1


1$
$ONDOLQHSKRVSKDWDVH
8/
,QFUHDVH
![8/1
![8/1
![8/1
![8/1
$P\ODVH8/
,QFUHDVH
![8/1
![8/1
![8/1
![8/1
/LSDVH8/
,QFUHDVH
!8/1
![8/1
![8/1
![8/1
*OXFRVHPPRO//RZ 'HFUHDVH
//1



*OXFRVHPPRO/
+LJK
,QFUHDVH
!8/1
!
!
!
*DPPD*OXWDP\O
7UDQVIHUDVH8/
,QFUHDVH
!8/1
![8/1
![8/1
![8/1


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





3RWDVVLXPPPRO/
/RZ
'HFUHDVH
1$
//1


3RWDVVLXPPPRO/
+LJK
,QFUHDVH
!8/1
!
!
!
&UHDWLQLQH&OHDUDQFH
&	*P/PLQ
'HFUHDVH
1$



+HPDWRORJ\





+HPRJORELQJ//RZ
'HFUHDVH
//1


1$
+HPRJORELQJ/+LJK
,QFUHDVH
!8/1RU
%/LI
%/!8/1
!8/1RU
%/LI
%/!8/1
!8/1RU
%/LI
%/!8/1
1$
3ODWHOHW(/3/7
'HFUHDVH
//1



/HXNRF\WHV(/
/RZ
'HFUHDVH
//1



/HXNRF\WHV(/
+LJK
,QFUHDVH
1$
1$
!
1$
1HXWURSKLOV(/
$EVROXWH1HXWURSKLOV
&RXQW$1&
'HFUHDVH
//1



/\PSKRF\WHV(/
/RZ
'HFUHDVH
//1



/\PSKRF\WHV(/
+LJK
,QFUHDVH
1$
!
!
1$
&RDJXODWLRQ





$FWLYDWHG3DUWLDO
7KURPERSODVWLQ7LPH
VHF
,QFUHDVH
!8/1
!8/1
!8/1
1$
3URWKURPELQ,QWO
1RUPDOL]HG5DWLR
,QFUHDVH
!%/RU
8/1
!%/RU
8/1
!%/RU
8/1
1$
%/ %DVHOLQH8/1 8SSHUOLPLWRIQRUPDOUDQJH//1 /RZHUOLPLWRIQRUPDOUDQJHU




7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





$33(1',; /$%25$725<5()(5(1&(5$1*(6
 


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

9HUVLRQ





 



7HSRWLQLE06&-
7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU
(05
0HWDVWDWLF16&/&,16,*+7


$SSHQGL[
'RFXPHQWDWLRQRI6WDWLVWLFDO0HWKRGV
x
(053KDVH,E6WDWLVWLFDO$QDO\VLV3ODQ
x
(053KDVH,,,QWHJUDWHG$QDO\VLV3ODQ


7HSRWLQLE06&-
7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05
3KDVH,,9HUVLRQ



,QWHJUDWHG$QDO\VLV3ODQ
&OLQLFDO7ULDO3URWRFRO
,GHQWLILFDWLRQ1R
(05
7LWOH
$3KDVH,E,,0XOWLFHQWHU5DQGRPL]HG2SHQ/DEHO7ULDOWR
&RPSDUH7HSRWLQLE06&-&RPELQHGZLWK*HILWLQLE
9HUVXV &KHPRWKHUDS\ DV 6HFRQGOLQH 7UHDWPHQW LQ 6XEMHFWV
ZLWK0(73RVLWLYH/RFDOO\$GYDQFHGRU0HWDVWDWLF1RQVPDOO
&HOO /XQJ &DQFHU 16&/& +DUERULQJ (*)5 0XWDWLRQDQG
+DYLQJ$FTXLUHG5HVLVWDQFHWR3ULRU(*)57\URVLQH.LQDVH
,QKLELWRU(*)57.,7KHUDS\
7ULDO3KDVH
3KDVH,E,,
,QYHVWLJDWLRQDO0HGLFLQDO
3URGXFWV
7HSRWLQLE06&-DQG*HILWLQLE
&OLQLFDO7ULDO3URWRFRO
9HUVLRQ
1RYHPEHU9HUVLRQ
,QWHJUDWHG$QDO\VLV3ODQ
$XWKRU

,QWHJUDWHG$QDO\VLV3ODQ
'DWHDQG9HUVLRQ
-DQY
,QWHJUDWHG$QDO\VLV3ODQ
5HYLHZHUV



0HGLFDO:ULWHU

7ULDO%LRVWDWLVWLFLDQ0HUFN

0HUFN

0HUFN
0HGLFDO5HVSRQVLEOH0HUFN

0HUFN

0HUFN

7KLVGRFXPHQWLVWKHSURSHUW\RI0HUFN.*D$'DUPVWDGW*HUPDQ\RURQHRILWVDIILOLDWHGFRPSDQLHV
,WLVLQWHQGHGIRUUHVWULFWHGXVHRQO\DQGPD\QRWLQIXOORUSDUWEHSDVVHGRQUHSURGXFHGSXEOLVKHGRUXVHGZLWKRXWH[SUHVV
SHUPLVVLRQRI0HUFN.*D$'DUPVWDGW*HUPDQ\RULWVDIILOLDWH
&RS\ULJKWE\0HUFN.*D$'DUPVWDGW*HUPDQ\RULWVDIILOLDWH$OOULJKWVUHVHUYHG
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD


PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







7DEOHRI&RQWHQWV
 
/LVWRI$EEUHYLDWLRQVDQG'HILQLWLRQRI7HUPV 
 
0RGLILFDWLRQ+LVWRU\ 
 
3XUSRVHRIWKH,QWHJUDWHG$QDO\VLV3ODQ 
 
2EMHFWLYHVDQG(QGSRLQWV 
 
2YHUYLHZRI3ODQQHG$QDO\VHV 
 
&KDQJHVWRWKH3ODQQHG$QDO\VHVLQWKH&OLQLFDO7ULDO3URWRFRO 
 
3URWRFRO'HYLDWLRQVDQG$QDO\VLV6HWV 
 
'HILQLWLRQRI3URWRFRO'HYLDWLRQV 
 
'HILQLWLRQRI$QDO\VLV6HWVDQG6XEJURXSV 
 
*HQHUDO6SHFLILFDWLRQVIRU6WDWLVWLFDO$QDO\VHV 
 
7ULDO6XEMHFWV 
 
'LVSRVLWLRQRI6XEMHFWVDQG'LVFRQWLQXDWLRQV 
 
%LRPDUNHU6FUHHQLQJ 
 
3URWRFRO'HYLDWLRQV 
 
,PSRUWDQW3URWRFRO'HYLDWLRQV 
 
5HDVRQV/HDGLQJWRWKH([FOXVLRQIURPDQ$QDO\VLV6HW 
 
'HPRJUDSKLFVDQG2WKHU%DVHOLQH&KDUDFWHULVWLFV 
 
'HPRJUDSKLFV 
 
0HGLFDO+LVWRU\ 
 
'LVHDVH+LVWRU\ 
 
3ULRU$QWL&DQFHU7UHDWPHQWV 
 
%DVHOLQH%LRPDUNHUV0HDVXUHGLQ7XPRU7LVVXH 
 
%DVHOLQH%LRPDUNHU9DULDEOHV 
 
'HVFULSWLYH6XPPDULHVRI%DVHOLQH%LRPDUNHUV 
 
%DVHOLQH%LRPDUNHUV0HDVXUHGLQ3ODVPD 
 
%DVHOLQH%LRPDUNHU9DULDEOHV 
 
'HVFULSWLYH6XPPDULHVRI%DVHOLQH%LRPDUNHU9DULDEOHV 
 
2WKHU%DVHOLQH&KDUDFWHULVWLFV 
 
%DVHOLQH7XPRU/HVLRQV 
 
3UHYLRXVDQG&RQFRPLWDQW0HGLFDWLRQV3URFHGXUHV 
 
0HGLFDWLRQVDQG3URFHGXUHV 


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







 
$QWL&DQFHU7UHDWPHQWDIWHU'LVFRQWLQXDWLRQ 
 
7UHDWPHQW&RPSOLDQFHDQG([SRVXUH 
 
(IILFDF\$QDO\VHV 
 
3ULPDU\(QGSRLQW$QDO\VHV 
 
3ULPDU\$QDO\VHVRI3URJUHVVLRQ)UHH6XUYLYDO 
 
6HFRQGDU\(QGSRLQW$QDO\VHV 
 
3)6$VVHVVHGE\,5& 
 
3)6LQWKH6LQJOH$UP&RKRUW 
 
2YHUDOO6XUYLYDO 
 
$QWLWXPRU$FWLYLW\ 
 
6DIHW\$QDO\VHV 
 
$GYHUVH(YHQWV 
 
$OO$GYHUVH(YHQWV 
 
$GYHUVH(YHQWV/HDGLQJWR7UHDWPHQW'LVFRQWLQXDWLRQ 
 
'HDWKV2WKHU6HULRXV$GYHUVH(YHQWVDQG2WKHU6LJQLILFDQW
$GYHUVH(YHQWV 
 
'HDWKV 
 
6HULRXV$GYHUVH(YHQWV 
 
$GYHUVH(YHQWRI6SHFLDO,QWHUHVW 
 
&OLQLFDO/DERUDWRU\(YDOXDWLRQ 
 
9LWDO6LJQV 
 
(&* 
 
2WKHU6DIHW\RU7ROHUDELOLW\(YDOXDWLRQV 
 
$QDO\VHVRI2WKHU(QGSRLQWV 
 
 
 
3KDUPDFRG\QDPLFVDQG
 
 
+HDOWK5HODWHG4XDOLW\RI/LIH 
 
/XQJ&DQFHU6\PSWRP6FDOH 
 
(257&4/4& 
 
 
 
5HIHUHQFHV 
 
$SSHQGL[ 
 
6FRULQJWKH(257&4/4&YHUVLRQ 
CCI
CCI
CCI


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ








 
/LVWRI$EEUHYLDWLRQVDQG'HILQLWLRQRI7HUPV

$EEUHYLDWLRQ
'HILQLWLRQ
$'D0
$QDO\VLV'DWD0RGHO
$(
$GYHUVH(YHQW
$(6,
$GYHUVH(YHQWVRI6SHFLDO,QWHUHVW
$6%,
$YHUDJH6\PSWRPDWLF%XUGHQ,QGH[
$7&
$QDWRPLF7KHUDSHXWLF&KHPLFDO
$8&
$UHD8QGHUWKH&XUYH
%0,
%RG\0DVV,QGH[
%25
%HVWRYHUDOOUHVSRQVH
%6$
%RG\6XUIDFH$UHD
&,
&RQILGHQFH,QWHUYDO
F0HW
0HVHQFK\PDO(SLWKHOLDO7UDQVLWLRQ)DFWRU*HQH
&5
&RPSOHWH5HVSRQVH
&65
&OLQLFDO6WXG\5HSRUW
&7&$(
&RPPRQ7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV
&73
&OLQLFDO7ULDO3URWRFRO
&9
&RHIILFLHQWRI9DULDWLRQ
'%3
'LDVWROLF%ORRG3UHVVXUH
(&*
(OHFWURFDUGLRJUDP
(&2*
(DVWHUQ&RRSHUDWLYH2QFRORJ\*URXS
H&5)
(OHFWURQLF&DVH5HSRUW)RUP
(*)5
(SLGHUPDO*URZWK)DFWRU5HFHSWRU
(*)57.,
(*)57\URVLQH.LQDVH,QKLELWRUV
(257&4/4&
(XURSHDQ2UJDQL]DWLRQIRU5HVHDUFKDQG7UHDWPHQWRI&DQFHU
4XDOLW\RI/LIH4XHVWLRQQDLUH&RUH
(27
(QGRI7UHDWPHQW


*&1
*HQH&RS\1XPEHU
*&3
*RRG&OLQLFDO3UDFWLFH
CCI


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







+*)
+HSDWLF*URZWK)DFWRU
+54R/
+HDOWK5HODWHG4XDOLW\RI/LIH
,'0&
,QGHSHQGHQW'DWD0RQLWRULQJ&RPPLWWHH
,+&
,PPXQRKLVWRFKHPLVWU\
,/
,QWHUOHXNLQ
,03
,QYHVWLJDWLRQDO0HGLFLQDO3URGXFW
,6+
LQVLWXK\EULGL]DWLRQ
,5&
,QGHSHQGHQW5HYLHZ&RPPLWWHH
,6+
,Q6LWX+\EULGL]DWLRQ
,77
,QWHQWWR7UHDW
,956
,QWHUDFWLYH9RLFH5HVSRQVH6\VWHP
/&66
/XQJ&DQFHU6\PSWRP6FDOH
//24
/RZHU/LPLWRI4XDQWLILFDWLRQ
0HG'5$
0HGLFDO'LFWLRQDU\)RU5HJXODWRU\$FWLYLWLHV
0(7
0(7'LDJQRVWLFSRVLWLYHVWDWXV
1&,
1DWLRQDO&DQFHU,QVWLWXWH
1(
,QHYDOXDEOH
16&/&
1RQ6PDOO&HOO/XQJ&DQFHU
25
2EMHFWLYH5HVSRQVH
255
2EMHFWLYH5HVSRQVH5DWH
26
2YHUDOO6XUYLYDO
3'
3URJUHVVLYH'LVHDVH
3G
3KDUPDFRG\QDPLFV
3)6
3URJUHVVLRQ)UHH6XUYLYDO


35
3DUWLDO5HVSRQVH
352
3DWLHQW5HSRUWHG2XWFRPH
36
3HUIRUPDQFH6WDWXV
37
3URWKURPELQ7LPH
44
)LUVW4XDUWLOH7KLUG4XDUWLOH
4R/
4XDOLW\RI/LIH
5(&,67
5HVSRQVH(YDOXDWLRQ&ULWHULDLQ6ROLG7XPRUV
CCI


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







53'
5HFRPPHQGHG3KDVH,,'RVH
6$)
6DIHW\$QDO\VLV6HW
6$(
6HULRXV$GYHUVH(YHQW
6%3
6\VWROLF%ORRG3UHVVXUH
6'
6WDEOH'LVHDVH
6'70
6WXG\'DWD7DEXODWLRQ0RGHO
6,
,QWHUQDWLRQDO6\VWHPRI8QLWV
62&
6\VWHP2UJDQ&ODVV
62/'
6XPRI/RQJHVW'LDPHWHUV
6W'
6WDQGDUG'HYLDWLRQ
W
+DOI/LIH
7($(
7UHDWPHQW(PHUJHQW$GYHUVH(YHQW
7.,
7\URVLQH.LQDVH,QKLELWRU
WPD[
7LPHWR0D[LPXP&RQFHQWUDWLRQ
710
7XPRU/\PSK1RGHV0HWDVWDVLV
7763
7LPHWR6\PSWRP3URJUHVVLRQ
9)
9ROXPHRI'LVWULEXWLRQ
9VV)
9ROXPHRI'LVWULEXWLRQDW6WHDG\6WDWH
9$6
9LVXDO$QDORJXH6FDOH
Ȝ]
7HUPLQDO3KDVH5DWH&RQVWDQW
:+2''
:+2'UXJ'LFWLRQDU\





7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







 
0RGLILFDWLRQ+LVWRU\
8QLTXH,GHQWLILHUIRU,$39HUVLRQ
'DWHRI,$39HUVLRQ
$XWKRU
&KDQJHVIURPWKH3UHYLRXV9HUVLRQ
)LQDO9
0DU
1RW$SSOLFDEOH±)LUVW9HUVLRQ
)LQDO9
-DQ
,QWURGXFWLRQRIPRQWKVIROORZXS
DQDO\VLV
$GGLWLRQRIIXUWKHUDQDO\VHVIRUWKH
VXEJURXSRISDWLHQWVZLWKJHQH
DPSOLILFDWLRQDQGRULQFUHDVHGF0HW
*&1E\,6+




 
3XUSRVHRIWKH,QWHJUDWHG$QDO\VLV3ODQ
7KH SXUSRVH RI WKLV ,QWHJUDWHG $QDO\VLV 3ODQ ,$3 LV WR GRFXPHQW WHFKQLFDO DQG GHWDLOHG
VSHFLILFDWLRQVIRUWKHSULPDU\DQDO\VLVWKHPRQWKVIROORZXSDQDO\VLVDQGWKHILQDODQDO\VLVRI
GDWDFROOHFWHGGXULQJ3KDVH,,SDUWRISURWRFRO(05RQO\5HVXOWVRIWKHDQDO\VHV
GHVFULEHG LQ WKLV ,$3 ZLOO EH LQFOXGHG LQ WKH &OLQLFDO 6WXG\ 5HSRUW &65 $GGLWLRQDOO\ WKH
SODQQHG DQDO\VHV LGHQWLILHG LQ WKLV ,$3 ZLOO EH LQFOXGHG LQ UHJXODWRU\ VXEPLVVLRQV RU IXWXUH
PDQXVFULSWV$Q\SRVWKRFRUXQSODQQHGDQDO\VHVSHUIRUPHGWRSURYLGHUHVXOWVIRULQFOXVLRQLQ
WKH&65EXWQRWLGHQWLILHGLQWKLVSURVSHFWLYH,$3ġZLOOEHFOHDUO\LGHQWLILHGLQWKH&65
7KH,$3LVEDVHGRQFOLQLFDOWULDOSURWRFRO&73YHUVLRQGDWHG1RYHPEHUYHUVLRQ
ORFDO-DSDQGDWHG1RYHPEHUYHUVLRQORFDO&DQDGDGDWHG$SULODQGLV
SUHSDUHGLQFRPSOLDQFHZLWK,QWHUQDWLRQDO&RQIHUHQFHRQ+DUPRQL]DWLRQ(
 
2EMHFWLYHVDQG(QGSRLQWV

2EMHFWLYH
(QGSRLQW
,$3
VHFWLRQ
3ULPDU\
2EMHFWLYH
7RHYDOXDWHZKHWKHUWKHHIILFDF\LQWHUPVRI
SURJUHVVLRQIUHHVXUYLYDO3)6RIVHFRQGOLQH
WHSRWLQLELQFRPELQDWLRQZLWKJHILWLQLELV
VXSHULRUWRSHPHWUH[HGFLVSODWLQFDUERSODWLQLQ
VXEMHFWVZLWK70QHJDWLYH0(7ORFDOO\
DGYDQFHGRUPHWDVWDWLF16&/&KDUERULQJDQ
HSLGHUPDOJURZWKIDFWRUUHFHSWRU(*)5
PXWDWLRQDQGKDYLQJDFTXLUHGUHVLVWDQFHWRILUVW
OLQH(*)57.,WKHUDS\LQFOXGLQJJHILWLQLE
HUORWLQLELFRWLQLERUDIDWLQLE
3ULPDU\(QGSRLQW
x 3)6DVVHVVHG
E\,QYHVWLJDWRU
LQWKH
UDQGRPL]HG
SDUW 

6HFRQGDU\
2EMHFWLYH
7RHYDOXDWHWKHVDIHW\DQGWROHUDELOLW\RI
WHSRWLQLELQFRPELQDWLRQZLWKJHILWLQLE
6HFRQGDU\
(QGSRLQWV
x 'UXJH[SRVXUH
x $(V

PPD


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







x ,QFLGHQFHDQG
UHDVRQVIRU
GHDWKVZLWKLQ
GD\V
DIWHUWKHODVW
GRVHRIVWXG\
GUXJ
x /DERUDWRU\
WHVWV
x 9LWDOVLJQV
OHDG(&*DQG
RWKHUV
7RHYDOXDWHWKHHIILFDF\RIWHSRWLQLELQ
FRPELQDWLRQZLWKJHILWLQLELQ70QHJDWLYH
0(7VXEMHFWV
6HFRQGDU\
(QGSRLQWV
x 3)6E\
LQGHSHQGHQW
UHYLHZ
FRPPLWWHH
,5&LQWKH
UDQGRPL]HG
SDUW
x 26
x 7XPRU
UHVSRQVHDQG
GLVHDVHFRQWURO

7RHYDOXDWHWKHDQWLWXPRUDFWLYLW\RIWHSRWLQLELQ
FRPELQDWLRQZLWKJHILWLQLELQ70
SRVLWLYH0(7VXEMHFWVLQDVHSDUDWHVLQJOH
DUPFRKRUWPDLQODQG&KLQDVLWHVRQO\
6HFRQGDU\
(QGSRLQWV
x 3)6DVVHVVHG
E\,QYHVWLJDWRU
DQG,5&LQ
VLQJOHDUP
FRKRUW
x 26
x 7XPRU
UHVSRQVHDQG
GLVHDVHFRQWURO

7RDVVHVVSDWLHQWUHSRUWHGRXWFRPHV352V
ZLWKUHVSHFWWRTXDOLW\RIOLIH4R/
DVPHDVXUHGE\WKH(XURSHDQ2UJDQL]DWLRQIRU
5HVHDUFKDQG7UHDWPHQWRI&DQFHU4XDOLW\
RI/LIH4XHVWLRQQDLUH&RUH(257&4/4
&9HUVLRQDQGWLPHWR
V\PSWRPSURJUHVVLRQ7763DVPHDVXUHGE\
/XQJ&DQFHU6\PSWRP6FDOH/&66
6HFRQGDU\
(QGSRLQW
x (257&4/4
&
x 7763E\/&66



7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







([SORUDWRU\
2EMHFWLYH
7RLQYHVWLJDWHELRPDUNHUVRIF0HWSDWKZD\
DFWLYDWLRQDQGRWKHUUHOHYDQW
RQFRJHQLFSDWKZD\VLQVHUXPDQGWXPRUWLVVXH
DQGWKHLUSRWHQWLDOFRUUHODWLRQZLWKSURJQRVLV
DQGWKHDFWLYLW\RIWHSRWLQLELQFRPELQDWLRQZLWK
JHILWLQLE
x 0DUNHUVRIF
0HWSDWKZD\
DFWLYDWLRQHJ
KHSDWLFJURZWK
IDFWRU>+*)@
OHYHOVDQGF
0HWPXWDWLRQV
RWKHUUHOHYDQW
RQFRJHQLF
SDWKZD\V

 
2YHUYLHZRI3ODQQHG$QDO\VHV
&XWRIIGDWH
7KHSULPDU\DQDO\VLVRIWKH3KDVH,,SDUWZLOOEHFRQGXFWHGRQFHDOOVXEMHFWVKDYHHLWKHUEHHQ
WUHDWHGIRUDWOHDVWPRQWKVGLHGRUKDYHSUHPDWXUHO\GLVFRQWLQXHGWULDOWUHDWPHQWIRUDQ\UHDVRQ
ZKLFKHYHUFRPHVILUVW7KLV,$3FRYHUVWKHDQDO\VHVIRUHIILFDF\DQGVDIHW\EDVHGRQWKHGDWDFXW
RIIIRUWKHSULPDU\DQDO\VLV6WDWLVWLFDODQDO\VHVZLOOEHSHUIRUPHGXVLQJFOHDQHGH&5)GDWDJDLQHG
XQWLOWKHFOLQLFDOFXWRIIGDWH
,QDGGLWLRQDQDQDO\VLVRIWKH3KDVH,,SDUWZLOOEHFRQGXFWHGRQFHDOOVXEMHFWVKDYHHLWKHUEHHQ
WUHDWHGIRUDWOHDVWPRQWKVGLHGRUKDYHSUHPDWXUHO\GLVFRQWLQXHGWULDOWUHDWPHQWIRUDQ\UHDVRQ
ZKLFKHYHUFRPHVILUVW7KLV,$3FRYHUVWKHDQDO\VHVIRUHIILFDF\DQGVDIHW\EDVHGRQWKHGDWDFXW
RIIIRUWKLVPRQWKVIROORZXSDQDO\VLV7KLVDQDO\VLVZLOOIRUPWKHEDVLVIRUWKH&656WDWLVWLFDO
DQDO\VHVZLOOEHSHUIRUPHGXVLQJFOHDQHGH&5)GDWDJDLQHGXQWLOWKHFOLQLFDOFXWRIIGDWH
7KHILQDODQDO\VLVZLOOEHFRQGXFWHGRQFHWKHODVWVXEMHFWGLVFRQWLQXHGWUHDWPHQWDQGFRPSOHWHG
WKHVXEVHTXHQWVDIHW\IROORZXSYLVLW6WDWLVWLFDODQDO\VHVZLOOEHSHUIRUPHGXVLQJFOHDQHGH&5)
GDWDZLWKRXWDSSO\LQJDFXWRIIGDWH2QO\OLPLWHGDQDO\VHVIRFXVLQJRQORQJWHUPIROORZXSHJ
RYHUDOOVXUYLYDOZLOOEHFRQGXFWHG
$GDWDUHYLHZPHHWLQJZLOOEHKHOGSULRUWRWKHGDWDEDVHORFNIRUHDFKRIWKHWZRDQDO\VHV,Q
DGGLWLRQQRGDWDEDVHFDQEHORFNHGDQGQRUDQGRPL]DWLRQFRGHVKRXOGEHXQEOLQGHGXQWLOWKLV,$3
KDVEHHQDSSURYHG
CCI
CCI


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







6DPSOH6L]H
7KHLQLWLDOVDPSOHVL]HSODQQLQJUHTXLUHG3)6HYHQWVDVVHVVHGE\,QYHVWLJDWRUWRHQVXUH
SRZHU ZLWK D WZRVLGHG VLJQLILFDQFH OHYHO RI  IRU UHMHFWLQJ WKH QXOO K\SRWKHVLV RI HTXDO
WUHDWPHQWHIIHFWEHWZHHQWUHDWPHQWDUPVDVVXPLQJDWUXHKD]DUGUDWLRRI$VVXPLQJDPHGLDQ
3)6WLPHRIPRQWKVLQWKHFRQWURODUPDKD]DUGUDWLRRIUHSUHVHQWVDPRQWKVLQFUHDVH
UHVXOWLQJLQDPHGLDQ3)6WLPHRIPRQWKVIRUWKHH[SHULPHQWDODUP:LWKRWKHUDVVXPSWLRQV
DFFUXDOSHULRGRIPRQWKVDQGIROORZXSSHULRGRIPRQWKVUDQGRPL]DWLRQUDWLRRI
H[SHULPHQWDOYVFRQWURODUPRYHUDOOGURSRXWUDWHRIaQRQELQGLQJIXWLOLW\DQDO\VLV
ZLWKIXWLOLW\ERXQGDU\Į ZDVSODQQHGWREHSHUIRUPHGDIWHUREVHUYDWLRQRIRI3)6
HYHQWV $ WRWDO RI DSSUR[LPDWHO\ VXEMHFWV ZHUH SODQQHG WR EH UDQGRPL]HG WR UHFHLYH
WHSRWLQLEJHILWLQLERUSHPHWUH[HGFLVSODWLQFDUERSODWLQ)URPVWXG\VWDUWWRDSSURYDORI3URWRFRO
9HUVLRQ  VXEMHFWV ZHUH UDQGRPL]HG DW D  UDWLR WR UHFHLYH HLWKHU WHSRWLQLEJHILWLQLE RU
SHPHWUH[HGFLVSODWLQ )URP WKH DSSURYDO RI 3URWRFRO 9HUVLRQ  RQZDUGV VXEMHFWV ZHUH
UDQGRPL]HGDWDUDWLRWRUHFHLYHHLWKHUWHSRWLQLEJHILWLQLERUSHPHWUH[HGFLVSODWLQFDUERSODWLQ
7KH6SRQVRUVXEVHTXHQWO\GHFLGHGWRKDOWSUHVFUHHQLQJHQUROOPHQW7KHVLWHVZHUHQRWLILHGDERXW
WKHHQUROOPHQWKDOWRQ0D\7KHODVWVXEMHFWZDVUDQGRPL]HGRQ-XQH8QWLOWKHQ
VXEMHFWVKDGEHHQUDQGRPL]HG
,QWKHVLQJOHDUPFRKRUWRI3KDVH,,XSWRVXEMHFWVZLWK70SRVLWLYH0(7VWDWXVZHUH
SODQQHG WR EH HQUROOHG PDLQODQG &KLQD VLWHV RQO\ $OO VXEMHFWV HQUROOHG XQGHU FOLQLFDO WULDO
SURWRFRO9HUVLRQZLWK70SRVLWLYHVWDWXVDQGUDQGRPL]DWLRQWRWKHH[SHULPHQWDODUPZLOO
FRXQWLQWRWKLVVLQJOHDUPFRKRUWDVZHOOPHDQLQJWKDWWKHQXPEHURIVXEMHFWVZLOOEHUHGXFHG
E\WKHVHVXEMHFWVDQG70SRVLWLYHVXEMHFWVHQUROOHGXQGHUFOLQLFDOWULDOSURWRFRO9HUVLRQ
DQG70SRVLWLYHVXEMHFWVIURPWKHPDLQODQG&KLQDVLWHVHQUROOHGXQGHUFOLQLFDOWULDOSURWRFRO
9HUVLRQZLOOEHDQDO\]HGDVRQHJURXS%\WKHWLPHRIWKHHQUROOPHQWKDOWDOOVXEMHFWVZLWK
0(770SRVLWLYH16&/&KDGEHHQHQUROOHG
5DQGRPL]DWLRQ
5DQGRPL]DWLRQRQO\RFFXUUHGLQWKHUDQGRPL]HGSDUWRI3KDVH,,DQGZDVSHUIRUPHGFHQWUDOO\E\
XVLQJDQLQWHUDFWLYHYRLFHUHVSRQVHV\VWHP,956
)URPVWXG\VWDUWWRDSSURYDORI3URWRFRO9HUVLRQVXEMHFWVZHUHUDQGRPL]HGDWDUDWLRWR
HLWKHUWKHH[SHULPHQWDODUPWHSRWLQLEJHILWLQLERUWKHFRQWURODUPSHPHWUH[HGFLVSODWLQ)URP
WKHDSSURYDORI3URWRFRO9HUVLRQRQZDUGVVXEMHFWVZHUHUDQGRPL]HGDWDUDWLRWRHLWKHUWKH
H[SHULPHQWDODUPWHSRWLQLEJHILWLQLERUWKHFRQWURODUPSHPHWUH[HGFLVSODWLQFDUERSODWLQ$
VWUDWLILHGSHUPXWHGEORFNUDQGRPL]DWLRQSURFHGXUHZDVHPSOR\HGXVLQJWKHIROORZLQJVWUDWD
x 7\SH RI 0(7 SURWHLQ RYHUH[SUHVVLRQ LPPXQRKLVWRFKHPLVWU\ ,+&  YV SURWHLQ
RYHUH[SUHVVLRQ,+&YVJHQHDPSOLILFDWLRQDQGRULQFUHDVHGF0HWJHQHFRS\QXPEHU
*&1ERWKE\LQVLWXK\EULGL]DWLRQ,6+
x 3ULRU(*)57.,WUHDWPHQWJHILWLQLEYVHUORWLQLEYVLFRWLQLEYVDIDWLQLE


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







3OHDVHQRWHWKDWVXEMHFWVZLWKWKHFRH[LVWHQFHRIDPSOLILFDWLRQDQGRULQFUHDVHGF0HW*&1DV
ZHOODVRYHUH[SUHVVLRQZLOOEHLQFOXGHGLQWKHDPSOLILFDWLRQDQGRULQFUHDVHGF0HW*&1VWUDWXP
,QGHSHQGHQW'DWD0RQLWRULQJ&RPPLWWHH
$VHSDUDWHDQDO\VLVSODQFRYHUVSHULRGLFUHYLHZVWRHYDOXDWHWKHVDIHW\RIWKHVXEMHFWVE\WKH
,QGHSHQGHQW'DWD0RQLWRULQJ&RPPLWWHH,'0&
x 6DIHW\DQDO\VLVZKHQDSSUR[LPDWHO\SDWLHQWGRVHGWRHQVXUHFRQWLQXHGVXEMHFWVDIHW\
x $GGLWLRQDOVDIHW\DQDO\VLVPD\RFFXURQUHTXHVWRIWKH,'0&RU0HUFN6HURQR
 
&KDQJHVWRWKH3ODQQHG$QDO\VHVLQWKH&OLQLFDO7ULDO
3URWRFRO
1R IXUWKHU H[SORUDWRU\ DQDO\VHV EDVHG RQ SHUSURWRFRO SRSXODWLRQ ZLOO EH SHUIRUPHG DQG
PHQWLRQHGLQWKLV,$3
6XEJURXSRIKLVWRORJLFDOVXEW\SHLHDGHQRFDUFLQRPDYVQRQDGHQRFDUFLQRPDZLOOEHRPLWWHG
GXHWRWKHYHU\VPDOOQXPEHURIQRQDGHQRFDUFLQRPD
 
3URWRFRO'HYLDWLRQVDQG$QDO\VLV6HWV
 
'HILQLWLRQRI3URWRFRO'HYLDWLRQV
3URWRFROGHYLDWLRQVGHVFULEHKRZFORVHO\WKHVWXG\KDVIROORZHGWKHSURWRFRODVH[SHFWHGSHU*RRG
&OLQLFDO3UDFWLFH*&36RPHRIWKHVHGHYLDWLRQVPD\EHVLJQLILFDQWFRQWULEXWRUVWRDQDO\VLVELDV
,PSRUWDQWSURWRFROGHYLDWLRQVDUHDVXEVHWRISURWRFROGHYLDWLRQVWKDWPLJKWVLJQLILFDQWO\DIIHFWWKH
FRPSOHWHQHVVDFFXUDF\DQGRUUHOLDELOLW\RIWKHVWXG\GDWDRUWKDWPLJKWVLJQLILFDQWO\DIIHFWD
VXEMHFW
VULJKWVVDIHW\RUZHOOEHLQJ
7KHIROORZLQJEXWQRWOLPLWHGWRDUHGHILQHGDVLPSRUWDQWSURWRFROGHYLDWLRQV
x 6XEMHFWVWKDWDUHGRVHGRQWKHVWXG\GHVSLWHQRWVDWLVI\LQJWKHLQFOXVLRQFULWHULD
x 6XEMHFWVWKDWGHYHORSZLWKGUDZDOFULWHULDZKLOVWRQWKHVWXG\EXWDUHQRWZLWKGUDZQ
x 6XEMHFWVWKDWUHFHLYHWKHZURQJWUHDWPHQWRUDQLQFRUUHFWGRVH
x 6XEMHFWVWKDWUHFHLYHDQH[FOXGHGFRQFRPLWDQWPHGLFDWLRQ
x 'HYLDWLRQIURP*&3
,PSRUWDQWSURWRFROGHYLDWLRQVZLOOEHEDVHGXSRQWKH&OLQLFDO7ULDO0DQDJHPHQW6\VWHPGDWDDQG
GHWHUPLQHG IRU DOO SDWLHQWV E\ HLWKHU VLWH PRQLWRULQJ PHGLFDO UHYLHZ RU SURJUDPPLQJ $OO
LPSRUWDQWSURWRFROGHYLDWLRQVZLOOEHLQFOXGHGLQ6WXG\'DWD7DEXODWLRQ0RGHO6'70GDWDVHWV


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







 
'HILQLWLRQRI$QDO\VLV6HWVDQG6XEJURXSV
$OO6FUHHQLQJ$QDO\VLV6HW
7KH$OO6FUHHQLQJ$QDO\VLV6HWLQFOXGHVDOOVXEMHFWVZKRKDYHSURYLGHGWKHLQIRUPHGFRQVHQWLH
VFUHHQLQJIDLOXUHVSOXVVXEMHFWVHQUROOHG
,QWHQWWR7UHDW$QDO\VLV6HW,775DQGRPL]HGSDUWRI3KDVH,,RQO\
7KH ,77 $QDO\VLV 6HW FRQVLVWV RI DOO VXEMHFWV LQ WKH UDQGRPL]HG SDUW RI 3KDVH ,, ZKR
ZHUHUDQGRPL]HGWRVWXG\WUHDWPHQW$QDO\VHVSHUIRUPHGRQWKH,77VHWZLOOWDNHLQWRDFFRXQW
VXEMHFWV¶DOORFDWLRQWRWUHDWPHQWJURXSVDVUDQGRPL]HG
7KH ,77 ZLOO EH XVHG IRU VXPPDULHV RI GHPRJUDSKLF DQG EDVHOLQH FKDUDFWHULVWLFV DV ZHOO DV
HIILFDF\
6DIHW\$QDO\VLV6HW6$)
7KH6DIHW\$QDO\VLV6HWLQFOXGHVDOOVXEMHFWVZKRKDYHUHFHLYHGDWOHDVWGRVHRIWHSRWLQLE
JHILWLQLESHPHWUH[HGFLVSODWLQRUFDUERSODWLQ
7KH6DIHW\$QDO\VLV6HWZLOOEHXVHGIRUDOOVXPPDULHVRIVDIHW\GDWD6XEMHFWVZLOOEHDOORFDWHG
DVWUHDWHG$VDQH[DPSOHLIDVXEMHFWZDVUDQGRPL]HGWRWKHLQYHVWLJDWLRQDODUPEXWUHFHLYHG
WUHDWPHQWRIWKHFRQWURODUPWKURXJKRXWWKHWULDOUDWKHUWKDQWKHLQYHVWLJDWLRQDOWUHDWPHQWWKH
VXEMHFW¶VVDIHW\GDWDVKRXOGEHUHSRUWHGXQGHUWKHFRQWUROJURXS
,QWKHVLQJOHDUPFRKRUWRI3KDVH,,WKH6DIHW\$QDO\VLV6HWZLOODOVREHXVHGIRUVXPPDULHVRI
GHPRJUDSKLFDQGEDVHOLQHFKDUDFWHULVWLFVDVZHOODVHIILFDF\
$QRYHUYLHZRIDQDO\VHVIRU,77$QDO\VLV6HWDQG6$)$QDO\VLV6HWLVJLYHQLQ7DEOH
7DEOH$QDO\VLV6HWV
$QDO\VHV
,776HW
UDQGRPL]HGSDUW
6$)6HW
UDQGRPL]HGSDUW
6$)6HW
VLQJOHDUPFRKRUW
%DVHOLQH$VVHVVPHQWV
9

9
3DVW&RQFRPLWDQWDQG3RVW7KHUDSLHV
9

9
0HGLFDO+LVWRU\
9

9
&RPSOLDQFHDQG([SRVXUH

9
9
(IILFDF\3ULPDU\
9

9
(IILFDF\6HFRQGDU\
9

9
6DIHW\DQG7ROHUDELOLW\

9
9
4R/HYDOXDEOHSRSXODWLRQ
,QWKHUDQGRPL]DWLRQSDUWRI3KDVH,,WKH4R/HYDOXDEOHSRSXODWLRQLQFOXGHVDOO,77VXEMHFWVZLWK
DEDVHOLQHDQGDWOHDVWRQHHYDOXDEOHRQWUHDWPHQW4R/TXHVWLRQQDLUH


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







,QWKHVLQJOHDUPFRKRUWRI3KDVH,,WKH4R/HYDOXDEOHSRSXODWLRQLQFOXGHVVXEMHFWVLQ6DIHW\
$QDO\VLV6HWZLWKDEDVHOLQHDQGDWOHDVWRQHHYDOXDEOHRQWUHDWPHQW4R/TXHVWLRQQDLUH
3G$QDO\VLV6HW
$OOVXEMHFWVZKRKDYHUHFHLYHGDWOHDVWGRVHRIVWXG\GUXJDQGKDYHWKHEDVHOLQHDQGDWOHDVW
SRVWEDVHOLQH3G%LRPDUNHUVDVVHVVPHQW
6XEJURXSVRILQWHUHVW
6XEJURXSDQDO\VHVZLOOEHSHUIRUPHGRQVXEJURXSVGHSHQGLQJRQWKHDFWXDOVL]HRIWKHVXEJURXS
DVGHILQHGEHORZ
x $JH\HDUVUHIHUHQFHOHYHOYV\HDUV
x *HQGHUPDOHUHIHUHQFHOHYHOYVIHPDOH
x 7\SHRI0(7SURWHLQRYHUH[SUHVVLRQ,+&UHIHUHQFHOHYHOYVSURWHLQRYHUH[SUHVVLRQ
,+&
x 7\SHRI0(7JHQHDPSOLILFDWLRQDQGRULQFUHDVHGF0HW*&1E\,6+UHIHUHQFHOHYHO
YVQHLWKHUJHQHDPSOLILFDWLRQQRULQFUHDVHGF0HW*&1
x 6PRNLQJKLVWRU\QHYHUVPRNHUVUHIHUHQFHOHYHOYVHYHUVPRNHUV
5HJDUGLQJ EDVHOLQH YDULDEOHV WR EH LQFOXGHG LQWR &R[
V SURSRUWLRQDO KD]DUGV PRGHO WKH DERYH
SDUDPHWHUL]DWLRQLVWREHXVHG)RUYDULDEOHVZLWKPRUHWKDQWZRFDWHJRULHVDQLQGLFDWRUYDULDEOH
ZLOOEHGHILQHGIRUHDFKFDWHJRU\H[FHSWIRUWKHILUVWFDWHJRU\ZKLFKGHILQHVWKHUHIHUHQFHDOZD\V
 
*HQHUDO6SHFLILFDWLRQVIRU6WDWLVWLFDO$QDO\VHV
'DWDKDQGOLQJDIWHUFXWRIIGDWH
'DWDREWDLQHGDIWHUWKHFXWRIIZLOOQRWEHGLVSOD\HGLQDQ\OLVWLQJVRUXVHGIRUVXPPDU\VWDWLVWLFV
HJODERUDWRU\YDOXHVRIVDPSOHVWDNHQDIWHUGDWDFXWRII$(ZLWKRQVHWGDWHDIWHUGDWDFXWRII
GHDWKHWFZLOOQRWEHLQFOXGHGLQDQ\DQDO\VLVRUOLVWLQJ
6WRSGDWHVDUHQRWDIIHFWHGE\WKLVUXOHHJDVWRSGDWHRI$(VZKLFKVWDUWVSULRUWRWKHFXWRIIEXW
VWRSVDIWHUGDWHRIFXWRIIZLOOQRWEHFKDQJHG
3RROLQJRIFHQWHUV
7RSURYLGHRYHUDOOHVWLPDWHVRIWUHDWPHQWHIIHFWGDWDZLOOEHSRROHGDFURVVFHQWHUV7KHIDFWRU
FHQWHUZLOOQRWEHFRQVLGHUHGLQVWDWLVWLFDOPRGHOVRUIRUVXEJURXSDQDO\VHVEHFDXVHRIWKHKLJK
CCI


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







QXPEHURISDUWLFLSDWLQJFHQWHUVDQGWKHDQWLFLSDWHGVPDOOQXPEHURIVXEMHFWVUDQGRPL]HGLQHDFK
FHQWHU
6LJQLILFDQFHOHYHO
$OOVWDWLVWLFDOWHVWVFRPSDULQJWUHDWPHQWDUPVLQWKHUDQGRPL]HGSDUWRI3KDVH,,ZLOOEHSHUIRUPHG
WZRVLGHGXVLQJDVLJQLILFDQFHOHYHORIĮ XQOHVVRWKHUZLVHVWDWHG,IFRQILGHQFHLQWHUYDOV
&,VDUHWREHFDOFXODWHGWKH\ZLOOEHWZRVLGHGZLWKDFRQILGHQFHSUREDELOLW\RIXQOHVV
RWKHUZLVHVWDWHG
3UHVHQWDWLRQRIFRQWLQXRXVDQGTXDOLWDWLYHYDULDEOHV


 

 

 

 

 




4XDOLWDWLYHYDULDEOHVZLOOEHVXPPDUL]HGE\PHDQVRIFRXQWVDQGSHUFHQWDJHV8QOHVVRWKHUZLVH
VWDWHGWKHFDOFXODWLRQRISURSRUWLRQVZLOOEHEDVHGRQWKHVDPSOHVL]HRIWKHSRSXODWLRQRILQWHUHVW
&RXQWVRIPLVVLQJREVHUYDWLRQVZLOOEHLQFOXGHGLQWKHGHQRPLQDWRUDQGSUHVHQWHGDVDVHSDUDWH
FDWHJRU\
,QFDVHWKHDQDO\VLVUHIHUVRQO\WRFHUWDLQYLVLWVSHUFHQWDJHVZLOOEHEDVHGRQWKHQXPEHURIVXEMHFWV
VWLOOSUHVHQWLQWKHWULDODWWKDWYLVLWXQOHVVRWKHUZLVHVSHFLILHG
'HILQLWLRQRIEDVHOLQH
,QJHQHUDOWKHODVWPHDVXUHPHQWSULRUWRRURQWKHGD\RIUDQGRPL]DWLRQILUVWDGPLQLVWUDWLRQRI
WKHWULDOWUHDWPHQWZLOOVHUYHDVWKHEDVHOLQHPHDVXUHPHQW
7ULDOGD\7UHDWPHQWGD\
7ULDOGD\7UHDWPHQWGD\DUHGHILQHGUHODWLYHWRWKHGDWHRIUDQGRPL]DWLRQVWDUWRIWUHDWPHQW7ULDO
GD\UHIHUHQFHVWDUWGDWHH[FHSWDQDO\VHVRITXHVWLRQQDLUHVGHILQHVWKHGD\RIUDQGRPL]DWLRQIRU
WKHUDQGRPL]HGSDUWDQGGD\RIILUVWVWXG\WUHDWPHQWIRUWKHVLQJOHDUPFRKRUWWKHGD\EHIRUHLV
GHILQHGDV7ULDOGD\±QR7ULDOGD\LVGHILQHG
x 7ULDOGD\ 
CCI


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







o GDWHRIHYHQW±UHIHUHQFHGDWHLIWKHGDWHRIWKHHYHQWLVRQRUDIWHUWKHUHIHUHQFH
GDWH
o GDWHRIHYHQW±UHIHUHQFHGDWHLIWKHGDWHRIWKHHYHQWLVSULRUWRWKHUHIHUHQFHGDWH
7UHDWPHQWGD\ZLOOEHFDOFXODWHGLQDFFRUGDQFHZLWKWUHDWPHQWGD\7UHDWPHQWGD\LVGHILQHG
DVWKHGDWHRIILUVWDGPLQLVWUDWLRQRIDQ\WKHIROORZLQJWULDOGUXJVWHSRWLQLEJHILWLQLESHPHWUH[HG
RUFLVSODWLQFDUERSODWLQ
7UHDWPHQWGD\ZLOOEHFRQVLGHUHGDVUHIHUHQFHVWDUWGDWHIRUDQDO\VHVRITXHVWLRQQDLUHV
'HILQLWLRQRIGXUDWLRQ
'XUDWLRQZLOOEHFDOFXODWHGE\WKHGLIIHUHQFHRIVWDUWDQGVWRSGDWHHJVXUYLYDOWLPHGD\V 
GDWHRIGHDWK±GDWHRIUDQGRPL]DWLRQLIQRWRWKHUZLVHVSHFLILHG
7KHWLPHVLQFHDQHYHQWRFFXUVHJWLPHVLQFHILUVWGLDJQRVLVZLOOEHFDOFXODWHGDVUHIHUHQFHGDWH
PLQXVGDWHRIHYHQW
&RPPRQFDOFXODWLRQV
)RUTXDQWLWDWLYHPHDVXUHPHQWVFKDQJHIURPEDVHOLQHZLOOEHFDOFXODWHGDV

x 7HVW9DOXHDW9LVLW;±%DVHOLQH9DOXH
&RQYHUVLRQIDFWRUV
7KHIROORZLQJFRQYHUVLRQIDFWRUVZLOOEHXVHGWRFRQYHUWGD\VLQWRPRQWKVRU\HDUV
x PRQWK GD\V
x \HDU GD\V
'HILQLWLRQRIRQWUHDWPHQWYDOXH
2QWUHDWPHQWGDWDUHIHUVWRDVVHVVPHQWYDOXHVFROOHFWHGDIWHUWKHILUVWVWXG\GUXJDGPLQLVWUDWLRQRI
DQ\WULDOGUXJDQGZLWKLQGD\VLQFOXVLYHDIWHUWKHODVWVWXG\GUXJDGPLQLVWUDWLRQ
(QGRIWUHDWPHQW
8QOHVV RWKHUZLVH VSHFLILHG HQG RI WUHDWPHQW (27 LV GHILQHG DV WKH HDUOLHVW QRQPLVVLQJ
PHDVXUHPHQW WDNHQ DIWHU UHIHUHQFH HQG VWDUW GDWH (27 PHDVXUHPHQWV LQ JHQHUDO VKRXOG EH
UHFRUGHGDWWKH³(QGRI7UHDWPHQW´YLVLW
5HWHVWVXQVFKHGXOHGYLVLWVDQGHDUO\WHUPLQDWLRQGDWD
,Q JHQHUDO IRU E\YLVLW VXPPDULHV GDWD UHFRUGHG DW WKH QRPLQDO YLVLW ZLOO EH SUHVHQWHG
8QVFKHGXOHGPHDVXUHPHQWVZLOOQRWEHLQFOXGHGLQE\YLVLWVXPPDULHV EXW ZLOO FRQWULEXWHWR
EHVWZRUVWFDVHYDOXHZKHUHUHTXLUHGHJVKLIWWDEOH


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







,QWKHFDVHRIDUHWHVWVDPHYLVLWQXPEHUDVVLJQHGWKHODWHVWZRUVWDYDLODEOHPHDVXUHPHQWIRUWKDW
YLVLWZLOOEHXVHGIRUE\YLVLWVXPPDULHVXQOHVVRWKHUZLVHVSHFLILHG
/LVWLQJVZLOOLQFOXGHDOOVFKHGXOHGXQVFKHGXOHGUHWHVWDQGHDUO\GLVFRQWLQXDWLRQGDWD
+DQGOLQJRIPLVVLQJGDWD
8QOHVVRWKHUZLVHVSHFLILHGPLVVLQJGDWDZLOOQRWEHLPSXWHG)RUWKHGHULYDWLRQRIQHZYDULDEOHV
WKHIROORZLQJUXOHVZLOODSSO\
x 3DUWLDOELUWKGDWHVZLOOEHKDQGOHGWKLVZD\
o 'D\ZLOOEHLPSXWHGDVLIPLVVLQJDQGPRQWKLPSXWHGDV-XQHLIPLVVLQJ,IERWK
WKHGD\DQGPRQWKDUHPLVVLQJWKH\ZLOOEHLPSXWHGDV-XO\ILUVW,IWKH\HDULV
PLVVLQJWKHQWKHGDWHZLOOQRWEHLPSXWHG
x ,QFRPSOHWH$(UHODWHGGDWHVZLOOEHKDQGOHGDVIROORZV
o ,IWKHRQVHWGDWHLVFRPSOHWHO\PLVVLQJRUWKHRQVHWLVLQWKHVDPH\HDULIRQO\WKH
RQVHW\HDULVDYDLODEOHRUWKHRQVHWLVLQWKHVDPHPRQWKDQG\HDULIWKHGD\LV
PLVVLQJDVVWDUWRIVWXG\WUHDWPHQWWKHRQVHWGDWHZLOOEHUHSODFHGE\WKHPLQLPXP
RIVWDUWRIVWXG\WUHDWPHQWDQG$(UHVROXWLRQGDWH
o ,QDOORWKHUFDVHVWKHPLVVLQJRQVHWGD\RURQVHWPRQWKZLOOEHUHSODFHGE\
o ,QFRPSOHWHVWRSGDWHVZLOOEHUHSODFHGE\WKHODVWGD\RIWKHPRQWKLIGD\LVPLVVLQJ
RQO\LIQRWUHVXOWLQJLQDGDWHODWHUWKDQWKHGDWHRIVXEMHFW
VGHDWK,QWKHODWWHU
FDVHWKHGDWHRIGHDWKZLOOEHXVHGWRLPSXWHWKHLQFRPSOHWHVWRSGDWH
o ,QDOORWKHUFDVHVWKHLQFRPSOHWHVWRSGDWHZLOOQRWEHLPSXWHG
x )RULPSXWLQJPLVVLQJSDUWVRIGDWHVIRUWKHHIILFDF\DQDO\VHVWKHPLVVLQJGD\LQDGDWHZLOO
EHLPSXWHGDVIROORZV
o 7KHILIWHHQWKRIWKHPRQWKLIPRQWKDQG\HDUDUHGRFXPHQWHG7KLVDOVRLQFOXGHV
DOVRGDWHVRIVWDUWRIIROORZXSWKHUDS\
o ,QDOORWKHUFDVHVPLVVLQJRULQFRPSOHWHGDWHVZLOOQRWEHLPSXWHGLIQRWLQGLFDWHG
RWKHUZLVH
x ,IWKHODVWDGPLQLVWUDWLRQGDWHLVLQFRPSOHWHWKHGDWHRIODVWDGPLQLVWUDWLRQZLOOEHWDNHQ
IURP WUHDWPHQW WHUPLQDWLRQ H&5) SDJHV ³75($70(17 7(50,1$7,21 )25
06&-´³75($70(177(50,1$7,21)25*(),7,1,%´³75($70(17
7(50,1$7,21 )25 3(0(75(;('´ ³75($70(17 7(50,1$7,21 )25
&,63/$7,1´RU³75($70(177(50,1$7,21)25&$5%23/$7,1´
,QLQGLYLGXDOVXEMHFWGDWDOLVWLQJVWKHGRFXPHQWHGGDWHDVJLYHQLQWKHH&5)ZLOOEHUHSRUWHG
HJBB0D\LQFDVHRIGD\PLVVLQJEXWPRQWKDQG\HDUDYDLODEOH,QVXEMHFWGDWDOLVWLQJV
LPSXWHGYDOXHVZLOOEHSUHVHQWHGLIDSSOLFDEOHDQGLPSXWHGLQIRUPDWLRQZLOOEHIODJJHG


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







0LVVLQJVWDWLVWLFVHJZKHQWKH\FDQQRWEHFDOFXODWHGVKRXOGEHSUHVHQWHGDV³QG´)RUH[DPSOH
LIQ WKHPHDVXUHRIYDULDELOLW\VWDQGDUGGHYLDWLRQFDQQRWEHFRPSXWHGDQGVKRXOGEHSUHVHQWHG
DV³QG´
6RIWZDUHYHUVLRQ
$OO DQDO\VHV ZLOO EH FRQGXFWHG XVLQJ 6$6 

YHUVLRQRUKLJKHU
 
7ULDO6XEMHFWV
7KH VXEVHFWLRQV LQ WKLV VHFWLRQ LQFOXGH VSHFLILFDWLRQV IRU UHSRUWLQJ VXEMHFW GLVSRVLWLRQ DQG
WUHDWPHQWWULDO GLVFRQWLQXDWLRQV $GGLWLRQDOO\ SURFHGXUHV IRU UHSRUWLQJ SURWRFRO GHYLDWLRQV DUH
SURYLGHG
 
'LVSRVLWLRQRI6XEMHFWVDQG'LVFRQWLQXDWLRQV
$OOVXEMHFWVZKRSURYLGHLQIRUPHGFRQVHQWZLOOEHDFFRXQWHGIRULQWKLVVWXG\6XEMHFWGLVSRVLWLRQ
DQGZLWKGUDZDOVZLOOEHSUHVHQWHGIRUWKHVFUHHQLQJDQDO\VLVVHW
6XEMHFWVZLOOUHPDLQLQWKHVWXG\XQWLOEXWQRWOLPLWHGWRGHDWKSURJUHVVLRQRIGLVHDVHORVVWR
IROORZXSRUZLWKGUDZDORIFRQVHQW6XEMHFWVDUHIUHHWRZLWKGUDZIURPWKHVWXG\DWDQ\WLPH
ZLWKRXWJLYLQJWKHLUUHDVRQV
,I D VXEMHFW ZLWKGUDZV FRQVHQW IURP WKH RSWLRQDO SKDUPDFRJHQRPLF DVVHVVPHQWV WKH\ PD\
FRQWLQXHRQWKHWULDO
7KHIROORZLQJVXPPDULHVZLOOEHSURYLGHGIRUDOOVFUHHQHGVXEMHFWVZLWKLQWKHUDQGRPL]HGSDUW
VLQJOHDUPFRKRUW
x 7RWDOQXPEHURIVXEMHFWVVFUHHQHGLHVXEMHFWVZKRJDYHLQIRUPHGFRQVHQW
x 1XPEHURIVXEMHFWVZKRGLVFRQWLQXHGIURPWKHWULDOSULRUWRUDQGRPL]DWLRQRYHUDOODQG
JURXSHGE\WKHPDLQUHDVRQHJ6XEMHFWGLGQRWPHHWDOOHOLJLELOLW\FULWHULD:LWKGUHZ
LQIRUPHGFRQVHQW3URJUHVVLYHGLVHDVH'HDWK$GYHUVH(YHQW/RVWWRIROORZXS/RVWWR
IROORZXS>)RUVLQJOHDUPFRKRUWQXPEHURIVXEMHFWVZKRGLVFRQWLQXHGIURPWKHWULDOSULRU
WRWUHDWPHQWZLOOEHGLVSOD\HG@
x 1XPEHURIUDQGRPL]HGVXEMHFWVIRUVLQJOHDUPFRKRUWQXPEHURIHQUROOHGVXEMHFWV>LH
WKRVHZKRJDYHLQIRUPHGFRQVHQWDQGZKRZHUHDOORFDWHGWRVLQJOHDUPFRKRUW@ZLOOEH
GLVSOD\HG
x 1XPEHURIVXEMHFWVZKRFRPSOHWHGWKHWUHDWPHQWLQHDFKWUHDWPHQWJURXS
$VXEMHFWZKRFRPSOHWHGWUHDWPHQWLVGHILQHGDVIROORZV
o WKHVXEMHFWGLHGRU
o WKHVXEMHFWKDVEHHQDVVHVVHGDVKDYLQJSURJUHVVLYHGLVHDVH
PPD
PPD


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







,QDGGLWLRQFLVSODWLQWUHDWPHQWFRPSOHWHGLVGHILQHGDVWKHVXEMHFWKDVFRPSOHWHGF\FOHV
FLVSODWLQFDUERSODWLQ WUHDWPHQW RU KDV FRPSOHWHG  F\FOHV DGPLQLVWUDWLRQ RI
FLVSODWLQFDUERSODWLQIROORZHGE\SHPHWUH[HGPDLQWHQDQFH
x 1XPEHU RI VXEMHFWV ZKR GLVFRQWLQXHG WKH WUHDWPHQW DIWHU UDQGRPL]DWLRQ JURXSHG E\
WUHDWPHQWDUPDQGPDLQUHDVRQVHSDUDWHO\IRUHDFKWUHDWPHQWFRPSRQHQWIRUVLQJOHDUP
FRKRUWQXPEHURIVXEMHFWVZKRGLVFRQWLQXHGWKHWUHDWPHQWDIWHUDOORFDWLRQWRWUHDWPHQW
x 1XPEHURIUDQGRPL]HGVXEMHFWVZKRFRQWLQXHGRQO\LQVXUYLYDODQGGLVHDVHIROORZXSDIWHU
UDQGRPL]DWLRQ JURXSHG E\ WUHDWPHQW DUP IRU VLQJOHDUP FRKRUW QXPEHU RI HQUROOHG
VXEMHFWVZKRFRQWLQXHGRQO\LQVXUYLYDODQGGLVHDVHIROORZXSDIWHUWUHDWPHQWDOORFDWLRQ
ZLOOEHGLVSOD\HG
x 1XPEHURIUDQGRPL]HGVXEMHFWVZKRGLVFRQWLQXHGWKHWULDODIWHUUDQGRPL]DWLRQJURXSHG
E\WUHDWPHQWDUPDQGPDLQUHDVRQIRUVLQJOHDUPFRKRUWQXPEHURIHQUROOHGVXEMHFWVZKR
GLVFRQWLQXHGDIWHUWUHDWPHQWDOORFDWLRQZLOOEHGLVSOD\HG
7KHQXPEHURIVXEMHFWVLQHDFKRIWKHIROORZLQJDQDO\VLVVHWVZLOOEHVXPPDUL]HG,QDGGLWLRQWKH
SHUFHQWDJHRIDQDO\VLVVHWVH[FHSWLQJVFUHHQLQJDQDO\VLVVHWZLOOEHSUHVHQWHGZLWKSHUFHQWDJH
EDVHGRQWKHQXPEHURIVXEMHFWVLQ,77$QDO\VLV6HW
x 6FUHHQLQJ$QDO\VLV6HW
x 6DIHW\$QDO\VLV6HW
x ,77$QDO\VLV6HW
x 4R/(YDOXDWLRQ3RSXODWLRQ
x 

x 3G$QDO\VLV6HW
,QDGGLWLRQDQDO\VLVVHWVE\VLWHZLOOEHSUHVHQWHG
7KHUHVXOWVRIWKHUDQGRPL]DWLRQDOJRULWKPDFFRUGLQJWR,956ZLOOEHVXPPDUL]HGDVIROORZV
XVLQJ,77DQDO\VLVVHWIRUUDQGRPL]HGSDUW
x 7KHQXPEHURIVXEMHFWVUDQGRPL]HG,956RYHUDOOE\UHJLRQE\FRXQWU\ZLWKLQUHJLRQ
x 1XPEHURIUDQGRPL]HGVXEMHFWVE\UDQGRPL]DWLRQVWUDWD,956
x &URVVWDEXODWLRQVXEMHFWVUDQGRPL]HGWHSRWLQLEJHILWLQLE
SHPHWUH[HGFDUERSODWLQFLVSODWLQYVWUHDWHGWHSRWLQLEJHILWLQLE
SHPHWUH[HGFDUERSODWLQFLVSODWLQ
 
%LRPDUNHU6FUHHQLQJ
$VXPPDU\WDEOHDQGOLVWLQJRIELRPDUNHUVFUHHQLQJDFWLYLWLHVZLOOEHSURYLGHGIRUWKHVFUHHQLQJ
DQDO\VLVVHWUHJDUGOHVVRIVWXG\DUP7KHVXPPDU\WDEOHZLOOSURYLGHWKHIROORZLQJLQIRUPDWLRQ
x (*)5JHQHWLFPXWDWLRQVWDWXV
o 1XPEHURISDWLHQWVWHVWHGZLOGW\SHPXWDWHGQRWDYDLODEOHIHDVLEOH
x 70VWDWXV
CCI


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







o 1XPEHURISDWLHQWVWHVWHGSRVLWLYHQHJDWLYHQRWDYDLODEOHIHDVLEOH
x 0(7VWDWXV,+&3URWHLQRYHUH[SUHVVLRQ
o 1XPEHU RI SDWLHQWV WHVWHG  ,+&  ,+&  ,+&  ,+&  QRW
DYDLODEOHIHDVLEOH
x 0(7VWDWXV,6+±*HQHDPSOLILFDWLRQF0HW&(3FRS\QXPEHUUDWLR
o 1XPEHURISDWLHQWVWHVWHGQRWDYDLODEOHIHDVLEOH
x 0(7VWDWXV,6+±0HDQ*HQH&RS\1XPEHU
o 1XPEHURISDWLHQWVWHVWHGQRWDYDLODEOHIHDVLEOH
x 0(7VWDWXV,6+±*HQHDPSOLILFDWLRQRU0HDQ*HQH&RS\1XPEHU
o 1XPEHURISDWLHQWVWHVWHG*HQHDPSOLILFDWLRQRU0HDQ*HQH&RS\1XPEHU
  1HLWKHU JHQH DPSOLILFDWLRQ QRU 0HDQ *HQH &RS\ 1XPEHU   QRW
DYDLODEOHIHDVLEOH
,QDGGLWLRQIRUWKRVHZLWK(*)5PXWDWLRQDVXPPDU\WDEOHRI0(7VWDWXV,6+E\70VWDWXV
SRVLWLYHQHJDWLYHQRWDYDLODEOHIHDVLEOHDQG0(7VWDWXV,+&,+&,+&,+&,+&
QRWDYDLODEOHIHDVLEOHZLOOEHSURYLGHGIRUWKHVFUHHQLQJDQDO\VLVVHWUHJDUGOHVVRIVWXG\DUP
7KHVXPPDU\WDEOHZLOOSURYLGHWKHIROORZLQJLQIRUPDWLRQ
x 0(7VWDWXV±*HQHDPSOLILFDWLRQF0HW&(3FRS\QXPEHUUDWLR
o 1XPEHURISDWLHQWVWHVWHGQRWDYDLODEOHIHDVLEOH
x 0(7VWDWXV±0HDQ*HQH&RS\1XPEHU
o 1XPEHURISDWLHQWVWHVWHGQRWDYDLODEOHIHDVLEOH
x 0(7VWDWXV±*HQHDPSOLILFDWLRQRU0HDQ*HQH&RS\1XPEHU
o 1XPEHURISDWLHQWVWHVWHG*HQHDPSOLILFDWLRQRU0HDQ*HQH&RS\1XPEHU
  1HLWKHU JHQH DPSOLILFDWLRQ QRU 0HDQ *HQH &RS\ 1XPEHU   QRW
DYDLODEOHIHDVLEOH
 
3URWRFRO'HYLDWLRQV
Population: ITT Analysis Set for the randomized part, Safety Analysis Set for the single-arm cohort 
unless otherwise specified.  
 
,PSRUWDQW3URWRFRO'HYLDWLRQV
7KH IROORZLQJ VXPPDU\ WDEOHV DQG OLVWLQJV RI LPSRUWDQW SURWRFRO GHYLDWLRQV ZLOO EH SURYLGHG
VHSDUDWHO\IRUSUHSRVWLQFOXVLRQGHYLDWLRQV
x )UHTXHQF\WDEOHSHUUHDVRQRILPSRUWDQWSURWRFROGHYLDWLRQV
x /LVWLQJRILPSRUWDQWSURWRFROGHYLDWLRQV
 
5HDVRQV/HDGLQJWRWKH([FOXVLRQIURPDQ$QDO\VLV6HW
1RWDSSOLFDEOHIRUWKLVVWXG\


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







 
'HPRJUDSKLFVDQG2WKHU%DVHOLQH&KDUDFWHULVWLFV
Population: ITT Analysis Set for the randomized part, Safety Analysis Set for the single-arm cohort 
unless otherwise specified.  
'HPRJUDSKLFGDWDDQGRWKHUEDVHOLQHFKDUDFWHULVWLFVZLOOEHSUHVHQWHGXVLQJVXPPDU\VWDWLVWLFVIRU
FRQWLQXRXVYDULDEOHVDQGIUHTXHQF\WDEOHVIRUFDWHJRULFDOYDULDEOHV
 
'HPRJUDSKLFV
'HPRJUDSKLF FKDUDFWHULVWLFV ZLOO EH VXPPDUL]HG XVLQJ WKH IROORZLQJ LQIRUPDWLRQ IURP WKH
6FUHHQLQJ%DVHOLQH9LVLWH&5)SDJHV
'HPRJUDSKLFFKDUDFWHULVWLFV
x *HQGHUPDOHIHPDOH
x $JH\HDUV
x $JHFDWHJRULHV\HDUV\HDUV\HDUV
x 5HJLRQ*UHDWHU&KLQD&KLQDDQG7DLZDQ2XWVLGHRI*UHDWHU&KLQDRWKHUFRXQWULHV
x 5DFH$VLDQQRQ$VLDQ
+HLJKW:HLJKW%RG\6XUIDFH$UHDDQG%RG\0DVV,QGH[
x +HLJKWFP
x :HLJKWNJ
x %RG\6XUIDFH$UHD%6$P
x %RG\0DVV,QGH[%0,NJP
(DVWHUQ&RRSHUDWLYH2QFRORJ\*URXS(&2*SHUIRUPDQFHVWDWXV
6PRNLQJ6WDWXVDW%DVHOLQH
x 1LFRWLQHXVHVWDWXVQHYHUXVHGUHJXODUXVHURFFDVLRQDOXVHUIRUPHUXVHU
x 6PRNLQJKLVWRU\QHYHUVPRNHGHYHUVPRNHG
5HVXOWRIFKHVW;UD\QRUPDODEQRUPDO
6SHFLILFDWLRQVIRUFRPSXWDWLRQ
x $JH\HDUVGDWHRI JLYHQLQIRUPHGFRQVHQW GDWHRIELUWKSUHVHQWHGWR
GHFLPDOSODFH
x %0,NJP ZHLJKWNJ>KHLJKWP@
x %6$Pð >KHLJKWFP[ZHLJKWNJ@
x 6LWHFRGHVZLOOEHXVHGIRUWKHGHWHUPLQDWLRQRIWKHVXEMHFW¶VJHRJUDSKLFUHJLRQ


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







 
0HGLFDO+LVWRU\
7KHPHGLFDOKLVWRU\ZLOOEHVXPPDUL]HGIURPWKH³0HGLFDO+LVWRU\´H&5)SDJHXVLQJWKH0HGLFDO
'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV0HG'5$9HUVLRQRUKLJKHUSUHIHUUHGWHUP37DV
HYHQWFDWHJRU\DQG0HG'5$V\VWHPRUJDQFODVV62&ERG\WHUPDV%RG\6\VWHPFDWHJRU\
0HGLFDOKLVWRU\ZLOOEHVXPPDUL]HGLQWHUPVRIIUHTXHQF\WDEOHVRUGHUHGE\SULPDU\62&DQG37
LQDOSKDEHWLFDORUGHU
 
'LVHDVH+LVWRU\
'LVHDVH KLVWRU\ LV FROOHFWHG RQ ³'LVHDVH +LVWRU\´ H&5) IRUP ,QIRUPDWLRQ RQ GLVHDVH KLVWRU\
FROOHFWHGDWWKHSUHWUHDWPHQWHYDOXDWLRQYLVLWZLOOEHSUHVHQWHG
6XPPDU\VWDWLVWLFVZLOOEHSUHVHQWHGIRU
x 6LWHRI3ULPDU\WXPRU8SSHUOREHOXQJ0LGGOHOREHOXQJULJKWOXQJRQO\/RZHUOREH
OXQJ2YHUODSSLQJOHVLRQRIOXQJ/XQJQRWRWKHUZLVHVSHFLILHG126
x 7LPHVLQFHLQLWLDOGLDJQRVLV\HDUV
x 7LPHVLQFHILUVWRFFXUUHQFHRIDGYDQFHGGLVHDVH\HDUV
x 7LPHVLQFHPRVWUHFHQWGLVHDVHSURJUHVVLRQ\HDUV
x 7XPRU KLVWRSKDWKRORJLFF\WRORJLF W\SH VTXDPRXV DGHQRFDUFLQRPD ODUJH FHOO
EURQFKRDOYHRODURWKHU
x +LVWRORJLF WXPRU JUDGHGLIIHUHQWLDWLRQ ZHOO GLIIHUHQWLDWHG PRGHUDWHO\ GLIIHUHQWLDWHG
SRRUO\GLIIHUHQWLDWHGQRWDSSOLFDEOH
x 710FODVVLILFDWLRQDWLQLWLDOGLDJQRVLVDQGDWVWXG\HQWU\GLVSOD\DOORSWLRQV
x 0HWDVWDVLVVLWHVDWLQLWLDOGLDJQRVLVDQGDWVWXG\HQWU\GLVSOD\DOORSWLRQV
x (*)5JHQHWLFPXWDWLRQVWDWXVZLOGW\SHPXWDWHGQRWDYDLODEOHIHDVLEOH
x /RFDWLRQRI(*)5VDPSOLQJSULPDU\PHWDVWDVLV
6SHFLILFDWLRQVIRUFRPSXWDWLRQ
x 7LPHVLQFHLQLWLDOGLDJQRVLV\HDUV  GDWHRILQIRUPHGFRQVHQW±GDWHRIGLDJQRVLV
SUHVHQWHGWRGHFLPDOSODFH
x 7LPHVLQFHILUVWRFFXUUHQFHRIDGYDQFHGGLVHDVH\HDUV GDWHRILQIRUPHGFRQVHQW±GDWH
RIILUVWRFFXUUHQFHRIDGYDQFHGGLVHDVHSUHVHQWHGWRGHFLPDOSODFH
x 7LPHVLQFHPRVWUHFHQWGLVHDVHSURJUHVVLRQ\HDUV GDWHRILQIRUPHGFRQVHQW±GDWHRI
PRVWUHFHQWGLVHDVHSURJUHVVLRQSUHVHQWHGWRGHFLPDOSODFH


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







 
3ULRU$QWL&DQFHU7UHDWPHQWV
,QIRUPDWLRQUHODWHGWRSULRUDQWLFDQFHUWKHUDSLHVDQGVXUJHULHVZHUHFROOHFWHGRQ³3ULRU$QWL
&DQFHU 'UXJ 7KHUDSLHV 'HWDLOV´ ³3ULRU $QWL&DQFHU 5DGLRWKHUDS\ 'HWDLOV´ DQG ³3ULRU $QWL
&DQFHU6XUJHULHV'HWDLOV´H&5)IRUPVDQGZLOOEHVXPPDUL]HG
7KHQXPEHURIVXEMHFWVLQHDFKRIWKHIROORZLQJDQWLFDQFHUWKHUDS\FDWHJRULHVZLOOEHWDEXODWHG
x 6XEMHFWVZLWKDWOHDVWRQHW\SHRISULRUDQWLFDQFHUWUHDWPHQW
x 6XEMHFWVZLWKDWOHDVWRQHSULRUDQWLFDQFHUGUXJWKHUDS\
x 6XEMHFWVZLWKDWOHDVWRQHSULRUDQWLFDQFHUUDGLRWKHUDS\
x 6XEMHFWVZLWKDWOHDVWRQHSULRUDQWLFDQFHUVXUJHU\
6XPPDU\VWDWLVWLFVZLOOEHSUHVHQWHGIRU
x 3ULRUDQWLFDQFHUGUXJWKHUDS\
o $Q\SULRUDQWLFDQFHUGUXJWKHUDS\
o 1XPEHURISULRUDQWLFDQFHUWKHUDS\UHJLPHQOLQHPLVVLQJ
o 7\SHRIV\VWHPLFWKHUDS\
o ,QWHQWRIWKHUDS\
o %HVWUHVSRQVH
x 3ULRUDQWLFDQFHUUDGLRWKHUDS\
o $Q\SULRUDQWLFDQFHUUDGLRWKHUDS\
o 1XPEHURISULRUDQWLFDQFHUUDGLRWKHUDS\UHJLPHQOLQHPLVVLQJ
o 7\SHRIWKHUDS\
o ,QWHQWRIWKHUDS\
o %HVWUHVSRQVH
x 3ULRUDQWLFDQFHUVXUJHU\
o $Q\SULRUDQWLFDQFHUVXUJHU\
o 1XPEHURISULRUDQWLFDQFHUVXUJHULHV
o 7KHVXUJHU\ZDVFXUDWLYHLQLQWHQW\HVQR
o 2XWFRPHRIVXUJHU\
3ULRUDQWLFDQFHU GUXJ WKHUDSLHV ZLOO EH VXPPDUL]HG LQ WHUPV RI IUHTXHQF\WDEOHVRUGHUHGE\
SUHIHUUHGWHUPIURP:+2'UXJ'LFWLRQDU\:+2''LQDOSKDEHWLFDORUGHU
/LVWLQJV RI SULRU DQWLFDQFHU WUHDWPHQWV DQG SURFHGXUHV ZLOO EH SURYLGHG D OLVWLQJ RI SULRU
DQWLFDQFHU GUXJ WKHUDSLHV E OLVWLQJ RI SULRU DQWLFDQFHU UDGLRWKHUDS\ DQG F OLVWLQJ RI SULRU
DQWLFDQFHUVXUJHULHV7KHVHZLOOLQFOXGHWKHVXEMHFWLGHQWLILFDWLRQQXPEHUDQGDOOWKHUHOHYDQW
FROOHFWHGGDWDILHOGVRQWKHFRUUHVSRQGLQJH&5)IRUP


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







 
%DVHOLQH%LRPDUNHUV0HDVXUHGLQ7XPRU7LVVXH
 
%DVHOLQH%LRPDUNHU9DULDEOHV
 
%DVHOLQH7XPRUF0HW([SUHVVLRQ
7KHIROORZLQJVFRUHVZLOOEHSURYLGHGE\WKHSDWKRORJLVWEDVHGRQF0HWH[SUHVVLRQUDZGDWD
PHDVXUHGE\,+&LQSUHWUHDWPHQWRUDUFKLYHGWXPRUELRSVLHV
x F0HW+VFRUHWXPRUFHOOF\WRSODVPDWEDVHOLQHFRQWLQXRXV
x F0HW+VFRUHWXPRUFHOOPHPEUDQHDWEDVHOLQHFRQWLQXRXV
x 0HWVFRUHDWEDVHOLQHSRVVLEOHYDOXHV
,QJHQHUDOPHDVXUHPHQWVIODJJHGDVQRQHYDOXDEOHZLOOQRWEHWDNHQLQWRDFFRXQWIRUDQDO\VLV
7KLVVFRUHZLOOEHXVHGLQDOOWDEOHVILJXUHVDQGOLVWLQJZKHUHWKHOHYHO0HWVFRUHLVSUHVHQWHG
H[FHSWOLVWLQJVRIUDZF0HWH[SUHVVLRQGDWD
 
%DVHOLQH7XPRUF0HW$PSOLILFDWLRQ
7KHIROORZLQJSDUDPHWHUVZLOOEHSURYLGHGIRU),6+DQDO\VLVRISUHWUHDWPHQWRUDUFKLYHGWXPRU
ELRSVLHV
x ),6+DQDO\VLV
o F0HWFRS\QXPEHU
o &(3FRS\QXPEHU
o F0HW&(3FRS\QXPEHUUDWLR
o 0HDQ*HQH&RS\1XPEHU
o ),6+VWDWXV
),6+LHHLWKHU0HDQ*HQH&RS\1XPEHURUF0HW&(3FRS\QXPEHUUDWLRZLOOEH
FRQVLGHUHGDVDPSOLILHG
,QJHQHUDOPHDVXUHPHQWVIODJJHGDVQRQHYDOXDEOHZLOOQRWEHWDNHQLQWRDFFRXQWIRUDQDO\VLV
 
%DVHOLQH7XPRU+*)([SUHVVLRQ
7KH IROORZLQJ VFRUH ZLOO EH SURYLGHG E\ WKH SDWKRORJLVW EDVHG RQ +*) H[SUHVVLRQ UDZ GDWD
PHDVXUHGE\,+&LQSUHWUHDWPHQWRUDUFKLYHGWXPRUELRSVLHV
x &$)+*)+VFRUHDWEDVHOLQHFRQWLQXRXV
x &\WRSODVPLF+*)+VFRUHDWEDVHOLQHFRQWLQXRXV
,QJHQHUDOPHDVXUHPHQWVIODJJHGDVQRQHYDOXDEOHZLOOQRWEHWDNHQLQWRDFFRXQWIRUDQDO\VLV


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







7KHEDVHOLQH+*)+VFRUHVZLOOQRWEHDQDO\]HGIRUFRUUHODWLRQDVVRFLDWLRQWRHIILFDF\SDUDPHWHUV
0RUHRYHUWKH+*)+VFRUHVZLOOEHFDWHJRUL]HGLQWKHIROORZLQJZD\
x 7KHYDULDEOHEDVHOLQH+*)+VFRUHJURXS>YVDQ\YDOXH@ZLOOKDYHWKHIROORZLQJOHYHOV
+VFRUH+VFRUH!+VFRUHQRWGRQH+VFRUHQRWHYDOXDEOH
 
'HVFULSWLYH6XPPDULHVRI%DVHOLQH%LRPDUNHUV
 
%DVHOLQH7XPRUF0HW([SUHVVLRQ
%DVHOLQH0HWVFRUHZLOOEHVXPPDUL]HGGHVFULSWLYHO\LQDIUHTXHQF\WDEOH
0RUHRYHU UDZ F0HW H[SUHVVLRQ GDWD IURP SUHWUHDWPHQW WXPRU ELRSVLHV ZLOO EH SUHVHQWHG LQ
OLVWLQJV
 
%DVHOLQH7XPRUF0HW$PSOLILFDWLRQ6WDWXV
%DVHOLQH ),6+ VWDWXV F0HW&(3 FRS\ QXPEHU UDWLR DQG PHDQ JHQH FRS\ QXPEHU ZLOO EH
VXPPDUL]HGGHVFULSWLYHO\XVLQJVXPPDU\VWDWLVWLFV,QDGGLWLRQWKHIROORZLQJFDWHJRULHVZLOOEH
VXPPDUL]HG
x 0HDQ*HQH&RS\1XPEHU
x F0HW&(3FRS\QXPEHUUDWLR
x ),6+6WDWXV),6+HLWKHU0HDQ*HQH&RS\1XPEHURUF0HW&(3FRS\QXPEHU
UDWLR),6+
 
&RUUHODWLRQEHWZHHQ%DVHOLQHF0HW([SUHVVLRQDQG
$PSOLILFDWLRQ6WDWXV
7KHFRUUHODWLRQDVVRFLDWLRQEHWZHHQF0HWH[SUHVVLRQDQGDPSOLILFDWLRQVWDWXVZLOOEHDQDO\]HG
E\SUHVHQWLQJDFURVVWDEXODWLRQWDEOHIRU0HWVFRUHE\F0HWDPSOLILFDWLRQVWDWXV&URVVWDEXODWLRQ
WDEOHVZLOORQO\EHSUHVHQWHGE\UHJLPHQ
 
%DVHOLQHWXPRU+*)H[SUHVVLRQ6WDWXV
%DVHOLQH+*)VFRUH&$)+*)+VFRUHDQG&\WRSODVPLF+*)+VFRUHZLOOEHVXPPDUL]HG
GHVFULSWLYHO\XVLQJVXPPDU\VWDWLVWLFV
0RUHRYHUUDZ+*)IURPSUHWUHDWPHQWWXPRUELRSVLHVZLOOEHSUHVHQWHGLQOLVWLQJV
 
%DVHOLQH%LRPDUNHUV0HDVXUHGLQ3ODVPD
 
%DVHOLQH%LRPDUNHU9DULDEOHV
)RUH[SORUDWRU\DQDO\VHVOHYHOVRIVKHGGHGF0HW,/DQG+*)ZLOOEHPHDVXUHGLQSODVPDE\
(/,6$DVVD\DWEDVHOLQH&\FOH'D\SUHGRVHDQGVHYHUDOSRVWEDVHOLQHWLPHSRLQWV


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







)RUDOOFRUUHODWLRQDVVRFLDWLRQDQDO\VHVEDVHGRQEDVHOLQHOHYHOVRIVKHGGHGF0HW,/DQG+*)
WKHEDVHOLQHOHYHOVZLOOEHFDWHJRUL]HGEDVHGRQWKHPHGLDQ7KHIROORZLQJFDWHJRULHVZLOOEHXVHG
DERYHWKHPHGLDQEHORZDWWKHPHGLDQQRWGRQHQRWHYDOXDEOH
$GGLWLRQDOO\IRU+*)DIXUWKHUFDWHJRUL]DWLRQEDVHGRQWKHXSSHUTXDUWLOHTXDQWLOHZLOOEH
LQWURGXFHG )RU WKLV DQDO\VLV WKH IROORZLQJ FDWHJRULHV ZLOO EH XVHG DERYH WKH XSSHU TXDUWLOH
EHORZDWWKHXSSHUTXDUWLOHQRWGRQHQRWHYDOXDEOH
 
'HVFULSWLYH6XPPDULHVRI%DVHOLQH%LRPDUNHU9DULDEOHV
%DVHOLQHOHYHOVRIVKHGGHGF0HW,/DQG+*)ZLOOEHVXPPDUL]HGGHVFULSWLYHO\XVLQJVXPPDU\
VWDWLVWLFV0RUHRYHUIUHTXHQFLHVRIFDWHJRUL]HGEDVHOLQHOHYHOVZLOOEHSUHVHQWHG
 
2WKHU%DVHOLQH&KDUDFWHULVWLFV
7XPRUELRSV\DQG0(7VWDWXVZLOOEHVXPPDUL]HGIRU
x /RFDWLRQRI0(7VDPSOLQJSULPDU\PHWDVWDVLV
x 70PXWDWLRQVWDWXVSRVLWLYHQHJDWLYHLQGHWHUPLQDWH
x 70 VWDWXV GRFXPHQWHG RU GHWHUPLQHG E\ FHQWUDO ODERUDWRU\ XVLQJ WKH 4,$*(1
WKHUDVFUHHQ(*)55*43&5.LW
x /RFDWLRQRI70VDPSOLQJSULPDU\PHWDVWDVLV
%DVHOLQH FKDUDFWHULVWLFV ZLWK UHVSHFW WR SK\VLFDO H[DPLQDWLRQV KHPDWRORJ\ELRFKHPLVWU\ YLWDO
VLJQVDQG(&*ZLOOEHSDUWRI6HFWLRQ6DIHW\$QDO\VHV
 
%DVHOLQH7XPRU/HVLRQV
7DUJHWOHVLRQDVVHVVPHQWVDWEDVHOLQHZLOOEHVXPPDUL]HGDV
x 1XPEHURIVXEMHFWVZLWKDWOHDVWRQHWDUJHWOHVLRQ
x 1XPEHURIWDUJHWOHVLRQVJURXSHGDV«$OVRVXPPDUL]HGDVFRQWLQXRXVYDULDEOH
x /HVLRQVLWH
x /HVLRQW\SHSULPDU\UHFXUUHQFHQRGHPHWDVWDVLV!
x $VVHVVPHQWPHWKRG
x 6XPRIORQJHVWGLDPHWHUIRUQRQQRGDOOHVLRQVDQGVKRUWD[LVIRUQRGDOOHVLRQV
1RQWDUJHWOHVLRQDVVHVVPHQWVDWEDVHOLQHZLOOEHVXPPDUL]HGDV
x 1XPEHURIVXEMHFWVZLWKDWOHDVWRQHQRQWDUJHWOHVLRQ
x 1XPEHURIQRQWDUJHWOHVLRQVJURXSHGDV «$OVRVXPPDUL]HGDVFRQWLQXRXV
YDULDEOH
x /HVLRQW\SHSULPDU\UHFXUUHQFHQRGHPHWDVWDVLV


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







x $VVHVVPHQWPHWKRG
 
3UHYLRXVDQG&RQFRPLWDQW0HGLFDWLRQV3URFHGXUHV
Population: ITT Analysis Set for the randomized part, Safety Analysis Set for the single-arm cohort 
unless otherwise specified.  
 
0HGLFDWLRQVDQG3URFHGXUHV
0HGLFDWLRQVUHFRUGHGRQWKH³&RQFRPLWDQW0HGLFDWLRQ'HWDLOV´H&5)IRUPDQGSURFHGXUHVRQWKH
³&RQFRPLWDQW3URFHGXUH'HWDLOV´H&5)IRUPZLOOEHXVHGDVGDWDVRXUFH
0HGLFDWLRQV ZLOO EH FRGHG DQG SUHVHQWHG XVLQJ :RUOG +HDOWK 2UJDQL]DWLRQ 'UXJ 'LFWLRQDU\
(QKDQFHG9HUVLRQ0DUFKRUKLJKHU$QDWRPLF7KHUDSHXWLF&KHPLFDO$7&FODVVOHYHO
$7&QGOHYHO3URFHGXUHVZLOOEHFRGHGXVLQJ0HG'5$9HUVLRQRUKLJKHUDQGUHSRUWHG
XVLQJ62&DQG37
0LVVLQJRUSDUWLDOGDWHVIRUPHGLFDWLRQVDQGSURFHGXUHVZLOOQRWEHLPSXWHG,ILWLVQRWSRVVLEOHWR
GHILQHDPHGLFDWLRQRUSURFHGXUHDVSULRURUFRQFRPLWDQWWKHHYHQWZLOOEHFODVVLILHGE\WKHZRUVW
FDVHLHFRQFRPLWDQW
x µ3UHYLRXV¶PHGLFDWLRQVRUSURFHGXUHVDUHWKRVHZKLFKVWDUWHGSULRUWRWKHILUVWGRVHRIVWXG\
WUHDWPHQW
x µ&RQFRPLWDQW¶PHGLFDWLRQVRUSURFHGXUHVDUHWKRVHZKLFK
o VWDUWHGSULRUWRRQRUDIWHUWKHILUVWGRVHRIVWXG\WUHDWPHQWDQGVWDUWHGQRODWHUWKDQ
GD\VIROORZLQJHQGRIVWXG\WUHDWPHQW
o $1'HQGHGRQRUDIWHUWKHGDWHRIILUVWGRVHRIVWXG\WUHDWPHQWRUZHUHRQJRLQJDW
WKHHQGRIWKHVWXG\
x µ3RVW¶PHGLFDWLRQVRUSURFHGXUHVDUHWKRVHZKLFKVWDUWHGPRUHWKDQGD\VIROORZLQJWKH
ODVWGRVHRIVWXG\WUHDWPHQW
7KHQXPEHURISDWLHQWVZLWKFRQFRPLWDQWPHGLFDWLRQVZLOOEHVXPPDUL]HGSHUWUHDWPHQWDUPDQG
RYHUDOO7KHQXPEHURISDWLHQWVZLOODOVREHSUHVHQWHGE\$7&QGOHYHODQGSUHIHUUHGWHUPIURP
WKH:+2''GLFWLRQDU\
7KHQXPEHURISDWLHQWVZLWKFRQFRPLWDQWSURFHGXUHVZLOOEHVXPPDUL]HGSHUWUHDWPHQWDUPDQG
RYHUDOO7KHQXPEHURISDWLHQWVZLOODOVREHSUHVHQWHGE\UHDVRQDQGE\62&DQG37
$OOPHGLFDWLRQVSURFHGXUHVZLOOEHOLVWHG
 
$QWL&DQFHU7UHDWPHQWDIWHU'LVFRQWLQXDWLRQ
$QWLFDQFHUWUHDWPHQWDIWHUWUHDWPHQWWHUPLQDWLRQREWDLQHGIURP³$QWL&DQFHU7UHDWPHQW$IWHU
'LVFRQWLQXDWLRQ'HWDLOV´H&5)SDJHZLOOEHVXPPDUL]HGIRUWKH6$)VHW


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







1HZ DQWLFDQFHUWKHUDS\ ZLOOEHUHFRUGHG IRU VXEMHFWV ZKR GLVFRQWLQXH IURP WKH WUHDWPHQWIRU
UHDVRQV RWKHU WKDQ 3' DW WKH DGGLWLRQDO IROORZXS YLVLWV 7KH IROORZLQJ VXPPDULHV ZLOO EH
SUHVHQWHGIRUDQWLFDQFHUWUHDWPHQWDIWHUGLVFRQWLQXDWLRQ
x $Q\DQWLFDQFHUWUHDWPHQWDIWHUGLVFRQWLQXDWLRQ\HVQR
x 7\SHRIV\VWHPLFWKHUDS\
x 7LPHWRVWDUWRIQHZDQWLFDQFHUWUHDWPHQWDIWHUGLVFRQWLQXDWLRQPRQWKVGHULYHGDVWKH
GXUDWLRQLQPRQWKVIURPUHIHUHQFHVWDUWGDWHWRWKHHDUOLHVWVWDUWGDWHRIDQWLFDQFHUGUXJV
DIWHUGLVFRQWLQXDWLRQ
x %HVWUHVSRQVH
 
7UHDWPHQW&RPSOLDQFHDQG([SRVXUH
Population: Safety Analysis Set
7KH H[WHQW RI H[SRVXUH WR WHSRWLQLE JHILWLQLE SHPHWUH[HG FLVSODWLQ DQG FDUERSODWLQ ZLOO EH
SUHVHQWHGIRUWKH6DIHW\DQDO\VLVVHW
$OOGRVLQJFDOFXODWLRQVDQGVXPPDULHVZLOOEHEDVHGRQ³06&-$'0,1,675$7,21
'(7$,/6´
³*(),7,1,%
$'0,1,675$7,21
'(7$,/6´
³3(0(75(;('
$'0,1,675$7,21
'(7$,/6´
³&,63/$7,1
$'0,1,675$7,21
'(7$,/6´
³&$5%23/$7,1 $'0,1,675$7,21 '(7$,/6´ ³$&&2817$%,/,7< ',63(16,1*
$1'5(7851*5283$´DQG³$&&2817$%,/,7<*5283%´H&5)VSDJHV
+DQGOLQJRIPLVVLQJGDWD
x ,IWKHVWDUWGDWHLVPLVVLQJLWLVDVVXPHGWKDWWKHILUVWGRVHRIWULDOGUXJLVJLYHQDWWKH
UHIHUHQFHVWDUWGDWH7KHUHIHUHQFHVWDUWGDWHZLOOUHSODFHLQFRPSOHWHGDWHVRIWKHHDUOLHVW
DGPLQLVWUDWLRQRIWULDOGUXJV
x ,IWKHODVWGRVLQJGDWHLVLQFRPSOHWHWKHGDWHRIODVWGRVLQJZLOOEHWDNHQIURPWKH7UHDWPHQW
7HUPLQDWLRQSDJH
x ,I%6$FDQQRWEHGHULYHGGXHWRPLVVLQJZHLJKWGDWDIURPWKHSUHYLRXVDYDLODEOHYLVLWZLOO
EHXVHGLQVWHDGLIGXHWRPLVVLQJKHLJKWDWVFUHHQLQJWKHQ%6$ZLOOEHPLVVLQJ,IQRRQ
WUHDWPHQW%6$WKHQEDVHOLQH%6$ZLOOEHXVHG
7KHIROORZLQJVXPPDULHVZLOOEHSUHVHQWHGIRUHDFKWUHDWPHQWFRPSRQHQWRQWKHH[SHULPHQWDODUP
WHSRWLQLEJHILWLQLE
LQFOXGLQJ
VLQJOH
DUP
FRKRUW
DQG
WKH
FRQWURO
DUP
SHPHWUH[HGFLVSODWLQFDUERSODWLQ
x 7RWDOQXPEHURILQIXVLRQVUHFHLYHGIRU3HPHWUH[HG&LVSODWLQDQG&DUERSODWLQVHSDUDWHO\
o 
o 'HVFULSWLYHVXPPDU\PHDQ6'PHGLDQ44PLQLPXPDQGPD[LPXP
x 'XUDWLRQRIWKHUDS\ZHHNV
o )RUWHSRWLQLERUJHILWLQLEGXUDWLRQ ቀ
GDWHRIODVWGRVHGDWHRIILUVWGRVH

ቁ


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







o )RUSHPHWUH[HGFLVSODWLQRUFDUERSODWLQGXUDWLRQ ቀ
GDWHRIODVWGRVHGDWHRIILUVWGRVH

ቁ
o ,QWHUUXSWLRQV FRPSOLDQFH DQG GRVH FKDQJHV DUH QRW WDNHQ LQWR DFFRXQW IRU WKH
FDOFXODWLRQRIGXUDWLRQRIWKHUDS\DVZHOO
x &XPXODWLYHGRVHPJ
o 7KHFXPXODWLYHGRVHPJSHUVXEMHFWLQDWLPHSHULRGLVWKHVXPRIWKHWRWDOGRVDJH
WKDWWKHVXEMHFWUHFHLYHG
x 'RVHLQWHQVLW\
o )RUWHSRWLQLERUJHILWLQLEPJGD\V'RVHLQWHQVLW\  ቀ
ୡ୳୫୳୪ୟ୲୧୴ୣ ୢ୭ୱୣ (୫୥)
ୢ୳୰ୟ୲୧୭୬ ୭୤ ୲୦ୣ୰ୟ୮୷ (ୢୟ୷ୱ)ቁ
o )RU
SHPHWUH[HG
RU
FLVSODWLQ
PJP
SHU
ZHHN
GRVH
LQWHQVLW\
 
ቀ
ୡ୳୫୳୪ୟ୲୧୴ୣ ୢ୭ୱୣ/୆ୗ୅ (୫୥/୫మ) 
ୢ୳୰ୟ୲୧୭୬ ୭୤ ୲୦ୣ୰ୟ୮୷ (୵ୣୣ୩ୱ) ቁ
o :KHUH%6$LVWKHDYDLODEOH%6$DWEDVHOLQHE\XVLQJKHLJKWDWVFUHHQLQJ
o )RUFDUERSODWLQ'RVHLQWHQVLW\  ቀ
ୡ୳୫୳୪ୟ୲୧୴ୣ ୢ୭ୱୣ (୫୥)
ୢ୳୰ୟ୲୧୭୬ ୭୤ ୲୦ୣ୰ୟ୮୷ (୵ୣୣ୩ୱ)ቁ
x 3ODQQHGGRVHLQWHQVLW\
o 7HSRWLQLE PJGD\JHILWLQLE PJGD\
o 3HPHWUH[HG PJPSHUZHHNFLVSODWLQ  PJPSHUZHHN
o &DUERSODWLQ 7DUJHW$8&PJP/îPLQî*)5P/PLQPJSHUZHHN
 :KHUH*)5P/PLQ &[íDJH>\HDUV@[ZHLJKW>NJ@[
VHUXPFUHDWLQLQHPJG/DQG& IRUIHPDOHVXEMHFWVDQG& 
IRUPDOHVXEMHFWVLHDFFRUGLQJWR&RFNFURIW*DXOW
x 5HODWLYHGRVHLQWHQVLW\
o 'RVHLQWHQVLW\3ODQQHGGRVHLQWHQVLW\î
o 7KHEUHDNGRZQRIUHODWLYHGRVHLQWHQVLW\
!ZLOOEHVXPPDUL]HG
x &RPSOLDQFHIRUWHSRWLQLERUJHILWLQLE
o 
 ୗ୳୫ ୭୤ (୲୭୲ୟ୪ ୬୳୫ୠୣ୰ ୭୤ ୲ୟୠ୪ୣ୲ୱ ୢ୧ୱ୮ୣ୬ୱୣୢכୢ୭ୱୟ୥ୣ ୭୤ ୲୦ୣ ୲ୟୠ୪ୣ୲ୱ)ିୗ୳୫ ୭୤ (୲୭୲ୟ୪ ୬୳୫ୠୣ୰ ୭୤ ୲ୟୠ୪ୣ୲ୱ ୰ୣ୲୳୰୬ୣୢכୢ୭ୱୟ୥ୣ ୭୤ ୲୦ୣ ୲ୟୠ୪ୣ୲ୱ) )
୮୪ୟ୬୬ୣୢ ୢ୭ୱୣ ୪ୣ୴ୣ୪ (୫୥)כୢ୳୰ୟ୲୧୭୬ ୭୤ ୲୦ୣ୰ୟ୮୷ (ୢୟ୷ୱ)

î
x 'RVHUHGXFWLRQV
o $GRVHUHGXFWLRQLVGHILQHGDVDQ\GRVHFKDQJHWROHVVWKDQRISODQQHGGRVH
OHYHO'RVHRPLVVLRQLVQRWFRQVLGHUHGDVGRVHUHGXFWLRQ
 7KHQXPEHURIVXEMHFWVZLWKDWOHDVWRQHGRVHUHGXFWLRQZLOOEHVXPPDUL]HG
E\IUHTXHQF\DQGSHUFHQWDJH


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







o 7KHGHULYHGPLQLPXPGRVHOHYHOVZLOOEHXVHGWRVXPPDUL]HGRVHUHGXFWLRQDV
IROORZV
 1XPEHURIVXEMHFWVSHUPLQLPXPGRVHOHYHOIRUHDFKWULDOGUXJ
 7KH PLQLPXP GRVHV RI WKH WULDO GUXJV ZLOO EH GHULYHG SHU VXEMHFW DQG
FDWHJRUL]HG DFFRUGLQJWRD DQGOHYHORIWKH
SODQQHGGRVH
x 2YHUGRVH
o $Q RYHUGRVH LV GHILQHG DV DQ\ GRVH JUHDWHU WKDQ WKH SODQQHG GDLO\ GRVH OHYHO
$SSOLHGIRUWHSRWLQLERUJHILWLQLE
 7KHQXPEHURIVXEMHFWVZLWKDWOHDVWRQHRYHUGRVHZLOOEHVXPPDUL]HGE\
IUHTXHQF\DQGSHUFHQWDJH
x 'RVHFKDQJHV
o 'RVHFKDQJHVDUHWKRVHFROOHFWHGE\WKH³$GPLQLVWUDWLRQ'HWDLOV´H&5)SDJHV
 1XPEHURIVXEMHFWZLWKDWOHDVWRQHRFFXUUHQFHRIGRVHDGMXVWHGRUQRGRVH
DQGWKHUHDVRQZLOOEHVXPPDUL]HG
x 7KHUDS\GHOD\V
o 'HOD\VRIZLOOEHGHULYHGDVIROORZLQJGHILQLWLRQDQGFDQRQO\EHFDOFXODWHGRQO\
IRU VXEMHFWV ZLWK DW OHDVW  DGPLQLVWUDWLRQV 'HOD\ ZLWKLQ  GD\V ZLOO QRW EH
FRQVLGHUHGDVWKHUDS\GHOD\V
o )RUSHPHWUH[HGFLVSODWLQRUFDUERSODWLQGHOD\LVGHILQHGDV
 DGPLQLVWUDWLRQVDVWKHQXPEHURIGD\VVLQFHWKHVWDUWRIODVWLQIXVLRQDQG
ZLOOEHSUHVHQWHGDVIROORZVQXPEHURIVXEMHFWVZLWKGHOD\HGLQIXVLRQVDQG
PD[LPXPOHQJWKRIGHOD\QRGHOD\!GD\VGD\VGD\V̢
ZRUVWFDVH
 DGPLQLVWUDWLRQVDVWKHQXPEHURIF\FOHVVLQFHODVWF\FOHZLWKLQWDNHDQGZLOO
EHSUHVHQWHGDVIROORZVQXPEHURIVXEMHFWVZLWKGHOD\HGDGPLQLVWUDWLRQ
DQGPD[LPXPOHQJWKRIGHOD\QRGHOD\F\FOHF\FOHVF\FOHV̢
ZRUVWFDVH
o )RUWHSRWLQLERUJHILWLQLEGHOD\LVGHILQHGDVKDYLQJPLVVHGRUPRUHSODQQHGGDLO\
GRVH DQG ZLOO EH SUHVHQWHG DV IROORZV QXPEHU RI VXEMHFWV ZLWK GHOD\HG
DGPLQLVWUDWLRQVDQGPD[LPXPOHQJWKRIGHOD\QRGHOD\GD\VGD\V
GD\V̢ZRUVWFDVH
 
(IILFDF\$QDO\VHV
8QOHVVRWKHUZLVHVSHFLILHGWKH,77DQDO\VLVVHWZLOOEHXVHGIRUWKHUDQGRPL]HGSDUWDQGWKH6$)
DQDO\VLVVHWZLOOEHXVHGIRUWKHVLQJOHDUPFRKRUW
$OOWUHDWPHQWFRPSDULVRQVRIHIILFDF\DUHEHWZHHQH[SHULPHQWDOWUHDWPHQWDQGFRQWUROWUHDWPHQW
RIUDQGRPL]HGSDUW7KHVLQJOHDUPFRKRUWGDWDZLOOEHRQO\SUHVHQWHGLQGHVFULSWLYHPDQQHU


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







 
3ULPDU\(QGSRLQW$QDO\VHV
 
3ULPDU\$QDO\VHVRI3URJUHVVLRQ)UHH6XUYLYDO
Population: ITT Analysis Set for the randomized part 
'HILQLWLRQRISULPDU\HQGSRLQW
7KHSULPDU\HQGSRLQWLV3)6DVDVVHVVHGE\WKH,QYHVWLJDWRUDFFRUGLQJWR5(&,67(LVHQKDXHU
($HWDO
3)6WLPHLVGHILQHGDVWKHWLPHLQPRQWKVIURPUHIHUHQFHVWDUWGDWHWRHLWKHUWKHILUVWREVHUYDWLRQ
RI3'DVDVVHVVHGE\,QYHVWLJDWRURUGHDWKGXHWRDQ\FDXVHZLWKLQGD\VRIHLWKHUDOORFDWLRQ
RIWUHDWPHQWRUWKHODVWWXPRUDVVHVVPHQW7KHGD\WLPHZLQGRZUHSUHVHQWVWZLFHWKHWLPHVSDQ
EHWZHHQVFKHGXOHGWXPRUDVVHVVPHQWV7KHHDUOLHVWVFDQGDWHRIWDUJHWQRQWDUJHWQHZOHVLRQVZLOO
EHXVHGDVWKHGDWHRIDQRYHUDOOUHVSRQVH
3)6PRQWKV GDWHRIVW3'RUGHDWK±UHIHUHQFHVWDUWGDWH
6WDUWGDWHRI3)6
(YHQWGDWHLVWKHHDUOLHVWGDWHRIWKHIROORZLQJHYHQWV
x 2EVHUYHG3'EHIRUHWKHVXEMHFWGURSVRXW2YHUDOOUHVSRQVHRI³QRWHYDOXDEOH´ZLOOEH
FKDQJHGWR3'LIVXEVHTXHQWVFDQLVD3'3'GDWDIURP³2YHUDOOUHVSRQVH´LQ$VVHVVPHQW
RI'LVHDVH%DVHGRQ,PDJLQJH&5)ZLOOEHXVHG
x 'HDWKZLWKRXWSUHYLRXVO\GRFXPHQWHG3'LVREVHUYHGZLWKLQGD\VRIUHIHUHQFHVWDUW
GDWHRUODVWWXPRUDVVHVVPHQW,QIRUPDWLRQRQ'HDWKLVFROOHFWHGRQWKH³'HDWK´IRUP
&HQVRULQJUXOHV
x 'DWDFXWRIIZLOOEHDSSOLHGILUVW
x &HQVRUHGRQWKHUHIHUHQFHVWDUWGDWHLIQREDVHOLQHRUSRVWEDVHOLQHDVVHVVPHQWLVDYDLODEOH
x &HQVRUHGRQWKHGDWHRIODVWWXPRUDVVHVVPHQWRUUHIHUHQFHVWDUWGDWHZKDWHYHURFFXUVODWHU
LI
o 'HDWK ZLWKRXW SUHYLRXVO\ GRFXPHQWHG 3' LV REVHUYHG QRW ZLWKLQ  GD\V RI
UHIHUHQFHVWDUWGDWHRUODVWWXPRUDVVHVVPHQWRU
o /RVWWRIROORZXSZLWKGUDZFRQVHQWZLWKRXW3'GHDWKREVHUYHGLQFOXGHVDOVR
VXEMHFWVZLWKDUDGLRORJLFDODVVHVVPHQWWKDWLVDWOHDVWGD\VEHIRUHGDWDFXWRII
RU
o 1R3'GHDWKREVHUYHGXSWRWKHFXWRIIGDWHDGPLQLVWUDWLYHFHQVRULQJ
$QRYHUYLHZRIHYHQWFHQVRULQJUXOHVLVJLYHQLQ7DEOH


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







7DEOH*HQHUDOHYHQWVFHQVRULQJUXOHV
6WDWXV
&HQVRULQJ
'DWHRIHYHQWFHQVRULQJ
3URJUHVVHG
RUGLHG
5DGLRORJLFDO 3' REVHUYHG
EHIRUHWKHVXEMHFWGURSVRXW
(YHQW
'DWHRI3'
5DGLRORJLFDO 3' DVVHVVHG
DIWHUWKHVXEMHFWGURSVRXW
(YHQW
'DWHRI3'
'HDWK
ZLWKRXW
SUHYLRXVO\
GRFXPHQWHG 3' LV REVHUYHG
ZLWKLQ  GD\V RI UHIHUHQFH
VWDUW GDWH RU ODVW WXPRU
DVVHVVPHQW
(YHQW
'DWHRIGHDWK
'HDWK
ZLWKRXW
SUHYLRXVO\
GRFXPHQWHG 3' LV REVHUYHG
QRW
ZLWKLQ

GD\V
RI
UHIHUHQFH VWDUW GDWH RU ODVW
WXPRUDVVHVVPHQW
&HQVRUHG
'DWH
RI
ODVW
NQRZQ
WXPRU
DVVHVVPHQWRUUHIHUHQFHVWDUWGDWH
ZKDWHYHURFFXUVODWHU
1HLWKHU
SURJUHVVHG
QRUGLHG
/RVWWRIROORZXSZLWKGUDZ
FRQVHQW ZLWKRXW 3'GHDWK
REVHUYHG
LQFOXGHV
DOVR
VXEMHFWV ZLWK D UDGLRORJLFDO
DVVHVVPHQWWKDWLVDWOHDVW
GD\VEHIRUHGDWDFXWRII
&HQVRUHG
'DWH
RI
ODVW
NQRZQ
WXPRU
DVVHVVPHQWRUUHIHUHQFHVWDUWGDWH
ZKDWHYHURFFXUVODWHU
1R3'GHDWKREVHUYHGXSWR
WKH
FXWRII
GDWH
DGPLQLVWUDWLYHFHQVRULQJ
&HQVRUHG
'DWH
RI
ODVW
NQRZQ
WXPRU
DVVHVVPHQWRUUHIHUHQFHVWDUWGDWH
ZKDWHYHURFFXUVODWHU
2WKHU
1R EDVHOLQH RU SRVWEDVHOLQH
DVVHVVPHQW
&HQVRUHG
'DWHRIUHIHUHQFHVWDUWGDWH
3ULPDU\DQDO\VLV
7KHSULPDU\DQDO\VLVZLOOWHVWWKHHTXDOLW\RI3)6WLPHEHWZHHQWUHDWPHQWDUPVLQWKHUDQGRPL]HG
SDUWRI3KDVH,,EDVHGRQWKH,77SRSXODWLRQDSSO\LQJDWZRVLGHGVWUDWLILHGORJUDQNWHVWDWD
VLJQLILFDQFHOHYHORIĮ WDNLQJLQWRDFFRXQWWKHVWUDWDXVHGIRUUDQGRPL]DWLRQLHW\SHRI
0(7,956VWUDWDRWKHUWKDQWKHH&5)VWUDWDZLOOEHXVHG
7KH IROORZLQJ QXOOK\SRWKHVLV LV WHVWHG E\ WKH &R[
V SURSRUWLRQDO KD]DUGV PRGHO VWUDWLILHG
DFFRUGLQJWRVWUDWDXVHGIRUUDQGRPL]DWLRQ
+OH[SHULPHQWDOW OFRQWUROW
+OH[SHULPHQWDOW TOFRQWUROWTz
ZKHUHOWUHSUHVHQWVWKHKD]DUGDWWLPHWDQGTWKHXQNQRZQFRQVWDQWRISURSRUWLRQDOLW\RIKD]DUGV
LQWKHDOORFDWHGWUHDWPHQWJURXSVLQWKHUDQGRPL]HGSDUW7LHVZLOOEHKDQGOHGE\UHSODFLQJWKH
SURSRUWLRQDOKD]DUGVPRGHOE\WKHGLVFUHWHORJLVWLFPRGHO:LWKWKLVRSWLRQIRUKDQGOLQJWLHVWKH
6FRUHWHVWLQWKH&R[
VSURSRUWLRQDOKD]DUGVPRGHOLVLGHQWLFDOWRWKHORJUDQNWHVW


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







proc phreg data=xxx;  
strata MET_TYPE EGFR-TKI_trt;  
model TTE×TTE_censor(1) = treatment / ties = discrete rl;  
ods output globaltests=logRank_TTE (where=(test='Score'))  
parameterestimates = HR_TTE ;  
run ;  
Where: 
TTE_censor = 1 if censored, 0 otherwise  
Treatment  = 1 if in experimental arm (tepotinib+gefitinib), =0 if in control arm (pemetrexed + 
cisplatin/carboplatin) 
TTE        = Time to event variables, for primary, it’s PFS by Investigator; for secondary, it will be 
OS, PFS by IRC . 
7KH KD]DUG UDWLR T DQG WKH  &, IRU TRI WHSRWLQLEJHILWLQLE FRPSDUHG WR FKHPRWKHUDS\
SHPHWUH[HGFLVSODWLQFDUERSODWLQ ZLOO EH FDOFXODWHG E\ &R[
V SURSRUWLRQDO KD]DUGV PRGHO
VWUDWLILHGE\W\SHRI0(7VWDWXVDQGSULRU(*)57.,WUHDWPHQW
.DSODQ0HLHU VXUYLYDO FXUYHV SURGXFWOLPLW HVWLPDWHV ZLOO EH SUHVHQWHG E\ WUHDWPHQW DUP
WRJHWKHUZLWKDVXPPDU\RIDVVRFLDWHGVWDWLVWLFVPHGLDQ3)6WLPHDQGPRQWKVXUYLYDOUDWH
HVWLPDWHVDQGHVWLPDWHVIRUHYHU\PRQWKVWKHUHDIWHUDVDSSOLFDEOHLQFOXGLQJWKHFRUUHVSRQGLQJ
WZRVLGHG &,V7KH&,VIRUWKHPHGLDQZLOOEHFDOFXODWHG DFFRUGLQJ WR %URRNPH\HUDQG
&URZOH\DQG&,VIRUWKHVXUYLYDOIXQFWLRQHVWLPDWHVDWDERYHGHILQHGWLPHSRLQWVZLOOEHGHULYHG
GLUHFWO\ IURP WKH .DSODQ0HLHU HVWLPDWHV &21)7<3( /,1($5 LQ SURF /,)(7(67 7KH
HVWLPDWHRIWKHVWDQGDUGHUURUZLOOEHFRPSXWHGXVLQJ*UHHQZRRG
VIRUPXOD6$63URF/,)(7(67
ZLOOEHXVHGWRREWDLQ.DSODQ0HLHUHVWLPDWHV
6XEJURXSDQDO\VLV
$QXQVWUDWLILHG&R[PRGHOZLOOEHILWWHGE\ZKLFKWKHKD]DUGUDWLRTWKH&,IRUTDQGWKH
DVVRFLDWHGSYDOXHZLOOEHFDOFXODWHG
0XOWLYDULDWHDQDO\VLVZLOOEHSHUIRUPHGZLWKDVWHSZLVHVHOHFWLRQWRDVVHVVWKHHIIHFWRIEDVHOLQH
FRYDULDWHVSUHGHILQHGDVVXEJURXSRILQWHUHVWLQVHFWLRQQDPHO\DJHYV\HDUV
JHQGHUKLVWRORJLFVXEW\SHVPRNLQJKLVWRU\QHYHUVPRNHUVYVHYHUVPRNHUV
7KH PRGHO VHOHFWLRQ LV SHUIRUPHG ZLWKRXW ILWWLQJ WUHDWPHQW JURXS LQ WKH SURSRUWLRQDO KD]DUGV
PRGHO7KHYDOXHVDQGDUHXVHGDVWKHSYDOXHIRUHQWU\LQWRWKHPRGHODQGSYDOXHIRU
VWD\LQJLQWKHPRGHOUHVSHFWLYHO\
proc phreg data=Eff_ITT ; 
class all-subgroup variables ... ; 
model TTE×censoring(1)= all-group variables /ties=discrete rl selection=stepwise 
slentry=0.15 slstay=0.40 details; 
ods output globaltests=logRank(where=(test='Score')) parameterestimates=HR; 
run ; 
Where: 
slentry= boundary for p-value of Score test for inclusion, other values than 0.15 can be 
considered 
slstay= boundary for p-value of Wald test for exclusion, other values than 0.40 can be considered 


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







2QFHWKHVHOHFWLRQSURFHGXUHLVILQDOL]HGWKHDQDO\VLVPRGHOLVUHILWWHGZLWKWKHVWUDWDDQGWKH
WUHDWPHQWJURXSSOXVWKHVHOHFWHGFRYDULDWHV
proc phreg data=xxx;  
strata MET_TYPE ;  
model TTE×TTE_censor(1) = treatment all-group variables ... / ties = discrete rl;  
ods output globaltests=logRank_TTE (where=(test='Score'))  
parameterestimates = HR_TTE;  
run;  
Where: 
TTE_censor = 1 if censored, 0 otherwise  
Treatment = 1 if in experimental arm, =0 if in control arm  
TTE        = Time to event variables, for primary, it’s OS; for secondary, it will be one of TTP by 
IRC, TTP by Investigator, PFS or TTSP. 
6XEJURXSDQDO\VHVZLOOEHSHUIRUPHGIRUHDFKSUHGHILQHGEDVHOLQHIDFWRUZLWKRXWVWUDWLILFDWLRQGXH
WRWKHSRWHQWLDOORZQXPEHURIVXEMHFWVSHUVXEJURXSFDWHJRU\&R[UHJUHVVLRQPRGHOVZLOOEH
ILWWHGIRU3)6DVGHSHQGHQWYDULDEOHDQGZLWKDVXEJURXSW\SHWKHWUHDWPHQWJURXSDVVLJQPHQWDQG
ZLWKDQGZLWKRXWWKHWUHDWPHQWE\VXEJURXSW\SHLQWHUDFWLRQDVH[SODQDWRU\YDULDEOHV+D]DUGUDWLR
LQFOXGLQJ  FRQILGHQFH LQWHUYDO RI WHSRWLQLEJHILWLQLE FRPSDUHG WR FKHPRWKHUDS\
SHPHWUH[HGFLVSODWLQ LV FRPSXWHG SHU VXEJURXS OHYHO 7KH SYDOXH IRU WKH LQWHUDFWLRQ WHVW
/LNHOLKRRG5DWLRWHVWZLOOEHSURYLGHGWRJHWKHUZLWKWKHKD]DUGUDWLRVDQGFRQILGHQFHLQWHUYDOV
RIWKHLQWHUDFWLRQPRGHOSDUDPHWHU)RUHVWSORWVZLOOEHSUHVHQWHGZLWKKD]DUGUDWLRVDQG&,V
RIWUHDWPHQWIRUWKHRYHUDOOWUHDWPHQWHIIHFWDQGIRUHDFKVXEJURXSOHYHO
,QDGGLWLRQWRWKHVXEJURXSDQDO\VHVGHILQHGDERYHWKHIROORZLQJDQDO\VHVZLOOEHFRQGXFWHGIRU
WKHVXEJURXSRISDWLHQWVZLWKJHQHDPSOLILFDWLRQDQGRULQFUHDVHGF0HW*&1E\,6+
'HPRJUDSKLFVDQG2WKHU%DVHOLQH&KDUDFWHULVWLFV
x 'HPRJUDSKLFFKDUDFWHULVWLFV
x (&2*SHUIRUPDQFHVWDWXVDWEDVHOLQH
x 6PRNLQJVWDWXVDWEDVHOLQH
x 3ULRUDQWLFDQFHUGUXJWKHUDS\
x %DVHOLQH),6+VWDWXVF0HW&(3FRS\QXPEHUUDWLRDQGPHDQJHQHFRS\QXPEHU
([SRVXUH
x 'XUDWLRQRIWKHUDS\ZHHNVIRUWHSRWLQLEDQGJHILWLQLE
x 'XUDWLRQRIWKHUDS\ZHHNVIRUSHPHWUH[HGFLVSODWLQDQGFDUERSODWLQ
6DIHW\
x 2YHUYLHZRI7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV7($(V


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







x $Q\7ULDO'UXJ5HODWHG7($(VE\62&DQG37
x $Q\7ULDO'UXJ5HODWHG7($(VZLWK&7&$(*UDGH! E\62&DQG37
7LPHRI)ROORZ8S3)6
,QRUGHUWRDVVHVVGXUDWLRQRIIROORZXSIRUSURJUHVVLRQIUHHVXUYLYDO.DSODQ0HLHUHVWLPDWHVZLOO
EHFDOFXODWHGXVLQJWKHIROORZLQJFHQVRULQJUXOHVUHYHUVHFHQVRULQJLQGLFDWRU
7KHGDWHRIHYHQWFHQVRULQJLVGHILQHGDVIROORZV
6WDWXV
&HQVRULQJ
'DWHRIHYHQWFHQVRULQJ
3URJUHVVHG
DVVHVVHG E\
,QYHVWLJDWRU
RUGLHG
5DGLRORJLFDO 3' REVHUYHG
EHIRUHWKHVXEMHFWGURSVRXW
&HQVRUHG
'DWH
RI
3'
DVVHVVHG
E\
,QYHVWLJDWRU
5DGLRORJLFDO 3' DVVHVVHG
DIWHUWKHVXEMHFWGURSVRXW
&HQVRUHG
'DWH
RI
3'
DVVHVVHG
E\
,QYHVWLJDWRU
'HDWK
ZLWKRXW
SUHYLRXVO\
GRFXPHQWHG 3' LV REVHUYHG
ZLWKLQ  GD\V RI UHIHUHQFH
VWDUW GDWH RU ODVW WXPRU
DVVHVVPHQW
&HQVRUHG
'DWHRIGHDWK
'HDWK
ZLWKRXW
SUHYLRXVO\
GRFXPHQWHG 3' LV REVHUYHG
QRW
ZLWKLQ

GD\V
RI
UHIHUHQFH VWDUW GDWH RU ODVW
WXPRUDVVHVVPHQW
(YHQW
'DWH
RI
ODVW
NQRZQ
WXPRU
DVVHVVPHQWRUUHIHUHQFHVWDUWGDWH
ZKDWHYHURFFXUVODWHU
1HLWKHU
SURJUHVVHG
E\
,QYHVWLJDWRU
QRUGLHG
/RVWWRIROORZXSZLWKGUDZ
FRQVHQW ZLWKRXW 3'GHDWK
REVHUYHG
LQFOXGHV
DOVR
VXEMHFWV ZLWK D UDGLRORJLFDO
DVVHVVPHQWWKDWLVDWOHDVW
GD\VEHIRUHGDWDFXWRII
(YHQW
'DWH
RI
ODVW
NQRZQ
WXPRU
DVVHVVPHQWRUUHIHUHQFHVWDUWGDWH
ZKDWHYHURFFXUVODWHU
1R3'GHDWKREVHUYHGXSWR
WKH
FXWRII
GDWH
DGPLQLVWUDWLYHFHQVRULQJ
(YHQW
'DWH
RI
ODVW
NQRZQ
WXPRU
DVVHVVPHQWRUUHIHUHQFHVWDUWGDWH
ZKDWHYHURFFXUVODWHU
2WKHU
1R EDVHOLQH RU SRVWEDVHOLQH
DVVHVVPHQW
(YHQW
'DWHRIUHIHUHQFHVWDUWGDWH
.DSODQ0HLHU HVWLPDWHV SURGXFWOLPLWHVWLPDWHVZLOOEHSUHVHQWHGLQWKHVDPHZD\DVLQWKH
DQDO\VLVGHVFULEHGDERYHIRUSURJUHVVLRQIUHHVXUYLYDO
 
6HFRQGDU\(QGSRLQW$QDO\VHV
7KHVHFRQGDU\HIILFDF\DQDO\VHVFRQVLGHUHGEHORZZLOOEHUHJDUGHGDVVXSSRUWLYHWRWKHSULPDU\
DQDO\VLV


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







 
3)6$VVHVVHGE\,5&
Population: ITT Analysis Set for the randomized part 
$VHQVLWLYLW\DQDO\VLVRIWKHSULPDU\HQGSRLQWZLOOEHGRQHE\DQDO\]LQJ3)6DVDVVHVVHGE\,5&
ZKLFKLVGHILQHGVLPLODUWR3)6DVDVVHVVHGE\,QYHVWLJDWRUGHVFULEHGLQ6HFWLRQEXW
WDNLQJLQWRFRQVLGHUDWLRQRQO\UDGLRORJLFDOWXPRUDVVHVVPHQWVSHUIRUPHGE\WKH,5&$QDO\VHV
DQDORJRXVWRWKHRQHVRI3)6E\,QYHVWLJDWRUZLOOEHSHUIRUPHG
$FURVVWDEOHRI3)6DVVHVVHGE\,5&YV3)6DVVHVVHGE\,QYHVWLJDWRUZLOOEHVXPPDUL]HGWRFKHFN
WKHFRQVLVWHQF\RIWZRGHILQLWLRQV7KHFRQVLVWHQF\LVGHILQHGDVWKHWZR3)6DUHDWPRVWGD\V
DSDUWGD\LQFOXGHG
 
3)6LQWKH6LQJOH$UP&RKRUW
Population: Safety Analysis Set for the single-arm cohort
3)6DVVHVVHGE\,QYHVWLJDWRUDQG,5&LQWKHVLQJOHDUPFRKRUWZLOOEHFRQGXFWHGDVGHVFULEHGLQ
6HFWLRQ7KHDQDO\VHVGHVFULEHGLQ6HFWLRQZLOOEHUHSHDWHGH[FHSWVXEJURXSDQDO\VLV
7KHVXEJURXSRILQWHUHVWZLOOEHRPLWWHGGXHWRVPDOOVDPSOHVL]H
 
2YHUDOO6XUYLYDO
Population: ITT Analysis Set for the randomized part, Safety Analysis Set for the single-arm cohort  
2YHUDOOVXUYLYDO26ZLOOEHPHDVXUHGDVWKHWLPHLQPRQWKVEHWZHHQUHIHUHQFHVWDUWGDWHWR
WUHDWPHQWDQGWKHGDWHRIGHDWK)RUVXEMHFWVQRWNQRZQWREHGHFHDVHGDWWLPHRIDQDO\VLV26WLPH
ZLOOEHFHQVRUHGDWWKHODVWGDWHWKHVXEMHFWZDVNQRZQWREHDOLYH,IWKLVGDWHLVDIWHUWKHGDWDFXW
RIIVXEMHFWVZLOOEHFHQVRUHGDWWKHGDWHRIGDWDFXWRII
26PRQWKV GDWHRIGHDWKRUODVWGDWHNQRZQWREHDOLYH±UHIHUHQFHVWDUWGDWH

7KHGDWHRIHYHQWFHQVRULQJIRU26LVGHILQHGDVIROORZ
6XUYLYDO6WDWXV
6RXUFH
&HQVRULQJ 'DWHRIHYHQWFHQVRULQJ
'LHG
%HIRUHFXWRII
'HDWKH&5)
(YHQW
'DWHRIGHDWK
$IWHUFXWRII
'HDWKH&5)
&HQVRUHG
'DWHRIFXWRII
$OLYH RU /RVW WR
)ROORZXS
:LWKGUHZ&RQVHQW
QRGDWHRIGHDWK
$IWHUFXWRII
)ROORZXS
H&5)
&HQVRUHG
'DWHRIFXWRII
2WKHUZLVH
6HHEHORZ
&HQVRUHG
/DVWGDWHNQRZQWREHDOLYH


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







7KHIROORZLQJGDWHVZLOOEHXVHGWRGHWHUPLQHWRODVWGDWHNQRZQWREHDOLYHSULRURUDWGDWDFXW
RII
x $OOSDWLHQWDVVHVVPHQWGDWHVEORRGGUDZVODERUDWRU\
YLWDOVLJQVSHUIRUPDQFHVWDWXV
(&*WXPRUDVVHVVPHQWV
x 6WDUW DQG HQG GDWHV RI DQWLFDQFHU WKHUDSLHV DGPLQLVWHUHG DIWHU VWXG\ WUHDWPHQW
GLVFRQWLQXDWLRQ
x $(VWDUWDQGHQGGDWHV
x /DVWGDWHRI FRQWDFW FROOHFWHGRQWKHµ6XUYLYDOLQIRUPDWLRQ¶H&5)GRQRWXVHGDWHRI
VXUYLYDOIROORZXSDVVHVVPHQWXQOHVVVWDWXVLVµDOLYH¶
x 6WXG\GUXJVWDUWDQGHQGGDWHV
x 5DQGRPL]DWLRQGDWH
x 'DWHRIGHDWKLIWKHGHDWKLVEHIRUHWKHFXWRIIGDWH
.DSODQ0HLHUHVWLPDWHVSURGXFWOLPLWHVWLPDWHVZLOOEHSUHVHQWHGWRJHWKHUZLWKDVXPPDU\RI
DVVRFLDWHGVWDWLVWLFVPHGLDQVXUYLYDOWLPHDQGPRQWKVXUYLYDOUDWHHVWLPDWHVDQGHVWLPDWHVIRU
HYHU\PRQWKVWKHUHDIWHUDVDSSOLFDEOHLQFOXGLQJWKHFRUUHVSRQGLQJWZRVLGHGFRQILGHQFH
LQWHUYDOV7KHFRQILGHQFHLQWHUYDOVIRUWKHPHGLDQZLOOEHFDOFXODWHGDFFRUGLQJWR%URRNPH\HUDQG
&URZOH\DQGFRQILGHQFHLQWHUYDOVIRUWKHVXUYLYDOIXQFWLRQHVWLPDWHVDWDERYHGHILQHGWLPH
SRLQWV ZLOO EH GHULYHG XVLQJ WKH ORJORJWUDQVIRUPDWLRQDFFRUGLQJ WR .DOEIOHLVFK DQG 3UHQWLFH
FRQIW\SH ORJORJGHIDXOWRSWLRQLQ6$63URF/,)(7(677KHHVWLPDWHRIWKHVWDQGDUG
HUURUZLOOEHFRPSXWHGXVLQJ*UHHQZRRG
VIRUPXOD.DSODQ0HLHUSORWVZLOODOVREHSUHVHQWHG
7KH FHQVRULQJ DQG HYHQW VWDWXV ZLWK UHVSHFW WR WKH VFHQDULRV IURP WKH DERYH WDEOH ZLOO EH
VXPPDUL]HG
'XUDWLRQRI)ROORZ8S26
,Q RUGHU WR DVVHVV GXUDWLRQ RI IROORZXS IRU RYHUDOO VXUYLYDO .DSODQ 0HLHU HVWLPDWHV ZLOO EH
FDOFXODWHGXVLQJWKHIROORZLQJFHQVRULQJUXOHVUHYHUVHFHQVRULQJLQGLFDWRU
7KHGDWHRIHYHQWFHQVRULQJIRU26IROORZXSLVGHILQHGDVIROORZV
6XUYLYDO6WDWXV
6RXUFH
&HQVRULQJ 'DWHRIHYHQWFHQVRULQJ
'LHG
%HIRUHFXWRII
'HDWKH&5)
&HQVRUHG
'DWHRIGHDWK
$IWHUFXWRII
'HDWKH&5)
(YHQW
'DWHRIFXWRII
$OLYH RU /RVW WR
)ROORZXS
:LWKGUHZ&RQVHQW
QRGDWHRIGHDWK
$IWHUFXWRII
)ROORZXS
H&5)
(YHQW
'DWHRIFXWRII
2WKHUZLVH
6HHDERYHIRU
WKH26
(YHQW
/DVWGDWHNQRZQWREHDOLYH
.DSODQ0HLHU HVWLPDWHV SURGXFWOLPLWHVWLPDWHVZLOOEHSUHVHQWHGLQWKHVDPHZD\DVLQWKH
DQDO\VLVGHVFULEHGDERYHIRURYHUDOOVXUYLYDO
CCI


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







 
$QWLWXPRU$FWLYLW\
Population: ITT Analysis Set for the randomized part, Safety Analysis Set for the single-arm cohort  
2XWSXWVIRUDQWLWXPRUDFWLYLW\ZLOOEHSURYLGHGDVDVVHVVHGE\,QYHVWLJDWRUDVZHOODVE\,5&
%HVW2YHUDOO5HVSRQVH
%HVWRYHUDOOUHVSRQVH%25LVGHILQHGDVWKHEHVWUHVXOWREWDLQHGDPRQJDOOWXPRUDVVHVVPHQW
YLVLWVIURPEDVHOLQHXQWLOHQGRIWUHDWPHQWRUGHWHUPLQDWLRQRI3'H[FOXGLQJDVVHVVPHQWVDIWHU
WXPRUVXUJHU\
,QHYDOXDEOH1(LVQRWFRQVLGHUHGDYDOLGPHDVXUHPHQW2YHUDOOUHVSRQVHRI1(ZLOOEHFKDQJHG
WR3'LIVXEVHTXHQWVFDQLVD3'$VDFRQVHTXHQFHD%25RI1(ZLOORQO\EHDVVLJQHGLI1(LV
WKHRQO\WXPRU DVVHVVPHQWIRULQVWDQFH DVXEMHFWKDYLQJDVVHVVPHQWVRI1(DQG3'ZLOOEH
DVVLJQHG%25RI3'
6XEMHFWVZLWK%25RIQRQ&5QRQ3'SRVVLEOHRQO\IRUVXEMHFWVZLWKRXWPHDVXUDEOHGLVHDVHDW
EDVHOLQHDUHQRWFRQVLGHUHGDVKDYLQJDFKLHYHGREMHFWLYHUHVSRQVHQRUFOLQLFDOEHQHILW
7KHIROORZLQJZLOOEHSURYLGHG
x 7KHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVZLWKD%25RI&535VWDEOHGLVHDVH6'3'
QRQ&5QRQ3'DQG1(ZLOOEHWDEXODWHG
x %DUFKDUWZLWKWLPHWRUHVSRQVHDQGGXUDWLRQRIVWXG\WUHDWPHQW
2EMHFWLYH5HVSRQVH5DWH255
7KHREMHFWLYHUHVSRQVHUDWHLVGHILQHGDVWKHSURSRUWLRQRIVXEMHFWVKDYLQJDFKLHYHG&5RU35DV
WKH %25 DFFRUGLQJ WR UDGLRORJLFDO DVVHVVPHQWV IURP UHIHUHQFH VWDUWGDWH WR HQGRIWUHDWPHQW
5HVSRQVHVGRQRWUHTXLUHFRQILUPDWLRQDFFRUGLQJWR5(&,67Y
7KH&RFKUDQ0DQWHO+DHQV]HOWHVWZLOOEHSHUIRUPHGIRUDQDO\VLVXVLQJWKHUDQGRPL]DWLRQVWUDWD
LHW\SHRI0HWġDQGSULRU(*)57.,WUHDWPHQW7KH&RFKUDQ0DQWHO+DHQV]HOZLOOWHVWWKH
IROORZLQJWZRVLGHGK\SRWKHVLV
+Ȍ 
+Ȍ
ZKHUHȌGHILQHVWKHFRPPRQRGGVUDWLRDFURVVDOOVWUDWD
7KH 255 UDWH ZLOO EH SUHVHQWHG IRU HDFK WUHDWPHQW JURXS LQFOXGLQJ WKH FRUUHVSRQGLQJ 
&ORSSHU3HDUVRQ&,V
7KHFRPPRQ0DQWHO+DHQV]HORGGVUDWLRDGMXVWHGE\VWUDWDDQGWKHFRUUHVSRQGLQJ&,VXVLQJ
WKHYDULDQFHIRUPXODIRUWKHORJRIWKHFRPPRQRGGVUDWLRHVWLPDWHZLOOEHSUHVHQWHG7KHRGGV
UDWLRLVGHILQHGDVWKHRGGVRIVKRZLQJUHVSRQVHZLWKWKHLQYHVWLJDWLRQDOGUXJGLYLGHGE\WKHRGGV


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







RIVKRZLQJUHVSRQVHZLWKWKHFRQWUROWUHDWPHQWLHDQRGGVUDWLRJUHDWHUWKDQRQHFRUUHVSRQGVWR
DEHQHILWRIWKHLQYHVWLJDWLRQDODUP7KHKRPRJHQHLW\RIWKHRGGVUDWLRDFURVVVWUDWDZLOOEHFKHFNHG
E\WKH%UHVORZ'D\WHVW7KHQXOOK\SRWKHVLVRIWKH%UHVORZ'D\WHVWLVWKDWWKHRGGVUDWLRLVWKH
VDPHIRUDOOVWUDWDDJDLQVWWKHDOWHUQDWLYHWKDWDWOHDVWRQHSDLURIVWUDWDKDYHDGLIIHUHQWRGGVUDWLR
$GGLWLRQDO WR WKH 0DQWHO+DHQV]HO HVWLPDWH RGGV UDWLRV SHU VWUDWXP DUH LQGLFDWHG ZLWK WKH
FRUUHVSRQGLQJH[DFWFRQILGHQFHLQWHUYDO7KHFRPPRQRGGVUDWLRZLWKQRDGMXVWPHQWE\VWUDWDDQG
LWV&,ZLOOEHSURYLGHGDVZHOO
'LVHDVH&RQWURO5DWH'&5
7KHGLVHDVHFRQWUROUDWHLVGHILQHGDVWKHSURSRUWLRQRIVXEMHFWVKDYLQJDFKLHYHG&535RU6'DV
WKH%25DFFRUGLQJWRORFDOUDGLRORJLFDODVVHVVPHQWVIURPUDQGRPL]DWLRQWKHILUVWDGPLQLVWUDWLRQ
XQWLO HQG RI VWXG\ WUHDWPHQW LQWKHUDQGRPL]HG SDUWWKH VLQJOHDUP FRKRUW ,Q WKH FDVH RI6'
PHDVXUHPHQWVPXVWKDYHPHWWKH6'FULWHULDDWOHDVWRQFHDIWHUVWXG\HQWU\DWDPLQLPXPLQWHUYDO
RIGD\VDIWHULQIRUPHGFRQVHQW
7KH'&5UDWHDQGLWV&ORSSHU3HDUVRQ&,ZLOOEHFDOFXODWHG
'XUDWLRQRIġ5HVSRQVH
'XUDWLRQRIUHVSRQVHLVGHILQHGDVWKHWLPHIURPILUVWGRFXPHQWHG&5RU35ZKLFKHYHULVILUVW
UHFRUGHGXQWLOWLPHRISURJUHVVLRQDVSHU,QYHVWLJDWRUDVVHVVPHQW7KHGHILQLWLRQRIWKHHQGRI
GXUDWLRQRIUHVSRQVHVKRXOGEHFRQVLVWHQWZLWKWKHGHILQLWLRQRIHQGRI3)67KLVGHILQLWLRQDSSOLHV
RQO\WRVXEMHFWVZKRH[SHULHQFHG&5RU35
6XPRI/RQJHVW'LDPHWHUV62/'
7KH VXP RI ORQJHVW GLDPHWHUV 62/' RI YLDEOH WDUJHW OHVLRQV LV FROOHFWHG RQ WKH ³6XP RI
'LDPHWHUV62/'´H&5)SDJH7XPRUVKULQNDJHZLOOEHVXPPDUL]HGDVWKHSHUFHQWFKDQJHIURP
EDVHOLQHLQWDUJHWOHVLRQVVXPRIORQJHVWGLDPHWHUIRUQRQQRGDOOHVLRQVDQGVKRUWD[LVIRUQRGDO
OHVLRQV62/'SHUWLPHSRLQW,WZLOOEHGHULYHGIRUVXEMHFWVZLWKSRVWEDVHOLQHWDUJHWOHVLRQ
DVVHVVPHQWDV
Percent change from baseline =  100 כ ( Sum of target lesion diameters at visit ܺ 
sum of target lesion diameters at baseline െ1)
7KHEHVWUHODWLYHFKDQJHLQWDUJHWOHVLRQVIURPEDVHOLQHZLOOEHGHULYHGDFURVVDOOWKHSRVWEDVHOLQH
DVVHVVPHQWVXQWLOGRFXPHQWHGGLVHDVHSURJUHVVLRQDV
Best relative change = ݐ݄݁ ݉݅݉݅݉ݑ݉ ݒ݈ܽݑ݁ ݋݂ ݌݁ݎܿ݁݊ݐ ݄ܿܽ݊݃݁ ݂ݎ݋݉ ܾܽݏ݈݁݅݊݁ 
7KHIROORZLQJZLOOEHSURYLGHG
7KH62/'DQGWKHSHUFHQWFKDQJHZLOOEHVXPPDUL]HGRYHUWLPH
:DWHUIDOOSORWIRUWKHEHVWUHODWLYHFKDQJHRIWKHVXPRIWKHORQJHVWGLDPHWHUIRUQRQQRGDOOHVLRQV
DQGVKRUWD[LVIRUQRGDOOHVLRQV


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







7KH SHUFHQW FKDQJH IURP EDVHOLQH LQ WDUJHW OHVLRQV SHU WLPH SRLQW DV ZHOO DV RWKHU UHOHYDQW
LQIRUPDWLRQZLOOEHSUHVHQWHGLQDGDWDOLVWLQJ7KHHDUOLHVWVFDQGDWHRIWDUJHWOHVLRQVZLOOEHXVHG
DVWKHGDWHRI62/'
 
6DIHW\$QDO\VHV
Population: Safety Analysis Set 
7KHVXEVHFWLRQVLQWKLVVHFWLRQLQFOXGHVSHFLILFDWLRQVIRUVXPPDUL]LQJVDIHW\HQGSRLQWVWKDWDUH
FRPPRQDFURVVFOLQLFDOWULDOVVXFKDVDGYHUVHHYHQWVODERUDWRU\WHVWVDQGYLWDOVLJQV$QDO\VHVZLOO
EHSHUIRUPHGXVLQJWKH6DIHW\$QDO\VLVVHWIRUERWKUDQGRPL]HGSDUWDQGVLQJOHDUPFRKRUW
6DIHW\DQDO\VHVZLOOEHGRQHRQWKHVDIHW\DQDO\VLVVHWDQGDFFRUGLQJWRWKHDVWUHDWHGSULQFLSOH
 
$GYHUVH(YHQWV
$(VZLOOEHFRGHGXVLQJWKH0HG'5$9HUVLRQRUKLJKHU7KH,QYHVWLJDWRUZLOOEHUHVSRQVLEOH
IRUDVVLJQLQJWKH&RPPRQ7R[LFLW\&ULWHULDJUDGHVIRU$(V1&,&7&$(XVLQJWKHPRVWFXUUHQW
YHUVLRQRI1&,&7&$(7KHVHYHULW\RI$(VZLOOEHJUDGHGXVLQJ1&,&7&$(9HUVLRQ
WR[LFLW\JUDGHV7KH,QYHVWLJDWRUZLOOEHUHVSRQVLEOHIRUDVVLJQLQJWKH&RPPRQ7R[LFLW\&ULWHULD
JUDGHVIRU$(V
7($(WKRVHHYHQWVZLWKRQVHWGDWHVRFFXUULQJZLWKLQWKHWUHDWPHQWSHULRGVLHVWDUWVRQRUDIWHU
WKHHDUOLHVWGRVLQJGDWHRIDQ\VWXG\WUHDWPHQWDQGSULRUWRWKHODWHVWGRVLQJGDWHRIDQ\WULDOGUXJ
GD\VLQFOXVLYH
³7LPLQJ UHODWHG WR 06&-´ ³7LPLQJ UHODWHG WR *HILWLQLE´ ³7LPLQJ UHODWHG WR
3HPHWUH[HG´³7LPLQJUHODWHGWR&LVSODWLQ´DQG³7LPLQJUHODWHGWR&DUERSODWLQ´IURPWKHH&5)
$(IRUPZLOOEHXVHGWRMXGJHZKHWKHUWKH$(LVD7($(ZKHQWKH$(RQVHWGDWHLVWKHVDPHGD\
DVILUVWGRVLQJGDWH
x &DVHRQO\WULDOGUXJLVGRVHGGXULQJWKHHDUOLHVWGRVLQJGDWHLI³7LPLQJUHODWHGWR
06&-´RU³7LPLQJUHODWHGWR*HILWLQLE´GHSHQGLQJRQZKLFKWULDOGUXJLVGRVHG
LQWKH$(H&5)LV³%HIRUH´WKHQWKH$(ZLOOQRWEHFRQVLGHUHGD7($(RWKHUZLVHD7($(
x &DVH  ERWK  WULDO GUXJV DUH GRVHG WKH HDUOLHVW GRVLQJ GDWH  LI ³7LPLQJ UHODWHG WR
06&-´DQG³7LPLQJUHODWHGWR*HILWLQLE´ERWKDUH³%HIRUH´WKHQWKH$(ZLOOQRW
EHFRQVLGHUHGD7($(RWKHUZLVHD7($(
,ILWLVQRWSRVVLEOHWRGHILQHDQ$(DVEHLQJWUHDWPHQWHPHUJHQWRUQRWWKH$(ZLOOEHFODVVLILHG
DVWUHDWPHQWHPHUJHQWDVWKHPRVWFRQVHUYDWLYHDSSURDFK
6XPPDULHVIRUWKHQXPEHURIVXEMHFWVLQWRWDODQGZLWKLQHDFKWUHDWPHQWJURXSZLOOEHSUHVHQWHG
IRUHDFKRIWKHFDWHJRULHVGHVFULEHGLQWKHVXEVHFWLRQVEHORZ
/LVWLQJVZLOOLQFOXGHDOO7($(VDQG1RQ7($(V6XPPDU\WDEOHVGHVFULEHGLQ6HFWLRQDQG
ZLOOEHEDVHGRQ7($(VLIQRWRWKHUZLVHVSHFLILHG%HVLGHVRQHDGGLWLRQDOOLVWLQJIRUDGYHUVH
HYHQWZLOOEHSUHVHQWHGEDVHGRQ$OO6FUHHQLQJ$QDO\VLV6HW
,QFRPSOHWH$(UHODWHGGDWHVZLOOEHKDQGOHGDVIROORZV


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







x ,IWKHRQVHWGDWHLVPLVVLQJFRPSOHWHO\RUPLVVLQJSDUWLDOO\EXWWKHRQVHWPRQWKDQG\HDU
RUWKHRQVHW\HDULVHTXDOWRWKHVWDUWRIWULDOWUHDWPHQWWKHQWKHRQVHWGDWHZLOOEHUHSODFHG
E\WKHPLQLPXPRIVWDUWRIWULDOWUHDWPHQWDQG$(UHVROXWLRQGDWH
x ,QDOORWKHUFDVHVWKHPLVVLQJRQVHWGD\RUPLVVLQJRQVHWPRQWKZLOOEHUHSODFHGE\
x ,QFRPSOHWHVWRSGDWHVZLOOEHUHSODFHGE\WKHODVWGD\RIWKHPRQWKLIGD\LVPLVVLQJRQO\
LIQRWUHVXOWLQJLQDGDWHODWHUWKDQWKHGDWHRIVXEMHFW
VGHDWK,QWKHODWWHUFDVHWKHGDWHRI
GHDWKZLOOEHXVHGWRLPSXWHWKHLQFRPSOHWHVWRSGDWH
x ,QDOORWKHUFDVHVWKHLQFRPSOHWHVWRSGDWHZLOOQRWEHLPSXWHG,IVWRSGDWHRI$(LVDIWHU
GDWHRIFXWRIIRXWFRPHRI$(LVRQJRLQJDWFXWRII
1RIRUPDOVWDWLVWLFDOFRPSDULVRQVDUHSODQQHGDQGSYDOXHVIRU$(VZLOOQRWEHJHQHUDWHG
 
$OO$GYHUVH(YHQWV
$(VZLOOEHFRGHGXVLQJWKH0HG'5$9HUVLRQRUKLJKHU7KH,QYHVWLJDWRUZLOOEHUHVSRQVLEOH
IRUDVVLJQLQJWKH&RPPRQ7R[LFLW\&ULWHULDJUDGHVIRU$(VXVLQJ1&,&7&$(9 
,QFLGHQFHUDWHVIUHTXHQFLHVDQGSHUFHQWDJHVRILQGLYLGXDO$(VWKDWLVWKHQXPEHURIVXEMHFWV
H[SHULHQFLQJHYHQWV$(VLQHDFK37RU62&DQGWKHSURSRUWLRQUHODWLYHWRWKHQXPEHURIVXEMHFWV
LQWKH6$)DQDO\VLVVHWZLOOEHSUHVHQWHG
8QOHVVRWKHUZLVHVWDWHGDGYHUVHHYHQWVZLOOEHGLVSOD\HGLQWHUPVRIIUHTXHQF\WDEOHV37DQG
SULPDU\62&LQDOSKDEHWLFDORUGHU
,IDQDGYHUVHHYHQWLVUHSRUWHGIRUDJLYHQVXEMHFWPRUHWKDQRQFHGXULQJWUHDWPHQWWKHZRUVW
VHYHULW\DQGWKHZRUVWUHODWLRQVKLSWRWULDOWUHDWPHQWZLOOEHWDEXODWHG
7KH UHODWLRQVKLS WR D WULDO GUXJ DV LQGLFDWHG E\ WKH ,QYHVWLJDWRU LV FODVVHG DV ³XQUHODWHG´ RU
³UHODWHG´ 7($(V ZLWK D UHODWHG RU PLVVLQJ UHODWLRQVKLS WR WKH WULDO GUXJ ZLOO EH UHJDUGHG DV
³UHODWHG´WRWKHWULDOGUXJ$Q\WULDOGUXJUHODWHG7($(DUHWKRVH7($(VZLWKDUHODWHGRUPLVVLQJ
UHODWLRQVKLSWRDQ\RIWKHWULDOGUXJVUDQGRPL]HGGRVHGWR,IDVXEMHFWUHSRUWVWKHVDPH$(PRUH
WKDQRQFHZLWKLQWKDW62&37WKH$(ZLOOEHFDWHJRUL]HGDV³XQUHODWHG´RQO\ZKHQDOOUHODWLRQVKLS
UHFRUGVDUH³XQUHODWHG´RWKHUZLVHLWZLOOEHFODVVHGDV³UHODWHG´LQWKHFRUUHVSRQGLQJUHODWLRQVKLS
VXPPDULHV
6HYHULW\LVFODVVHGDV*UDGHLQFUHDVLQJVHYHULW\E\UHIHUHQFLQJWKH1&,&7&$(
9,IDVXEMHFWUHSRUWVD7($(PRUHWKDQRQFHZLWKLQWKDW62&37WKH$(ZLWKWKHZRUVWFDVH
VHYHULW\ZLOOEHXVHGLQWKHFRUUHVSRQGLQJVHYHULW\VXPPDULHV,QFDVHDVXEMHFWKDGHYHQWVZLWK
PLVVLQJDQGQRQPLVVLQJVHYHULWLHVWKHPD[LPXPRIWKHQRQPLVVLQJVHYHULWLHVZLOOEHGLVSOD\HG
,QFDVHDOOWKH7($(VRIDVXEMHFWDUHDOOZLWKPLVVLQJVHYHULWLHVWKH*UDGHVHYHUHZLOOEHXVHG
XQOHVVWKHUHLVDQ\HYLGHQFHWKDWLWVKRXOGEH*UDGHRU
$QRYHUYLHZVXPPDU\RI7($(VZLOOEHSURYLGHGE\WUHDWPHQWJURXSIRU
x $Q\7($(V
x 7ULDOWUHDWPHQWUHODWHG7($(V


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







o UHODWHGWRDQ\GUXJ
o UHODWHGWRWHSRWLQLE
o UHODWHGWRJHILWLQLE
o UHODWHGWRSHPHWUH[HG
o UHODWHGWRFLVSODWLQ
o UHODWHGWRFDUERSODWLQ
x $Q\VHULRXV7($(
x $Q\QRQVHULRXV7($(
x 7ULDOWUHDWPHQW6HULRXVUHODWHG7($(V
o UHODWHGWRDQ\GUXJ
o UHODWHGWRWHSRWLQLE
o UHODWHGWRJHILWLQLE
o UHODWHGWRSHPHWUH[HG
o UHODWHGWRFLVSODWLQ
o UHODWHGWRFDUERSODWLQ
x $Q\7($(RI*UDGHE\1&,&7&$(
x 7ULDOWUHDWPHQWUHODWHG7($(VRI*UDGHE\1&,&7&$(
o UHODWHGWRDQ\GUXJ
o UHODWHGWRWHSRWLQLE
o UHODWHGWRJHILWLQLE
o UHODWHGWRSHPHWUH[HG
o UHODWHGWRFLVSODWLQ
o UHODWHGWRFDUERSODWLQ
x 7($(VRIVSHFLDOLQWHUHVW
x 5HODWHG7($(VRIVSHFLDOLQWHUHVW
o UHODWHGWRDQ\GUXJ
o UHODWHGWRWHSRWLQLE
o UHODWHGWRJHILWLQLE
o UHODWHGWRSHPHWUH[HG
o UHODWHGWRFLVSODWLQ
o UHODWHGWRFDUERSODWLQ
x 7($(OHDGLQJWRGHDWK$(VZLWK*UDGHRURXWFRPH³IDWDO´LI*UDGHQRWDSSOLFDEOH


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







x 7ULDOWUHDWPHQWUHODWHG7($(OHDGLQJWRGHDWK$(VZLWK*UDGHRURXWFRPH³IDWDO´LI
*UDGHQRWDSSOLFDEOH
o UHODWHGWRDQ\GUXJ
o UHODWHGWRWHSRWLQLE
o UHODWHGWRJHILWLQLE
o UHODWHGWRSHPHWUH[HG
o UHODWHGWRFLVSODWLQ
o UHODWHGWRFDUERSODWLQ
x 7($(VOHDGLQJWRGRVHUHGXFWLRQRI
o DQ\WUHDWPHQW
o WHSRWLQLE
o JHILWLQLE
o SHPHWUH[HG
o FLVSODWLQ
o FDUERSODWLQ
x 7($(VOHDGLQJWRWHPSRUDU\GLVFRQWLQXDWLRQRI
o DQ\WUHDWPHQW
o WHSRWLQLE
o JHILWLQLE
o SHPHWUH[HG
o FLVSODWLQ
o FDUERSODWLQ
x 7($(VOHDGLQJWRSHUPDQHQWGLVFRQWLQXDWLRQRI
o DQ\WUHDWPHQW
o WHSRWLQLE
o JHILWLQLE
o SHPHWUH[HG
o FLVSODWLQ
o FDUERSODWLQ
$OVRWKHIROORZLQJWDEOHVZLOOEHSUHVHQWHGLQDOSKDEHWLFDORUGHUIRU7($(V
x ,QFLGHQFHRI7($(VE\62&37
x ,QFLGHQFHRI7($(VE\62&37DQGZRUVWVHYHULW\&7&$(*UDGH


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







x ,QFLGHQFHRIUHODWHG7($(VE\62&37
o UHODWHGWRDQ\GUXJ
o UHODWHGWRWHSRWLQLE
o UHODWHGWRJHILWLQLE
o UHODWHGWRSHPHWUH[HG
o UHODWHGWRFLVSODWLQ
o UHODWHGWRFDUERSODWLQ
x ,QFLGHQFHRI7($(VZLWK&7&$(*UDGHE\62&DQG37
x ,QFLGHQFHRIDQ\GUXJUHODWHG7($(VZLWK&7&$(*UDGHE\62&DQG37
x ,QFLGHQFHRIQRQVHULRXV$(VH[FOXGLQJ6$(V
 
$GYHUVH(YHQWV/HDGLQJWR7UHDWPHQW'LVFRQWLQXDWLRQ
$(VOHDGLQJWRWHPSRUDU\RUSHUPDQHQWGLVFRQWLQXDWLRQRIVWXG\WUHDWPHQWZLOOEHLGHQWLILHGDV
WKRVH$(VZKRVHDFWLRQWDNHQZLWKVWXG\WUHDWPHQWZDVUHSRUWHGDV³GUXJLQWHUUXSWHG´RU³GUXJ
ZLWKGUDZQ´LQWKH$GYHUVH(YHQWV'HWDLOV´H&5)  
7KHIROORZLQJZLOOEHSUHVHQWHGE\62&DQG37LQDOSKDEHWLFDORUGHU 
x ,QFLGHQFHRI7($(VOHDGLQJWRSHUPDQHQWGLVFRQWLQXDWLRQRIDQ\WUHDWPHQWE\62&37
x ,QFLGHQFHRI7($(VOHDGLQJWRWHPSRUDU\GLVFRQWLQXDWLRQRIDQ\WUHDWPHQWE\62&37
x ,QFLGHQFHRI7($(VOHDGLQJWRGRVHUHGXFWLRQRIDQ\WUHDWPHQWE\62&37
 
'HDWKV2WKHU6HULRXV$GYHUVH(YHQWVDQG2WKHU6LJQLILFDQW
$GYHUVH(YHQWV
 
'HDWKV
$OOGHDWKVGHDWKVZLWKLQGD\VDIWHUODVWGRVHRIWULDOGUXJGHDWKZLWKLQGD\VDIWHUILUVWGRVH
DVZHOODVUHDVRQIRUGHDWKZLOOEHWDEXODWHGEDVHGRQLQIRUPDWLRQIURPWKH³'HDWK´H&5)
6XPPDULHVZLOOEHSUHVHQWHGIRU
x 1XPEHURIGHDWKV
x 1XPEHURIGHDWKVZLWKLQGD\VDIWHUODVWGRVHRIWULDOWUHDWPHQW
x 1XPEHURIGHDWKVZLWKLQGD\VDIWHUILUVWGRVHRIWULDOWUHDWPHQW
x 3ULPDU\UHDVRQRIGHDWK
o 'LVHDVHSURJUHVVLRQV
o $GYHUVHHYHQWUHODWHGWRVWXG\WUHDWPHQW
o $GYHUVHHYHQWQRWUHODWHGWRVWXG\WUHDWPHQW


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







o 2WKHU
o 8QNQRZQ
x 3ULPDU\UHDVRQRIGHDWKZLWKLQGD\VDIWHUODVWGRVHRIWULDOWUHDWPHQW
x 3ULPDU\UHDVRQRIGHDWKZLWKLQGD\VDIWHUILUVWGRVHRIWULDOWUHDWPHQW
$OOGHDWKVIRUVFUHHQLQJDQDO\VLVVHWZLOOEHOLVWHG
x ,QDGGLWLRQGDWHDQGFDXVHRIGHDWKZLOOEHSURYLGHGLQLQGLYLGXDOVXEMHFWGDWDOLVWLQJ
WRJHWKHUZLWKVHOHFWHGGRVLQJLQIRUPDWLRQGDWHRIILUVWODVWDGPLQLVWUDWLRQGRVHLQWHQVLW\
HWF
x ,QFOXGLQJFROXPQVIRU
o $(VZLWKIDWDORXWFRPHOLVWSUHIHUUHGWHUPVRI$(VZLWKRXWFRPH IDWDO
o IODJIRUGHDWKZLWKLQGD\VRIODVWWULDOWUHDWPHQW
o IODJIRUGHDWKZLWKLQGD\VRIILUVWWULDOWUHDWPHQW
 
6HULRXV$GYHUVH(YHQWV
6$(VDUHWKRVHHYHQWVZLWKDUHVSRQVHRI³<HV´IRUWKHLWHP³6HULRXV$GYHUVH(YHQW´RQWKH
³$GYHUVH(YHQWV'HWDLOV´IRUPRIWKHH&5)6HULRXV7($(VHULRXVUHODWHG7($(VDQGDIXOOOLVW
RIDOO6$(VZLOOEHSUHVHQWHG
x ,QFLGHQFHRI6HULRXV7($(VE\62&DQG37
x ,QFLGHQFHRIDQ\GUXJUHODWHG6HULRXV7($(VE\62&DQG37
x /LVWLQJRIDOO6$(VIRUWKH6$)VHW
x ,QFLGHQFHRI7($(VOHDGLQJWRGHDWKE\62&DQG37
x ,QFLGHQFHRIDQ\GUXJUHODWHG7($(VOHDGLQJWRGHDWKE\62&DQG37
x /LVWLQJRIDOO7($(VOHDGLQJWRGHDWKIRUWKH6$)VHW
 
$GYHUVH(YHQWRI6SHFLDO,QWHUHVW
$GYHUVH(YHQWVRI6SHFLDO,QWHUHVWV$(6,VDUHWKRVHHYHQWVZLWKDUHVSRQVHRI³<HV´IRUWKHLWHP
³,VWKLVDQDGYHUVHHYHQWRIVSHFLDOLQWHUHVW"´RQWKH³$GYHUVH(YHQWV'HWDLOV´IRUPRIWKHH&5)
7KHIROORZLQJDUHFROOHFWHGDQGZLOOEHSUHVHQWHG
x ,QFLGHQFHRIWUHDWPHQWHPHUJHQW$(6,VE\62&DQG37$OOFDVHVRIDV\PSWRPDWLFOLSDVH
DQGRUDP\ODVHHOHYDWLRQVRI*UDGHZLOOEHUHSRUWHGDV$(6,
x ,QFLGHQFHRIDQ\GUXJUHODWHGWUHDWPHQWHPHUJHQW$(6,VE\62&DQG37
x $Q\OLSDVHRUDP\ODVHLQFUHDVHZLOOEHOLVWHGIRU6$)VHW


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







 
&OLQLFDO/DERUDWRU\(YDOXDWLRQ
8ULQDO\VLVDVVHVVPHQWV
'LSVWLFNXULQDO\VLVDVVHVVPHQWVZLOOEHFRQGXFWHGE\VLWHV6LWHVZLOOGHFLGHZKHWKHURUQRWVHQGLQJ
XULQHVDPSOHVWRFHQWUDOODERUDWRU\IRUPLFURVFRSLFH[DPLQDWLRQ
7KHIROORZLQJLQIRUPDWLRQZLOOEHSURYLGHG
x 'LSVWLFNXULQDO\VLVDVVHVVPHQWVRXWFRPHE\YLVLWQRUPDODEQRUPDO
x /LVWRIDEQRUPDOPLFURVFRSLFH[DPLQDWLRQILQGLQJV
%LRFKHPLVWU\KHPDWRORJ\DQGFRDJXODWLRQ
/DERUDWRU\YDOXHVLQFOXGLQJFRUUHVSRQGLQJQRUPDOUDQJHVIURP&HQWUDO/DEZLOOEHXVHGIRU
VXPPDU\VWDWLVWLFVDQGVKLIWWDEOHV2QO\ VXEMHFWV ZLWK SRVWEDVHOLQH ODERUDWRU\ YDOXHV ZLOOEH
LQFOXGHGLQWKHVHDQDO\VHV'DWDZLOOEHSURYLGHGE\WKHFHQWUDOODERUDWRU\XVLQJWKH,QWHUQDWLRQDO
6\VWHPRI8QLWV6,DQGDOOSUHVHQWDWLRQVZLOOXVH6,XQLWV
4XDQWLWDWLYHGDWDZLOOEHH[DPLQHGIRUWUHQGVXVLQJGHVFULSWLYHVWDWLVWLFVPHDQVWDQGDUG
GHYLDWLRQPHGLDQ44PLQLPXPDQGPD[LPXPRIDFWXDOYDOXHVDQGFKDQJHVIURPEDVHOLQH
WRHDFKYLVLWRYHUWLPH
4XDOLWDWLYHGDWDEDVHGRQUHIHUHQFHUDQJHVZLOOEHGHVFULEHGDFFRUGLQJWRWKHFDWHJRULHVLH/RZ
1RUPDO+LJK7KHQXPEHURIVXEMHFWVZLWKFOLQLFDOODERUDWRU\YDOXHVEHORZZLWKLQRUDERYH
QRUPDOUDQJHVDWEDVHOLQHFRPSDUHGWRZRUVWRQWUHDWPHQWHQGSRLQWZLOOEHWDEXODWHGIRUHDFKWHVW
E\WUHDWPHQW
7KHIROORZLQJVXPPDULHVZLOOEHGLVSOD\HGSHUFRKRUWDQGDOOFRKRUWVFRPELQHG
x 1XPEHUDQGSHUFHQWDJHRIVXEMHFWVE\ZRUVWRQWUHDWPHQWYDOXHV/RZ1RUPDO+LJK
3OHDVHUHIHUWRWKH$QDO\VLV'DWD0RGHO$'D0WHPSODWHWRILQGSDUDPHWHUVWREHVSOLW
LQWRKLJKDQGORZ)RUH[DPSOHJOXFRVHZLOOEHSUHVHQWHGE\³JOXFRVHKLJK´DQG³JOXFRVH
ORZ´VHSDUDWHO\
x 6KLIWIURPEDVHOLQHWRKLJKHVWDQGORZHVWRQWUHDWPHQWYDOXH
)RU JUDGDEOH SDUDPHWHUV DFFRUGLQJ WR 1&,&7&$( Y WKH IROORZLQJ VXPPDULHV ZLOO EH
GLVSOD\HGSHUFRKRUWDQGDOOFRKRUWVFRPELQHG
x 1XPEHUDQGSHUFHQWDJHRIVXEMHFWVE\ZRUVWRQWUHDWPHQWYDOXHV*UDGH*UDGH
*UDGH
x 6KLIWLQWR[LFLW\JUDGLQJIURPEDVHOLQHWRKLJKHVWSRVWEDVHOLQHWR[LFLW\
7KHIROORZLQJILJXUHVZLOODOVREHSURYLGHG
x %R[SORWVRIWKHODERUDWRU\YDOXHVE\WLPHSRLQW
x %R[SORWVRIWKHFKDQJHIURPEDVHOLQHE\WLPHSRLQW


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







 
9LWDO6LJQV
,QIRUPDWLRQIURPWKH³9LWDO6LJQV´H&5)ZLOOEHXVHG 
7KHIROORZLQJYLWDOSDUDPHWHUVZLOOEHUHSRUWHG
x $XULFXODU7HPSHUDWXUHÛ&
x 7HPSHUDWXUH&RQYHUVLRQV
x $XULFXODUWHPSHUDWXUHÛ& 2UDOWHPSHUDWXUHÛ& 5HFWDOWHPSHUDWXUHÛ& 
$[LOODU\WHPSHUDWXUHÛ&
x 5HVSLUDWRU\5DWHEUHDWKVPLQ
x 6\VWROLF%ORRG3UHVVXUH6%3PP+J
x 'LDVWROLF%ORRG3UHVVXUH'%3PP+J
x +HDUW5DWHESP
x +HLJKWFPRQO\DWEDVHOLQH
x :HLJKWNJ
x %0,NJP
x %6$P
7KHIROORZLQJVXPPDULHVZLOOEHSURYLGHGIRUYLWDOVLJQVGDWD
x 9LWDOVLJQVDWEDVHOLQHZLOOEHSUHVHQWHGGHVFULSWLYHO\
x 6XPPDU\VWDWLVWLFVRYHUWLPHRQO\VXEMHFWVDWWKHYLVLWZLOOEHVXPPDUL]HG
x &DWHJRULFDOFKDQJHIURPEDVHOLQHWRZRUVWRQWUHDWPHQWYDOXHLHWKHKLJKHVWYDOXHIRU
LQFUHDVH DQG WKH ORZHVW YDOXH IRU GHFUHDVH IRU YLWDO VLJQV H[FOXGLQJ ZHLJKW ZLOO EH
JURXSHGDVIROORZV
9LWDO6LJQ
3DUDPHWHU
,QFUHDVH
GHFUHDVH
%DVHOLQHFDWHJRU\
&KDQJHIURPEDVHOLQHFDWHJRU\
7HPSHUDWXUH
,QFUHDVH
&
&
&
&
&
q&
q&
q&
tq&
+HDUWUDWH
,QFUHDVH
ESP
ESP
dESP
!±ESP
!ESP
'HFUHDVH
ESP
ESP
dESP
!±ESP
!ESP


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ




6%3
,QFUHDVH
PP+J
PP+J
dPP+J
!±PP+J
!PP+J
'HFUHDVH
PP+J
PP+J
dPP+J
!±PP+J
!PP+J
'%3
,QFUHDVH
PP+J
PP+J
dPP+J
!±PP+J
!PP+J
'HFUHDVH
PP+J
PP+J
dPP+J
!±PP+J
!PP+J
5HVSLUDWLRQUDWH
,QFUHDVH
ESP
ESP
dESP
!±ESP
!ESP
'HFUHDVH
ESP
ESP
dESP
!±ESP
!ESP
x &DWHJRULFDOFKDQJHVLQERG\ZHLJKWIURPEDVHOLQHWRPHDVXUHPHQWVGXULQJWKHWUHDWPHQW
SKDVHFODVVLILHGDFFRUGLQJWRWKH1&,&7&$(YHUVLRQ
9DULDEOH
*UDGH
*UDGH
*UDGH
:HLJKW
*DLQ
IURP
EDVHOLQH
IURP
EDVHOLQH
IURP
EDVHOLQH
:HLJKW
/RVV
IURP
EDVHOLQH
IURP
EDVHOLQH
IURP
EDVHOLQH
:HLJKWFKDQJHVIURPEDVHOLQHZLOOEHFDWHJRUL]HGDV*UDGH
x ,QDGGLWLRQWRGDWDOLVWLQJIRUYLWDOVLJQVDQDGGLWLRQDOVXEMHFWGDWDOLVWLQJZLOOSUHVHQWDOO
FKDQJHVIURPEDVHOLQHUHSRUWHGLQWKHKLJKHVWFDWHJRULHVIRUDXULFXODUWHPSHUDWXUHKHDUW
UDWHV\VWROLFEORRGSUHVVXUHGLDVWROLFEORRGSUHVVXUHUHVSLUDWLRQUDWHDQGZHLJKW
 
(&*
,QIRUPDWLRQIURPWKH³(OHFWURFDUGLRJUDP´H&5)ZLOOEHXVHG
$OO(&*UHDGLQJVZLOOEHUHFRUGHGDVOHDGUHVWLQJ(&*VLQWULSOLFDWHV7KHDYHUDJHRIWKHVH
UHVXOWVZLOOEHXVHGIRULQFOXVLRQLQWKHUHSRUWLQJRIWKLVVWXG\IRUQXPHULFSDUDPHWHUV,IVRPH
RIWKHUHVXOWVDUHPLVVLQJWKHDYHUDJHRIDYDLODEOHUHVXOWVZLOOEHXVHG5HVXOWRI(&*ZLOOXVH
WKHZRUVWUHVXOWDPRQJWKHUHVXOWVLH1RUPDO$EQRUPDOQRWFOLQLFDOO\VLJQLILFDQW$EQRUPDO
FOLQLFDOO\VLJQLILFDQW5K\WKPZLOORQO\EHOLVWHG
7KHIROORZLQJ(&*SDUDPHWHUVZLOOEHUHSRUWHGIRUWKLVVWXG\EDVHGRQWKH6$)VHW


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







x 35,QWHUYDOPVHF
x 456,QWHUYDOPVHF
x 47F),QWHUYDOPVHF
x 55PVHF
x 5HVXOW RI (&* 1RUPDO $EQRUPDO QRW FOLQLFDOO\ VLJQLILFDQW $EQRUPDO FOLQLFDOO\
VLJQLILFDQW
7KHIROORZLQJVXPPDULHVZLOOEHSURYLGHGIRU(&*GDWD
x $FWXDODQGFKDQJHIURPEDVHOLQHE\YLVLWIRUTXDQWLWDWLYHPHDVXUHPHQWV
x )UHTXHQF\DQGSHUFHQWDJHVIRUUHVXOWRI(&*E\YLVLW
x &DWHJRULFDOVKLIWIURPEDVHOLQHWRZRUVWRQWUHDWPHQWYDOXHIRUWKH47F)WKHEDVHOLQHDQG
WKHZRUVWRQWUHDWPHQWYDOXHLHWKHKLJKHVWYDOXHZLOOEHJURXSHGDVIROORZV
3DUDPHWHU
%DVHOLQHFDWHJRU\
:RUVWRQWUHDWPHQWYDOXH
47F)
PV
!PV
!PV
!PV
PV
!PV
!PV
!PV
x &DWHJRULFDOFKDQJHIURPEDVHOLQHWRZRUVWRQWUHDWPHQWYDOXHIRU47F)WKHEDVHOLQHDQG
WKHZRUVWFKDQJHIURPEDVHOLQHYDOXHZLOOEHJURXSHGDVIROORZV
o :RUVW DEVROXWH FKDQJH IURP EDVHOLQH  _ ZRUVW RQWUHDWPHQW YDOXH ± YDOXH DW
EDVHOLQH_
3DUDPHWHU
%DVHOLQHFDWHJRU\
:RUVWDEVROXWHFKDQJHIURP
EDVHOLQH
47F)
1RUPDOLHPV
$EQRUPDOLH!PV

PV
!PV
!PV
!PV
x ,QFLGHQFHRI47F)SURORQJDWLRQV
3DUDPHWHU
3URORQJDWLRQV
47F)
!PV
!PV
!PV
$EVROXWH47F)FKDQJH
!PV
!PV 


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







 
2WKHU6DIHW\RU7ROHUDELOLW\(YDOXDWLRQV
3K\VLFDO([DPLQDWLRQ
,QIRUPDWLRQIURPWKH³3K\VLFDO([DPLQDWLRQ´H&5)ZLOOEHXVHG
$ OLVWLQJ RI VXEMHFWV FRPSOHWLQJ SK\VLFDO H[DPLQDWLRQV UHVXOWV ZLOO EH SUHVHQWHG +RZHYHU
FOLQLFDOO\VLJQLILFDQWDEQRUPDOILQGLQJVZLOOEHUHSRUWHGDV$(V
(&2*
,QIRUPDWLRQIURPWKH³(&2*3HUIRUPDQFH6WDWXV´DQG³3UHJQDQF\7HVW´H&5)SDJHVZLOOEH
XVHG 
(&2*SHUIRUPDQFHVWDWXVDQGSUHJQDQF\ZLOOEHOLVWHGVHSDUDWHO\
 
$QDO\VHVRI2WKHU(QGSRLQWV
 












 
3KDUPDFRG\QDPLFVDQG

7KHFKDQJHVRIWKHFLUFXODWLQJOHYHOVRIVKHGGHGF0HW,/DQG+*)XQGHUWUHDWPHQWPLJKWEH
LQGLFDWLYHRIDQWLWXPRUDFWLYLW\7KHELRPDUNHUVVKHGGHGF0HW,/DQG+*)ZLOOEHPHDVXUHG
LQSODVPDE\(/,6$DVVD\
7KHIROORZLQJYDULDEOHVZLOOEHFDOFXODWHGWRPHDVXUHRQWUHDWPHQWFKDQJHVLQPDUNHUOHYHOVIRU
HDFKRIWKHWKUHHELRPDUNHUVVKHGGHGF0HW,/DQG+*)
x DEVROXWHDQGIROGFKDQJHIURPEDVHOLQHOHYHOWRRQWUHDWPHQWOHYHOV
)XUWKHUH[SORUDWRU\HQGSRLQWVPD\LQFOXGH
x )XUWKHUH[SORUDWRU\ELRPDUNHUVWKDWPD\FRUUHODWHZLWKDQWLWXPRUDFWLYLW\
CCI
CCI
CCI


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







$OOSKDUPDFRG\QDPLFVDQGSKDUPDFRJHQRPLFVZLOOEHSUHVHQWHGLQGDWDOLVWLQJVWRJHWKHUZLWK
%25IRUWKHUHVSHFWLYHSDWLHQWV
 
+HDOWK5HODWHG4XDOLW\RI/LIH
7KH352VZLWKUHVSHFWWR4R/DVPHDVXUHGE\WKH(XURSHDQ2UJDQL]DWLRQIRU5HVHDUFKDQG
7UHDWPHQWRI&DQFHU4XDOLW\RI/LIH4XHVWLRQQDLUH&RUH(257&4/4&9HUVLRQ
/XQJ&DQFHU6\PSWRP6FDOH/&66DQG

ZLOOEHDQDO\]HG,QIRUPDWLRQREWDLQHGIURP³4XDOLW\RI/LIH4XHVWLRQQDLUH´³4XDOLW\RI/LIH
(257&4R/&´³(XURSHDQ4XDOLW\RI/LIHDQG'LPHQVLRQV´$QG³/XQJ&DQFHU6\PSWRP
6FDOH´RIH&5)ZLOOEHXVHG
,QWKHUDQGRPL]DWLRQSDUWRI3KDVH,,4R/HYDOXDEOHSRSXODWLRQLQFOXGHVDOO,77VXEMHFWVZLWKD
EDVHOLQHDQGDWOHDVWRQHHYDOXDEOHRQWUHDWPHQW4R/TXHVWLRQQDLUH
,QWKHVLQJOHDUPFRKRUWRI3KDVH,,4R/HYDOXDEOHSRSXODWLRQLQFOXGHVVXEMHFWVLQ6DIHW\$QDO\VLV
6HWZLWKDEDVHOLQHDQGDWOHDVWRQHHYDOXDEOHRQWUHDWPHQW4R/TXHVWLRQQDLUH
(YDOXDELOLW\
4XHVWLRQQDLUHVILOOHGLQGXULQJWKHILUVWGD\VDIWHUWKHEHJLQQLQJRIDWUHDWPHQWF\FOHGD\RI
SHPHWUH[HG RU FLVSODWLQFDUERSODWLQ LQIXVLRQ ZLOO EH FRQVLGHUHG QRQHYDOXDEOH DV WKHVH
TXHVWLRQQDLUHV ZRXOG EH SULPDULO\ LQIOXHQFHG E\ WKH DFXWH VLGHHIIHFWV RI
FKHPRWKHUDS\ ,Q DGGLWLRQ TXHVWLRQQDLUHV ILOOHG LQ ³RQWUHDWPHQW´ EXW DIWHU WKH GDWH RI
SURJUHVVLRQZLOOEHFRQVLGHUHGQRQHYDOXDEOH
7KHSDWWHUQVRIFRPSOHWLRQRITXHVWLRQQDLUHVZLOOEHH[SORUHGWRLQYHVWLJDWHWKHPDJQLWXGHRI
PLVVLQJGDWDDQGWRH[SORUHWKHH[WHQWRILQWHUPLWWHQWPLVVLQJGDWDDQGPRQRWRQHPLVVLQJGDWD
7KHIROORZLQJZLOOEHSURYLGHGIRUHDFKDVVHVVPHQWSHULRGDQGRYHUDOO
x 7KHQXPEHURIVXEMHFWVZLWKDWOHDVWRQHHYDOXDEOH4R/TXHVWLRQQDLUHV
x 3HUFHQWDJH FRPSOLDQFH  î QXPEHU RI VXEMHFWV ZLWK DW OHDVW RQH HYDOXDEOH 4R/
TXHVWLRQQDLUHVQXPEHU RI VXEMHFWV ZLWK DW OHDVW RQH HYDOXDEOH 4R/ TXHVWLRQQDLUH
H[SHFWHG
7KHUHDVRQVIRUPLVVLQJHYDOXDEOHTXHVWLRQQDLUHVZLOOEHSUHVHQWHGE\HDFKDVVHVVPHQWSHULRG
 
/XQJ&DQFHU6\PSWRP6FDOH
'HILQLWLRQRI$YHUDJH6\PSWRPDWLF%XUGHQ,QGH[$6%,
7KH$6%,LVWKHPHDQRIDOOVL[V\PSWRPVFRUHVWUHDWHGDVDVLQJOHGRPDLQ
,IRUPRUHLWHPVDUHPLVVLQJWKHVXEMHFWZLOOEHFRQVLGHUHGQRQHYDOXDEOHDWWKDWWLPHSRLQW)RU
HDFKV\PSWRPVFRUHWKHGLVWDQFHIURPWKHOHIWERXQGDU\WRWKHSRLQWZKHUHWKHVXEMHFWKDVPDUNHG
WKHOLQHLVPHDVXUHGLQPLOOLPHWHUV7KHWRWDOVFDOHOHQJWKLVPP
CCI


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







'HILQLWLRQRI7LPHWR6\PSWRP3URJUHVVLRQ
6\PSWRPSURJUHVVLRQZLOOEHGHILQHGDVDQLQFUHDVHZRUVHQLQJRIWKH$6%,VFRUHRIRIWKH
VFDOHEUHDGWKPPRQDVFDOHRIPPIURPWKHEDVHOLQHVFRUHRQDWOHDVWWZRFRQVHFXWLYH
DVVHVVPHQWVGXULQJWKHSHULRGZKHQDVVHVVPHQWVDUHSHUIRUPHGHYHU\F\FOHVDQGWKHQHYHU\
F\FOHV2QFHWKHIUHTXHQF\RIDVVHVVPHQWVLVUHGXFHGWRHYHU\F\FOHVWKHQDQLQFUHDVHDWRQO\
RQHDVVHVVPHQWLVUHTXLUHGDVSURRIRIZRUVHQLQJ 
7763ZLOOEHGHILQHGDVWKHWLPHIURPGDWHRI&\FOH'D\XQWLOGDWHRIV\PSWRPSURJUHVVLRQ
,IV\PSWRPSURJUHVVLRQUHTXLUHVWZRFRQVHFXWLYHDVVHVVPHQWVPHHWLQJWKHFULWHULDRIZRUVHQLQJ
WKHQWKHGDWHRIV\PSWRPSURJUHVVLRQZLOOEHWDNHQDVWKHGDWHRIWKHHDUOLHURIWKHWZRDVVHVVPHQWV
6XEMHFWVGLDJQRVHGZLWK3'DWWLPHRIGHDWKZLOOEHFRQVLGHUHGDVKDYLQJDQXQFHQVRUHG7763
GHILQHGDVWLPHEHWZHHQGDWHRIUDQGRPL]DWLRQILUVWDGPLQLVWUDWLRQRIWULDOWUHDWPHQWDQGGDWHRI
GHDWK
7KHIROORZLQJSDUDPHWHUVZLOOEHVXPPDUL]HGE\WKHPHDQDQG6'IRUHDFKWUHDWPHQWDUPDQG
RYHUDOOIRUHDFKDVVHVVPHQWSHULRG
x 7RWDO6FRUH
x $6%,
x $SSHWLWH
x )DWLJXH
x &RXJK
x '\VSQHDVKRUWQHVVRIEUHDWK
x +HPRSW\VLVEORRGLQVSXWXP
x 3DLQ
x 6\PSWRPGLVWUHVVV\PSWRPVIURPOXQJFDQFHU
x $FWLYLW\OHYHODELOLW\WRFDUU\RXWQRUPDODFWLYLWLHV
x *OREDOTXDOLW\RIOLIH
$WZRVDPSOHWWHVWWRFRPSDUHWKHWZRWUHDWPHQWDUPVZLOOEHSURYLGHGIRUWKHUDQGRPL]HGSDUW
7KHDQDO\VLVZLOOWHVWWKHHTXDOLW\RI7763EHWZHHQWUHDWPHQWDUPVLQWKHUDQGRPL]HGSDUWRI3KDVH
,,EDVHGRQWKH,77SRSXODWLRQDSSO\LQJDWZRVLGHGVWUDWLILHGORJUDQNWHVWDWDVLJQLILFDQFHOHYHO
RIĮ WDNLQJLQWRDFFRXQWWKHVWUDWDXVHGIRUUDQGRPL]DWLRQLHW\SHRI0(7VWDWXVDQG
SULRU(*)57.,WUHDWPHQW


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







$QXQVWUDWLILHG&R[PRGHOZLOOEHILWWHGE\ZKLFKWKHKD]DUGUDWLRTWKH&,VDQGSYDOXH
ZLOOEHFDOFXODWHG
 
(257&4/4&
7KH (257& 4/4& TXHVWLRQQDLUH FRQVLVWV RI PXOWLSOHġ FKRLFH TXHVWLRQV WKDW FDQ EH
FODVVLILHGLQWRIROORZLQJFDWHJRULHV
x )XQFWLRQDOVFDOHVSK\VLFDOUROHFRJQLWLYHHPRWLRQDOVRFLDO
x 6\PSWRPVFDOHVIDWLJXHQDXVHDDQGYRPLWLQJSDLQ
x $JOREDOKHDOWKVWDWXVVFDOH
x 6LQJOH LWHPV G\VSQHD ORVV RI DSSHWLWH LQVRPQLD FRQVWLSDWLRQ GLDUUKHD ILQDQFLDO
GLIILFXOWLHV
)LUVWWKHDYHUDJHRIWKHLWHPVWKDWFRQWULEXWHWRWKHVFDOHLVHVWLPDWHGWKLVLVWKHUDZVFRUHWKHQD
OLQHDUWUDQVIRUPDWLRQLVXVHGWRVWDQGDUGL]HWKHUDZVFRUHVRWKDWVFRUHVUDQJHIURPWRD
KLJKHUVFRUHUHSUHVHQWVDKLJKHUEHWWHUOHYHORIIXQFWLRQLQJRUDKLJKHUZRUVHOHYHORI
V\PSWRPV5HIHUWR$SSHQGL[IRUGHWDLOVRQVFRULQJ(DFKVFDOHDQGLWHPZLOOEHVXPPDUL]HG
XVLQJ VXPPDU\ VWDWLVWLFV GHVFULSWLYHO\ 6XPPDU\ VWDWLVWLFV PHDQ >DQG VWDQGDUG GHYLDWLRQ@
PHGLDQUDQJHDQG&,RIUDZDQGVWDQGDUGL]HGVFRUHVZLOOEHUHSRUWHGIRUWKHVFDOHVRIWKH
(XURSHDQ (257& 4/4& TXHVWLRQQDLUH 7KHVH VXPPDU\ VWDWLVWLFV ZLOO EH SUHVHQWHG IRU
REVHUYHGDQGFKDQJHIURPEDVHOLQHVFRUHV
0LVVLQJGDWD ZLOO EH KDQGOHG LQ DFFRUGDQFH ZLWK WKH VFRULQJPDQXDO1DPHO\IRUPXOWLLWHP
VFDOHVLIDWOHDVWKDOIRIWKHLWHPVIURPWKHVFDOHKDYHEHHQDQVZHUHGDVVXPHWKDWWKHPLVVLQJ
LWHPVKDYHYDOXHVHTXDOWRWKHDYHUDJHRIWKRVHLWHPVZKLFKDUHSUHVHQWIRUWKDWUHVSRQGHQW
 











 

CCI


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ







 
5HIHUHQFHV
 (LVHQKDXHU($7KHUDVVH3%RJDHUWV-6FKZDUW]/+6DUJHQW')RUG5HWDO1HZUHVSRQVH
HYDOXDWLRQFULWHULDLQVROLGWXPRUVUHYLVHG5(&,67JXLGHOLQHYHUVLRQ(XU-&DQFHU

 -DFNPDQ'3DR:5LHO\*-HWDO&OLQLFDO'HILQLWLRQRI$FTXLUHG5HVLVWDQFHWR(SLGHUPDO
*URZWK)DFWRU5HFHSWRU7\URVLQH.LQDVH,QKLELWRUVLQ1RQ±6PDOO&HOO/XQJ&DQFHU-&2-DQ
SXEOLVKHGRQOLQHRQ1RYHPEHU

CCI


7HSRWLQLE06&-

7HSRWLQLEZLWK*HILWLQLELQ6XEMHFWVZLWK/RFDOO\$GYDQFHGRU0HWDVWDWLF16&/&,16,*+7
(05

3KDVH,,9HUVLRQ




 
$SSHQGL[
 
6FRULQJWKH(257&4/4&YHUVLRQ
,WHPUDQJHLVWKHGLIIHUHQFHEHWZHHQWKHSRVVLEOHPD[LPXPDQGWKHPLQLPXPUHVSRQVHWR
LQGLYLGXDOLWHPVPRVWLWHPVWDNHYDOXHVIURPWRJLYLQJUDQJH 
UHYLVHGVFDOHVDUHWKRVHWKDWKDYHEHHQFKDQJHGVLQFHYHUVLRQDQGWKHLUVKRUWQDPHV
DUHLQGLFDWHGLQWKLVPDQXDOE\DVXIIL[³´±IRUH[DPSOH3)
)RUDOOVFDOHVWKH5DZ6FRUH56LVWKHPHDQRIWKHFRPSRQHQWLWHPV
ܴܽݓܵܿ݋ݎ݁= ܴܵ= (ܫଵ+ ܫଶ+ ڮ + ܫ௡) ݊
Τ 
7KHQIRUIXQFWLRQDOVFDOHV
ܵܿ݋ݎ݁= ቊ1 െ(ܴܵെ1)
ݎܽ݊݃݁ቋכ 100
DQGIRU6\PSWRPVFDOHVLWHPVDQG*OREDOKHDOWKVWDWXV4R/
ܵܿ݋ݎ݁ {(RS െ1) range
Τ
}כ
J


'RFXPHQW$SSURYDO6LJQDWXUHV
7KLVGRFXPHQWKDVEHHQVLJQHGHOHFWURQLFDOO\LQFRPSOLDQFHZLWK
DQG

&RPSDQLHV
HOHFWURQLFVLJQDWXUHSROLFLHVDQGSURFHGXUHV7KLVSDJHLVDPDQLIHVWDWLRQRIWKH
HOHFWURQLFVLJQDWXUHVZKLFKPD\EHFRQILUPHGZLWKLQWKH
DQG
&RPSDQLHV

VRXUFHV\VWHPLQDFFRUGDQFHZLWK
DQG
&RPSDQLHV
UHFRUGVUHWHQWLRQSROLFLHV
1RWHWKH7LWOHILHOGLQWKHVLJQDWXUHEORFNKDVEHHQLQWHQWLRQDOO\OHIWEODQN

8VHU1DPH
7LWOH
'DWH7KXUVGD\-DQXDU\30(DVWHUQ7LPH
0HDQLQJ,$SSURYHWKH'RFXPHQW
                                                
8VHU1DPH
7LWOH
'DWH)ULGD\-DQXDU\$0(DVWHUQ7LPH
0HDQLQJ,$SSURYHWKH'RFXPHQW
                                                
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD